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Abstract 
The serine-threonine kinase mammalian target of rapamycin (mTOR) is an important 
integrator of nutrient, cytokine and growth factor sensing in T cells and controls 
transcriptional programs that determine CD8+ cytotoxic T cell fate and trafficking. 
mTORC1 is inhibited by the drug rapamycin which is a powerful immunosuppressant 
used in the clinic in the context of organ transplantation. However, not much is known 
about the full extent of the role of mTOR signalling in CTL. 
We thus utilised high resolution quantitative mass spectrometry to define the mTOR 
regulated CTL proteome and map the abundance and isoform expression of more than 
6700 proteins in CTL. The data provide unbiased analysis of how mTORC1 reprograms 
the transcriptional and proteome landscape of T cells. The results show that mTORC1 
controls expression of approximately 700 proteins with equal numbers of up and down 
regulated proteins. This illustrates that mTORC1 inhibition does not lead to a general 
decreases in protein levels but initiates a diverse reprogramming in gene expression and 
in particular drives selective decreases and increases in the expression of key metabolic 
regulators, effector molecules, adhesion molecules and adapter proteins. The proteomic 
approach also allowed us to detect effects caused by mTORC1 inhibition that were not 
caused by changes in the corresponding transcripts but solely due to posttranscriptional 
mechanisms. 
One striking result was the dominance of mTORC1 negative feedback control of the 
serine/threonine kinase PKB. This prompted detailed analysis of the role of mTOR in 
the regulation of the phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signalling effector 
PKB in CTL. A striking observation was that mTOR inhibitors allow T cells to 
accumulate very high levels of PIP3 and cause T cells to hyperactivate the 
serine/threonine kinase PKB and moreover reprogram PKB activation. PKB activity 
18 
 
was thus uncoupled from mTORC2 activity and explained the similar phenotype of 
selective mTORC1 vs combined mTORC1/2 inhibition. 
Collectively these experiments highlight the power of high resolution analysis of 
proteomes to uncover critical signalling checkpoints that control T cell differentiation 
and give new insights about how mTORC1 inhibitors control T cell function.  
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1. Introduction 
1.1. An introduction to the immune system 
Every living being is constantly confronted with a multitude of pathogens – viruses, 
bacteria, fungi and other uni- and multicellular parasites – and thus requires a complex 
network of cells and molecules to defend the body from these threats. 
Skin, cornea and mucosal membranes represent the first line of defence to keep 
pathogens at bay. However, breaches in these protective layers are inevitable and thus 
further mechanisms are required to deal with inevitable infections. Pathogens entering 
the body are usually initially detected in the body by the innate immune system. The 
innate immune system is also known as the unspecific immune system as it uses 
generic, but rapid responses to deal with pathogens. An important strategy of the innate 
response is the employment of pattern recognition receptors that detect molecules that 
are characteristic of pathogens but not of the host like lipopolysaccharides derived from 
gram-negative bacteria or double stranded RNA derived from viruses. Once these 
molecules have been detected the innate immune response is triggered which leads to 
the recruitment of immune cells to the site of infection via cytokine release, the 
activation of the complement system and the removal of foreign substances and cell 
debris by specialised white blood cells. The innate immune response also leads to the 
activation of the adaptive immune system via a process known as antigen presentation. 
In contrast to the unspecific and generic response of the innate immune system, the 
purpose of the adaptive immune system is to develop a specific and long-lasting 
response to particular pathogens when these are encountered for a second time. This 
specific response comes at a price, as the adaptive immune response takes several days 
to develop and is thus not able to react as quickly to infection as the rapid response of 
the innate system. Humoral components like antibodies (which are made and released 
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by B cells) as well as cell-mediated components (with T cells playing a central role) 
contribute to the adaptive immune response. Pluripotent hematopoietic stem cells in the 
bone marrow (BM) are the source for cells constituting the innate and the adaptive 
immune system. The stem cells in the BM give rise to two kinds of progenitor cells, 
common myeloid and common lymphoid progenitors. Macrophages, dendritic cells, 
granulocytes and mast cells are all derived from the myeloid progenitor, whereas B 
cells, T cell and natural killer all derived from the common lymphoid progenitor. “B” 
and “T” cell indicate the different fates of these cells: B cells mature in the bone 
marrow, whereas T cell progenitors migrate into the thymus, where they undergo further 
differentiation into different CD4+ and CD8+ T cells. Initially, these naïve B and T cells 
are small, quiescent cells which circulate through the body via the blood and the 
lymphatic which they enter and exit several times a day. However, if a suitable antigen 
is presented to the lymphocytes by a specialised antigen presenting cell, lymphocytes 
are activated and thus exit their quiescent state. This activation is accompanied by a 
massive surge in anabolic activity to enable a rapid proliferative burst that leads to a 
dramatic increase in cell numbers and the differentiation into effector cells. These 
effector cells then migrate to the site of infection and attempt to eliminate the pathogen 
or pathogen infected cell. Most effector lymphocytes collapse and die once the infection 
is cleared. But a few long-lived cells remain which subsequently form the memory of 
the immune system. These memory cells then form the basis for a faster and increased 
immune response if a pathogen carrying the same antigen is encountered again. 
 
1.2. T cell development in the thymus 
As mentioned before, all lymphocytes are generated from a common lymphoid 
progenitor in the bone marrow. T cell progenitors then migrate to the thymus where 
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they undergo further development. One of the most important aspects of T cell 
development is the generation of a functioning T cell receptor (TCR) on a cell that 
expresses either a CD4 or CD8 co-receptor. The diversity of TCR expressed by T cells 
is one of the foundations of the adaptive immune system as the TCR is responsible for 
the detection of specific antigens presented to them by major histocompatibility 
complexes (MHC). Two major classes of TCR expressing cells can be distinguished: T 
cells expressing an αβ-TCR, which make up the vast majority of T cells in the human 
body, or T cells expressing a γδ-TCR. Several other invariant proteins are associated 
with the αβ or γδ subunits and collectively form the T cell receptor complex: Two TCRζ 
subunits (linked to each other via disulphide bonds) as well as the CD3 complex, which 
consists of CD3γ, CD3δ and two CD3ε subunits. The αβ-TCR is restricted to the 
recognition of antigens presented to it by either a MHC class I (if the CD8 co-receptor 
is expressed) or MHC class II (if the CD4 co-receptor is expressed). In contrast to that, 
the γδ TCR is not MHC restricted. The T cell progenitors which enter the thymus are 
so-called double-negative (DN) thymocytes as they express neither the CD4 nor the 
CD8 co-receptor. Through various intermediate steps these cells then enter a double 
positive (DP, positive for both CD4 and CD8) stage. Successful rearrangement of the 
TCRβ chain orchestrated by RAG proteins1 and subsequent expression of a pre-TCR 
complex is crucial for development to the DP stage as the pre-TCR is required for 
survival signalling that prevents the thymocytes from entering apoptosis. CD4/CD8 DP 
cells then perform rearrangement and maturation of the TCRα chain and the successful 
outcome of this process leads to the formation of a functional TCR. The nascent TCR, 
together with the CD4 or CD8 co-receptor will then interact with MHC Class I and II 
molecules loaded with host derived self-peptides which are expressed by epithelial cells 
in the thymus. The strength and duration of the interaction of this TCR-MHC 
interaction will determine whether the T cells pass the positive selection process and 
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commit to the CD4 or CD8 lineage2. Furthermore, TCR which bind too strongly to the 
MHC complexes in the thymus will initiate apoptotic signalling which ensures the 
removal of T cells with potential autoimmune properties (negative selection)2. The 
result of this stringent maturation process is the generation of either CD4 or CD8 
positive cells which will leave the thymus and populate the periphery. 
 
1.3. T cell receptor signalling 
As mentioned earlier, the T cell receptor (TCR) is an octomeric transmembrane 
complex consisting of a TCRα and a TCRβ chain linked to each other by a disulphide 
bond which is joined by three dimeric molecules: a CD3γ/ε and a CD3δ/ε heterodimer 
as well as a TCRζ/ζ (CD247) homodimer. The TCRα and β chains only contain a short 
cytoplasmic tail without any significant domains whereas CD3γ, δ and ε contain one 
and TCR3ζ three immunoreceptor-tyrosine-based activation motif (ITAM) domains. 
ITAM motifs contain a characteristic YxxI/Lx(6-8)YxxI/L sequence motif3 whose 
tyrosine residues can be phosphorylated upon ligand binding of the TCR by tyrosine 
kinases of the Src family, Lck and Fyn4,5,6,7. It has been demonstrated that the ITAM 
motifs are sequestered in the cell membrane in the absence of TCR ligand and that this 
mechanism is involved in the regulation of ITAM phosphorylation8. However, further 
studies contradicted the importance of this mechanism9 and the role of this sequestration 
mechanism in regulating ITAM phosphorylation remains disputed. TCR binding to 
ligands leads to the juxtaposition of the TCR with the CD4/8 co-receptors. This leads to 
the recruitment of the tyrosine kinase Lck to the TCR/CD3 complex. The activity of 
Lck is regulated by two tyrosine-phosphorylation sites: Tyr394, which can be 
phosphorylated by either trans-autophosphorylation or by Fyn, lies within the catalytic 
domain activation loop and needs to be phosphorylated for Lck activity. The 
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phosphorylation of Lck on Tyr505 by Csk on the other hand locks Lck in an auto-
inhibitory state via binding to its Src homology (SH) 2 domain10 and needs to be 
relieved by CD45 in order to enable phosphorylation of Tyr39411. However, high CD45 
or other tyrosine phosphatase activity can also negatively regulate Lck activity by 
dephosphorylating Tyr39411,12. Activated Src kinases are able to phosphorylate the 
Tyrosine residues on the ITAM motifs which leads to the recruitment Zeta-chain-
associated protein kinase 70 (ZAP70)13,14 via its tandem SH domains15, however, 
ZAP70 also needs to be phosphorylated on Tyr493 by Lck to enable binding to 
ITAMs16. Active ZAP70 is then able to phosphorylate linker for T cell activation (LAT) 
on tyrosine residues 127, 132, 171, 191 and 22617 and Src homology 2 domain 
containing-containing leukocyte phosphoprotein 76 (SLP-76). Additional adaptor 
proteins of the GRB2 family including GRB2, GADS and GRAP contain SH2 domains 
and can bind to phosphorylated tyrosine residues of LAT18. GADS can also associate 
with SLP-76 and thus links SLP-76 and LAT19. LAT, SLP-76 and the GRB2 family 
member do not show catalytic activity themselves but are scaffolding proteins whose 
assembly triggers multiple biochemical pathways. 
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Figure 1.1: T cell antigen receptor signalling. 
ITAM motifs of αβTCR and CD subunits protrude into the cytoplasm and can be 
tyrosine-phosphorylated by Lck to provide docking sites for ZAP70 via SH2 domains. 
ZAP70 activates several scaffolding proteins including LAT, Gads and SLP-76. 
Phosphorylation of these proteins leads to further recruitment of PLCγ, VAV, ITK and 
other signalling molecules. Upon signalling, membrane bound (DAG, PIP3) and soluble 
(IP3, Ca2+) second messengers are formed which transduce the ligand binding by the 
TCR. 
 
Phospolipase C (PLC)γ1 contains a SH2 domain and can bind to phosphorylated 
Tyr132 on LAT17,20 which is critical for PLCγ1 activity. However, binding of PLCγ1 to 
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LAT is not sufficient to fully activate PLCγ1 as it also needs to be phosphorylated on 
Tyr783 by IL-2–inducible T cell kinase ITK21. ITK and PLCγ1 are also both able to 
bind to SLP-76 via their SH2 domains and the binding is required for the activity of 
both enzymes22,23. 
PLCγ1 is a key signalling initiator as it catalyses the generation of the second 
messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from 
phosphatidylinositol 4,5-bisphosphate (PIP2)24. IP3 is released from the membrane and 
can bind to its receptor on the surface of the endoplasmatic reticulum (ER) which is 
linked to a ligand-gated Ca2+ channel. The IP3 binding to its receptor activates the 
channel leading to the release of Ca2+ from the ER lumen into the cytoplasm25. The 
rapid decrease of Ca2+ levels in the ER also leads to the accumulation of stromal 
interacting molecule 1 (STIM1) in the membrane of the ER which in turn can interact 
with Orai1 Ca2+ channels on the plasma membrane which increase Ca2+ levels even 
further26. The combined effects of Ca2+ release from the ER and influx from the 
extracellular space lead to a drastic increase of intracellular Ca2+ levels from 10-100 nM 
in the resting state to 500-1000 nM in stimulated cells27. The increase in Ca2+ levels 
then leads to the activation of Calcineurin, a protein-phosphatase, and calmodulin-
dependent kinase (CAMKK). Calcineurin is an important regulator of T cell activation 
as it controls the phosphorylation of nuclear factor of activated T cell, cytoplasmic 
(NFATc)28. NFATc dephosphorylation leads to the translocation of the transcription 
factor into the nucleus where initiates the transcription of genes like IL-2, TNF-α and 
IFN-γ. The importance of this pathway is further illustrated by the effcts of calcineurin 
inhibitors like cyclosporin which have been used as immunosuppressants in the context 
of organ transplantation for more than 30 years29. An important substrate of TCR 
activated CaMKK is the serine/threonine kinase adenosine monophosphate-activated 
kinase (AMPK)30, an important regulator of the energy balance in the cell31. 
26 
 
PLCγ1 activity also leads to the formation of another second messenger, DAG. In 
contrast to IP3 which is hydrophilic and thus freely diffuses into the cytoplasm upon 
PIP2 hydrolysis, DAG remains anchored in the plasma membrane and thus leads to the 
recruitment of proteins to the membrane. Proteins shown to bind to DAG are members 
of the protein kinase C and D families (PKC and PKD) of which several are expressed 
in T cells32 but also RASGRP1 which is a GTP exchange factor that activates down-
stream effectors like RAS33 and thus mitogen-activated protein kinase (MAPK) 
signalling. The activation and recruitment of protein of the PKC family, particularly 
PKCθ, forms the basis for the formation of the immunological synapse (IS), the 
interface between T cell and antigen presenting cells (APC)34,35. DAG generated by 
TCR activation only accumulates in close proximity to the contact area of the T cell 
with the APC and the sharp DAG gradient thus enables the localised accumulation of 
PKC and PKD members36. This accumulation of PKC at the plasma membrane is 
considered to be the rate limiting step of PKC activation, as other regulatory 
mechanisms of PKC, like the phosphorylation of the T loop residues by 
phosphoinositide-dependent kinase 1 (PDK1)37, also occur in the absence of TCR 
triggering. PKC isoforms control a wide range of T cell functions involved in cytotoxic 
activity of CTL by PKCδ38, activation of NF-κB signalling via CARMA139 and cell 
motility40,41. Another substrate of PKC proteins are PKD family members like the 
highly expressed PKD2. As mentioned before, these proteins are also recruited to the 
plasma membrane by DAG42. However, unlike PKC members which are constitutively 
phosphorylated by PDK1 on their T loop activation sites and which are activated by the 
DAG recruitment, sustained association of PKD2 with DAG is not required for their 
catalytic function43. Once bound to DAG, PKD2 can be phosphorylated by PKC on 
Ser707 and Ser711 within the activation loop of the kinase domain of PKD2 which in 
turn stabilises the active conformation of the kinase. This allows PKD2 to dissociate 
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from the membrane into the cytoplasm while retaining its catalytic activity44. PKD2 
thus provides a link of the membrane bound TCR signalling to the cytosol. The 
importance of PKD2 signalling in T cells has been demonstrated by PKD2 variants with 
mutated T loop residues which cannot be phosphorylated by PKC. These cells are not 
able to transduce TCR signalling and fail to produce pro-inflammatory cytokines like 
IFN-γ and IL-245,46. 
MAPK signalling is also initiated by the generation of DAG as DAG activates the 
aforementioned GTP exchange factor (GEF) RASGRP. RASGRP associates with and 
activates the small G-protein RAS by exchanging RAS-bound GDP for GTP. RAS can 
also be activated by another GEF, Son of Sevenless (SOS)47, which is associated with 
the LAT-GRB2 adaptor complex. RASGTP then subsequently activates the serine-
threonine kinase RAF1 by binding to its RAS-binding domain which relieves the auto-
inhibition of RAF-148. RAF-1 is a MAPKKK and as such phosphorylates its down-
stream substrate MEK which in turn phosphorylates the MAPK extracellular signal-
regulated kinase (ERK) 1 and 2. The MAPKK are dual-specificity kinases and are able 
to phosphorylate threonine and tyrosine residues within a TxY motif in their substrates 
and thus lead to their activation. ERK1 and 2 on the other hand are serine-threonine 
kinases. One of the down-stream targets of ERK is ELK1 which is an activator of the 
activator protein (AP)-1 complex, which is a heterodimeric complex consisting of JUN 
and FOS. AP-1 is a key transcription factor which regulates processes like 
differentiation, proliferation and apoptosis in lymphocytes49. 
TCR triggering also recruits class I phosphoinositide 3-kinases (PI3K) to the plasma 
membrane where they can phosphorylate phosphatidylinositol-4,5-bisphosphate 
(PI(4,5)P2) at the 3’ position to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). 
PIP3 levels are tightly controlled by the activity of two lipid phosphatases: phosphatase 
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and tensin homolog (PTEN) dephosphorylates PIP3 at the 3’ position to revert it back to 
PI(4,5)P2, while another lipid phosphatase, SH2-domain containing inositol 
polyphosphate 5-phosphatase (SHIP) 1/2, dephosphorylates PIP3 at the 5’ position to 
generate PI(3,4)P2. Increased PIP3 can be detected within seconds of TCR 
triggering50,51,52,53. Elevated PIP3 levels can be maintained for hours, however, PI3K 
activity is required for maintaining these high levels as inhibition of activated PI3K with 
PI3K inhibitors like LY294002 rapidly decreases PIP3 levels. PI3K is a heterodimer 
consisting of a p110 catalytic subunit and a p85 regulatory subunit. The p110δ isoform 
has been shown to be the major p110 subunit in lymphocytes54. However, the exact 
mechanism by which PI3K is activated upon TCR triggering is not known. Early studies 
proposed a mechanism by which p85 is recruited directly to phosphorylated LAT via its 
SH2 domains55 while later studies showed that p85 can also bind to SLP-76 on 
phosphorylated tyrosine residues 113 or 12856. Moreover, PIP3 generation through the 
CD28 co-stimulator was not abrogated when p110δ was not able to bind to the phospho-
tyrosine binding motif of CD2852. PI3K activation via Ras is another potential 
mechanism by which PIP3 levels can be controlled in T cells57,58. 
 
1.4. T cell subpopulations 
As all experiments in this thesis have been performed in CD8+ cytotoxic T lymphocytes 
(CTL), the following chapter will focus on the description of this particular T cell 
subset. However, several other subsets with specific roles exist in the immune system. 
Most of these cells express an αβ-TCR and either the CD4 or the CD8 co-receptor and 
can thus be divided into CD4+ and CD8+ T cells and their respective subsets. 
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1.4.1. CD4+ T cells 
In contrast to CTL which are the effector T cells in the body and deliver the lethal blow 
to infected cells, CD4 cells do not actively perform effector function but assist CTL as 
well as B cell formation and function and are thus termed T helper (TH) cells59 which 
can be further classified into TH1, TH260,61 and TH17 cells. TH1 cells secrete pro-
inflammatory cytokines like IFN-γ, IL-2, TNFα and lymphotoxins and thus support 
macrophages, CTL and IgG B cells. Intracellular pathogens like bacteria and viruses 
trigger a TH1 response while extracellular parasites and helminths trigger a TH2 
response. TH2 cells secrete IL-4, IL-5, IL-6 and IL-13 and enhance B-cell mediated 
humoral immune responses. TH17 cells represent a third subset62 and are characterised 
by the expression of IL-17 and IL-22 which helps the immune system battle fungal 
infections63,64. 
An emerging theme of helper T cell biology is the fact that fate decisions of CD4 cells 
are not definite and that these cells are not necessarily terminally differentiated. The 
tacit assumption was that helper T cells express a single master transcriptional regulator 
which controls a transcriptional program leading to the differentiation into a specific 
subset. However, it became clear that many ‘signature’ cytokines which were thought to 
be uniquely expressed by certain subsets can actually be expressed by a wide range of 
immune cell subsets. For example, IL-10 was initially considered to be exclusively 
expressed by TH2 cells but was later discovered to be expressed by TH1, Tregs and a 
variety of other innate immune cells as well (reviewed in65). Furthermore, elegant 
studies using fate markers showed that T cells can change their phenotype66. Following 
the fate of cells expressing IL-17, the hallmark cytokine of TH17 cells, revealed that 
these cells are able to stop expressing this cytokine and adapt a phenotype similar to 
TH1 cells characterised by expressing IFN-γ66. It became clear that CD4+ T cells are 
actually able to express several master transcription factors simultaneously and thus 
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drive different transcriptional programs depending on the transcription cytokine milieu, 
master regulator and other transcription factors (reviewed in67).    
A critical population are CD4+ T regulatory cells (Treg). These are cells that generally 
suppress the immune response by down regulating the induction and proliferation of 
effector T cells in order to prevent excessive immune reactions68. They are characterised 
by high expression of CD4, the IL-2 receptor α-chain (CD25) as well as FoxP3, an 
unique transcriptional regulator of Treg function69,70,71. The importance of Tregs is 
illustrated by so-called ‘scurfy’ mice with non-functional FoxP3: These mice suffer 
from over-proliferation of CD4+ cells, multi-organ infiltration and excessive levels of 
several cytokines and die within 16-25 days after birth69. Human immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is the equivalent of the 
scurfy phenotype in humans72. The exact mechanisms by which Tregs exert their 
immune-regulatory effects are not known yet. However, several mechanisms have been 
proposed: Depriving effector T cells of IL-2 due to high expression of IL-2R on Tregs73, 
involvement of the negative regulator of T cell activation, CTLA-474 as well as the 
secretion of cytokines and growth factors including IL-10, IL-35, granzyme B, IL-9 and 
TGF-β (reviewed in 75,76). 
 
1.4.2. CD8+ cytotoxic T lymphocytes 
If an infection occurs in the body, CD8+ T cells will be primed by APC expressing a 
suitable MHC class I-antigen complex in lymph nodes or other secondary lymphoid 
organs. However, the TCR-MHC interaction is not enough and CD8+ T cells require 
further signals triggered by co-stimulatory molecules. The successful activation of the 
naïve T cells will then induce dramatic changes in the metabolism of CTL as 
characterised by the drastic up regulation of amino acid, glucose and iron transporters77. 
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This is also necessary as the T cell will thereafter initiate a massive clonal expansion; 
studies have estimated that a single T cell may undergo up to 19 cell divisions 
(equivalent to a 500,000 fold increase in numbers)78 and might undergo cell divisions 
within 4-6 hoursvan 79 or even as little as two hours80. The metabolic reprogramming is 
characterised by a switch from a metabolic state that mainly relies on the oxidative 
phosphorylation of fatty acids to a state where the cells predominantly use aerobic 
glycolysis and glutaminolysis to fuel their growth81. Even though this metabolic switch 
or “Warburg effect”82 is not as efficient in terms of molecules ATP gained per molecule 
of glucose (2 mol ATP per mol glucose for anaerobic glycolysis vs 34-36 mol ATP per 
glucose mol for the complete oxidation of glucose) it does however enable the cell to 
utilise intermediates of the glycolytic pathway for the synthesis of nucleotides, 
phospholipids and other macromolecules81 and thus to satisfy their anabolic demands. 
The transcription factor Myc has been shown to be crucial for the induction of the 
transcriptional changes underlying the activation induced metabolic switch, as deletion 
of Myc in T cells blocked activation induced growth and proliferation due to reduced 
overall metabolic activity83. The high metabolic rates of clonally expanding CTL are 
maintained by high activity of MAPK84 and PDK1-mTOR-Hif1α85 signalling. In 
contrast to other cell systems, the activity of PKB is not required for CTL proliferation 
and metabolic activity86. This work will be discussed later in the thesis. 
If TCR signalling is activated in a fully differentiated T cell it will prompt the T cell to 
trigger its effector, i.e. cytotoxic function. This second TCR triggering occurs if the 
CTL recognises MHC class I molecules loaded with non-self-antigens usually derived 
from cells infected with either viruses or intracellular bacteria or tumourigenic cells. 
Virus infections caused by lymphocytic choriomeningitis virus (LCMV), cytopathic 
vaccinia virus, influenza virus87, hepatitis B virus, or human immunodeficiency virus88 
have been shown to be effectively cleared by CTL, while intracellular bacterial 
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infections with salmonella enterica Typhi89, chlamydia trachomatis90 mycobacterium 
tuberculosis, and listeria monocytogenes have also shown to be resolved by CTL. TCR 
triggering stops CTL migration and leads to the formation of the immunological 
synapse (IS) at the interface of CTL and target cell. This highly organised structure 
forms within minutes of dramatic rearrangements of the cell membranes and the 
microtubule organising centre (MTOC) and consists of three concentric regions, known 
as the central, peripheral and distal supramolecular activation complexes (c, p or 
dSMAC, respectively)91. As the cSMAC is enriched in proteins involved in TCR 
signalling like TCRζ, Lck, ZAP-70 and PKCθ, it was initially assumed this site was 
where the actual TCR signalling occurred, however, later studies indicated that TCR 
signalling originates in fact in the dSMAC and then migrates to the cSMAC, which is 
where the TCR is ultimately internalised and signalling is degraded92.  The pSMAC on 
the other hand is an actin- and integrin rich region which has been proposed to act as an 
‘O-ring’ and thus seal the IS to prevent leakage of effector molecules93. PLCγ activation 
due to TCR signalling leads to the association of the MTOC with the IS94,36 and 
subsequently to a migration of cytolytic vesicles to the MTOC and thus an accumulation 
of vesicles at the IS within the cSMAC. The vesicles then release their contents into the 
intercellular space: Effector molecules include perforin, granzymes, cathepsins and 
hexaminidases and trans-membrane receptors like Fas ligand. How do these molecules 
then kill the target cells? Perforin contains a lytic membrane-inserting MACPF domain 
and it was initially suggested that perforin forms pores in the target cell’s membrane 
through which other effector proteins might enter95. Later studies96 then showed that the 
delivery of granzymes by perforin involves a two-step process that initially leads to the 
formation of transient pores in the cell membrane of the target cells. These pores then 
trigger endocytosis by the target cell in an attempt to repair the damaged cell membrane. 
Perforin then facilitates pore formation within the endosomal membrane which 
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ultimately delivers the granzymes into the target cell’s cytosol. The best characterised 
granzyme is granzyme B which is a serine protease that cleaves after aspartic residues97, 
a unique specificity among eukaryotic serine proteases which is only shared with 
caspases and lead to discovery of an caspase-3 activating mechanism responsible for 
CTL mediated killing98. Later studies revealed cytotoxic activity of granzyme by cell 
death via the mitochondrial pathway as well99. Cathepsin B on the other hand is a 
protease that is able to cleave perforin and is thought to be a mechanism by which CTL 
protect themselves from their own cytolytic granules100. However, Cathepsin B 
deficient CTL do not show high rates of ‘self-destruction’101 indicating that other 
protective mechanisms must be active as well. Fas ligand (FasL or CD95L), another 
effector molecule within cytolytic vesicles102, kills target cells by a different 
mechanism. Membrane-bound FasL is the ligand for the Fas receptor (CD95), a death 
receptor whose oligomerisation leads to the formation of the death-inducing signalling 
complex (DISC) after binding FasL. The formation of DISC ultimately leads to the 
activation of caspase-8 and thus to the triggering of apoptosis in the target cell103. 
Mechanisms to prevent autotoxicity via FasL include the inactivation of FasL activity 
by shedding its extracellular domain104, which actively blocks the induction of 
apoptosis105. A third mechanism of CTL mediated killing utilises tumour necrosis factor 
α (TNFα). TNFα is primarily produced as a membrane bound homotrimer106, but can be 
cleaved by the metalloprotease TACE/ADAM17 to produce a soluble homotrimer107. 
Both forms of TNFα are biologically active and have distinct and overlapping 
properties108. However, killing via TNFα is thought to be relatively insignificant as it 
takes several hours to induce apoptosis in the target cell and thus Fas and perforin 
mediated mechanism are considered to be the major mediators of CTL killing109,110,111. 
More recent studies suggest that TNFα mediated killing may play a critical role in the 
killing of virus-infected cells with down-regulated or absent MHC I expression via 
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endothelial cell cross-presentation112. In addition to that, TNFα is also thought to recruit 
neutrophils and eosinophils to infected sites113,114 and to increase the expression of 
epithelial adhesion molecules to enhance the entry of lymphocytes into peripheral 
tissues115. In addition to TNFα, CTL release other pro-inflammatory cytokines as well. 
Particularly IL-2 and IFN-γ are noteworthy as they possess various important functions 
in the immune system. IFN-γ is an important activator of macrophage function and also 
enhances the expression of MHC class II as well as Fas116,117. 
 
1.4.3. CD8+ memory T cells 
The activation of naïve CD8 T cells leads to a proliferative burst and the generation of 
large number of CTL. Most of these CTL die by a process called activation induced cell 
death (AICD) or because they are deprived of the cytokines necessary for survival. This 
massive onset of apoptosis leads to a decrease in cell numbers to 5-10% of the cells at 
the height of the response. The surviving cells will differentiate into long-living 
memory cells which form the key element of the adaptive immune response. Upon re-
encounter with their antigen they will rapidly activate resulting in a faster and stronger 
immune response than in their first encounter118. The exact mechanisms and signals that 
decide whether an effector T cell differentiates into a memory cell are not known. 
Initially the selection was thought to be random119, whereas recent studies proposed 
different models of T cell diversification like the asymmetric cell fate model or 
decreasing potential model. The different models are discussed extensively 
elsewhere120,121,118. 
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1.5. Cytokine signalling 
1.5.1. IL-2 (and other γc-cytokines) 
Interleukin-2 (IL-2) is a cytokine with diverse function that is produced after antigen 
activation and plays a key role in the immune response. It was discovered 35 years ago 
as a biological agent found in the supernatant that was sufficient to promote growth of 
lymphocytes in vitro122,123. IL-2 is a four α-helix bundle type I cytokine124 and played a 
fundamental role as a general model for cytokine signalling as it was the first class I 
cytokine to be cloned125 and the first class I cytokine for which the receptor was 
cloned126,127. The high-affinity IL-2 receptor (Kd = 10-11 M) is a heterotrimer which 
consists of IL-2Rα (CD25), IL-2Rβ (CD122) and the common gamma chain (γc or 
CD132). The IL-2Rα contributes to this high affinity with a high association rate (k = 
107/M/s) while the βγ-complex contributes a slow dissociation rate (k` = 10-4/s)128,129. 
The β-chain is also shared with the IL-15 receptor while γc is shared with the receptors 
for IL-4, IL-7, IL-9, IL-15 and IL-21. The importance of γc as a subunit of so many 
receptors is illustrated by humans with defects in this subunit: patients suffering severe 
combined immunodeficiency (SCID) have virtually no T cells and are extremely 
vulnerable to infectious diseases130. Apart from the high-affinity IL-2 receptor, 
alternative receptor combinations can also occur as IL-2Rβ and γc are able to form a 
dimeric receptor with an intermediate affinity (Kd = 10-9 M) and IL-2Rα is able to bind 
IL-2 without any other subunit, albeit at low affinity (Kd = 10-8 M). The IL-4, IL-7, IL-9 
and IL-21 receptors are all heterodimers consisting of the γc and their respective unique 
α-chains. IL-15 shares the IL-2Rβ and γc but possesses a unique IL-15Rα subunit. 
Interestingly, this subunit signals in trans, i.e. with βγ subunits on neighbouring cells 
but not βγ complexes on the same cell. IL-2 and IL-15 are similar mitogens but 
differences in the signal strength of these two cytokines ultimately leads to different 
effects on cell size and growth of IL-2 and IL-15 maintained CD T cells131. 
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How do cytokine receptors like the IL-2 receptor signal upon ligand binding? The γc 
receptors are similar to the TCR in that their cytoplasmic domains do not show any 
catalytic activity but serve as scaffold and adaptor proteins to kinases. Binding of IL-2 
leads to the dimerization of the IL-2Rβ and γc chain which leads to a conformational 
change in their cytoplasmic tails which activates the Janus family tyrosine kinases 
JAK1 and JAK3. JAK1 associates with IL-2Rβ whereas JAK3 is bound to γc132,133. The 
JAK kinases will then phosphorylate and activate each and also phosphorylate key 
tyrosine residue on IL-2Rβ. One of this sites, Tyr341 (Tyr338 in humans) serves as a 
binding motif for the SH2 domain of Src homology 2 containing transforming protein 1 
(SHC1)134. Further recruitment of other adaptor molecules including GRB and SOS 
leads to the activation of RAS-MAPK and PIP3 signalling and thus promoting cell 
growth and metabolism. Other sites (Tyr395 and Tyr498 in mice, Tyr392 and Tyr510 in 
humans) lead to the recruitment of STAT transcription factors, particularly STAT5a/b134 
but also to a lesser extent STAT3 or STAT1 via their respective SH2 domains. 
Binding of the STAT transcription factors to IL-2Rβ leads to their phosphorylation by 
JAKs, dimerization and release from IL-2Rβ and translocation into the nucleus where 
they initiate a transcriptional programme required for effector function, cell growth134, 
and differentiation135,136. Recent studies also revealed higher order structures for 
STAT5137. STAT5-tetramers control the transcription of a subset of genes which is not 
regulated by STAT5 dimers, including IL-2Rα. 
STAT signalling is a critical mediator of the transcriptional program induced by IL-2 
and other γc cytokines. This is illustrated by mice lacking STAT5a and STAT5b which 
show a 99% perinatal lethality rate and the few mice that survived showed abnormal 
lymphoid development with atrophic thymuses and few remaining thymocytes similar 
to SCID138. T cell specific knockouts of STAT5 showed relatively modest effects on 
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thymocytes numbers but drastic defects on peripheral T cells, particularly CD8+ T 
cells138. IL-2 dependent Treg cells were also virtually absent138. Thus STAT5a/b play an 
important role not only T cell development but also in the homeostasis of mature T 
cells.  
One the other hand, mice lacking only one isoform showed less pronounced 
phenotypes: STAT5a deletion leads to mice with defects in IL-2 induced proliferation139 
due to decreased expression of the IL-2Rα chain. However, maximal proliferation could 
still be achieved at IL-2 levels high enough to signal through the intermediate affinity 
βγ receptor complex. However, despite the role of STAT5 in mediating IL-7 signalling, 
there was no major defect in the lymphoid development and splenocytes numbers were 
only modestly decreased139. The STAT5b deficient mice show a similar phenotype to 
STAT5a deficient mice regarding the IL-2 induced proliferation of splenocytes, 
however, as STAT5b is important for the expression of the IL2-Rαas well as the IL-2Rβ 
chain, high levels of IL-2 are not able to overcome the proliferative defects140. STAT5b 
deficient mice also show a marked defect in IL-15 mediated proliferation of T cells as 
well as defects in IL-15 mediated proliferation and function of NK cells140. On the other 
hand, T cell development was only slightly affected by STAT5b deletion. 
Another signalling pathway which is regulated by the IL-2 receptor is the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway141. PI3K is a 
heterodimer consisting of a catalytic (p110, in lymphocytes particularly the p110δ isoform142) and a regulatory subunit (p85) and is readily activated upon IL-2 binding. 
How is PI3K activity regulated upon IL-2R triggering? One possibility is that IL-2Rβ is 
phosphorylated on Tyr338 and bound by SHC via its phosphotyrosine-binding-domain 
(PTB)143 and the binding subsequently leads to the phosphorylation of tyrosine residues 
of SHC. The SH2 domain on GRB2 is able to bind to these residues and proline rich 
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motifs within GRB2 are bound by SH3 domains on GAB2 which leads to tyrosine 
phosphorylation of GAB2. The PI3K subunit is then able to bind to this phosphorylated 
GRB2/GAB complex via its SH2 domains144,145. PI3K is a lipid kinase and its activity 
leads to the generation of phosphatidylinositol-3,4,5-trisphosphate (PIP3) by 
phosphorylation of phosphatidylinositol-4,5-bisphosphate. The reverse reaction is 
facilitated by phosphatase and tensin homolog (PTEN) whereas another lipid 
phosphatase, SH2 containing inositol phosphatase (SHIP), hydrolyses PIP3 to 
phosphatidylinositol-3,4-bisphosphate and thus also controls PIP3 levels. PIP3 serves as 
a second messenger for proteins containing a pleckstrin homology (PH) domain and 
recruits these proteins to the plasma membrane. One of the best studied proteins which 
is activated by PIP3 is protein kinase B (PKB), a serine/threonine kinase of the AGC 
protein kinase family146. Binding of PKB to PIP3 via its PH domain leads to a rate-
limiting conformational change147 which allows PKB to be phosphorylated on Thr308 
within its T-loop by phosphoinositide-dependent kinase-1 (PDK1). Once activated, 
PKB can dissociate from the membrane and remain active to phosphorylate substrates 
distal to the membrane. Co-localisation of PKB and PDK1 is facilitated via two 
different mechanisms: The first one is dependent on high levels of PIP3 to which PDK1 
can bind via its PH domain. While this PH-domain depending binding to PIP3 does not 
affect the activity of PDK1 as it is constitutively active148, it does allow for the co-
localisation with PKB and subsequent phosphorylation of Thr308. The second 
mechanism relies on the phosphorylation of Ser473 at the C-terminal hydrophobic motif 
of PKB by mTORC2149. PDK1 contains a so-called PIF-binding pocket which can bind 
to phosphorylated PKB Ser473 and thus facilitate binding. Interestingly, most of the 
AGC protein kinases members which are phosphorylated by PDK1 contain recognition 
motifs for this PIF pocket but PKB is the only kinase that can be phosphorylated by 
PDK1 via the PIP3 dependent mechanism146. mTORC2 not only phosphorylates Ser473 
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on PKB but also the equivalent hydrophobic motif sites on several other AGC kinases 
like protein kinase C (PKC) and serum- and glucocorticoid-induced kinase 1 (SGK)146. 
The upstream signals which regulate mTORC2 activity are not known but PKB Ser473 
phosphorylation is sensitive to PI3K inhibitors indicating that PI3K activity is important 
for mTORC2 function. The PIF-pocket and the PIP3-dependent mechanism of PKB 
activation are able to compensate for each other if one mechanism is inactive. Mice 
expressing a PDK1 mutant which is not able to bind PIP3 still show residual PKB 
phosphorylation at Thr308150 and cells lacking the mTORC2 subunit Rictor and thus 
mTORC2 activity also still show low levels of PKB Thr308 phosphorylation149. 
What is the role of PKB in transducing IL-2 signalling? PKB activity controls the 
subcellular localisation and transcriptional activity of the FoxO1/3 transcription factors: 
Phosphorylation of FoxOs by PKB on several residues leads to their exclusion from the 
nucleus, binding to 14-3-3 protein and thus termination of transcriptional activity151,152. 
FoxO target genes include several cytokines, cytokine receptor and other transcription 
factors. For example, the expression of the α-chain of the receptor for IL-7, an important 
cytokine in T homeostasis is regulated by FoxO153. Krüppel-like factor 2 (KLF2) is 
another protein controlled by FoxO transcription factors. KLF2 controls the expression 
of CD62L, the chemokine receptor CCR7153 and S1P1154 all of which are important for 
the normal trafficking program of T cells. The exclusion of FoxOs from the nucleus due 
to PKB activity leads to the loss of KLF2 and consequently to changes in the trafficking 
behaviour of T cells153,155. PKB also controls effector function and differentiation in 
CTL: Expression of several granzymes, FasL, perforin and IFN-γ in CTL is sustained 
by PKB86. PKB also regulates the expression of several cytokine receptors. It is a 
positive regulator of the IL-12Rβ1 subunit but represses the expression of the IL-6 
receptor and the CD27 co-receptor86,156. How does PKB act as a transcriptional activator 
or repressor? Both effects can be explained by the control of FoxO localisation by PKB: 
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FoxOs act as transcriptional activators for the Klf2 and Il7r genes but act as repressors 
of Ifng. However, PKB does not control metabolism and protein biosynthesis in T cells 
as suggested by several studies149,157,131 but is restricted to control the transcriptional 
program controlling T cell differentiation and function86. PKB activity is furthermore 
not required for proliferation or survival of CTL which is inconsistent with the idea that 
PKB is involved in the regulation of CTL metabolism86. 
A simplified illustration of IL-2 signalling is shown in Figure 1.2. 
At this point it is important to mention that TCR triggered CD8+ T cells can be 
maintained in vitro in the presence of IL-2. In fact, these primed and treated cells will 
maintain rapid proliferation rates for several days and differentiate into effector 
CTL131,158,159. Constant replenishment of fresh IL-2 is necessary as the cells will 
otherwise stop proliferation and enter apoptosis160. 
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Figure 1.2: IL-2 signalling. 
The high affinity IL-2 receptor consists of the IL-2Rα, IL-2Rβ and the common gamma 
chain (γc) subunits. JAK1/3 are constitutively associated with IL-2Rβ and the γc, 
respectively and activated upon cytokine induced receptor dimerization. Activation 
leads to the trans-autophosphorylation of the JAKs and phosphorylation of the cytolic 
domains of the receptors which then serve as docking domains for STAT5. Bound 
STAT5 is phosphorylated, dimerises with a second p-STAT5 molecule and translocates 
into the nucleus. SHC is also recruited to the receptor and phosphorylated by the JAKs. 
Recruitment of further adaptor molecules then triggers MAPK signalling. IL-2 also 
induce PI3K signalling leading to the translocation of FoxO transcription from the 
nucleus into the cytoplasm effectively stopping their transcriptional activity. 
 
1.5.2. IL-12 
The following description of IL-12 cytokine family members will mostly focus on IL-
12 itself, as it was used along IL-2 for the in vitro generation of cytotoxic T-
lymphocytes throughout the PhD project.  
42 
 
Unlike IL-2 described before, the IL-12 cytokine family does not bind to receptors of 
the common gamma chain family. IL-12 is rather the founding member of a family of 
four known interleukins, apart from IL-12 these are IL-23, IL27 and IL-35. IL-12 
cytokines show a unique structure, as they are the only heterodimeric cytokines and 
several members of the family share their subunits: IL-12 and IL-23 both contain a p40 
subunit apart from another specific subunit (p19 for IL-23, p35 for IL-12), while IL-27 
and IL-35 share the Ebi3 subunit, and while IL-27 contains a unique p28 subunit, IL-35 
shares the p35 subunit together with IL-12. The corresponding receptors also show this 
chain sharing theme161,162: IL-12 signals via the IL-12Rβ1 and IL-12Rβ2 chains163, IL-
23 via IL-12Rβ1 and IL-23R164, IL-27 via gp130 and IL-27R165 and IL-36 signals via 
IL-12Rβ2 and gp130, but can also signal via gp130-gp130 and IL-12Rβ2-IL-12Rβ2 
homodimers166. All receptors signal via the JAK-STAT pathway167, in a similar way as 
described previously for IL-2. IL-12 transduces its signalling via STAT4, IL-23 via 
STAT3 and STAT4, IL-27 via STAT1 and STAT3 and IL-35 via STAT1 and STAT4. 
Figure 1.3 illustrates the relationship between the different IL-12 cytokines, their 
receptors and major down-stream signalling components. 
 
Figure 1.3: Cytokine receptors of the IL-12 family. 
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Members of the IL-12 of cytokines and their corresponding receptor and JAK-STAT 
signalling components are shown. 
Figure adapted from168  
 
IL-12 is produced by macrophages, dendritic cells and B cells as a response to microbial 
pathogens169. The importance of IL-12 family signalling has been shown in human 
patients with IL-12Rβ1 deficiency and thus impaired pro-inflammatory signalling via 
IL-12 and IL-23. These patients showed an increased susceptibility to otherwise 
harmless pathogens like mycobacteria and salmonella170. The effects of IL-12Rβ2 
deletion on the other hand seem to be dominated by signalling defects in the IL-35 
pathway. The development of autoimmunity, lymphoproliferation and B cell tumours 
indicates that IL-35 signalling plays an important role in controlling B-cell activation171. 
The importance of the IL-12Rβ1-p40 signalling in battling microbial infections is 
further illustrating by mice lacking the IL-12 p40 subunit which were more susceptible 
to bacterial infections, showed decreased IFN-γ expression and generally a higher 
mortality rate172. Mice lacking the p35 subunit were still able to moderately control 
bacterial infections and survived longer after infection172. This indicates that IL-23 plays 
a more important role in protective responses against microbial infection172. 
Interestingly, IL-12 triggers a positive feedback loop in which IL-12 increases the 
expression of IFN-γ which in turn stimulates additional antigen-presenting cells to 
produce even more IL-12. Early studies showed that even though TCR triggering and 
co-receptor stimuli were sufficient to generate effector CTL, addition of IL-12 led to 
increased CTL numbers in vitro173 and later studies showed the importance of IL-12 
signalling in the context of listeria monocytogenes infection in vivo as well174. Further 
studies then showed that IL-12 signalling together with IFN-γ leads to the up regulation 
of CD25 and thus augments IL-2 receptor signalling in CTL leading to increased 
proliferation but not survival175. It was also shown that IL-12 signalling is able to 
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increase IFN-γ production in CD8+ T cells and the differentiation of KLRG1+ effector 
subpopulation in the context of Toxoplasma gondii infections176. Studies in OT-I TCR 
transgenic CD8+ T cells proposed that IL-12 enhances mTORC1 activity and thus 
regulates the effector versus memory fate177. 
 
1.6. mTOR and the integration of nutrient signalling 
1.6.1. Overview 
The aim of the thesis was determine the full impact of the immunosuppressant 
rapamycin on CTL. Rapamycin is a macrolide produced by Streptomyces hygroscopicus 
and was identified in 1975 as an antifungal agent178, however, later studies suggested 
the use of rapamycin as an immunosuppressant179. Why is rapamycin an 
immunosuppressant? Early studies used T cell models like CTLL or Kit-225 cells, both 
of which are absolutely depending on IL-2123,180, to describe the effects of rapamycin. 
Rapamycin treatment led to decreased proliferation rates in these cells which led to the 
assumption that rapamycin inhibition was interfering with IL-2 signalling and thus 
leading to a cell cycle block181. However, later studies then showed that rapamycin 
selectively inhibited IL-2 induced S6K activity182 but did not interfere with IL-2 
induced MAPK signalling and the expression of transcription factors like MYC and 
FOS183 or the phosphorylation of STAT5184. Further studies then showed that the 
proliferation of primary T cells was in fact not abrogated upon rapamycin treatment185 
and thus rapamycin must exert its immunosuppressive effects by other mechanisms 
which are still not fully understood. 
The yeast model played an important role in the identification of the molecular basis of 
rapamycin as the target of rapamycin (TOR) was initially identified in yeast in 1991186. 
Four different groups then independently identified RAFT1187/FRAP188/RAPT189/ 
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mTOR190,190 as the homolog to yeast TOR and thus the mammalian target of rapamycin 
(mTOR). mTOR is a 289 kDa protein of the family of the phosphatidylinositol 3-
kinase-releated kinase family191 and is the catalytic component of two complexes, 
mTORC1 and mTORC2 which are defined by their respective subunits. As it was the 
case with TOR itself, the existence of two distinct TOR signalling complexes was 
initially shown in yeast192 and later documented in mammals as well149. Apart from 
mTOR itself, mTORC1 contains the scaffolding protein regulatory-associated protein of 
mTOR (Raptor), mammalian lethal with Sec13 protein 8 (mLST8), the inhibitory 
protein proline-rich Akt substrate 40 kDa (PRAS40), and the DEP-containing mTOR-
interacting protein (Deptor)193. mTORC2 shares some components with mTORC1 like 
mTOR and mLST8 but furthermore contains unique subunits like the scaffolding 
protein rapamycin-insensitive companion of mammalian TOR (Rictor), protein 
observed with rictor (Protor) and several isoforms of MAPKAP1 (mSIN1). Rapamycin 
selectively inhibits mTORC1 by initially binding to the protein FKBP12187 in the cell 
and the resulting FKBP12-rapamycin complex is then able to bind to and inhibit 
mTORC1. A detailed crystal structure of mTORC1 has been recently published194 
which showed that rapamycin-FKBP12 inhibits mTORC1 by binding to the so-called 
FRB domain within the mTOR subunit, which is an important substrate binding site for 
mTOR. However, it is not known why rapamycin only directly inhibits mTORC1 but 
not mTORC2. On the other hand, chronic exposure to rapamycin has shown to be able 
to affect mTORC2 as well, as it leads to the sequestration of the mTOR-raptor complex 
and reduces the pool of freely available mTOR in the cell leading to disturbed mTORC2 
assembly and function195. The magnitude of this effect is thought to be dependent on the 
relative levels of mTOR, Raptor and Rictor within the cells and thus varies for different 
cell types149,195. Catalytic inhibitors of mTOR itself have been developed196 which 
inhibit both mTORC1 and mTORC2 and are currently tested in several clinical trials 
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due to their potential anti-tumour properties197. Rapamycin is currently used as an 
immunosuppressant to prevent organ – particularly kidney – rejection198 and as 
coronary stent coating199. 
The exact mechanism by which rapamycin promotes immunosuppression is not known. 
Some studies showed that rapamycin negatively affects CD8 effector T cell 
differentiation while promoting CD8 memory formation via its control of the 
transcription factor T-bet and Eomesodermin200,177,201. Rapamycin is also thought to 
affect the immune response by promoting the formation of CD4+FoxP3+ T regulatory 
cells202. 
mTORC1 is also a sensor for nutrient signalling and thus links metabolism and immune 
function of T cells. Environmental cues like growth factors, cytokines, nutrients like 
glucose and amino acids are integrated by mTORC1 and control the cell’s metabolic 
profile203,204,205. 
 
1.6.2. Signalling up-stream of mTOR 
Given the importance of mTOR signalling, what signals control the activity of mTOR? 
mTORC1 is a central integrator of nutrient and cytokine signalling (positive regulators 
of mTORC1 activity) and negative inputs like hypoxia, ER stress and low energy levels. 
Recent studies have shown that all these signals are integrated at the focal point of 
mTORC1 activation, the lysosome206,207, and most of them signal through the tuberous 
sclerosis complex (TSC), an upstream inhibitor complex of mTORC1 that consists of 
TSC1, TSC2208 and TBC1D7209. TSC inhibits mTORC1 activity by acting as a GTPase-
activating protein (GAP) for the Rheb GTPase, the immediate upstream regulator of 
mTORC1210,211,212,213. High TSC activity thus correlates with low mTORC1 activity 
while low TSC activity or TSC knockout lead to hyperactivation of mTORC1. TSC 
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integrates several upstream signals that control mTORC1 activity. TSC2 can be 
phosphorylated by PKB on several sites214,215, some of which (Ser939 and Thr1462) are 
highly conserved and also found in Drosophila TSC2. Recent studies216,217 have shown 
how these phosphorylations affect the ability of TSC to inhibit mTORC1 signalling: 
Unphosphorylated TSC is located to the lysosome and thus in close proximity to Rheb, 
where it can exert its GAP activity and down regulate mTORC1 signalling. 
Phosphorylation of TSC2 by PKB on several sites leads to the dissociation of TSC from 
the lysosome resulting in mTORC1 activation. Phosphorylated residues on TSC2 have 
also been proposed to facilitate binding to 14-3-3 proteins and thus further sequestering 
TSC away from lysosomally bound Rheb218. MAPK signalling via ERK1/2 has also 
been proposed to inhibit TSC function and thus increases mTORC1 activity219. 
However, residues phosphorylated by ERK (Ser660 and Ser540) are different from the 
sites phosphorylated by PKB and also effect TSC function differently: Phosphorylation 
on TSC Ser660 by ERK leads to disintegration of the TSC complex219 whereas PKB 
mediated phosphorylation maintained TSC integrity and preserved GAP-activity of 
TSC216,217. PKB has also been shown to phosphorylate and inactivate PRAS40, a 
negative regulator of mTORC1 signalling220,221,222. AMPK is also able to phosphorylate 
TSC2 on Ser1388215 and in contrast to the aforementioned phosphorylations by PKB 
and ERK, phosphorylation of TSC2 by AMPK leads to increased TSC activity and thus 
reduced mTORC1 signalling215. However, the exact mechanism by which 
phosphorylation of TSC2 by AMPK controls TSC activity is not known.  
In addition to the inputs mentioned above, it has long been appreciated that amino acids 
are also crucial for mTORC1 signalling, particularly L-leucine and L-glutamine. 
However, mouse embryonic fibroblasts derived from TSC2 deficient mice were still 
sensitive to changes in amino acid availability, indicating that amino acids are sensed 
via a TSC independent pathway223,224.So how do L-leucine and other amino acids like 
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L-glutamine activate mTORC1 signalling? Amino acid levels within a cell are sensed 
by a still unknown mechanism at the lysosome which is dependent on RAG 
GTPases206,207. Active heterodimers of RagA/B and RagC/D (RagA/BGTP-RagC/DGDP) 
are formed in the presence of amino acids by the GEF activity of the so-called 
Ragulator complex225 and recruit mTORC1 via its Raptor subunit to the lysosome206,226. 
Once at the lysosome, mTORC1 is activated by Rheb, which is constitutively present at 
the lysosome.225,213. 
What is known about the components of mTORC1 signalling in T cells? Many of the 
aforementioned pathways which regulate mTORC1 activity depending on the nutrient 
availability are also active in T cells227,228,229. Interestingly, naïve T cells only show low 
mTORC1 activity accompanied with low rates of metabolic activity. However, the 
demands of an activated T cells are not to be understated and in fact it has become clear 
now that the reprogramming of metabolism is crucial for the activation, differentiation 
and function of T cells230. TCR activation leads to the activation of MAPK signalling 
and thus ERK1/2 which in turn control the expression of the transcription factor c-Myc 
which initiates a metabolic shift84,231,83. TCR signalling via the calcium-calcineurin 
pathway also leads to the up regulation of the large amino acid transporter Slc7a5 which 
facilitates L-leucine transport into activated T cells227. Leucine is known to be an 
important regulator for mTORC1 activity232 and does not only enable high protein 
biosynthesis rates due its role as a building block for proteins but also as a positive 
regulator for mTORC1 activity. Interestingly, the deletion of Slc7a5 did not lead to 
defects in T cell development or the homeostasis of the naïve T cell pool227. However, 
Slc7a5 deficient naïve T cells were not able to differentiate or proliferate as they were 
not able to perform the metabolic switch required to sustain the high metabolic demand 
of activated T cells. This could be explained by the fact that Slc7a5 deficient T cells 
failed to up-regulate the transcription factor c-Myc, which is known to be crucial for the 
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metabolic reprogramming of T cells upon TCR triggering83. The glucose transporter 
Glut1 is among the genes controlled by c-Myc expression. Thus, T cells derived from 
Slc7a5 deficient mice showed a drastic decrease in both L-leucine and glucose uptake, 
explaining why these cells were not able to activate mTORC1 signalling upon TCR 
triggering and failed to perform the metabolic switch required for proliferation and 
differentiation of effector T cells227. The TCR thus ‘hijacked’ the evolutionary 
conserved mechanism by which amino acid uptake regulates mTORC1 activity, a 
strategy which is further complemented by the TCR-controlled expression of the L-
glutamine transporter ASCT2 and thus glutamine flux into the cell229. 
T cells express AMPK-α130 which is a crucial sensor for glucose levels in activated T 
cells and restricts mTORC1 activity to cells which do not meet the metabolic rates to 
enable their energy demanding effector function233. The expression of glucose 
transporters is mandatory for T cells as they are otherwise not able to sustain glucose 
levels sufficient to maintain high ATP/AMP levels in order to restrict AMPK-α1 
activity and thus maintain high Rheb activity. Effector T cells require low levels of 
AMPK-α1 activity to sustain high mTORC1 activity and in fact, AMPK-α1 is 
dispensable for the generation, proliferation and function of CTL233. However, these 
cells need to down-regulate mTORC1 activity and thus T cell metabolism to perform 
the transition from effector into memory T cells. AMPK-α1 deficient CD8+ T cell 
showed striking defects in this transition, indicating that AMPK-α1 might be important 
in the down regulation of the metabolic program that underlies the effector-to-memory 
transition233,200. 
Most models of lymphocyte signalling postulate a linear PI3K-PKB-mTORC1 pathway, 
assuming that phosphorylation and thus inactivation of TSC and PRAS40 by PKB is 
crucial for mTORC1 activity234,235. Unfortunately, many experiments used the  
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unspecific yet popular PI3K inhibitor LY294002 which is in fact also a potent mTORC1 
inhibitor and thus leads to a misinterpretation of the results gained from these studies236. 
The idea of a linear PI3K-PKB-TSC-mTORC1 pathway was further supported by the 
fact that TSC deficient T cells show increased mTORC1 activity upon TCR stimulation 
leading to disturbed immune homeostasis237. However, there is no direct biochemical 
evidence that PKB phosphorylation of TSC2 does indeed lead to a relocalisation or 
decrease in the GAP activity of TSC in T cells. Thus TSC2 phosphorylation by PKB 
and mTORC1 activity are often only correlating in T cells. We have also shown that 
specific PI3K and PKB inhibitors do not abolish mTORC1 activity85 whereas the 
deletion of PDK1 in T cells completely abolished mTORC1 activity86. PDK1 and not 
PKB is thus a major regulator of mTORC1 activity in T cells. 
 
1.6.3. Substrates down-stream of mTOR 
Ribosomal protein S6 kinase (S6K) and the eukaryotic initiation factor 4E binding 
protein1 (4EBP1) are mTORC1 substrates which have been studied in great detail. S6K 
has been proposed to be involved in the transcription of ribosomal RNA (rRNA) and 
ribosomal mRNA as well as cap dependent translation and ribosomal biogenesis in 
general238. Phosphorylation of 4EBP1 by mTORC1 leads to its dissociation and thus 
activation of eIF4E which has been demonstrated to play a crucial role in the translation 
of mRNA containing a so-called 5’-terminal oligopyrimidine (TOP) motif239. The TOP 
motif is a common motif of mRNA coding for ribosomes and proteins belonging to the 
eukaryotic initiation factor 2 and 3 family and thus expression of these proteins is 
significantly affected by mTOR inhibition239. High protein synthesis rates require 
mechanisms to deal with the cellular stress caused by high levels of unfolded proteins. 
mTORC1 has been shown to be a regulator of global proteasomal degradation rates by 
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controlling the expression of subunits of the 26S proteasome240 and thus coupling 
protein biosynthesis and quality control mechanisms. mTORC1 activity has also been 
shown to promote lipid biosynthesis by regulating the expression of many lipogenic 
genes. Key transcription factors which regulate the expression of these genes are sterol-
regulatory-element-binding proteins (SREBPs) whose maturation has been shown to be 
controlled by mTORC1241. Studies showed that mTORC1 regulates the processing and 
nuclear accumulation of these transcription factors via S6K, however, the exact 
mechanism is still not known241. Autophagy processes have also been shown to be 
controlled by mTORC1. Autophagy describes the basic catabolic mechanism by which 
a cell degrades dysfunctional or unnecessary proteins and other cellular components via 
lysosomes and serves as a major mechanism to promote cell survival and to maintain 
cellular energy levels242. mTORC1 signalling has been shown to inhibit autophagy 
while mTORC1 inhibition leads to a stimulation of this process in order to maintain 
intracellular amino acid levels even in poor environmental conditions243,244. ULK1 and 
ATG13 have been shown to be the major down-stream substrates of mTORC1 whose 
phosphorylation by mTORC1 leads to their inactivation and thus inhibition of 
autophagy245. mTOR has furthermore been linked to control STAT signalling in the 
innate immune response246. This study showed that rapamycin inhibited Tyr 
phosphorylation on STAT3 and thus repressed its transcriptional activity. Interestingly, 
this STAT3 dephosphorylation led to decreased expression of the anti-inflammatory 
cytokine IL-10 but led to increased expression of pro-inflammatory cytokines via NF-
κB signalling and thus mTORC1 inhibition led to the promotion of an overall pro-
inflammatory phenotype rather than immune-suppression. As mentioned before, many 
models propose a linear PI3K-PKB-mTOR signalling pathway by which mTORC1 
activity is controlled by PI3K activity. However, mTORC1 has also been shown to 
affect PI3K signalling via an S6K-depending feedback mechanism247. According to this 
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model, mTORC1 controls the protein levels of the insulin receptor substrate (IRS) 1/2 
which serves as an adaptor molecule for the PI3K p85 subunit. Inhibition of mTORC1 
and thus S6K leads to decreased phosphorylation of IRS1/2 and reduced targeting to the 
26S proteasome which in turn increases IRS levels and thus PI3K activity. Furthermore, 
global phospho-proteomic studies have proposed a second feedback mechanism by 
which mTORC1 controls PI3K activity248,249. According to this model, mTORC1 
phosphorylates and thus sustains high levels of the adaptor protein GRB10 which is a 
negative regulator of receptor tyrosine kinase (RTK) activity. Inhibition of mTORC1 
activity thus leads to decreased levels of GRB10 and relieves the RTK block. However, 
it is not known whether the IRS1/2 or the GRB10 mediated feedback mechanism are 
relevant for T cell biology. 
Many mechanisms and ideas regarding mTOR biology are derived from studies in 
transformed cell lines and are thus not necessary valid for lymphocyte biology. The 
rather minor role for PKB in controlling mTORC1 activity in lymphocytes is an 
example for this dilemma, as it illustrates that ideas and models derived from other cell 
systems are not automatically transferable to other systems. 
An overview illustrating mTORC1 signalling in T cells is shown in Figure 1.4. 
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Figure 1.4: mTOR signalling in CD8 T cells. 
TCR triggering leads to increased expression of amino acid, glucose and cytokine 
receptors. Amino acid levels are detected at the lysosome and lead to the formation of 
the RagAGTP/CGDP-complex via the Ragulator complex. RagAGTP/RagCGDP tethers 
mTORC1 to the lysosome. Glucose signalling (via AMPK) and cytokine signalling (via 
PIP3 and MAPK) are integrated at the TSC complex. TSC is the GAP for Rheb, the 
direct up-stream activator of mTORC1 at the lysosome. Active mTORC1 controls T cell 
metabolism, trafficking and effector partially via Hif1α. Expression and maturation of 
SREBP1/2 via mTORC1 controls fatty acid biosynthesis. mRNA translation and 
protein biosynthesis are controlled by the direct mTORC1 substrates S6k and 
4EBP1. mTORC1 also controls the balance of the transcription factors T-bet and 
Eomesodermin and thus affects CD8 T cell differentiation. The contribution of T-
bet/Eomesodermin independent pathways to CD8 T cell differentiation is not 
clear. mTORC2 activation is less well understand but dependent PIP3 signalling. 
Important substrates of mTORC2 are PKB and PKC, PKB has also been shown to be 
a positive regulator of mTORC1. 
 
 
1.6.4. mTOR control of CD8+ effector function and trafficking 
As mentioned before, deletion of the negative regulator of mTORC1, TSC, in T cells 
leads to mTORC1 hyperactivation and hyperactive responses to TCR triggering as 
shown by increased levels of CD25 and expression of nutrient transporters237. However, 
hyperactivated mTORC1 signalling in these cells also led to increased apoptosis and 
disturbed immune homeostasis in general. Other studies showed that the transcription 
factor T-bet plays an important role in the effector function CTL and that mTORC1 
controls the expression of T-bet177. Inhibition of mTORC1 thus led to suppression of T-
bet expression but on the other hand increased levels of another transcription factor, 
Eomesodermin which drives the transcriptional program for a memory phenotype. 
mTORC1 thus controls the effector vs memory fate in CD8 T cells by controlling these 
two crucial transcription factors and inhibition of mTOR skews the balance towards the 
generation of memory T cells200,250. Araki et al.200 illustrated in a lymphocytic 
choriomeningitis virus (LCMV) model that rapamycin treatment led to an increases of 
virus specific memory T cells. This increase was mainly caused by reduced levels of 
apoptotic cell death rather than increasing the proliferation of memory T cell precursors. 
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Furthermore, inhibition of mTORC1 during the contraction phase of CD8 T cells also 
lead to memory cells of higher quality as mTORC1 inhibition accelerated the memory 
T-cell differentiation programme. The findings of this study were confirmed by the 
results by He et al.250, who also used a LCMV model but used cells generated and 
treated with rapamycin in vitro and then adoptively transferred them into mice. 
Furthermore, rapamycin treated cells in this study showed higher tolerance to nutrient 
and growth factor withdrawal.  
mTORC1 has also been shown to control T cell trafficking. The adhesion molecule 
CD62L (L-selectin) is required for the tethering and rolling of naïve T cells along blood 
vessel walls251 which is followed by the binding of endothelial chemokines like CCL19 
and CCL21 to their receptor, CCR7, which is expressed on naive lymphocytes252,253. 
Subsequent activation of integrins expressed on T cells and their interaction with 
intercellular interaction molecules (ICAM) will eventually lead to a firm adhesion of 
cells to and transmigration through the high endothelial venules (HEV) and thus will 
cause the T cells to enter lymph nodes. Unless naïve T cells encounter an APC 
presenting a suitable MHC-antigen complex, they will migrate out of the lymph node 
back into the blood vasculature. The process is regulated by the sphingosine-1-
phosphate receptor (S1PR1) and the concentration gradient of its ligand, S1P1, directs 
the egress of T cells out of the lymph. T cells down regulate the expression of CD62L 
and CCR7 as part of the differentiation into effector T cells but up regulate other 
receptors that control homing to inflamed tissue, including inflammatory cytokine 
receptors like CXCR3 and CCR5254. Studies showed that the down regulation of CD62L 
and CCR7 during effector T cell differentiation is mediated by mTORC155. High mTOR 
activity causes down regulation of Krueppel-like factor 2 (KLF2) which is a key 
transcription factor for CCR7 and CD62L. However, the exact mechanism by which 
mTORC1 signalling controls the expression of KLF2 is not known. 
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1.7. Thesis aims 
In order to reveal the role of mTOR signalling pathways in CTL we decided to use 
quantitative mass spectrometry based proteomics approaches to describe the mTOR 
regulated proteome in CTL. More specifically we want to use a label-free quantification 
(LFQ) approach to 
• define the total proteome of CTL and map abundance and isoform specificity of 
proteins expressed by T cells and to 
• define the mTOR regulated proteome. 
We furthermore want to benchmark our label-free quantification approach with 
established strategies of quantitative proteomics like SILAC in order to see whether 
universally applicable approaches like LFQ are suitable for quantitative mass 
spectrometry studies in lymphocytes. 
We will also compare the effects of mTOR inhibition on the proteome with the effects 
on the mTOR controlled transcriptome to gain deeper insight into the mechanisms by 
which mTOR controls gene expression. 
Catalytic inhibitors of mTOR like KU-0063794 not only inhibit mTORC1 but also 
mTORC2. We will thus compare the effects of mTORC1 inhibition by rapamycin with 
the effects of combined mTORC1/mTORC2 inhibition to describe the role of mTORC2 
signalling in CTL. 
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1.8. Mass spectrometry 
A substantial part of the experiments performed during the PhD project utilised 
quantitative mass spectrometry. Thus it is important to understand principles of mass 
spectrometry and analysis of data generated by these approaches. We therefore 
summarised the basic knowledge in the field of proteomics on the following pages. 
 
1.8.1. Introduction to mass spectrometry 
A mass spectrometer can be a considered a (very accurate) balance which is able to 
determine the mass/charge (m/z) ratio of any kind of ions. The basics of mass 
spectrometry go back to the late 19th century when researchers observed rays in gas 
discharges that travelled either from cathode to anode or vice versa. It was later 
discovered that strong magnetic field could change the direction of travel of these rays 
according to their mass-to-charge ratio. Even though early mass spectrometers were 
already used in the Manhattan Project during World War II to separate uranium 
atoms255 it was not until 1958 when the first peptide ions were analysed. 
A mass spectrometer consists of three main components 
• an ion source which acts as an entry point for the sample into the mass 
spectrometer and ionises the sample and transfers it into the gas phase 
• one (or more) mass analyser that separates the different ions within the sample 
by their mass-to-charge by applying a magnetic field and thus enables the 
analysis of more than one ion within the sample 
•  a detector that records a mass spectrum by analysing the abundance of the ions 
Macromolecules like proteins or peptides are easily fragmented when ionised and thus 
prevented mass spectrometry based approaches from a wide spread use in biology. Only 
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since the advent of softer ionisation methods like matrix assisted laser 
desorption/ionisation (MALDI)256 and electrospray ionisation (ESI)257 mass 
spectrometers are being used more frequently in life sciences. ESI is now the preferred 
method of sample ionisation in MS based proteomics and its discovery and developent 
for the analysis of biomolecules by John Fenn was awarded with the Nobel Prize in 
Chemistry in 2002258. 
ESI works by solubilising the sample in a suitable liquid which is then being charged. 
Subsequent evaporation of the carrier liquid will result in the charge to remain on the 
peptides themselves (Figure 1.5). The sample is injected into a chromatography column 
and a high electric potential is applied at the fine tip of the column. Due to the 
accumulation of the same charge the liquid then disperses into several small droplets 
whose size further decrease due to the evaporation of the liquid in the evaporation 
chamber. Eventually the coulombic charges will lead to a bursting of the droplets as the 
decrease in droplet size increases the charge concentration in the liquids. Eventually all 
liquid will evaporate leaving multiple charged ions which are typical for ESI as 
compared to MALDI which preferable generates singly charged ions259. 
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Figure 1.5: electrospray ionisation 
A sample consisting of concentrated peptides is injected into a chromatography column. 
At the end of the capillary the sample is ionised and enters the mass spectrometer. 
The image was reproduced from: 
http://www.lamondlab.com/MSResource/LCMS/MassSpectrometry/electrosprayIonisati
on.php 
 
The mass spectrometer used for the experiments in this thesis was a LTQ Orbitrap 
Velos (Thermo)260 which is depicted in Figure 1.6. The sample is ionised using the nano 
ESI and passes into the mass spectrometer via the S lens. The S lens serves as a ring 
guide which focusses the sample into the mass spectrometer. The lens consists of two 
stacks of metal rings which are charged and thus focus the ion beam of the sample. The 
electrostatic field of the S lens also ensures that only charged particles are focused and 
enter the mass spectrometer which is advantageous as the mass spectrometer is only 
able to detect charged ions. The S lens also transfers the sample from atmospheric 
pressures into the low pressure environment within the mass spectrometer. 
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Figure 1.6: Schematic drawing of a LTQ Orbitrap Velos mass spectrometer. 
The figure was adapted from Olsen, Schwartz, et al., 2009260 
 
Once inside the mass spectrometer, the ion beam passes through the transmission 
quadrupole which is facilitated by an electromagnetic field. The quadropole acts as 
another filter mechanism which removes unwanted solvent droplets and solvent clusters 
from the sample. This is facilitated by a slight bend in the quadropole through which 
only charged ions will be guided. The ion beam then enters the octopole which works in 
a similar fashion as the qudrupole but also serves as a passage to the ions. Quadropole 
and octopole together facilitate the entry of the ions into the low pressure environment 
of the ion traps. From there, the sample can then be either analysed in the C trap for 
mass/charge analysis or fragmented in the ion trap and analysed for their MS/MS 
spectra. 
The first scan or MS1 scan takes places in the Orbitrap after samples have been 
collected in the C trap. The Orbitrap is a spindle shaped electrode in which the ions are 
electrostatically trapped in an orbit around the electrode. The ions oscilliate along the 
length of the Orbitrap electrode and their mass/charge ratios can be obtained from the 
frequency of these oscilliations via Fourier Transformation. After the MS1 data has been 
generated, ions to be fragmented are selected and fragmented in the high-pressure 
compartment of the linear ion trap. The fragmented ions are then send to the low-
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pressure compartment and sequentially send to the detector to generate the MS/MS or 
MS2 data. The dual pressure system of the LTQ Orbitrap Velos as well as the Orbitrap 
electrode are the main factors that provide the increased resolution, sensitivity and fast 
cycle times when compared to other mass spectrometers. These factors contribute to the 
high rate of identified ions that enable the application of quantitative mass spectrometry 
to complex biological samples.    
 
1.8.2. Quantitative mass spectrometry based proteomics 
The term proteomics was coined in 1997261 and describes the goal of achieving a 
comprehensive and quantitative description of protein expression in a steady-state or its 
changes due to the effect of perturbations like drugs and diseases262. Modern proteomics 
and quantitative MS are now strongly connected as a number of methodical and 
technological advances in the field of mass spectrometry as well as international 
initiatives263 led to the first near complete characterisations of the total proteome not 
only of yeast264 or human cultured cell lines265 but also more recently to first drafts of 
the human proteome by combining proteomic data derived from a wide range of 
tissues266,267. Projects that led to the sequencing of the human genome and those of other 
species form the foundation for recent proteomic advances as these databases are crucial 
for current mass spectrometry based approaches. The combination of advanced liquid 
chromatography with new generation tandem mass spectrometers (LC-MS/MS)268 now 
allows the identification and quantification of tens of thousands of spectra within  
several hours which enables mass spectrometry to be used for a wide range of proteomic 
applications. The high performance liquid chromtatography (HPLC) allows the 
separation of very small peptide amounts due to columns with very small inner 
diameters allowing flow rates in the range of nL/min. This ensures that the peptides are 
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resuspended in a very small volume and at low speeds which in return aids the analysis 
in the mass spectrometer as it leads to a reduction in sample complexity as well as an 
increase in signal intensity. Once an ionised peptide is detected it will be recorded as a 
mass/charge peak over intensity (the MS spectrum) which is then followed by a further 
fragmentation of a specific number of the most abundant peptide peaks within a given 
time frame which depends on the type of mass spectrometer used. The pattern of the 
fragmented ions (the MS/MS spectrum) is also recorded as mass/charge peaks over 
intensity and generally creates a more complex spectrum than the MS spectrum. The 
data derived from the MS/MS spectrum ideally contains enough information to be 
compared to protein databases like Uniprot which serve to generate a library of possible 
peptides which are matched to the MS/MS spectra. The cycle is repeated several times 
within the time frame of a second and thus leads to the generation of thousands of 
MS/MS spectra from a peptide mixture during a run which typically is processed within 
a couple of hours.   
A major problem when using mass spectrometry in proteomic approaches is the fact that 
mass spectrometry is not inherently quantitative. Major reason for this problem is the 
fact that peptides can show a range of different physical attributes which affect their 
‘flyability’ in the mass spectrometer caused by different solubility properties, ionisation 
efficiencies or detector  responses. Thus the most abundant peptide ion in a biological 
sample is not necessarily the one that is detected by the mass spectrometer as the most 
intense. Furthermore, changes in the digestion efficiency of peptides or fluctuations in 
the mass spectrometer itself can cause large variations between experiments. Several 
approaches have thus been developed to minimise variability. The most quantitative 
approaches involve metabolic labelling of proteins of an organism with amino acids 
enriched in non-radioactive atoms269. Samples labelled this way can be combined right 
at the beginning of the sample preparation protocol and will behave identically during 
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cell lysis, degradation, fractionation and will only be distinguished in the actual MS run 
itself leading to a an accurate relative quantification. The most commonly used strategy 
of metabolic labelling is called stable isotopic labelling of amino acids in cell culture 
(SILAC)270. In its simplest form it uses two pools of amino acids (usually L-lysine and 
L-arginine) containing either ‘light’ – naturally occurring – or ‘heavy’ isotopes of 
hydrogen, carbon or nitrogen. Two populations of cells are grown with these different 
amino acids which will be incorporated into all nascent proteins. Trypsin, which cleaves 
peptides after L-lysine or L-arginine, is mostly used for the digestion of proteins and 
thus leads to the generation of peptides which ideally only contain one labelled amino 
which in turn leads to a defined shift in the mass of the peptides which can easily 
detected by modern mass spectrometers. However, this difference in mass, which is 
usually in the range of 2 – 10 Da per peptide, does not affect the general chemical 
properties of peptides like their pI or intramoleculear structures and thus peptides 
labelled with ‘light’ or ‘heavy’ amino acids have been shown to behave exactly same in 
equal culture conditions271,272. However, SILAC requires complete labelling of all 
proteins within a cell and thus the cells to undergo at least 5 cell divisions (25 = 32 fold 
increase in cell numbers and thus more than 95% incorporation of light or heavy amino 
acids). Therefore, metabolic approaches can only be used actively proliferating cells 
like  bacteria273, funghi274, parasites275 or human276 and mice270 cell lines in tissue 
cultures but only for a handful of primary non-transformed cells277,46. More recently the 
SILAC approach could also successfully be adopted to label whole organisms like 
worms278, flies279 or even mammals like mice280. Further disadvantages of the technique 
are the relatively high costs of the labelled amino acids required and the fact that the 
SILAC approach leads to fewer protein identification as the mass spectrometer has to 
detect peptides ions for both members of a SILAC pair and thus has to effectively detect 
every peptide twice. 
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Label-free approaches281 stand in contrast to metabolic labelling strategies like SILAC. 
The biological samples are handled and processed in parallel throughout the whole 
work flow and are only combined at the in silico data analysis step. In order to avoid or 
correct biases that will be introduced by a parallel handling of samples this strategy 
requires the use of highly reproducible sample handling and fractionation techniques. 
The strategy used in this chapter is hydrophilic strong anion exchange (SAX) 
chromatography which is a highly reproducible fractionation method which is also very 
orthogonal to the reverse phase (RP) chromatography used in the LC-MS/MS stage, i.e. 
different physical properties of peptides are used for fractionation282. This approach has 
been shown to highly effective in achieving near-complete coverage of mammalian 
proteomes283. 
 
1.8.3. Computational analysis of MS-based proteomics 
In order to identify the peptides generated by the mass spectrometer the MS/MS spectra 
are typically compared to a theoretical database of peptides which have been generated 
by an in silico digest of protein sequences284. This crucial aspect of MS-based 
proteomics approaches thus relies on the technological advances in genome sequencing 
which build the basis for protein databases like Uniprot. A commonly used software 
analysis suite is MaxQuant285 which is freely available and developed by the group of 
Matthias Mann. This mapping of theoretical and observed peptides is performed by the 
database search engine Andromeda286 which is part of the MaxQuant software package. 
The search engine performs an in silico digest of the peptide sequences with the relevant 
protein database and creates a list of peptides with all possible combinations of defined 
post translational modifications and other chemical modifications or digestions with 
different endopeptidases. Fragmented ions of these peptides are then calculated as well 
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as the predicted mass of the precursor ion of the MS spectra. If the mass of an observed 
precursor ion matches its calculated predicted mass (taking in consideration PTMs and 
other modification) within a defined deviation the MS/MS spectrum of this ion is then 
matched to the theoretical fragmentation pattern. This procedure is repeated for each 
peptide within the database and leads to assignment of a score to each peptide 
depending on the quality of the match between observed and theoretical spectra. As 
theoretical and observed peptides are matched in a random and non-ideal fashion, 
search engines inevitably create false positive identifications. Other factors like the size 
of the protein database used or the performance of the mass spectrometer affect the 
whole population of peptides287 and this problems cannot be fully addressed by a simple 
matching of peptide fragmentation patterns with a generated database. 
In order to assess the extent of false positives identification in MS-based proteomics a 
target-decoy search is typically used288. This approach involves the creation of decoy 
peptides which are non-existing in the sample but are still representative of the actual 
peptide sample that is being analysed. This decoy database typically consists of the 
reversed sequences of the ‘target’, real database. As the decoy database is representative 
of the real database the FDR for the decoy and the target database should be the same 
and thus a number of false positive hits can be estimated. User specified criteria and the 
amount of decoy hits then leads to the calculation of a false discovery rate which 
estimates the proportion of falsely identified hits the total population (as opposed to a 
probability score for each single peptide).  
Parallel handling of samples and their MS analysis inevitable introduces variation in the 
observed peptide ion intensities and also other properties like chromatography retention 
times. The label-free quantification (LFQ) algorithm within the MaxQuant package 
addresses this problem by performing several normalisation steps across all MS runs 
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that are used in the analysis281,289. The two most important features of the algorithm are 
the alignment of retention times of peptides as well as the transfer of identification 
across runs. This will lead to a maximisation of the number of peptides that can be used 
for quantification beyond the levels of the identification that is done by the peptide 
search engine. As the robustness of quantification of proteins is strongly linked to the 
amount of peptides that can be detected (and thus quantified) in the analysis this 
approach is crucial for a robust label-free quantification. 
Whereas LFQ is used to measure changes in the abundance of the same protein when 
comparing across samples, intensity based absolute quantification (IBAQ)290 can be 
used to estimate the abundance of proteins within a sample. The IBAQ uses the sum of 
all peak intensities of all peptides matching to a specific protein. As longer proteins 
generate more peptides than shorter proteins at equal abundance levels, this raw peptide 
intensity is then divided by the number of theoretically observable peptides to give an 
IBAQ intensity value which provides an accurate proxy for protein levels290,283. 
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2. Materials and Methods 
2.1. Transgenic mice 
All mice used were bred and maintained under specific pathogen-free conditions in the 
Biological Resource Unit at the University of Dundee. The procedures used were 
approved by the University Ethical Review Committee and authorised by a project 
licence under the UK Home Office Animals (Scientific Procedures) Act 1986. 
 
2.1.1. P14 LCMV 
Transgenic mice expressing a Vα2/Vβ28.1 T cell receptor specific for the amino acid 
sequence KAVYNFATM of the lymphocytic choriomeningitis virus glycoprotein 
(LCMV-GP33-41)291. This peptide was synthesised and purified in the Cancer Research 
UK production laboratory, London. 
 
2.1.2. PTENfl/fl LckCre+/- 
Mice carrying PTENfl/fl alleles with the Cre recombinase under the control of the Lck 
promotor were generated as described previously292. This leads to a deletion of PTEN 
early in T cell development at the double negative stage293. 
 
2.1.3. PDK1-K465E 
Mice carrying a K465E point mutation in the PH domain of PDK1 that inhibits binding 
to PIP3 were described previously150. 
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2.2. Cell culture 
2.2.1. Reagents 
reagent manufacturer 
2C11 (hamster anti-mouse CD3) R&D Systems/CRUK hybridoma unit 
anti-CD28 antibody Life technologies 
β-mercaptoethanol Sigma 
Dialysed fetal bovine serum (10 kDa) Life technologies 
Fetal bovine serum Life technologies 
Insulin-transferrin-Selenium-G (100x) Life technologies 
L-arginine Sigma 
L-arginine:HCl “R10” (13C6, 15N4) CK Gas Products Ltd. 
L-glutamine (200 mM) Life technologies 
L-lysine:HCl Sigma 
L-lysine:2HCl “K8” (13C6, 15N2) CK Gas Products Ltd. 
L-proline Sigma 
MEM vitamin solution (100x), liquid Life technologies 
Penicillin/Streptomycin Life technologies 
Recombinant human IL-2 (Proleukin®) Novartis 
Recombinant mouse IL-12 (p35/40) R&D systems 
RPMI 1640 (+L-glutamine, +glucose) Life technologies 
RPMI media for SILAC Thermo Fisher 
Sodium pyruvate Life technologies 
0.22 μm Stericup Millipore 
 
 
2.2.2. Cell culture media and solutions 
T cell medium: RPMI 1640 pre-supplemented with 25 mM glucose and 300 mg/mL L-
glutamine, 10% heat-inactivated FBS, 100 μM β-mercaptoethanol, 100 U/mL 
penicillin-G, 100 μg/mL streptomycin 
SILAC T cell medium: RPMI media for SILAC pre-supplemented with 25 mM 
glucose and 300 mg/mL L-glutamine, 10% heat-inactivated dialysed FBS, 100 μM β-
mercaptoethanol, 100 U/mL penicillin-G, 100 μg/mL streptomycin, 84 mg/mL L-
arginine or 106 mg/mL L-arginine:HCl “R10”, 40 mg/mL L-lysine:HCl or 49.7 mg/mL 
L-lysine:2HCl “K8”, 200 mg/mL L-proline, 2 mM glutamine, MEM vitamin solution, 
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Insulin-transferrin-Selenium-G, 1 mM sodium pyruvate. The medium was then filter 
sterilised using a 0.22 μm filter. 
ACK buffer: 155 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM 
ethelenedieaminetetraacetic acid. Adjusted to pH 7.8 and autoclaved. 
 
2.2.3. In vitro cytotoxic T cell generation 
Spleens were obtained from mice between 8 and 26 weeks old and passed through a 
70μm cell strainer to obtain a single cell suspension. Red blood cells were lysed by 
resuspension in ACK buffer for 10 seconds. Cells were washed and resuspended in T 
cell medium. T cells were activated by addition of 100 ng/mL gp33 peptide (for p14 
LCMV TCR transgenic T cells) or 500 ng/mL 2C11 and 4 ng/mL αCD28 (for non-TCR 
transgenic T cells) in the presence of 20 ng/mL IL-2 and 2 ng/mL IL-12. After up to 48 
hrs cells were washed and resuspended in T cell medium (or SILAC T cell medium 
where indicated) and maintained in exponential growth with 20 ng/mL IL-2 and 2 
ng/mL IL-12. 
 
2.2.4. Inhibitor treatments and stimulations 
Where indicated cells were treated with inhibitors at the following concentrations: 
antagonist of inhibitor concentration 
ATP synthase oligomycin 1 μM 
Cytochrome c reductase Antimycin A 1 μM 
Complex I rotenone 1 μM 
mTOR KU-0063794 1 μM 
mTORC1 rapamycin 20 nM 
PKB Akt inhibitor VII 1 μM 
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2.3. SDS-PAGE and Western Blotting 
2.3.1. Reagents 
reagent manufacturer 
4x LDS sample buffer Life technologies 
cOmplete protease inhibitor cocktail Roche 
PhosStop phosphatase inhibitor tablet Roche 
Powdered milk Marvel 
TCEP (tris(2-carboxyethyl)phosphine) Thermo 
 
2.3.2. Solutions 
RIPA buffer: 50 mM HEPES pH 7.4, 150 mM NaCl, 1% (w/v) NP40, 0.5% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS, 10% (w/v) glycerol, 1 mM EDTA, 1 mM 
EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium β-Phosphoglycerate, 
0.5 mM sodium orthovanadate, 5 mM NEM, 1 mM neutralised TCEP, 1 tablet 
cOmplete Protease Inhibitor Cocktail tablet per 10 mL 
SDS-PAGE gel (resolving): 4-14% acrylamide, 0.1% SDS, 0.375 M Tris-HCl pH 8.8 
SDS-PAGE gel (stacking): 4% acrylamide, 0.1% SDS, 0.125 M Tris-HCl pH 6.8 
SDS-PAGE running buffer: 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
Transfer buffer: 48 mM Tris, 39 mM glycine in 20% (v/v) methanol 
PBST: phosphate buffered saline (PBS), 0.05% (w/v) Tween-20 
Ponceau S: 0.1% Ponceau S, 0.5% (v/v) acetic acid 
Stripping buffer: 0.7% (v/v) β-ME, 2% (w/v) SDS, 62.5 mM Tris (pH 7.4) 
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2.3.3. Antibodies 
antigen manufacturer 
4EBP1 Cell Signaling Technology #9452 
p-4EBP1 (Thr37/46) Cell Signaling Technology #2855 
p-4EBP1 (Thr65) Cell Signaling Technology #9451 
PKB Cell Signaling Technology #9272 
p-PKB (Thr308) Cell Signaling Technology #4056 
p-PKB (Ser473) Cell Signaling Technology #4058 
cMyc Cell Signaling Technology #9402 
ERK Cell Signaling Technology #3372 
p-ERK1/2 ( Cell Signaling Technology #4377 
FoxO1 Cell Signaling Technology #9454 
FoxO3a Cell Signaling Technology #2497 
p-FoxO1/3a (Thr24/Thr32) Cell Signaling Technology #9464 
Glut-1 DSTT 
Hif-1α Santa cruz sc-10790 
Histone H3 Cell Signaling Technology #4499 
IRS2 Cell Signaling Technology #4502 
NDRG1 Cell Signaling Technology #5482 
p-NDRG1 (Thr346) Cell Signaling Technology #9485 
Perforin DSTT 
PTEN Santa cruz sc-7974 
RSK Cell Signaling Technology #9333 
p-RSK (Ser227) Santa cruz sc-12445 
S6K Cell Signaling Technology #9202 
p-S6K (Thr389) Cell Signaling Technology #9239 
SMCI Bethyl Laboratories, Inc A300-055A 
T-bet eBioscience 14-5825 
 
2.3.4. Sample preparation, SDS-PAGE and Western blotting 
Cells where washed once with ice cold HBSS and lysed in RIPA buffer at 20x106 
cells/mL for 30 minutes and sonicated with a Branson Digital Sonicator to shear DNA. 
The lysates were spun down in a refrigerated bench mini centrifuge at 16,100 g for 10 
minutes to remove non soluble proteins. Samples were mixed with 4x LDS sample 
buffer and TCEP followed by 5 minutes incubation at 95° to denature and reduce. 
Samples were loaded on a SDS-PAGE gel with a fixed acrylamide concentration of 4 to 
12% depending on the molecular weight of the proteins analysed. A Mini-Protean 
system (BioRad) was used for electrophoresis and blotting of proteins. Samples were 
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run at a fixed voltage of 100 V for 2 hrs or until the dye running front had left the gel. 
The proteins were then transferred onto Hybond-C Extra membranes (Amersham) for 1 
½ h on ice. Transfer and equal loading was confirmed by Poncaeu S staining. The 
membrane was washed with water and was blocked with 5% milk in PBST or 5% BSA 
in PBST at room temperature for 1 h. Blots were probed with primary antibodies at 
optimized concentrations (1 μg/mL in most cases)  in 5% milk PBS-T or in 5% BSA 
PBS-T at 4°C overnight. Membranes were then washed thrice in PBST at room 
temperature for 10 minutes followed by incubation with HRP tagged secondary 
antibody diluted in 5% milk or BSA in PBST (1:5000) at room temperature for 1 hour. 
Membranes were washed thrice with PBST for 20 minutes at room temperature before 
being visualised using ECL. 
 
2.4. ELISA 
2.4.1. Reagents 
item manufacturer 
Ready-Set-Go! ELISA mouse CD62L eBioscience 
Ready-Set-Go! ELISA mouse IFN-γ eBioscience 
1x TMB substrate solution eBioscience 
 
2.4.2. General ELISA protocol for CD62L and IFN-γ 
A 96-well plate was coated with a capture antibody (2 μg/mL), sealed and incubated 
overnight at 4 °C. CTL were seeded at a concentration of 1 x 106 cells/mL in 96-well 
cell culture plates and cultured in T cell medium and freshly added cytokines and 
inhibitors for 5 h.  After the incubations the plates were centrifuged and the supernatant 
used for further analysis. The capture antibody was aspirated and the plate was washed 
twice with PBST. The plate was then blocked for 1 h in room temperature by adding 
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300 μL of 1% BSA in PBST to each well. Following reagent diluent aspiration, 100 μL 
of standards and diluted cell supernatants samples were added into each well. The plate 
was covered with an adhesive strip and incubated two hours at room temperature. After 
incubation, the samples were aspirated and the plate was washed with PBST. A volume 
of 100 μL of detection antibody at a concentration of 400 ng/mL was incubated for 20 
min at RT in each of the wells. Following this incubation step, the plate was washed 
with a wash buffer and 50 μL of substrate solution was incubated for 20 min in each 
well. Once the colour reaction was complete, 50 μL of 1 M H2SO4 was added and the 
absorbance of each well was measured at 450 nm. A standard curve generated using the 
recombinant protein was used to determine CD62L and IFN-γ concentrations in the 
samples.  
 
2.5. Metabolic assays 
2.5.1. Reagents 
item manufacturer 
[U-14C] glutamine Perkin Elmer 
7 mL glass vials Thermo 
Cell-Tak BD biosciences 
Optiphase HiSafe 3 Perkin Elmer 
Rubber septum Thermo 
Screw vial Thermo 
Seahorse calibrant solution Seahorse 
Unbuffered RPMI (powdered) Sigma 
XF24 FluxPak Seahorse 
 
2.5.2. O2 consumption and media acidification 
A XF24 cell culture microplate was coated with 50 μL/well of a 22.4 μg/mL Cell-Tak, 
0.1 M NaHCO3, pH 8.0 solution for 30 minutes. The plate was then washed twice with 
sterile H2O and air dried at room temperature overnight. A XF24 cartridge was 
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equilibrated with 1 mL Seahorse calibrant solution and equilibrated at 37 °C overnight. 
Unbuffered RPMI media without FBS was prepared as per manufacturer’s instruction 
and sterile filtered. 150,000 cells/well were used in the experiments. The manufacturer’s 
recommended settings for an oxygen conmption rate of 200-500 pmol/min were used (3 
minutes mixing, 2 minutes waiting, 3 minutes measuring). A mitochondrial stress test 
was performed and oligomycin, DNP and roteneone/antimycin were sequentially used 
to affect the ATP synthase and electron transport chain. Three measurements were taken 
for the baseline OCR and ECAR and each inhibitor treatment giving a total of 12 
measurements. The average for each data point was calculated from at least 3 wells and 
3 biological replicates were performed.  
 
2.5.3. Glutaminolysis assay 
1 x 106 cells per data point were harvested and resuspended in 1 mL fresh glutamine 
free media containing appropriate cytokines and required drugs. The cells were then 
transferred into 7 mL vials with a PCR tube containing 50 μL 1.0M KOH glued to the 
inner side wall to collect produced CO2. 50 μL of a 20% [U-14C]-glutamine (equivalent 
to 0.5 μCi [U-14C] glutamine) were added to each sample and the vial closed with a 
screw cap with rubber septum. Samples were then incubated for 1 hr at 37 °C and the 
assay was stopped by injecting 100 μL 5M HCl through the septum with a Hamilton 
syringe. The vials were then kept at room temperature over night to trap the released 
CO2. The KOH solution in the PCR inside the glass vials was then transferred to 
scintillation vials, 3 mL of Optiphase HiSafe 3 was added and the samples were 
analysed in a scintillation counter. All measurements were performed in technical 
triplicates.  
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2.6. Quantitative Mass spectrometry 
2.6.1. Reagents 
item  manufacturer 
Deepwell Plate 96/500, LoBind Eppendorf 
Deepwell Plate 96/1000, LoBind Eppendorf 
Pierce Detergent Removal Spin Plates Thermo 
Sep-Pak C18 SPE cartridges Waters 
Sep-Pak tC18 96-well μElution Plate Waters 
Subcellular Protein Fractionation Kit for Cultured Cells Thermo 
Trisethanolamine (TEAB) Sigma 
 
2.6.2. Solutions 
Urea lysis buffer: 8 M urea, 100 mM Tris-HCl pH 8.0, 2x complete protease inhibitor 
tablet per 10 mL buffer, 1x PhosStop phosphatase inhibitor tablet  
Digest buffer: 100 mM Tris-HCl pH 8.0, 1 mM CaCl2 
Desalting wash buffer: 0.1% TFA 
Desalting elution buffer: 0.1% TFA in 50% acetonitrile 
SAX sample buffer: 10 mM sodium borate, pH 9.3 in 20% acetonitrile 
SEC sample buffer: 4% SDS, 100 mM NaCl, 10 mM phosphate buffer pH 6.0 
 
2.6.3. Strong anion exchange 
2.6.3.1. Sample lysis and in-solution digest 
25 x 106 CTL treated with either DMSO or rapamycin were harvested in a 50 mL falcon 
tube and washed three times in cold HBSS and transferred into a 2.0 mL Eppendorf 
tube. Cells were lysed in 0.5 mL urea lysis buffer and vigorously mixed for 15 minutes 
at room temperature. The samples were then sonicated with a Branson digital sonicator 
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before vigorously mixed for another 15 minutes. The protein concentration was 
determined by BCA assay as per manufacturer’s instructions before DTT at a working 
concentration of 10 mM was added. Lysates were incubated at 30 °C for 30 minutes. 
Iodoacetamide was added to a working concentration of 50 mM and lysates were 
incubated in the dark at room temperature for 45 minutes. Lysates were diluted with 
digest buffer to 4 M urea. LysC was added to the samples in a 50:1 (protein:LysC) ratio 
and  the samples were then incubated at 30 °C over night. The samples were then split 
in half. One half was diluted to 0.8 M urea with digest buffer and Trypsin was added in 
a 50:1 ratio. The other half was kept a LysC fraction. The samples were then incubated 
at 30 °C for a further 8 hours. 
 
2.6.3.2. Sample desalting using Sep-Pak cartridges 
Samples were adjusted to 1% TFA using 10% TFA. In case of strong precipitation of 
urea the samples were spun down to remove the urea. The Sep-Pak cartridges were 
washed twice with 1 mL elution buffer and equilibrated twice with 1 mL wash buffer 
before the acidified peptide samples were loaded. The flow through was loaded again to 
ensure maximal peptide binding. The peptide loaded cartridges were washed three times 
with 1 mL washing buffer. Peptides were eluted into 2 mL Eppendorf Protein LoBind 
tubes by 2 subsequent elutions with 600 μL elution buffer each. The eluted samples 
were reduced to dryness in a vacuum concentrator. 
 
2.6.3.3. Strong anion exchange chromatography 
Samples were resuspended in 210 μL SAX sample buffer and the pH was readjusted to 
pH 9.3 with 1 M NaOH if necessary. Samples were injected and peptides separated by a 
Dionex Ultimate 3000 HPLC system equipped with an AS24 strong anion exchange 
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column; similar experimental approaches have been reported recently282,283. The 
following buffers were used for the separation of peptides: 10 mM sodium borate, pH 
9.3 (Buffer A) and 10 mM sodium borate, pH 9.3, 500 mM NaCl (Buffer B). An 
exponential elution gradient starting with Buffer A was used to sepearte the peptides 
into 12 fractions of 750 μL which were desalted using the protocol described in 
paragraph 2.6.5.  
 
2.6.4. Size exclusion chromatography 
2.6.4.1. Sample lysis and in solution digest 
50 x 106 CTL grown in ‘light’ SILAC media and treated with either rapamycin or KU-
0063794 were mixed with 50 x 106 CTL grown in ‘heavy’ SILAC treated with DMSO 
and washed twice with ice cold HBSS. Cells were lysed and fractionated into five 
different subcellular fractions (cytoplasmic, membrane, soluble nuclear, chromatin-
bound nuclear and cytoskeletal fractions) using a Subcellular Fractionation Kit for 
Cultured Cells (Pierce) following the manufacturer’s instructions for a 200 μL packed 
cell volume. Protein contents for each fraction were measured by BCA assay.  
 
2.6.4.2. Chloroform-methanol precipitation 
300 μg of each subcellular fraction were used for the precipitation. Samples were 
adjusted to a final concentration of 2% SDS, 10 mM TCEP and 20 mM NEM in 1 mL 
and heated to 65 °C for 10 minutes to denature proteins. 4 mL of methanol was added 
and samples were vortexed for 5 seconds. 1 mL chloroform was added and samples 
were mixed before 3 mL H2O were added and samples vortexed for another 60 seconds. 
Samples were centrifuged at 9000 x g for 5 minutes with a low deceleration setting. 
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Approx. 80% of the aqueous upper phase was removed without disturbing the 
precipitated protein at the interface. 3 mL methanol were added and the samples were 
centrifuged at 9000 x g for 5 minutes at a low deceleration setting. The supernatant was 
taken off and the samples air dried. 
 
2.6.4.3. Size exclusion chromatography of proteins 
The precipitated cytoplasmic, membrane, nuclear and chromatin bound nuclear fraction 
were resuspended in 60 μL SEC sample buffer and boiled for 10-30 minutes with 
vortexing. Samples were separated by a mAbPacSEC column (Dionex) using a 0.2% 
SDS, 100 mM NaCl, 10 mM sodium phosphate buffer, pH 6.0. The flow rate was 0.2 
ml min−1 and 8 fractions of 200 μL were collected into Protein LoBind 1 mL 96-deep 
well plates (Eppendorf) as described previously294. 
 
2.6.4.4. In solution digest of proteins from denaturing SEC and SDS removal 
TEAB was added to the SEC fractions to a final concentration of 0.1 M. Trypsin was 
resuspended in 0.1 M TEAB and added to the SEC fractions in a 50:1 (protein:trypsin) 
ratio. The unseparated cytoskeletal fraction was diluted with digest buffer to a urea 
concentration of 1 M. Trypsin was added in a 50:1 (protein:trypsin) ratio. All samples 
were incubated at 37 °C over night. The Detergent Removal Spin plates were 
centrifuged at 1,000 x g at room temperature for 1 minute. The plate was washed three 
times with 300 μL PBS and centrifuged at 1,000 x g at room temperature for 1 minute. 
All SDS containing samples were loaded onto the plate and incubated on the resin for 2 
minutes. Samples were then collected in a 500 μL low protein binding collection plate 
by centrifugation at 1,000 x g at room temperature for 1 minute. The detergent free flow 
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through and the cytoskeletal fraction were then kept for desalting and further sample 
processing.  
 
2.6.5. Desalting with tC18 Sep-Pak 96-well plate 
Fractions from either strong anion exchange or size exclusion chromatography were 
adjusted to 1% TFA with 10% TFA. Each well of the desalting plate was washed with 
0.2 mL acetonitrile and equilibrated with 0.2 mL desalting wash buffer. The samples 
were then slowly applied onto the columns and washed first with 0.8 mL and then with 
0.2 mL desalting wash buffer. The samples were then eluted into an Eppendorf 1000 μL 
96-well-plate with 0.2 mL desalting elution buffer. Samples were reduced to dryness in 
a vacuum concentrator. 
 
2.6.6. Liquid chromatography mass spectrometry analysis (LC-MS/MS) 
Samples from desalting were resuspended at a concentration 0.066 μg/μL in 5% formic 
acid and 15 μL (equivalent to 1 μg of peptides) was used for analysis. A Dionex 
RSLCnano HPLC was used for the peptide chromatography. A 5 mm PepMap-C18 pre-
column with an inner diameter of 0.3 mm was used and a 75 μm x 15 cm PepMap-C18 
column was used for the subsequent chromatography. The mobile phase consisted of 
2% acetonitrile + 0.1% formic acid (solvent A) and 80% acetonitrile + 0.1% formic acid 
(solvent B). A constant flow rate of 300 nL/min was used and the linear gradient 
increased from 5% to 35% solvent B over a runtime of 156 minutes. The eluted peptides 
were injected into a Velos Orbitrap mass spectrometer (Thermo Fisher, San Jose, CA) 
through a nanoelectrospray emitter. A typical ‘Top15’ acquisition method was used. 
The primary mass spectrometry scan (MS1) was performed at a resolution of 60,000. 
The aforementioned top 15 most abundant m/z signals from the MS1 scan were selected 
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for subjected for collision-induced dissociation and MS2 analysis in the Orbitrap mass 
analyzer at a resolution of 17,500.  
 
2.6.7. Mass Spectrometric Data Analysis by MaxQuant  
The data were processed, searched, and quantified using the MaxQuant software 
package version 1.4.1.2 as described previously285, using the default settings and 
employing the mouse Uniprot database from October 2013 and the contaminants 
database supplied by MaxQuant. The following settings were used: two miscleavages 
were allowed; for the SAX samples fixed modification was carbamidomethylation on 
cysteine, for the SEC samples N-ethylmaleimide on cysteine; enzyme specificities were 
Trypsin and/or LysC were applicable; variable modifications included in the analysis 
were methionine oxidation, deamidation of glutamine or asparagine, N-terminal 
pyroglutamic acid formation, and protein N-terminal acetylation. Default MaxQuant 
settings included a mass tolerance of 7 ppm was for precursor ions, and a tolerance of 
0.5 Da for fragment ions. A reverse database was used to apply a maximum false 
positive rate of 1% for both peptide and protein identification. This cut-off was applied 
to individual spectra and whole proteins in the MaxQuant output. The match between 
runs feature was activated with an allowed time window of 2 minutes. All proteins were 
quantified on the basis of unique proteins with the requantification enabled. 
Further down-stream analysed was performed using Microsoft Excel and the 
programming language R. Student’s t-test were performed to determine statistical 
significance of recurring ratios. Pathway analyses were performed using the Database 
for Annotation, Visualisation and Integrated Discovery (DAVID)295,296 bioinformatics 
tools based on Kyoto Encyclopedia of Genes and Genomes (KEGG). 
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2.7. Flow Cytometry 
Flow cytrometric data was obtained on a FACS Calibur or FACS Verse (Becton 
Dickinson) with the appropriate machine specific software. A minimum of 20,000 
relevant events were collected and stored ungated. Data were analysed FlowJo data 
analysis software version 10 for Microsoft Windows (Treestar Inc.). 
 
2.7.1. Reagents 
item manufacturer 
αCD8 (FITC 1:200) BD Biosciences 
αCD62L (APC 1:200) BD Biosciences 
αIFN-γ (APC 1:200) BD Biosciences 
GolgiPlugTM  BD Biosciences 
IC Fixation Buffer eBioscience 
Permeabilization Buffer eBioscience 
 
2.7.2. Solutions 
FACS buffer: 0.5% BSA in PBS 
 
2.7.3. Live cell staining 
Cells were stained at 1-2x106 cells per mL at 4ºC for 20 min in FACS buffer. Cells were 
then washed and resuspended in RPMI + 1% FCS prior to acquisition on a FACS 
Calibur or Verse. Live cells were gated according to their forward light scatter (FCS) 
and side scatter (SSC) 
 
2.7.4. Fixed cell staining for intracellular IFN-γ staining 
CTL were treated with Golgi plug for 4 hours followed by staining for CD8. Cells were 
then washed and fixed using fixation buffer while mixing the tubes and followed by 
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incubation in the dark at room temperature for 20 min. The fixed cells were then 
permeabilised and washed once with permeabilization Buffer. The samples were then 
stained with IFN-γ antibody resuspended in Permeabilization Buffer in the dark for 20 
minutes. Cells were then washed twice with 1 mL of Permeabilization Buffer and 
resuspended in FACS buffer. 
 
2.8. Data analysis and statistical evaluation 
All quantified data were processed in Microsoft Excel 2010 for PC. Generation of 
scatter and bar diagrams, histograms and heatmaps was done using Excel. Statistical 
tests to determine significant differences were two-tailed t-tests and one-way ANOVA. 
Differences were considered significant for p-values < 0.05 with exception for some 
mass spectrometry data. 
Unless stated otherwise, experiments were performed in at least biological triplicates.  
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3. Proteomic characterisation of Cytotoxic T Lymphocytes   
3.1. Introduction 
We decided to use an unbiased quantitative mass spectrometry based approach to not 
only map the global changes caused by mTORC1 inhibition but also to gain information 
about the undisturbed CTL proteome. The aim of this chapter is to investigate whether a 
label-free proteomics approach based on fractionating cell lysates using strong anion 
exchange chromatography can be used to assess the total proteome of a CD8 cytotoxic 
T lymphocyte. We will then describe and discuss the results obtained from the proteome 
of an undisturbed CTL while Chapter 4 will summarise our observation of the mTORC1 
controlled CTL proteome. 
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3.2. Results 
3.2.1. Label-free quantification (LFQ) based proteomics with strong anion 
exchange chromatography (SAX) fractionation is robust and highly 
reproducible  
We used a well establish protocol to generate CD8 cytotoxic T lymphocytes in vitro 
based on P14 LCMV T cell receptor transgenic mice. The TCR of these mice recognises 
the peptide sequence KAVYNFATM derived from the lymphocytic choriomeningitis 
virus (LCMV) presented by the MHC class I molecule H-2Db. Naïve T cells expressing 
this TCR can be activated by this peptide-MHC complex and differentiate into a 
homogenous population of CTL when cultured in the presence of interleukin-2 and 
interleukine-12131,158,159. An important aspect of the massive clonal expansion of CTL 
with several cell divisions per day is the fact that relative high cell numbers are required 
for MS based proteomic approaches. The approach we followed (Figure 3.1) required 
approx. 2 mg of cell lysate per condition which is equivalent to 40-50 x 106 CTL. Cells 
were activated for 2 days with the TCR ligand in the presence of IL-2 and IL-12 and 
then cultivated in IL-2 and IL-12 for another 4 days for clonal expansion. Cells were 
then lysed and subjected to the MS sample processing workflow (Figure 3.1). 
We initially assessed the robustness of our LFQ SAX approach. Three biological 
replicates derived from the spleens of different mice were performed in the timeframe 
of approximately 4 months. The first biological replicate was performed on its own, 
whereas biological replicates 2 and 3 were processed in parallel 4 months later. We thus 
plotted the IBAQ values obtained for each protein from each of the three replicates and 
correlated the obtained values to each other (Figure 3.2, A-C). All three replicates show 
very strong Spearman correlations of 0.95 to 0.97 with very few outliers. There was no 
significant difference in the correlation of the samples despite parallel handling of 
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samples 2 and 3. Typically proteins with higher IBAQ intensity showed a higher 
correlation than less abundant proteins. We furthermore looked at the overlap between 
the replicates in terms of detected proteins (Figure 3.2, D) We identified more than 6500 
protein groups in each replicate, leading to a total number of protein groups of 6792. A 
core subset of 6288 proteins (93% of all proteins) was detected in all replicates whereas 
159 proteins (2% of all proteins) were only detected in only one of the three replicates 
with the remaining 341 (5%) protein groups detected in 2 of the 3 replicates. 
 
 
 
Figure 3.1: Experimental workflow. 
T cells were isolated from LCMV TCR transgenic mice and activated with cognate 
peptide. Antigen was washed out after 48 hours and CTL were clonally expanded for 96 
hours. Cells were treated with DMSO (control) or Rapamycin for the last 48 hrs of 
culture. Cells were collected, lysed and processed prior to digest with LysC or 
LysC/Trypsin double digest. Peptides were separated by strong anion and reverse phase 
chromatography prior to analysis by an Orbitrap Velos mass spectrometer. The 
generated data was analysed using MaxQuant. 
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Figure 3.2: Reproducibility of LFQ approach 
(A-C) Log-transformed IBAQ intensities for each replicate are plotted against each 
other and the Spearman correlation coefficient (r) is depicted in red. The calculated 
linear regression is depicted as red line. (D) Venn diagram showing the overlap of 
identified proteins in biological replicates. 
 
 
3.2.2. LFQ based proteomics with SAX fractionation is unbiased  
We next investigated whether our approach showed any bias toward different classes of 
proteins occurring in the cell. We thus calculated the frequencies of several Gene 
Ontology297 terms that the protein groups in our data set were annotated with and 
compared these frequencies with the frequencies of these terms in the complete Uniprot 
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protein data set that was used for our analysis (Figure 3.3). The frequencies show very 
strong positive correlation as indicated by Spearman coefficients of 0.98 and more. Of 
the three terms analysed (biological process (GOBP), cellular compartment (GOCC) 
and molecular function (GOMF)) only the cellular function annotation showed a few 
outliers which were associated with a localisation to the membrane and were 
underrepresented in our dataset (Figure 3.3, B). Thus the frequencies with which these 
terms occur in the proteins detected by our approach are very similar to the frequencies 
of the total mouse proteome and therefore indicate that our dataset is an unbiased 
representation of the total theoretically achievable proteome. 
 
 
 
Figure 3.3: Estimation of detection bias in LFQ approach 
Frequencies of GO terms in this dataset were compared with predicted frequencies 
based on total mouse proteome. GO terms for (A) biological process (B) cell 
compartment (C) molecular function are shown. Spearman correlation coefficient (r) is 
depicted in red, red lines indicates calculated linear regression. Outliers are indicated by 
purple label. 
 
 
 
3.2.3. Transcript and protein levels show a moderate correlation 
In parallel to sampling replicates for our proteomics approach we also prepared samples 
for a transcriptional analysis using the affymetrix platform298. We compared protein 
abundance as estimated by the IBAQ value for each protein with the transcript intensity 
of their corresponding mRNA by using the probe intensities derived from micro arrays 
as reported previously299. The values for RNA and proteins show a moderate correlation 
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according to a Spearman correlation of 0.56 (Figure 3.4) which is similar to previous 
reports in other cells systems299. 
 
 
 
Figure 3.4: Correlation between transcript and proteins levels in CTL 
Log-transformed micro array probe intensities and log-transformed IBAQ-scaled 
protein intensities are plotted. The calculated Spearman correlation coefficient (r) is 
depicted. The red line indicates the linear regression of the data. 
 
We then investigated the correlation between transcript and protein for cytoplasmic and 
mitochondrial ribosomes and the 26S proteasome as the subunits of the multi protein 
complexes appear in equal abundances and should thus form a subset of proteins with 
tightly regulated abundances265. There is a clear difference in the protein abundance 
between cytoplasmic and mitochondrial isoforms with the cytoplasmic isoforms being 
one of the most abundant proteins in CTL and approx. 100 times more abundant than 
the mitochondrial isoforms (Figure 3.5, A and Figure 3.6) The protein abundances of 
the two populations are very tight and show a very low coefficient of variation of less 
than 5%. The same tight regulation of protein abundance can be seen for subunits of the 
26S proteasome (Figure 3.5, B). In contrast to the tight protein levels the corresponding 
transcript levels for the ribosomal and proteasomal complexes show a wide spread over 
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the whole range of detected transcript intensities (Figure 3.4) which is illustrated by the 
high CV values associated with the average of the transcript intensities. 
 
Figure 3.5: Correlation between transcript and proteins levels of ribosomal and 
the 26S proteasome subunits. 
Log-transformed micro array probe intensities and log-transformed IBAQ-scaled 
protein intensities are plotted. (A) Cytoplasmic (purple) and mitochondrial (yellow) 
ribosomal subunits are highlighted. (B) Subunits of the 26S proteasome are shown. 
Grey dots: background data points. 
 
 
protein complex transcript protein average CV average CV 
ribosome (cytoplasmic) 2.8 30% 8.6 3% 
ribosome (mitochondrial) 1.3 41% 6.6 5% 
26S proteasome 1.6 45% 7.8 7% 
 
Figure 3.6: Comparison of variation between transcript and protein levels of 
protein complexes. 
Average log10 transformed transcript and protein intensities as well as coefficients of 
variation are shown. 
 
3.2.4. Characterisation of CTL proteome 
When we analysed the contribution of each protein to the total mass of cell we saw that 
only a small subset of protein (21 proteins) contributed to 25% of the bulk total cell 
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mass. The 100 most abundant proteins make up over 50% of the cell mass and 75% of 
the total cell mass is made up the 346 most abundant proteins. The least abundant 6446 
taken together only contribute to 25% of the total cell mass. 
 
 
Figure 3.7: Cumulative plot of protein abundance. 
Proteins were ranked by abundance as estimated by IBAQ intensities and plotted 
against the cumulative mass of the whole dataset. Proteins follow an exponential 
increase in abundance, with the 21 most abundant proteins constituting 25% of the bulk 
cell protein mass and 346 proteins constituting 75% of the total mass. 6446 proteins 
contribute to the remaining 25% of the cell mass. 
 
A list of the 20 most abundant proteins in CTL is shown in Figure 3.8. Among the list 
are histones (histone H4 and H3.2), components of the cytoskeleton (several thymosin 
isoforms, vimentin, cofilin, protein S100-4) components of the translational machinery 
(petidyl-petidyl cis-trans isomerase A, ribosomal proteins, initiation and elongation 
factors, chaperones) and glycolytic enzymes (enolase, GAPDH, LDH). Granzyme B is 
an effector molecule expressed by CTL, γδT and NKT cells300. With the exception of 
granzyme B the list is similar to studies performed in several cancer cell lines265,283. 
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Vimentin is also known to be major component and marker of cells of the mesenchymal 
lineage like cells of the lymphocytic and circulatory systems301. Many of the proteins in 
this list also show very high transcript intensities with the histones being notable 
exceptions.  
 
 
As depicted in Figure 3.9 the abundance of proteins ranges of seven orders of 
magnitudes. We used the KEGG DAVID bioinformatics tool295,296 to perform a 
pathway enrichment analysis on our dataset. The highest intensity quartile was enriched 
protein 
rank 
transcript 
rank Protein name 
fracti. 
abund. 
cumul. 
abund. 
1 2778 Histone H4 3% 3% 
2 3 Isoform Short of Thymosin beta-4 2% 5% 
3 64 Vimentin 2% 7% 
4 47 Prothymosin alpha 2% 9% 
5 9 Peptidyl-prolyl cis-trans isomerase A 2% 10% 
6 4 60S acidic ribosomal protein P2 1% 12% 
7 348 Cofilin-1 1% 13% 
8 96 Alpha-enolase 1% 14% 
9 7 60S acidic ribosomal protein P1 1% 16% 
10 120 Eukaryotic translation initiation factor 5A-1 1% 17% 
11 1 Granzyme B(G,H) 1% 18% 
12 75 Glyceraldehyde-3-phosphate 
dehydrogenase 
1% 19% 
13 56 L-lactate dehydrogenase A chain 1% 19% 
14 2642 Putative RNA-binding protein 3 1% 20% 
15 2 Elongation factor 1-alpha 1 1% 21% 
16 5301 Histone H3.2 1% 21% 
17 201 Protein S100-A4 1% 22% 
18 100 Heat shock protein HSP 90-beta 1% 23% 
19 173 Fructose-bisphosphate aldolase A 1% 23% 
20 76 Phosphoglycerate kinase 1 1% 24% 
 
Figure 3.8: List of 20 most abundant proteins in a CTL. 
The list shares many proteins with similar studies published in different cell lines with 
proteins involved in chromatin and cytoskeletal organisation, translation and glycolysis. 
The high expression of granzyme B is specific to effector immune cells. 
fract. abund.: fractional abundance for specific protein; cum. abund.: cumulative 
abundance 
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in pathways involved in transcription and translation (ribosomes, aminoacyl-tRNA 
synthetases) and metabolic pathways involved in oxidative phosphorylation, glycolysis, 
the TCA cycle and glycolysis. Pathways involved in the replication of DNA and other 
anabolic pathways like the pentose phosphate pathway are also enriched in this quartile. 
In contrast to the cytoplasmic aminoacyl-tRNA synthases the mitochondrial isoforms of 
these enzymes are much less abundant. The low abundance quartile does not show any 
enriched pathway apart from regulators of the cell cycle. 
 
 
Figure 3.9: Histogram of log-transformed protein abundance as estimated by 
IBAQ intensity. 
Protein abundances span seven orders of magnitude. Enriched KEGG ontology terms (p 
< 0.05) are depicted above each quartile. The highest expressed quartile is enriched in 
proteins involved in several metabolic pathways whereas transcription factors and cell 
cycle regulator are expressed at lower levels. 
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3.2.5. Relative quantification of key CTL molecules, nutrient transporters and 
protein isoforms 
We then looked specifically at the expression of selected groups of molecules (Figure 
3.11) namely surface proteins (A), molecules important for CTL effector function (B), 
nutrient receptors (C) and kinase isoforms (D). We detected all three subunits of the IL-
2 receptor in a ratio that correlates to previous reports. All IL-2 receptor subunits are 
also more abundant than the detected IL-7 receptor subunit. We furthermore detected 
the constant regions of the TCRα and TCRβ subunits at roughly the same levels. All 
CD3 receptor subunits were detected (at slightly higher abundance than the TCR 
subunits) with the CD3ε subunit being the most abundant. With the exception of the IL-
2Rα subunit all molecules are detected at levels that roughly correspond to the median 
protein abundance. IL-2Rα, CD45 and Thy1 are expressed at high levels. CD4 was not 
detected in our dataset. Of all effector molecules depicted in Figure 3.11 (B) granzyme 
B is expressed at extremely high levels (see Figure 3.8), whereas the transcription factor 
Eomes is expressed at very low levels. The balance between the transcription factor 
Eomes and T-Bet has been reported to be important for CD8 effector T cell fate 302,303; 
according to our data T-bet is significantly more abundant than eomesodermin. 
 
protein transcript abundance protein abundance 
Eomes 30 1.4x105 
T-bet 38 4.9x106 
Glut1 103 1.2x107 
Glut3 5 1.4x107 
PKM1 207* 3.3x106 
PKM2 207* 2.0x108 
 
Figure 3.10: Comparing expression levels of selected protein isoforms and 
transcription factors 
Transcript and proteins levels for Glut1/3, PKM1/2 and Eomesdodermin/T-bet are 
shown. *: The Affymetrix microarray probes are directed again a shared region of 
PKM1 and PKM2 and thus no PKM1/2 specific intensities are available. 
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Interestingly, the differences in the Eomesodermin:T-bet-ratio were more evident on the 
protein level than on the transcript level (Figure 3.10).   
 
 
Figure 3.11: Histograms of log-transformed protein abundance as estimated by 
IBAQ intensity with key CTL molecules highlighted. 
Distribution of a selection of receptor subunits expressed by CTL. (B) Histogram 
showing the distribution of markers used to characterise CTL in flow cytometry based 
assys. (C) Expression of selected nutrient transporters in CTL showing equal expression 
of the glucose transporters Glut1 and Glut3. (D) Comparison of isoform expression in 
CTL. Levels of PKM2 are more than 80x higher than PKM1 levels. The p90 RSK 
isoforms 1 and 2 are expressed at equal levels whereas Akt1 and p70 S6K1 are 
expressed at higher levels than their respective isoforms. 
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As rapidly proliferating cells CTL require a steady supply of nutrients in order to fulfil 
the metabolic demand of the rate of proliferation. In this context, the glucose receptor 
Glut1 and the large amino acid transporter Slc7a5 have been shown to be crucial for 
CTL clonal expansion81,84,227. Slc7a5 is indeed expressed at high levels whereas several 
other known amino acid transporters (Slc7a6, Slc38a/1, Slc5a1) were only expressed at 
average levels. The glucose transporters Glut1 and Glut3 were also expressed at average 
levels whereas their corresponding transcripts suggest a more than 20-fold excess of 
Glut1 over Glut3 (Figure 3.10). 
The overexpression of pyruvate kinase M2 isoform has been reported to be hallmark of 
cancer and other rapidly proliferating cells304,305 so we assessed its expression and 
compared it to the levels of the PKM1 isoform. PKM2 is highly expressed in CTL and 
approximately 60 times more abundant than the PKM1 isoform. As the Affymetrix 
micro array platform used does not include PKM1 or PKM2 specific probes this 
difference could only be picked up in our proteomics approach. Other pyruvate kinase 
isoforms were not detected in our data. We furthermore compared expression of several 
kinases of the AGC family, namely p90 RSK, p70 S6K and PKB. We could detect 
RSK1 and RSK2 at approximately equal levels whereas the RSK3 isoforms could not 
be detected. PKB1 and PKB2 were also expressed at approximately equal levels 
whereas the PKB3 was not detected. Both known homologues of p70 S6K were 
detected with S6K1 being expressed at slightly higher levels. 
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3.3. Discussion 
The results presented in this chapter show that our LFQ mass spectrometry approach in 
conjunction with SAX chromatography could successfully be adapted to the use with 
CTL. The approach proved to be robust and highly reproducible (Figure 3.2) and 
showed only little detection bias (Figure 3.3). One explanation for the slight 
underrepresentation of membrane proteins might be the use of a urea based lysis buffer 
which does not contain any detergents which might have aided the solubilisation of the 
hydrophobic membranes. However, detergents like SDS are not compatible with the 
subsequent fractionation as the detergent will bind irreversibly to the fractionation 
column and thereby render it useless. 
We detected 6800 proteins in our 3 biological replicates with more than 6500 proteins 
found in each single replicate, with an instrument time of 1 ½ days per replicate. We know 
this is not complete coverage. For example we failed to detect the transcription 
factor  Hif1α, which is known to be expressed in CTL85. Previous studies with a similar 
instrumental approach of the proteome of mouse macrophage282 or human promyelocytic 
cell lines283 led to the identification of 9469 or more than 10,000 proteins, respectively and 
thus approached near-total coverage of the predicted proteome . It is thus estimated that the 
number of proteins expressed by mammalian cells is in the order of 10,000265,306. However, 
these studies used slightly different fractionation strategies nearly tripling the samples 
numbers analysed by the machine and thus increasing run time to one week282 or used the 
same fractionation strategy but increased the sample size by pre-fractionating the human 
cell line used according to their cell cycle stage283. Moreover, these experiments used 
human cells and the human Uniprot database contains more database entries than the mouse 
database (approx. 20,000 entries for the human versus 16,000 entries for the mouse 
database). There is hence a bigger library of peptides to match any identified MS/MS 
spectra for peptides from human cells compared to the options for mouse cells. This enables 
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higher identification rates of studies of human peptides. However, the study by Ritorto et 
al.282 also illustrates the scalability of our approach which might help to close the gap of 
missing identifications of proteins.  It should be noted that one limitation is practical: 
there would be better peptide identifications with longer run times but machine access time 
is limited by funding and the need to share access with other users. 
The results depicted in Figure 3.4 show the importance of our proteomics approach. 
Transcriptional analyses have been used for a long time and are a powerful tool to study 
changes in global gene expression. However, the approximations for transcript 
intensities gained from these experiments cannot be used to predict the abundance of the 
corresponding protein as the low correlation in our experiment showed and which has 
been reported for other cell lines as well299,307,308,309,310,311,283. 
The wide range of proteins abundance spanning over seven or more orders of magnitude 
(Figure 3.7, Figure 3.8) is typical for eukaryotic cells and has been reported 
previously265,283. Despite this wide range of protein abundances, several 
macromolecular complexes like the ribosomal and 26S proteasomal complex show a 
tight and seemingly coupled regulation of the abundance of their respective subunits to 
effectively maintain the defined stoichiometry of these complexes. A similar behaviour 
can be seen with other macromoulcar complexes with a defined stoichiometry like the 
TCR (the constant regions of the α and β subunits are expressed at a roughly equimolar 
ratio) as well as the CD3 subunits whose expression levels comply with the reported 
stoichiometry of the complex. The list of the most abundant proteins acquired by our 
experiment is also similar to previous studies. However, the high expression of 
granzyme B is unique to CTL (NKT and γδ T cells) and emphasises the importance of 
this protein for effector function. Granzyme B is also the protein with the highest 
transcript levels in CTL. With the exception of the histones many of the proteins in 
Figure 3.8 also show high transcript levels indicated that high protein levels usually 
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correlate with high transcript levels which is also illustrated by the tight ribosomal 
cluster in the high transcript-high protein part of Figure 3.5, A. The discrepancy 
between the abundance of histone mRNA and protein levels can be explained by the 
lack of polyadenylation at the 3’-end of their mRNA312. As oligo(dT) primers are used 
in the generation of the cDNA which is analysed by the micro array, a lack of 
polyadenylation will inevitably lead to a underrepresentation of these transcript in the 
analysis. 
The high abundance of glycolytic enzymes also emphasises the importance of this 
metabolic pathway for CTL. Naïve T cells perform a glycolytic switch when their TCR 
is stimulated and massively up regulate glycolysis and maintain high glycolytic rates 
during their clonal expansion313,314. Nevertheless, our pathway analysis showed that 
enzymes involved in oxidative phosphorylation are also still highly expressed. The 
translational machinery of the cells is also strongly expressed and enables the rapid 
proliferation of CTL together with anabolic pathways like the pentose phosphate 
pathway. Subunits of the 26S proteasome are also expressed at very high levels which 
might indicate that the high rate of protein biosynthesis requires high proteasomal 
activity to serve as a quality control for nascent proteins as well as a regulator of 
intracellular amino acid pools315. Misfolds and other errors occurring during protein 
translation can stress a cell and lead to apoptosis316 so resolving these problems is 
crucial for cells which employ strategies like the ubiquitin-proteasome system to deal 
with the aggregation of misfolded proteins. The high levels of proteasomal subunits 
might reflect a high activity of this quality control system due to an equally high 
translational activity. 
The balance between the transcription factors T-bet and Eomesodermin is crucial for the 
formation of CD8 effector or memory T cells, with T-bet favouring an effector and 
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Eomesodermin a memory phenotype302,303,317. Our data suggests that T-bet is more than 
30 times more abundant than Eomesdermin (Figure 3.11, B) which supports this 
hypothesis. Interestingly, the transcript levels of these two proteins are roughly the same 
which suggest that non-transcriptional mechanisms are regulating the balance between 
these two proteins. The importance of other molecules is also illustrated by their high 
abundance: Slc7a5 which is essential for CTL differentiation227 is expressed at very 
high levels, particularly when compared to other amino acid transporters (Figure 3.11, 
C). As high levels of glucose are required to fuel the high proliferation rates of 
CTL228,318 glucose has to be transported into the cells at high rates by glucose 
transporters like Glut1. Glut3, which has a higher affinity as well as a higher transport 
capacity than other glucose transporters and is important in neuronal glucose 
transport319, is expressed at equal levels to Glut1 which might indicate that Glut3 is the 
most important glucose transporter in CTL and might thus be critical in maintaining 
high metabolic rates in CTL. Interestingly, transcript levels of Glut1 are 20 times higher 
than those of Glut3, indicating that differences in translational efficiency or 
posttranslational regulation are responsible for the equal protein levels of the glucose 
transporters. Another enzyme involved in glucose metabolism, pyruvate kinase is also 
expressed in the form of two different isoforms which could be distinguished in the 
proteomic analysis. The highly similar splice variants PKM1 and PKM2 are expressed 
at very different levels, with PKM2 expressed at an approximately 60-fold higher level 
than PKM1 (Figure 3.11, D). This is important as high levels of PKM2 are typical for 
cancer and other highly proliferative cells as PKM2 (and not PKM1) can exist in a 
dimeric form with low catalytic activity. At the cost of ATP generation, this lower 
catalytic activity leads to the accumulation of phosphoenolpyruvate and other glycolytic 
intermediates and thus aids cell proliferation as it supplies building blocks required for 
the synthesis of amino acids and phospholipids304. The tetrameric forms of PKM1 and 
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PKM2 show a high catalytic activity which does not show a proliferative phenotype as 
it maintains high glycolytic flux and thus does not cause the accumulation of glycolytic 
intermediates. 
Despite the high coverage of our proteome and the detection of nearly 7000 proteins, we 
noticed that we were not able to detect some proteins known to play a key role in T cell 
biology. We discussed the slight underrepresentation of membrane protein before and 
an example for a membrane protein that we were not able to identify in our approach is 
PD-1, which has emerged as an important negative regulator of the immune response of 
CTL320. But we also struggled to find several key transcription factors like Hif1-α85 
which are also known to fulfil critical roles in CD8+ effector function. This failed 
identification of these proteins further illustrates the importance of high coverage in 
quantitative mass spectrometry experiments. 
Based on this proteomic approach, the following chapter will describe the global effects 
of mTORC1 inhibition with rapamycin on the CTL proteome. 
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4. Characterisation of the mTORC1 controlled CTL proteome 
4.1. Introduction 
Whereas the previous chapter described our approach to define the global proteome of a 
cytotoxic T cell, the following chapter will investigate the effects that mTORC1 
inhibition causes in CTL. The mTORC1 complex serves as an integrator for nutrient 
availability and cytokines signalling321 and controls CTL trafficking155 as well as CD8 T 
cell differentiation200,322,177. mTORC1 is widely considered a regulator of translation323 
and hence analysis of the role of mTORC1 in regulating the CTL proteome should give 
insights as to how this drug control CTL function. 
Global proteomics approaches in the context of mTORC1 inhibition have been used 
before324, however these experiments were done using transformed cell lines and not 
primary lymphocytes thus missing cell specific effects of mTORC1 signalling 
regulation in these specific cell types.  
We therefore wished to examine the proteome of CTL exposed to rapamycin, a highly 
specific inhibitor of the mTORC1 complex. We wished to assess the impact of long 
term mTORC1 inhibition on the proteome of CTL and accordingly, the following 
chapter will describe the effects of 2 days inhibition of mTORC1 on the CTL proteome.  
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4.2. Results 
4.2.1. mTORC1 inhibition in CTL leads to decreased cell proliferation, translation 
rates and cell size 
As mentioned before, we used a well-established in vitro model of CTL differentiation 
based on LCMV P14 TCR-transgenic mice for our approach. Treatment of these cells 
with 20 nM of rapamycin led to the dephosphorylation of ribosomal protein kinase S6 
(S6K) at Thr389 and the translational inhibitor 4EBP1 at several sites (Figure 4.1, A) 
showing that treatment of CTL with rapamycin inhibits these established mTORC1 
substrates325. It has been proposed that long term inhibition of the mTORC1 complex 
can disrupt the activity of the mTORC2 complex195. The data in Figure 4.1, A show that 
long term treatment of CTL with rapamycin did not prevent the phosphorylation of PKB 
on the mTORC2 substrate sequence Ser473. Rapamycin thus selectively targets the 
activity of the mTORC1 complex in CTL even after prolonged treatment. 
mTORC1 can control cell cycle progression and thus cell proliferation in transformed 
cell lines326 and early studies showed a complete block of IL-2 driven proliferation of 
the in vitro CTL clone CTL327. We therefore examined whether IL-2 induced 
proliferation of the primary murine CTL used in the present experiments was effected 
by mTORC1 inhibition (Figure 4.1, B). CTL can undergo several cell divisions per day 
which is illustrated by the nearly 10-fold increase in cell numbers from day 4 to day 6 in 
culture. In contrast to that, the rapamycin treated CTL increased their cell numbers 
approximately 5-fold and thus showed a reduced proliferation rate. However, this rate 
still corresponds to more than one cell doubling per 24 hrs. Inhibition of mTORC1 thus 
slows down but does not fully prevent CTL proliferation. 
mTORC1 phosphorylation of 4EBP1 and S6K1 has been proposed to control protein 
synthesis in  transformed cell models238 but it is not known how mTORC1 inhibition 
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affects protein translation rates in CTL. We measured the effects of rapamycin on the 
global translation rate in CTL in a time dependent manner by monitoring the 
incorporation of a short pulse (15 mins) of radio labelled L-methionine into nascent 
proteins328. Long term inhibition with rapamycin decreased the incorporation rate of L-
methionine into proteins by 50% in a time dependant manner and thus indicates that 
mTORC1 controls protein synthesis rates in CTL. The maximal inhibition of 
methionine incorporation was achieved between the 24 h and 48 h time point. Thus we 
decided to treat CTL with rapamycin for 48 h in order to examine the steady state effect 
of mTORC1 inhibition; the term ‘long term treatment’ will thus refer to a 48 h 
treatment.  
The ability of rapamycin to decrease rates of protein synthesis made us explore the 
impact of rapamycin treatment on the cell size of CTL. The analysis of rapamycin 
treated CTL by flow cytometry indicated that these cells had reduced forward (Figure 
4.1, F) and side light scatter (Figure 4.1, E) characteristics compared to control cells 
which is indicative that these cells have reduced cell size although it could also reflect 
that rapamyicn treated CTL change in cell shape or cell granularity. We therefore 
quantified the protein content of rapamycin treated CTL compared to control CTL. 
These data (Figure 4.1, F) show a 15% reduction in the total protein content of 48 hour 
rapamycin treated CTL compared to controls. We also examined the cytoplasmic 
protein content of rapamycin treated CTL and determined a 35% reduction in 
cytoplasmic protein of long term rapamycin treated CTL compared to controls. 
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Figure 4.1: Effects of rapamycin on mTORC1 kinase activity, cell proliferation, 
protein biosynthesis and cell size 
(A) immunoblot analysis of mTOR activity in Ctrl and Rapamycin treated cells. 
Phospho-S6K and phospho-4EBP1 used as a measure of mTORC1 activity. PKB was 
used as a loading control. (B) Growth curve showing effects of mTORC1 inhibition on 
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CTL growth. Rapamycin was given from day 4 on. (C) Analysis of protein biosynthesis 
rate by methionine incorporation. (D) Flow cytometric analysis of effect of mTORC1 
inhibition on CTL forward scatter. (E) Flow cytometric analysis of effect of mTORC1 
inhibition on CTL side scatter. (F) Cell mass determination of vehicle and rapamycin 
treated cells. Comparison of total lysis (8M urea buffer) and cytoplasmic fraction (low 
detergent lysis). Data are mean ±SD or representative of at least three experiments (*, p 
≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001) 
 
 
4.2.2. Long term inhibition leads to translational reprogramming of the CTL 
proteome and not a general down regulation 
As the data in Figure 4.1, F demonstrated that long term rapamycin treatment leads to a 
decrease in overall cell mass we sought to identify the proteins down regulated due to 
mTORC1 inhibition. The protein synthesis data could thus indicate that there was a 
global reduction in the production of all cellular proteins or that there were selective 
losses of very rapidly synthesised abundant proteins. We chose a proteomic approach 
based on quantitative mass spectrometry to address the problem. We used a label-free 
quantification strategy similar to the approach chosen in the previous chapter. In short, 
we used the P14 LCMV TCR-transgenic model for in vitro generation of CTL by 
activating TCR-transgenic splenocytes with the cognate peptide KAVYNFATM for 2 
days in the presence of IL-2 and IL-12. Cells were then washed and clonally expanded 
in IL-12/IL-12 for a further 4 days. 20 nM Rapamycin or DMSO (control) were added 
to the cell culture for the last 48 hrs of clonal expansion. Cells were then urea lysed and 
digested and the resulting peptides were separated using strong anion exchange (SAX) 
chromatography. Control and rapamycin treated samples were further processed and 
submitted to reverse phase (RP) liquid chromatography coupled to Orbitrap Velos mass 
spectrometer. The data was then analysed using the label-free quantification algorithm 
of the MaxQuant package. Ratios for each protein were calculated comparing the 
peptide intensities of control and rapamycin treated samples. Three biological replicates 
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of control and rapamycin treated cells derived from three different LCMV mice were 
used for the subsequent data analysis. 
By following the aforementioned approach we could calculate the changes in protein 
expression upon rapamycin treatment for 6733 proteins in our three replicates. The 
global proteomic analyses indicated that rapamycin treatment regulated expression of 
719 proteins (as judged by a p-value of < 0.05) of which 376 proteins were decreased in 
expression and 343 proteins showed increased expression following the rapamycin 
treatment (Figure 4.2). Proteins that could only be detected in either the control or the 
untreated samples due to sensitivity issues were considered ‘not detected’ for that 
particular replicate and thus no ratio was assigned. Previous studies have shown that 
inhibition of mTORC1 with rapamycin causes CTL to decrease perforin expression and 
increase expression of CD62L (L-Selectin). Both perforin and L-Selectin were amongst 
the significant changed proteins identified in the dataset or mTORC1 regulated proteins 
(Figure 4.2). 
 
Figure 4.2: global changes in the CTL proteome induced by mTORC1 inhibition as 
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determined by LFQ SAX 
6733 protein groups were detected in 3 biological replicates. Blue/red circles represent 
reproducibly down/up regulated proteins respectively. The dashed line indicates the p ≤ 
0.05 threshold. Perforin and L-Selectin, known mTOR regulated proteins329, are marked 
in the plot. 
 
The changes in expression levels of perforin and L-Selectin/CD62L were then 
confirmed by orthogonal approaches. Flow cytometry analysis confirms the increased 
expression of CD62L on the CTL plasma membrane (Figure 4.3, A). These data have 
been previously reported155. However, CD62L is rapidly cleaved at the plasma 
membrane of CTL and thus released into the extra cellular medium. Therefore 
measuring CD62L levels in the cell culture supernatants is a more accurate way to 
monitor cellular production of CD62L. The ELISA (Figure 4.3, B) shows a more than 
100-fold increase of CD62L levels in the supernatant derived from rapamycin treated 
cells compared to control cells. 
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Figure 4.3: Effect of rapamycin on CD62L and perforin expression in CTL. 
(A) flow cytometric analysis of intracellular CD62L levels in control and rapamycin 
treated CTL. (B) ELISA analysis of CD62L cleaved from CTL surface. (C) Immunoblot 
analysis of perforin expression in CTL. SMC1 was used as a loading control. 
Data are mean ±SD or representative of at least three experiments (*, p ≤ 0.05; ***, p ≤ 
0.001) 
 
Even though we could derive a ratio for most of the proteins detected in the comparison 
between control and rapamycin treated samples, there was a sub-class of proteins for 
which this was not possible as these proteins were consistently only detected in one of 
the conditions and thus showed a theoretically infinite up or down regulation. A list 
with these proteins can be found in Figure 4.4. In order to be listed, proteins had to be 
found in one condition in at least two biological replicates but not detected in any of the 
replicates of the other condition. This was done to filter out proteins with generally low 
abundance which might have fallen below the detection limit by chance and not due to a 
genuine regulation upon mTORC1 inhibition. 
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Protein name Up / down regulated # of repl. 
Ig lambda-3 chain C region Up 2 
Isoform 2 of Zinc finger protein 1 Up 3 
Ubiquitin-conjugating enzyme E2 D1 Up 2 
Isoform Short of Extracellular matrix protein 1 Up 3 
DNA polymerase sigma Up 2 
Pre-miRNA 5-monophosphate methyltransferase Up 2 
Napsin-A Down 2 
Tumor necrosis factor Down 2 
B-cell differentiation antigen CD72 Down 2 
JmjC domain-containing protein 8 Down 2 
Zinc finger and BTB domain-containing protein 17 Down 2 
RNA exonuclease 1 homolog Down 2 
SH2 domain-containing protein 5 Down 3 
Isoform 2 of Transmembrane protein 129 Down 2 
Bifunctional apoptosis regulator Down 2 
Sprouty-related, EVH1 domain-containing protein 2 Down 2 
UBX domain-containing protein 8 Down 3 
 
Figure 4.4: Protein only found only in control or rapamycin treated cells. 
Proteins found only in control or rapamycin treated CTL. Proteins had to be detected in 
at least 2 biological replicates of the corresponding condition but not detected in any 
biological replicate of the other conditions.  
 
Among the proteins with drastic down regulation due to mTORC1 inhibition is TNF 
(tumor necrosis factor), a crucial CTL effector molecule. Another example is the UBX 
domain-containing protein 8, a protein involved in the protein proof-reading-mechanism 
of cells.  
Despite the decreased overall protein synthesis in CTL upon mTORC1 inhibition we 
found equal numbers of up and down regulated proteins in rapamycin treated cells. In 
order to understand this phenomenon we investigated the relationship between 
regulation of expression and protein abundance. The average down regulated protein is 
more than twice as abundant as the average up regulated protein (Figure 4.5) and thus 
leads to a net loss in protein content. 
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Figure 4.5: proteins down regulated due to rapamycin treatment are more 
abundant then up regulated proteins. 
Fold change of significantly changed proteins is plotted against their abundance as 
estimated by IBAQ intensity. Up regulated proteins are shown in red, down regulated 
protein in blue. Average distribution of the two populations is indicated by bell curves. 
 
 
4.2.3. Rapamycin treatment decreases the expression of CTL effector molecules 
As perforin is not the only effector molecule important for CTL function, we mined our 
dataset for potential changes in other effector molecules. As discussed above, 
rapamycin also decreased expression of TNFα (Figure 4.4). The data in Figure 4.6 show 
that rapamycin treatment also regulated expression of granzymes, a family of serine 
proteases which induce apoptosis in targeted cells330.  
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Figure 4.6: Effect of mTORC1 inhibition on effector molecule expression. 
Heatmap illustration of affected protein levels of granzyme family members, 
Lymphotoxins, perforin, Interferon-γ and IL-12 receptor subunit β-1. Red hues indicate 
up regulation of protein, white no regulation and blue down regulation. Fold changes 
and associated p-values are given. Black fields indicate no ratio determined in replicate. 
 
Rapamycin treatment of CTL led to differential regulation of effector molecules. 
granzyme A and granzyme C show up regulation, whereas perforin, Interferon-γ and IL-
12 receptor subunit β-1 are down regulated. The granzyme isoforms D, E and G are not 
affected by rapamycin treatment. In contrast to TNFα itself, other members of the TNF 
family, like lymphotoxin A and B, are not significantly down regulated upon rapamycin 
treatment. 
In order to validate the indicated drastic down regulation of IFN-γ picked up in the mass 
spectrometry experiments, we performed intracellular staining of control and rapamycin 
treated CTL (Figure 4.7, A) and measured the levels of IFN-γ secreted into CTL tissue 
culture supernatant (Figure 4.7, B). The FACS analysis confirmed the decreased IFN-γ 
expression as mTORC1 inhibition leads to a reduction in IFN-γ positive cells as well as 
reduced levels of IFN-γ in these IFN-γ positive cells. Rapamycin treatment also led to a 
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4-fold decrease of IFN-γ levels in the CTL supernatant. The proteomics experiments 
furthermore indicated a down regulation of the IL-12 receptor subunit β-1 so we used 
the phosphorylation of STAT at the Tyrosine residue 693 as a read out for functional 
IL-12 signalling331. IL-12 induces the phosphorylation of STAT4 on Y693 in the 
presence of IL-12 (Figure 4.7, C), and the phosphorylation level of  STAT4 Y693 is 
slightly decreased when cells were treated with rapamycin indicative for decreased 
signalling through the IL-12 receptor and its downstream kinases. Interestingly, IL-12 
stimulation down regulates total STAT4 levels in CTL. 
 
Figure 4.7: Validation of selected mTORC1 regulated proteins. 
(A) Flow cytometric analysis of intracellular IFN-γ levels in control and rapamycin 
treated CTL. (B) ELISA analysis of IFN-γ secretion by CTL. (C) immunoblot analysis 
of mTOR activity in Ctrl and Rapamycin treated cells. STAT4 pY693 phosphorylation 
was used as a readout for IL-12 receptor activity. SMC1 was used as a loading control. 
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Data are mean ±SD or representative of at least three experiments (*, p ≤ 0.05) 
 
 
4.2.4. Inhibition of mTORC1 leads to the up regulation of pathways involved in 
catabolic pathways and oxidative phosphorylation and down regulation of 
glycolytic and anabolic pathways 
We next performed a pathway analysis of mTORC1 regulated genes (as defined by the 
p-value obtained from student’s t-test) using the DAVID Bioinformatics resource295,296. 
The pathways which are enriched among the up (Figure 4.8) and down regulated 
(Figure 4.9) proteins are displayed. The pathway analysis revealed that several 
metabolic pathways were affected by the treatment in a distinctive way: Catabolic 
pathways like the degradation pathway of the terpenoids limonene and pinene (which 
includes enzymes responsible for the metabolism of fatty acids) and several amino acids 
degradation pathways are up regulated whereas anabolic pathways involved in protein 
translation, nucleotide biosynthesis steroid biosynthesis are down regulated. 
KEGG pathway identifier # of genes p-value 
Mismatch repair 5 4x10-4 
Oxidative phosphorylation 9 1x10-3 
Parkinson's disease 9 2x10-3 
Limonene and pinene degradation 4 2x10-3 
DNA replication 5 3x10-3 
Huntington's disease 10 3x10-3 
Valine, leucine and isoleucine degradation 5 7x10-3 
Alzheimer's disease 9 1x10-2 
Ether lipid metabolism 4 2x10-2 
Lysine degradation 4 3x10-2 
 
Figure 4.8: pathways up regulated by mTORC1 inhibition as determined by LFQ 
SAX 
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KEGG pathway identifier # of genes p-value 
Aminoacyl-tRNA biosynthesis 9 4x10-6 
Terpenoid backbone biosynthesis 5 2x10-4 
Pentose phosphate pathway 5 3x10-3 
Steroid biosynthesis 4 6x10-3 
Ubiquitin mediated proteolysis 9 1x10-2 
Glycolysis / Gluconeogenesis 6 2x10-2 
Proteasome 5 2x10-2 
Galactose metabolism 4 2x10-2 
Porphyrin and chlorophyll metabolism 4 3x10-2 
Endocytosis 10 4x10-2 
 
Figure 4.9: pathways down regulated by mTORC1 inhibition as determined by 
LFQ SAX 
 
 
A striking result was the impact of mTORC1 inhibition due to rapamycin treatment on 
proteins that control glucose metabolism in T cells. CTL treated with rapamycin down 
regulate the expression of both glucose transporters Glut1 and Glut3 and they also show 
a consequent down-regulation of multiple enzymes that control glycolysis (Figure 4.10).  
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Figure 4.10: Effects of rapamycin treatment on glycolytic enzymes in CTL as 
determined by label-free proteomics approach 
Heat map representation of enzymes involved in glycolysis and the fold changes in 
protein levels due to rapamycin treatment are shown. Red hues indicate up regulation of 
protein, white no regulation and blue down regulation. Fold changes for each protein are 
given. Black fields indicate no ratio determined in replicate. 
 
These data indicate that CTL treated with rapamycin may undergo a metabolic switch as 
enzymes in oxidative phosphorylation are up regulated and glycolytic enzymes are 
down regulated, the opposing regulation of these two metabolic pathways is highlighted 
in Figure 4.13, A. 
As rapamycin decreased the expression of the glucose transporters Glut1 and Glut3 we 
next investigated the effects of mTORC1 inhibition on the expression of all detected 
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Solute carrier (Slc) family of membrane transport families expressed by CTL. We also 
had a closer look at the expression of the system L amino acid transport system subunits 
and the transferrin transporter. We identified the expression of all subunits of the system 
L and y+L amino acid transporters, the transferrin receptor as well as 66 further Slc 
family members with varying coverage. The CD98 subunit was consistently down 
regulated by nearly 40%, and the transferrin receptor also showed a slight down 
regulation. Recent studies have shown that ASCT is an important glutamine transporter 
in T cells229 but the expression of this transporter and other possible glutamine 
transporters Slc7a6 or the large neutral amino acid transporer showed no change in 
expression due to the rapamycin treatment. The heat map for the other members of the 
Slc family members show that mTORC1 inhibition leads to both up and down 
regulation of receptors. 
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Figure 4.11: Effects of mTORC1 inhibition on expression on system L-amino acid 
transporters, the transferrin transporter and other members of the solute carrier 
membrane transport proteins. 
Heat map representation of the system L amino acid transporter subunits, transferrin 
receptor and other members of the solute carrier family of membrane transporters is 
shown. Red hues indicate up regulation of protein, white no regulation and blue down 
regulation. Black fields indicate no ratio determined in replicate. 
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Glutaminolysis utilises reactions performed by the TCA to metabolise glutamine and is 
known to play a crucial role in activated lymphocytes83. The primary L-glutamine 
transporter in T cells, ASCT2229 was not affected by rapamycin treatment (Figure 4.11), 
in contrast to the glucose transporters Glut1 and Glut3 which were drastically down 
regulated by the drug. We thus investigated whether enzymes performing the rate 
limiting steps of glutaminolysis, which feed L-glutamine into the TCA cycle by 
converting it into α-ketoglutarate, were affected by mTORC1 inhibition (Figure 4.12). 
 
Figure 4.12: Effect of mTORC1 inhibition up regulates key enzymes in 
glutaminolysis as determined by LFQ SAX 
Heat map representation of the enzymes facilitating the conversion of L-glutamine into 
α-ketoglutarate. Red hues indicate up regulation of protein, white no regulation and blue 
down regulation. 
 
We saw a consistent up regulation of all relevant enzymes upon mTORC1 inhibition, 
indicating increased glutaminolysis rates. 
We also noted that rapamycin treatment caused changes in expression of the family of 
aminoacyl-tRNA synthetases in CTL. These enzymes are involved in the esterification 
of amino acid to their cognate tRNA and thus are critical regulators of protein 
biosynthesis. The pathway analysis suggested that enzymes of this category are 
significantly enriched in the group of proteins down regulated upon mTORC1 
inhibition. However at closer inspection it became clear that rapamycin treatment of 
CTL caused down regulation of the expression of cytoplasmic isoforms of these 
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enzymes, whereas the mitochondrial isoforms of the aminoacyl-tRNA synthetases 
family show a trend towards up regulation (Figure 4.13, B). The aforementioned effect 
of mTORC1 inhibition on the anabolic pathways involved in terpenoid and steroid 
biosynthesis is further illustrated in (Figure 4.13, C). Enzymes of the pentose phosphate 
pathway, as another major anabolic pathway in CTL does not show any change upon 
mTORC1 inhibition. 
 
Figure 4.13: Selected pathways affected by mTORC1 inhibition as determined by 
KEGG analysis of LFQ dataset. 
Plots showing regulation of (A) glucose metabolism, (B) aminoacyl-tRNA biosynthesis 
in cytoplasm and mitochondria and (C) anabolic pathways. 
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In conclusion, our label-free mass spectrometry approach enabled us to detect global 
changes in genes expression of 6733 proteins induced by mTORC1 inhibition. Despite 
an even number of up and down regulated proteins we discovered a net decrease in 
protein content of rapamycin treated cells due to the preferred down regulation of high 
abundance proteins. We discovered that mTORC1 controls the expression of several 
CTL effector molecules like granzymes, Interferon-γ, perforin and affects IL-12 
signalling in CTL. Rapamycin treatment furthermore led to decreased rates of protein 
biosynthesis and other anabolic pathways. mTORC1 inhibition also led to a profound 
effect on CTL metabolism as evident by decreased levels of glycolytic enzymes but 
increased levels of proteins involved in in Glutaminolysis and OxPhos as well as 
reprogramming of nutrient transporter expression. 
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4.2.5. Our LFQ proteomics approach shows comparable results to a SILAC 
quantification based approach. 
Proteomic approaches using metabolic labelling strategies like SILAC (stable isotope 
labelling of amino acids in cell culture) are reported to be more quantitative than label 
free approaches as the combined sample processing minimises variation during the 
sample processing and analysis; these approaches are thus considered the gold standard 
in terms of accurate quantification. 
In order to use SILAC as a quantification strategy in mass spectrometry cells are grown 
in the presence of regular ‘light’ or modified ‘heavy’ amino acids, which differ in their 
molecular weight due to the incorporation of heavy H, C or N isotopes. The ‘heavy’ 
amino acids are incorporated into nascent proteins like the normal amino acids and thus 
lead to the generation of heavy peptides and proteins. Modern mass spectrometers are 
capable of distinguishing ‘light’ and ‘heavy’ peptides within in a sample and thus 
enable measurements of different experimental conditions within the same sample run. 
Biological samples that are metabolically labelled this way can be combined right from 
the beginning of the sample processing procedure and thus eliminate any bias 
introduced by different sample handling. This stands in stark contrast to our 
aforementioned label-free approach in which samples derived from different 
experimental conditions are completely run in parallel and are not combined at any 
point before the in silico data analysis. These approaches thus rely heavily on 
standardised and robust sample processing procedures to avoid introduction of any kind 
of bias. 
We wished to see if the use of quantitative SILAC proteomics would enable us to gain 
additional insights about the role of mTORC1 in regulating the T cell proteome that 
might have been missed in the label free proteomic experiments. We thus followed an 
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established protocol for the generation of SILAC labelled CTL in vitro46 and combined 
it with a subcellular fractionation followed by size exclusion chromatography (SEC) 
which separates proteins under denaturing conditions according to their molecular size 
294,332 to increase the coverage of our experiments. 
In order to control precise amino acids levels in the media used for growing and 
metabolically labelling of CTL dialysed FBS, which does not contain amino acids and 
other small molecules with a molecular weight smaller than 10 kDa, has to be used as 
naturally occurring amino acids in the FBS would interfere with the SILAC labelling. 
Previous studies in the lab had shown that CTL grown in SILAC proliferate normally 
and show normal expression of surface molecules. However, we noted that the cells 
showed decreased forward scatter when compared to cells grown in media 
supplemented with regular FBS (Figure 4.14, A). Moreover, CTL cultured in media 
where FBS was substituted with dialysed FBS show down regulated expression of 
perforin (Figure 4.14, B). This indicated to us that the SILAC labelling protocol was not 
optimal for CTL cultures. Nevertheless, cells grown in SILAC media with the dialysed 
FBS show the expected response to rapamycin treatment. For example, the data in 
Figure 4.14 show that rapamycin treatment caused a further decrease in forward scatter 
of CTL and the cells also lost mTORC1 activity as judged by a decrease in the 
phosphorylation of S6K T389 in the rapamycin treated cells compared to controls. 
Rapamycin treatment also causes CTL grown in SILAC media to further decrease levels 
of perforin (Figure 4.14, B). Accordingly we judged that it would still be useful to use 
SILAC to explore the role of mTORC1 in regulating the CTL proteome. 
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Figure 4.14: Effects of SILAC media on CTL forward scatter and effector protein 
expression. 
The effects of limited nutrient availability due to dialysed FBS are shown. (A) Flow 
cytometry analysis of CTL grown in different media. (B) Immunoblot analysis of 
perforin expression of CTL grown under different nutrient conditions. R: RPMI 
medium with FBS, D: RPMI medium with dialysed FBS, S: RPMI medium with 
dialysed FBS plus additional supplements, S+Ra: like S, but additional long term 
rapamycin treatment. 
 
The experimental approach used the same P14 LCMV TCR transgenic mouse model as 
the label-free approach. In order to facilitate the metabolic labelling of the cells, CTL 
were cultured in SILAC T cell medium after activation and clonally expanded for 4 
days. The cells were treated with rapamycin for 48 hrs before harvesting. Cells were 
then combined in a 1:1 ratio and subjected to subcellular fraction before being separated 
by size exclusion chromatography into 33 fractions and analysed via LC-MC/MS and 
analysed by the MaxQuant software package (Figure 4.15). 
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Figure 4.15: Experimental approach for SILAC quantification 
T cells were isolated from LCMV TCR transgenic mice and activated with cognate 
peptide. Antigen was washed out after 48 hours and CTL were clonally expanded for 96 
hours in ‘light’ and ‘heavy’ SILAC T cell medium. Cells were treated with DMSO 
(control) or Rapamycin for the last 48 hrs of culture. Cells were combined in a 1:1 ratio 
and subjected to a subcellular fractionation (Subcellular Protein Fractionation Kit for 
Cultured Cells, Thermo). Peptides were separated by size exclusion chromatography 
prior to analysis by an Orbitrap Velos mass spectrometer. The generated data was 
analysed using MaxQuant. 
 
We compared the different subcellular fractions obtained by the subcellular 
fractionation kit by separating the lysates via SDS-PAGE. All five band fractions 
showed different patterns of protein bands indicating that the subcellular fractionation 
indeed led to differential extraction of proteins (Figure 4.16). 
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Figure 4.16: subcellular fractionation of CTL 
Coomassie stained SDS PAGE gel showing the separation of protein via the 
fractionation protocol. CTL were separated into cytoplasmic, membrane, soluble 
nuclear, chromatin bound nuclear and cytoskeletal fraction using a commercially 
available subcellular fractionation kit. 
 
However, upon initial data analysis it became clear that the fractionations of the 
different biological replicates were not consistent enough to be confidently compared 
with each other. We thus decided to combine the protein ratios derived from each 
fraction to a total cell protein ratio. Ratios derived from each fraction were weighted 
according to the number of quantifiable events in each subcellular fraction. 
  
The SILAC approach led to the identification and quantification of 4795 proteins, of 
which 278 were down and 440 were up regulated (Figure 4.17). The mTORC1 
regulated effector molecule perforin was detected among the down regulated proteins, 
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albeit with a high p-value (0.22, detected in 2 out of the 3 replicates), whereas L-
selectin, whose expression is known to be suppressed by mTORC1 activity155, could not 
be detected in the experiment.   
 
Figure 4.17: global changes in protein expression as measured by SILAC 
approach. 
4895 protein groups were detected in 3 biological replicates. Blue/red circles represent 
reproducibly down/up regulated proteins respectively. The dashed line indicates the p ≤ 0.05 
threshold. Perforin as a known mTORC1 regulated protein is highlighted. 
 
 
 
 
Apart from perforin we detected a robust decrease in the expression of several CTL 
effector molecules (Figure 4.18). Granzyme family members B and F showed 
significantly decreased protein levels as well as the cytokines Lymphotoxin A and 
Interferon-γ. We furthermore observed a decrease in the level of the IL-12 receptor 
subunit β-1. 
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Figure 4.18: Effects of mTORC1 inhibition on the expression of CTL effector 
molecules as determined by SILAC quantification. 
Heatmap illustration of affected protein levels of granzyme family members, 
Lymphotoxin A, perforin, Interferon-γ and IL-12 receptor subunit β-1. Red hues 
indicate up regulation of protein, white no regulation and blue down regulation. Fold 
changes and associated p-values are given. Black fields indicate no ratio determined in 
replicate. 
 
 
We performed a pathway analysis using the DAVID bioinformatics tool to assess which 
pathways in a CTL are over represented in the up (Figure 4.19) or down regulated 
(Figure 4.20) proteins of our SILAC approach. Oxidative Phosphorylation and the 
Citrate cycle are among the proteins up regulated upon rapamycin treatment. Several 
other catabolic pathways related to fatty acid and amino acid metabolism were also 
included in the list. Pathways involved in DNA maintenance and replication are also 
among the up regulated proteins.  
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KEGG pathway identifier # of genes p-value 
Oxidative phosphorylation 63 4x10-46 
Parkinson's disease 62 4x10-44 
Huntington's disease 68 8x10-41 
Alzheimer's disease 62 2x10-34 
DNA replication 25 2x10-23 
Citrate cycle (TCA cycle) 15 1x10-10 
Mismatch repair 13 1x10-10 
Propanoate metabolism 13 1x10-08 
Valine, leucine and isoleucine degradation 15 5x10-08 
Nucleotide excision repair 14 2x10-07 
Cardiac muscle contraction 18 4x10-07 
Cell cycle 19 1x10-04 
Base excision repair 10 2x10-04 
Limonene and pinene degradation 6 8x10-04 
Lysine degradation 9 1x10-03 
Butanoate metabolism 8 3x10-03 
beta-Alanine metabolism 6 5x10-03 
Pyruvate metabolism 8 5x10-03 
Fatty acid elongation in mitochondria 4 7x10-03 
 
Figure 4.19: pathways up regulated by mTORC1 inhibition as determined by 
SILAC 
 
On the other hand, the list of down regulated pathways (Figure 4.20) is dominated by 
pathways involved in transcription and translation (ribosome, aminocacyl-tRNA 
biosynthesis, spliceosome), and anabolic fatty acid synthesis and glycan biosynthesis. 
Glycolysis is also down regulated. 
KEGG pathway identifier # of genes p-value 
Ribosome 59 1x10-53 
Aminoacyl-tRNA biosynthesis 13 1x10-06 
Terpenoid backbone biosynthesis 7 4x10-05 
Protein export 5 5x10-04 
Proteasome 10 7x10-04 
SNARE interactions in vesicular transport 8 3x10-03 
Glycolysis / Gluconeogenesis 10 9x10-03 
N-Glycan biosynthesis 8 1x10-02 
Spliceosome 14 1x10-02 
 
Figure 4.20: pathways down regulated by mTORC1 inhibition as determined by 
SILAC 
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As glycolytic and other metabolic enzymes were among the list of pathways regulated 
by rapamycin treatment, we focussed on these pathways and investigated the whole full 
extent of their regulation.  
 
Figure 4.21: Effects of mTORC1 inhibition on expression of glycolytic enzymes as 
determined by SILAC. 
Heat map representation of enzymes involved in glycolysis and the fold changes in 
protein levels due to rapamycin treatment are shown. Red hues indicate up regulation of 
protein, white no regulation and blue down regulation. Fold changes for each protein are 
given. Black fields indicate no ratio determined in replicate. 
 
Figure 4.21 shows the consequent down regulation of glycolytic of nearly every 
glycolytic enzyme. The glucose transporters Glut1 and Glut3 show the highest decrease 
in protein levels due to rapamycin treatment. 
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Due to the striking effect on Glut1 and Glut3 we then examined the global effect on 
nutrient transporter expression CTL. We determined changes in the protein ratio of the 
system L and y+L amino acid transporters subunits, ASCT2, the transferrin receptor and 
46 other members of the family of solute carrier membrane transport proteins (Figure 
4.22). 
 
Figure 4.22: mTORC1 inhibition leads to reprogramming of nutrient transporter 
expression in CTL 
Heat map representation of the system L amino acid transporter subunits, transferrin 
receptor and other members of the solute carrier family of membrane transporters is 
shown. Red hues indicate up regulation of protein, white no regulation and blue down 
regulation. Black fields indicate no ratio determined in replicate. 
 
Rapamycin treatment of CTL led to a down regulation of the Large amino acid 
transporter subunit 1 (Slc7a5) as well as CD98, both protein together form the System L 
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amino acid transporter. The glutamine transporter ASCT2 and transferrin receptor 
CD71 were also slightly down regulated. mTORC1 inhibition also led to changes in the 
expression of many members of the Slc family as illustrated by different proteins being 
up and down regulated due to the drug treatment. 
We further investigated whether enzymes involved in glutaminolysis were up regulated 
as an effect of the mTORC1 inhibition, as the slight effect on ASCT2 indicated an 
effect on L-glutamine uptake. 
 
Figure 4.23: Effect of mTORC1 inhibition up regulates key enzymes in 
glutaminolysis as determined by LFQ SAX 
Heat map representation of the enzymes facilitating the conversion of L-glutamine into 
α-ketoglutarate. Red hues indicate up regulation of protein, white no regulation and blue 
down regulation. 
 
All enzymes detected by our SILAC experiment showed increased expression by 
approx. 25% upon rapamycin treatment. 
 
Figure 4.24 further highlights some of the findings regarding findings of the pathway 
analysis of the SILAC (A-C) dataset. The differential regulation of OxPhos when 
compared to glycolytic enzymes can be seen (Figure 4.24, A), with the importance of 
mitochondrial pathways further emphasised by up regulation of the mitochondrial 
translational machinery in from of ribosomal subunits (Figure 4.24, B) and, to a certain 
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extent, members of the aa-tRNA synthetases (Figure 4.24, C).  Cytoplasmic subunits on 
the other hand tend to be down regulated. 
 
 
Figure 4.24: Selected pathways affected by mTORC1 inhibition as determined by 
KEGG analysis of SILAC dataset. 
Plots showing regulation of (A) effector molecules, (B) glucose metabolism, (C) 
ribosomes and (D) aminoacyl-tRNA biosynthesis in cytoplasm and mitochondria. 
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4.2.6. mTORC1 does not control Eomesodermin or T-bet expression 
It has been reported that the mTORC1 complex controls the balance of the two crucial 
transcription factors Eomesodermin and T-bet177 by supressing Eomesodermin and 
promoting T-bet expression. We thus analysed our datasets to see whether we could 
find any evidence for this hypothesis of CD8 differentiation control (Figure 4.25). 
Neither the label-free nor the SILAC data set showed any robust up regulation of 
Eomesodermin. The SILAC data showed a slight increase of T-Bet upon mTORC1 
inhibition which contradicts previous studies177.  
 
protein name gene name fold change SAX (p-value) 
fold change 
SILAC (p-value) 
Eomesodermin Eomes 1.56 (0.17) 0.92 (0.36) 
T-bet Tbx21 1.14 (0.42) 1.47 (0.04) 
 
Figure 4.25: effect of mTORC1 inhibition on expression levels of Eomoesdermin 
and T-bet 
The fold changes derived from LFQ and SILAC approach for the transcription factors 
Eomesodermin and T-bet are shown. 
 
We further validated the results derived from the proteomic approaches by 
immunoblotting (Figure 4.26). The western blot analysis confirmed the MS data and 
showed no difference in T-bet expression upon mTORC1 inhibition with rapamycin. 
 
Figure 4.26: mTORC1 inhibition does not affect expression levels of T-bet. 
Immunoblot to investigated T-bet expression levels in control and rapamycin treated 
CTL.  
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4.2.7. Validation of metabolic changes induced by mTORC1 inhibition 
We then wanted to validate the effects of sustained rapamycin treatment on CTL 
metabolism. The mass spectrometry based approaches showed a decrease in the glucose 
transporters Glut1 and Glut3, so we used immunoblotting to validate the control of 
Glut1 expression by mTORC1 (Figure 4.27). 
As an increase in enzymes involved in oxidative phosphorylation predicts increased 
oxygen consumption we used a Seahorse analyser to measure the oxygen consumption 
rate of control and rapamycin treated CTL (Figure 4.27, B). However, we could not find 
any differences in the two populations at any time of the mitochondrial stress test, 
which not only determines the baseline oxygen consumption rate (first three time 
points) but also the maximally possible cellular respiration rate and (and thus the spare 
respiratory capacity as determined at time points 7 - 9). In contrast to this finding, we 
could detect changes in the extracellular acidification rate (ECAR) which was measured 
in parallel to the oxygen consumption rate and is an indicator for the glycolytic activity 
of cells due to the excretion of lactic acid. There was a twofold decrease in the baseline 
ECAR as a result of rapamycin treatment (Figure 4.27, C, first three time points) and 
also a significant difference in the total glycolytic capacity (as seen by ECAR values at 
later time points). In a published study85 we furthermore directly measured the levels of 
lactate secretion by CTL treated with rapamycin as well as the uptake of glucose by 
measuring the uptake of radio labelled 2-deoxyglucose. Both measures of glycolytic 
activity were decreased by more than 2-fold, and thus further validate our findings.  
CTL maintain high proliferation rates even when long term treated with rapamycin 
(Figure 4.1, B) despite down regulation of the glycolytic pathway (Figure 4.13, B; 
Figure 4.27, A, C) and glucose uptake85 and a lack of compensation of ATP generation 
by other mechanisms (Figure 4.27, B). On the other hand, while glycolysis was down 
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regulated due to rapamycin treatment, we noticed an up regulation of the enzymes in the 
conversion of L-glutamate into α-ketoglutarate (Figure 4.12, Figure 4.23), indicative for 
higher glutaminolytic activity. We thus measured the glutaminolysis activity in CTL 
treated with or without Rapamycin by measuring the formation of 14CO2 derived from 
L-glutamine83 and detected a more than 50% higher glutaminolytic rate in the 
rapamycin treated cells (Figure 4.27, D). 
 
 
Figure 4.27: Effects of mTORC1 on CTL metabolism. 
(A) Immunoblotting for the glucose transporter Glut1 validates down regulation of 
expression upon rapamycin treatment. (B) Oxygen consumption rate (OCR) and (C) 
extracellular acidification rate (ECAR) as indicators for oxidative phosphorylation and 
glycolytic rates were determined using a Seahorse Analyser. Rates for control (grey 
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circles) and rapamycin treated (red circles) are shown. Arrows in (B) and (C) indicate 
the addition of inhibitors of the electron transport chain; oligo: oligomycin; DNP: 2,4-
dinitrophenol; AA: antimycin A; rot: rotenone  (D) glutaminolytic rates of CTL were 
determined by measuring 14CO2 release from [1-14C]-glutamine Data are mean ±SD or 
representative of at least three experiments (**, p ≤ 0.01) 
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4.3. Discussion 
This is the first time to our knowledge that the impact of mTORC1 inhibition on global 
protein expression levels has been assessed using a proteomics work flow.  
The results above describe the impact of mTORC1 inhibition on the CTL proteome. 
The most striking result from the data is that mTORC1 is not a global regulator of 
translation in T cells. It has very selective effects and only controls expression of a very 
small subset of the CTL proteome. 
 
4.3.1. Comparison between SILAC and label-free approach 
Two different strategies were used to probe the role of mTORC1 on the CTL proteome: 
A SILAC and a label-free quantification approach. The SILAC approach relies on the 
metabolic labelling of protein in vitro which requires high proliferation rates of the 
desired cells in suboptimal tissue culture media. However, the metabolic labelling 
enables very robust quantification, as samples can be combined right from the 
beginning of the sample processing work flow and thus avoid technical bias. SILAC is 
thus considered to be the gold standard in quantitative proteomics. The label-free 
approach on the hand does not require any metabolic or chemical labelling of the 
protein to be analysed and is thus adoptable to any protein sample, so primary, 
quiescent cells can be quantified and compared to highly proliferative transformed 
tumour cell lines. This flexibility comes at a cost, as label-free approaches require a 
highly reproducible and robust work flow to introduce as little bias as possible into the 
analysis and thus cannot compete with the accuracy of a SILAC approach. 
However, the data presented in this chapter illustrate that using a label-free 
quantification approach yielded very similar results as a SILAC based quantification. 
The LFQ approach also led to the identification of a significant higher number of 
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protein ratios (6733 for LFQ vs 4795 for SILAC) for which the more complicated 
MS/MS spectra in SILAC approaches can be held responsible. A relevant example for a 
protein that had been missed in the SILAC analysis is L-selectin, emphasising the 
importance of a high coverage of the proteome. The effects of the SILAC media on 
perforin expression (Figure 4.14) illustrates another disadvantage of the SILAC 
approach: As the less nutritious SILAC media is affecting baseline expression levels of 
perforin (and probably a range of other proteins as well) it impedes the detection of 
these proteins in the proteomics experiments which is also exemplified by the fact that 
perforin could only be detected in two out of three SILAC experiments but in all three 
replicates of the SAX approach. However, the higher accuracy of the SILAC approach 
is shown by the fact that the average statistical significance of the obtained proteins 
ratios was higher than in the LFQ approach. This increased accuracy did nevertheless 
not lead to major differences on the outcome of the subsequent analysis.  
One problem that was apparent from the label free analysis when analysing the effect of 
mTORC1 on the expression of nutrient transporters was the amount of missing data 
points, i.e. problems with the robust identification of these protein. This can be 
explained by the fact in the label free experiments we used urea based lysis buffers and 
this may not be optimal for solubilisation of membrane spanning proteins that contain 
hydrophobic stretches which lead to a poor solubility of these proteins in urea based 
lysis buffers. Thus biophysical properties are most likely the reason for the 
underrepresentation of membrane spanning proteins as mentioned in the previous 
chapter which ultimately explains the missing data points. In the SILAC protocol we 
used a subcellular fractionation approach which made use of different detergent based 
buffers including a dedicated membrane fraction buffer. Hence the identification of 
membrane proteins was not as big a problem in the SILAC approach. The SILAC 
approach allowed the usage of detergent based lysis buffers as the subsequent size 
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exclusion chromatography was compatible with detergents, whereas the strong anion 
exchange chromatography used for the label free approach was not. However, 
alternative lysing techniques are now enabling the usage of detergents, as they allow the 
removal of these substances after cell lysis. 
 
4.3.2. What were the major conclusions from the mTORC1 proteomic 
experiments?  
Firstly, inhibition of mTORC1 causes down regulation of a whole range of CTL 
effector molecules like several granzymes, perforin, Interferon-γ and the IL-12 receptor. 
The term “foot soldiers” has been used to describe CTL and sticking to ‘foot soldier’ 
analogy inhibition of mTORC1 in CTL has the effect of disarming the troops of the 
immune system. 
Our CTL do not show a significant effect on mTORC2 signalling due to long term 
mTORC1 inhibition with rapamycin whereas reports in the literature have shown that 
long term inhibition of mTORC1 also disrupts mTORC2 signalling195 in transformed 
cell lines. The authors propose a mechanism by which prolonged inhibition of the 
mTOR-Raptor leads to the removal of available mTOR subunits and thus eventually 
decreases free mTOR levels so that mTORC2 signalling is also affected. However, the 
authors of the study also conclude that the magnitude of this effect depends on the cell-
line and relative expression levels of mTOR, Raptor and Rictor subunits and is thus not 
necessary a general phenomenon. We know from our experiments in the previous 
chapter that mTOR is approx. twice as abundant as Rictor which in turn is expressed at 
more than 5-fold higher levels than Raptor. Thus even inactivating all mTOR-Raptor 
complexes by rapamycin treatment in a CTL would not be sufficient to remove all 
available mTOR molecules in order to affect mTORC2 signalling. 
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One of the most striking effects of mTORC1 inhibition of the T cell proteome was the 
effect of rapamycin on glucose uptake and glycolysis.  A key finding was that mTORC1 
activity is required for immune-activated CD8+ T cells to sustain high rates of glucose 
uptake. mTORC1 activity is also necessary for CD8+ T cells to initiate and sustain a 
switch to a glycolytic metabolism. One way in which mTORC1 controls glucose uptake 
in CD8+ T cells is by controlling expression of the glucose transporter Glut1. CD8+ T 
cells also show mTORC1 dependence for the expression of hexokinase 2, a key enzyme 
which phosphorylates glucose to produce glucose-6-phosphate, an essential 
intermediate in most pathways for glucose metabolism. Importantly, mTORC1 controls 
expression of key rate-limiting glycolytic enzymes in CD8+ T cells such as 
phosphofructokinase 1, lactate dehydrogenase, and pyruvate kinase M2. 
The high glycolytic rate of CTL is thought to be essential to meet the metabolic 
demands caused by the rapid proliferation of clonally expanding CD8+ T cells. 
However, despite the down regulated glycolytic enzymes and decreased glucose uptake, 
rapamycin treated CTL still maintain an impressive proliferation rate. How do 
rapamycin treated cells fuel their proliferation? Glutaminolysis has been reported to be 
important in the proliferation and effector function of T cells83,229. At the same time that 
CTL down regulate glycolysis rates due to mTORC1 inhibition they also show an up 
regulation of glutaminolysis as an alternative measure of generating ATP and supplying 
substrates for anabolic pathways. L-glutamine is the most abundant free amino acid in 
the blood stream333 and might represent an important energy for source for cells when 
blood glucose levels are low. It has been shown that mTOR signalling controls the 
trafficking of T cells155 and that T cells treated with rapamycin home to lymph nodes. 
The rapamycin induced switch from the utilisation of glucose to glutamine might thus 
also represent a mechanism by which T cells adapt to the different nutrient levels in 
blood and lymph. Unfortunately, not much is known about nutrient levels in the lymph 
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to further support this possibility. TORC1 inhibition also led to a diverse regulation of 
nutrient transporters as illustrated by the different effects of long term rapamycin 
treatment on the expression of solute carrier membrane transporters. In combination 
with the increased expression of subunits of the electron transport chain this illustrates 
that mTORC1 inhibition leads to a complicated regulation of CTL metabolism rather 
than a general down regulation. However, this reprogramming does not justify the term 
“metabolic switch” as CTL do not completely switch from using glycolysis to OxPhos 
to fulfil their energetic demand but merely show a shift in the relative importance of 
these pathways, as OxPhos levels are not changed upon mTORC1 inhibition. 
One of the frequent generalisations about the role of mTORC1 is that it controls protein 
synthesis. The impact of rapamycin on methionine incorporation rates into nascent 
proteins is consistent with this idea. However, the conclusions from the global 
proteomic data show that rapamycin effects on the proteome are complex. There was  a 
decrease in the total protein content of a rapamycin treated cell but  in mTORC1 caused 
loss of only 300-400 of the proteins that make up a CTL approx. 6000 either remained 
expressed at the same level and 350 were actually increased in expression.  
We had a closer look at the abundance levels of up and down regulated proteins. 
Despite up and down regulating approximately equal numbers of proteins, the 
abundance levels of the affected pathways are very different. We have shown in the 
previous chapter that some of the most abundant proteins of a CTL are enzymes 
involved in glycolysis or the splicing apparatus as well as the subunits of ribosomes and 
the proteasome. All these pathways and protein complexes are down regulated upon 
rapamycin treatment and thus explain the decrease in overall cell size in rapamycin 
treated CTL. 
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The coordinated down regulation of ribosomal subunits and the aminoacyl-tRNA 
loading apparatus also illustrates that CTL down regulate their whole translational 
machinery to adapt to decreased protein translation demands. It has been shown in 
transformed cell lines that mTOR regulates the transcription of ribosomal RNA (rRNA) 
and mRNA334 the consequences of this regulation had never been shown on the protein 
level on a global scale before, particularly not for CTL. Thoreen et al.239 illustrate in 
another study in mouse embryonic fibroblasts that mTORC1 signalling regulates the 
translation efficiency of mRNA containing a 5’ terminal oligopyrimidine (TOP) motif. 
This study also highlights the differences between expression control of cytoplasmic 
and mitochondrial ribosomes, as only the cytoplasmic isoforms, which are known to 
contain a 5’-TOP motif335, showed a decrease in expression upon mTORC1 inhibition. 
The mitochondrial isoforms of both ribosomes and aa-tRNA synthetases on the other 
hand are not affected or even show a slight up regulation (Figure 4.13; Figure 4.24). 
This suggests a) a different mechanism by which these isoforms are regulated and b) a 
special role for mitochondria in the context of mTORC1 inhibition. 
One of the more surprising results from the proteome work was that inhibition of 
mTORC1 caused increases in the expression of a subset of proteins and in some cases 
e.g. in the case of CD62L the increases in expression were quite large (Figure 4.3, A - 
B). These data could reflect that certain proteins are more effectively translated in the 
absence of mTORC1 activity. It could also reflect that mTORC1 controls protein 
degradation pathways. In this respect, a recent study by Zhang, et al.240 illustrated the 
role of the 26S proteasome in protein homeostasis by regulation general global protein 
half-life. This study showed that proteasomal expression is regulated by mTORC1 
signalling and that mTORC1 inhibition led to a global decrease in protein turnover. 
However, the down regulation of the proteasome is unlikely to be the sole the 
mechanism by which proteins are up regulated upon mTORC1 inhibition as it is not the 
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26S proteasome itself that targets specific proteins for degradation but the interplay of 
ubiquitin-activating (E1), -conjucating (E2) and ligating (E3) enzymes336.  The pathway 
analysis of proteins down regulated upon rapamycin treatment (Figure 4.9) shows 
indeed that proteins involved in “ubiquitin mediated proteolysis” are affected and 
Figure 4.4 also contains several enzymes involved in the regulation of ubiquitinylation. 
Recent studies have shown how sophisticated mass spectrometry based approaches310,337 
can be used to assess global turnover rates of protein in a cell which would tell us 
whether differences in translation efficiencies or protein half-lives are indeed the 
mechanism by which mTORC1 inhibition leads to the up regulation of proteins. 
 
Another obvious mechanism by which protein levels could be regulated is the control of 
transcription of the corresponding mRNA. The following chapter will thus present the 
data we obtained from a global transcriptomic analysis of long term rapamycin treated 
cells using the Affymetrix micro array platform.   
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5. Control of gene CTL gene transcription by mTORC1 
5.1. Introduction 
The previous chapter described the changes induced by long term mTORC1 inhibition 
on the total proteome of CTL. However, these experiments did not tell us how 
mTORC1 controls protein levels in CTL. mTORC1 is usually perceived as a regulator 
of translation and less so of transcription. However, as the long term mTORC1 
inhibition might have induced changes on the transcriptome (due to indirect effects) as 
well as on the proteome, we decided to use a global transcriptomic approach to 
investigate the role of mTORC1 in controlling the CTL transcriptional program. 
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5.2. Results 
After having described the effects of rapamycin treatment on the proteome of CTL we 
used a transcriptional approach to investigate the effects of mTORC1 inhibition on 
global transcription in CTL. We used the Affymetrix Mouse genome 430.2 platform to 
measure the expression levels of thousands of transcripts in parallel. The assay utilises 
oligonucleotide probes which hybridise to targeted transcripts and thus enable an in 
vitro transcription to generate a library of reverse transcripts complementary to the 
cDNA generated from the biological sample. The complimentary RNA is then 
biotinylated, fragmented and hybridised to an array of approx. 45000 probes 
immobilised on the array. The array is then stained with fluorescent tags which bind to 
the biotinylated samples. The samples are then excited by a laser source and the 
resulting fluorescence can be used to assign intensity values to each probe set which can 
be linked to specific genes. 
We generated cDNA samples derived from control and long term rapamycin treated 
CTL from three different mice; differences in cell size and lack of S6K Thr389 
phosphorylation were used as validation for effective mTORC1 inhibition. The 
Affymetrix analysis was performed by Eveliina Vertanen at the Turku Centre for 
Biotechnology, Finland.   
  
5.2.1. mTORC1 leads to reprogramming of CTL transcription 
The mouse genome 430.2 platform includes 45000 probes corresponding to 
approximately 34000 genes, of which 10521 were expressed in our dataset. The levels 
of 618 transcripts were robustly affected by the rapamycin treatments by more than 1.5-
fold, with 327 transcripts being up and 291 transcripts being down regulated (Figure 
5.1). mTORC1 inhibition thus led to equal up and down regulation of transcripts in 
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CTL. The most up regulated transcript were those of L-Selectin which has been shown 
to be controlled by mTORC signalling155 whereas the most down regulated transcripts 
were those of several granzyme isoforms as well as Interferon-γ and perforin which are 
all essential for cytolytic effector function. The glucose transporters Glut1 and Glut3 are 
also ranked among the most down regulated transcripts. 
 
Figure 5.1: micro array analysis of mTORC1 controlled transcriptome. 
Transcripts are ranked by their fold change upon rapamycin treatments in ascending 
order. Down regulated transcripts are highlighted in blue, up regulated transcript in red. 
A selection of the most regulated genes is annotated. 
 
 
All significantly changed genes with a difference in expression of more than 1.5-fold 
were then subjected to pathway analysis using the DAVID tools which is based on the 
KEGG databank. The up regulated genes are enriched in pathways involved in the 
regulation of the cell cycle and general DNA maintenance (Figure 5.2). 
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KEGG pathway identifier # of genes p-value 
Cell cycle 17 2x10-11 
DNA replication 5 2x10-3 
Oocyte meiosis 7 6x10-3 
Homologous recombination 4 7x10-3 
Progesterone-mediated oocyte maturation 6 7x10-3 
Base excision repair 4 2x10-2 
Mismatch repair 3 4x10-2 
Ubiquitin mediated proteolysis 6 5x10-2 
Pyrimidine metabolism 5 5x10-2 
 
Figure 5.2: Pathway analysis of up regulated transcripts. 
 
The down regulated genes on the other hand (Figure 5.3) are enriched in genes which 
are either components of glycolysis (including Glut1, Glut3, hexokinase 2, 
phosphofructokinase and the aldolase isoforms 1 and 3) and other metabolic pathways 
or anabolic pathways involved in the biosynthesis of terpenoids and steroids, including 
HMG-CoA reductase, a major rate limiting enzyme of these pathways. 
 
KEGG pathway identifier # of genes p-value 
Steroid biosynthesis 5 2x10-4 
Terpenoid backbone biosynthesis 4 2x10-3 
Glycolysis / Gluconeogenesis 6 6x10-3 
Valine, leucine and isoleucine degradation 5 8x10-3 
Alanine, aspartate and glutamate metabolism 4 1x10-2 
Fructose and mannose metabolism 4 3x10-2 
Insulin signaling pathway 7 3x10-2 
Pyruvate metabolism 4 3x10-2 
 
Figure 5.3: Pathway analysis of down regulated transcripts 
 
 
Closer interrogation of the results of the pathways analyses revealed that mTORC1 
activity is required for the expression of many effector molecules (Figure 5.1), as many 
of these molecules were down regulated upon rapamycin treatment. However, we saw 
quantitative differences between several granzyme family members. The family 
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members A, B and C only show moderate down regulations whereas D, E, F and G are 
down regulated by at least seven-fold (Figure 5.4). Tumor necrosis factor showed a 
slight decrease in transcript levels upon rapamycin treatment, whereas Lymphotoxin A, 
another member of the TNF family, showed a strong transcriptional down regulation 
due to the drug treatment. Lymphotoxin B was not affected. Other effector molecules 
down regulated by the rapamycin treatment are IFN-γ and the IL-12 receptor subunit β-
1. 
 
Figure 5.4: mTORC1 controls CTL effector molecule transcription. 
Heat map showing the fold changes in transcript levels of selected effector molecules. 
The fold change of each molecule is also indicated. Red hues indicate up regulated 
genes, blue hues down regulated genes. 
 
We then investigated the effect of mTORC1 inhibition on the transcription of metabolic 
enzymes as these pathways were enriched in the pathway analysis (Figure 5.5, A). 
Rapamycin treatment led to a general decrease in glycolytic gene transcription with an 
average decrease in transcription levels by 25%. However, several transcript levels were 
significantly decreased by more than 50%; in fact, the two glucose transporters Glut1 
and Glut3 are amongst the most down regulated transcripts in a CTL upon mTORC1 
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inhibition. We then compared the effect on glycolytic gene transcriptions with the 
effects on the level of genes transcribing genes of the electron transport chain (Figure 
5.5, B). There was no effect on the transcription on any of the complexes I – IV or the 
ATP synthase subunits. There was however, an effect on all three micro array probes of 
a single subunit of complex IV, Cox7a2l, which was consistently up regulated by 
approximately 50%. 
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Figure 5.5: Transcriptional regulation of glycolysis but not OxPhos by mTORC1. 
Heat map showing the fold changes in transcript levels of glycolytic enzymes and 
subunits of the complexes I – IV of the electron transport chain and the ATP synthase. 
The fold change of each molecule is also indicated. Red hues indicate up regulated 
genes, blue hues down regulated genes. 
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As we noticed a drastic down regulation of the glucose transporters Glut1 and Glut3 
upon mTORC1 inhibition, we examined whether other members of the Solute Carrier 
transport protein family which are expressed in CTL (Figure 5.6). We were particularly 
interested in the changes of transcription of the LAT1 (Slc7a5/CD98 heterodimer) and 
y+LAT (Slc7a6/CD98 heterodimer) amino acid transporter subunits, the glutamine 
ASCT2 and the transferrin receptor CD71 as these transporters are known to be 
important for T cell biology. Apart from the three aforementioned SLC members and 
the transferrin receptor our micro array revealed the expression of another 83 members 
of the SLC membrane transporter family (Figure 5.6). 
The LAT1 amino acid transporter showed a down regulation of both complex subunits 
due to mTORC1 inhibition whereas the y+LAT2 subunit was not affected. ASCT was 
also consistently down regulated. The transferrin receptor was not affected by 
rapamycin treatment. 
Of all up and down regulated transporters that we say in our micro array experiment, the 
two glucose transporters mentioned before showed the strongest down regulation due to 
rapamycin treatment. On the other hand, Slc30a4, a zinc transporter, was the most up 
regulated transporter detected when CTL were treated with the drug. 
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Figure 5.6: mTORC1 inhibition leads to a reprogramming of nutrient transporter 
transcription 
Heatmap representation of all solute carrier family members expressed in CTL. The fold 
change of each molecule is also indicated. Red hues indicate up regulated genes, blue 
hues down regulated genes. 
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We noted some decrease in the expression of mRNA encoding the principal L-
glutamine transporter ASCT2 in rapamycin treated CTL. We therefore wondered 
whether there were changes in transcript levels of enzymes faciliting the reactions 
which convert L-glutamine into α-ketoglutarate which initiate the glutaminolytic 
pathway (Figure 5.7). 
 
Figure 5.7: Effect of rapamycin treatment on the transcript levels of proteins 
initiating glutaminolysis. 
Heatmap representation of the enzymes involved in the conversion of L-glutamine into 
α-ketoglutarate. The fold change of each molecule is also indicated. Red hues indicate 
up regulated genes, blue hues down regulated genes. 
 
The transcript levels of Gls, which catalyses the first reaction of glutaminolysis, were 
not affected by mTORC1 inhibition. Got2 was also not affected by rapamycin 
treatment, whereas Glud1 and Gpt reproducibly showed moderate up or strong down 
regulation, respectively.  
We then further investigated the expression of mRNA encoding proteins that mediate 
the synthesis of the anabolic intermediate isopentenyl pyrophosphate as well as 
transcripts encoding for enzymes involved in the biosynthesis of cholesterol.The 
proteomic data had shown loss of expression of proteins in these pathways in CTL 
treated with rapamycin. Figure 5.8 shows a moderate but consistent regulation of the 
corresponding transcripts. 
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Figure 5.8: Terpenoid and steroid biosynthesis enzymes transcription is reduced 
upon mTORC1 inhibition. 
Heat map representation of the effects on mTORC1 inhibition on the transcription of 
genes involved in terpenoid and steroid biosnyhtesis. The fold change of each molecule 
is indicated. Red hues indicate up regulated genes, blue hues down regulated genes. 
 
 
It has been reported before that mTORC1 inhibition of CTL leads to increased 
expression of the adhesion molecule L-Selectin/CD62L155, and transcripts encoding 
CD62L are indeed the most drastically up regulated transcript in our micro array data. 
CD62L controls T cell trafficking338 and we thus investigated whether CTL  expression 
of mRNA encoding other adhesion molecules or chemokines and chemokine receptors  
are affected by mTORC1 inhibition (Figure 5.9).  
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Figure 5.9: mTORC1 controls the expression of chemokines, chemokines receptor 
and adhesion molecules. 
Heat map representation of changes in transcription of selected chemokines, chemokine 
receptors and adhesion molecules. The fold change of each molecule is indicated. Red 
hues indicate up regulated genes, blue hues down regulated genes. 
 
 
Of all molecules that are potentially involved in chemotaxis and trafficking of CTL, 
CCL5, CCR7, CXCR3 and CD62L showed increased transcript levels upon rapamycin 
treatment, whereas CCL4 was transcribed at lower rates in rapamycin treated cells.   
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5.2.2. Comparison between transcriptome and proteome analyse 
We described the changes on protein expression in a CTL treated with rapamycin in the 
previous chapter and investigated the mTORC1 controlled transcriptome in the 
beginning of this chapter. How do the data compare? The biological samples for our 
micro array analysis were generated from the same cells used for the SILAC 
proteomics, so we will compare these two data sets with each other. 
Generally speaking, we detected 10521 transcribed genes in our micro array of which 
327 transcripts were up and 291 transcripts down regulated. On the other hand, our 
SILAC quantified 4795 proteins, of which 278 were down and 440 were up regulated. 
Out of the up regulated proteins, 72 were up regulated on the transcriptome (16%), 
whereas 68 (24%) out of significantly down regulated proteins were also down 
regulated on the transcriptome. 
We then looked at the most drastically changed proteins within our SILAC data set to 
investigate the correlation between transcript and protein correlation in more detail. 2 
out of the 10 most up regulated proteins were already up regulated on the transcript 
level (Figure 5.10), whereas 7 out of the 10 most down regulated proteins were also 
down regulated on the transcript (Figure 5.11). At this point it is worthwhile to point 
out, that for 4 out of these 20 proteins no micro array probe was available. 
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Protein name Gene name SILAC fold change 
transcript 
regulated? 
PDZ domain-containing protein Pdzd11 13.5 NO 
Uncharacterised protein KIAA2022 Kia2022 10.2 N/A 
Dymeclin Dym 9.1 NO 
Programmed cell death protein 4 Pdcd4 2.7 YES 
Interferon-induced guanylate-binding 
protein 2 
Gbp2 2.5 YES 
O-acetyl-ADP-ribose deacetylase 
MACROD1 
Macrod1 2.5 NO 
SUN domain-containing protein 2 Sun2 2.2 N/A 
C-type lectin domain family 2 member D Clec2d 2.0 NO 
Epimerase family protein SDR39U1 Sdr39u1 1.9 N/A 
Placenta-specific gene 8 protein Plac8 1.9 NO 
 
Figure 5.10: Correlation between transcript and protein levels of most up 
regulated proteins. 
Comparison between protein changes and underlying transcript changes for 10 most up 
regulated proteins upon rapamycin treatment. N/A indicates missing micro array probes 
for that specific protein. 
 
Protein name Gene name SILAC fold change 
transcript 
regulated? 
Protein slowmo homolog 2 Slmo2 0.24 NO 
Granzyme F Gzmf 0.29 YES 
Interferon gamma Ifng 0.33 YES 
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic Hmgcs1 0.39 YES 
Asparagine synthetase [glutamine-
hydrolyzing] Asns 0.43 YES 
Complement component C1q receptor Cd93 0.43 YES 
Glia-derived nexin Serpine2 0.47 YES 
Protein FAM134B Fam134b 0.50 N/A 
Fos-related antigen 2 Fosl2 0.53 YES 
E3 ubiquitin-protein ligase ZNRF2 Znrf2 0.53 NO 
 
Figure 5.11: Correlation between transcript and protein levels of most down 
regulated proteins. 
Comparison between protein changes and underlying transcript changes for 10 most 
down regulated proteins upon rapamycin treatment. N/A indicates missing micro array 
probes for that specific protein. 
 
 
Moving away from single protein comparison we were then wondering how CTL 
regulate the different pathways that we detected to be controlled by mTORC1. We 
compiled all pathways that we found to be regulated by mTORC1 and investigated 
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whether these pathways were found to be regulated on the transcriptional, translational 
or both levels. 
 
Up regulated pathway transcriptome proteome 
Cell cycle YES YES 
DNA replication YES YES 
Base excision repair YES YES 
Mismatch repair YES YES 
Oocyte meiosis YES NO 
Homologous recombination YES NO 
Progesterone-mediated oocyte maturation YES NO 
Ubiquitin mediated proteolysis YES NO 
Pyrimidine metabolism YES NO 
Oxidative phosphorylation NO YES 
Parkinson's disease NO YES 
Huntington's disease NO YES 
Alzheimer's disease NO YES 
Citrate cycle (TCA cycle) NO YES 
Propanoate metabolism NO YES 
Valine, leucine and isoleucine degradation NO YES 
Nucleotide excision repair NO YES 
Cardiac muscle contraction NO YES 
Limonene and pinene degradation NO YES 
Lysine degradation NO YES 
Butanoate metabolism NO YES 
beta-Alanine metabolism NO YES 
Pyruvate metabolism NO YES 
Fatty acid elongation in mitochondria NO YES 
 
Figure 5.12: Differential expression control of pathways up regulated due to 
mTORC1 inhibition. 
All pathways that were found in either the transcriptional or the proteomic analysis to 
be up regulated are displayed. ‘YES’ and ‘NO’ indicate whether pathways were 
detected in transcriptional or proteomic analysis. 
 
Of all 24 pathway found to be up regulated (Figure 5.12), 4 (17%) pathways (cell cycle, 
DNA replication, Base excision repair, mismatch) were detected in the micro array and 
the mass spectrometry approaches. 5 (21%) were specific for the transcriptomic and 15 
(62%) specific for the proteomic experiment. 
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Down regulated pathway transcriptome proteome 
Terpenoid backbone biosynthesis YES YES 
Glycolysis / Gluconeogenesis YES YES 
Steroid biosynthesis YES NO 
Valine, leucine and isoleucine degradation YES NO 
Alanine, aspartate and glutamate 
metabolism 
YES NO 
Fructose and mannose metabolism YES NO 
Insulin signaling pathway YES NO 
Pyruvate metabolism YES NO 
Ribosome NO YES 
Aminoacyl-tRNA biosynthesis NO YES 
Protein export NO YES 
Proteasome NO YES 
SNARE interactions in vesicular transport NO YES 
N-Glycan biosynthesis NO YES 
Spliceosome NO YES 
 
Figure 5.13: Differential expression control of pathways down regulated due to 
mTORC1 inhibition. 
All pathways that were found in either the transcriptional or the proteomic analysis to 
be up regulated are displayed. ‘YES’ and ‘NO’ indicate whether pathways were 
detected in transcriptional or proteomic analysis. 
 
 
15 pathways were detected to be down regulation upon rapamycin treatment (Figure 
5.13). 2 (13%) pathways were detected by both approaches (glycolysis, and terpenoid 
backbone biosynthesis) whereas 6 (40%) pathways were only detected by changes in 
transcript levels and 7 (47%) detected on the protein level only. 
To further illustrate the relation between changes in transcript and proteins for a 
selected set of pathways, we plotted the changes in transcript and protein levels for 
selected pathways to visualise correlations that way (Figure 5.14). The effector 
molecules detected in both pathways show a very strong correlation between the 
approaches (Figure 5.14, A), as the changes in the effector protein levels are likely the 
results of the transcriptional control. A different situation can be seen when examining 
the glycolytic and OxPhos pathways (Figure 5.14, B). Whereas the glycolytic enzymes 
(purple) are already affected on the transcript level, the OxPhos components (yellow) 
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only show a change on the protein, but not transcript level, with the exception of 
Cox7a2l, which is up regulated on the transcript level as well (cf. Figure 5.5, B). The 
actual effect on the protein expression of this subunit is comparable to and within the 
range of the other OxPhos subunits. Cytoplasmic and mitochondrial subunits of the 
ribosomal complexes (Figure 5.14, C) are are only affected on the protein level but do 
not show any signs of transcriptional regulation upon mTORC1 inactivation. 
Furthermore, a clear separation between cytoplasmic (down regulated) and 
mitochondrial subunits (up regulated) can be seen. A further disconnection between 
cytoplasmic and mitochondrial isoforms of the same class of proteins can be seen for 
the different isoforms of aminoacyl-tRNA synthetases (Figure 5.14, D). The 
cytoplasmic isoforms show a trend towards down regulation on the transcriptional as 
well as the translational level, whereas the cytoplasmic isoforms are up regulated solely 
on the translational level. 
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Figure 5.14: Comparison between of transcript and protein level changes upon 
mTORC1 inhibition for selected pathways. 
Regulation of (A) effector molecules, (B) glucose metabolic enzymes, (C) ribosomal 
subunits and (D) aminoacyl-tRNA synthetases. 
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5.3. Discussion 
The present data show that rapamycin treatment of CTL caused reduced expression of 
mRNA encoding multiple CTL effector molecules e.g. several granzyme isoforms, 
interferon-γ, the IL-12 receptor beta subunit 1 and TNF family members like TNF-α and 
lymphotoxin A. This concerted down regulation of mRNA transcripts encoding these 
effector molecules explains why rapamycin treatment reduces expression of effector 
proteins in T cells. These effector molecules are paramount to CTL function and hence 
the present data give some insight as to basis for the immunosuppressive effects of 
rapamycin. But how can the effects on the transcription of these genes and genes in 
general be explained when mTORC1 and its downstream effector like 4EBP1 and S6K 
are mostly effecting translation by interfering with translational initiation339 or 
ribosomal biogenesis? One strategy with which mTORC1 can exert its control gene 
transcription is by (post-)translationally controlling the expression of key transcription 
factors, which in turn control the transcription of their substrate genes.  
The expression of the genes encoding enzymes that control glucose metabolism can be 
controlled by the HIF1-α and HIF1-β (also known as ARNT or Aryl hydrocarbon 
receptor [AHR] nuclear translocator) complex340. Do CD8+ T cells express HIF1 
complexes? We did not find HIF1-α in our proteomics experiments but found ARNT to 
be expressed in CTL. The coordinated down regulation of a number of HIF-1α target 
genes by rapamycin treatment prompted us to look at HIF directly using immunblotting. 
We showed85 that CTL maintain high levels of Hif-α even under normoxic conditions 
and mTORC1 inhibition leads to a repression of Hif1-α protein levels. However, we 
found no difference in HIF1-α transcript levels in cells treated with rapamycin, 
indicating that its expression is regulated by non-transcriptional mechanism. As HIF1-α 
and ARNT are both required for the function of the transcription factor complex we 
used CTL deficient in ARNT to look at the effects of HIF down-stream signaling. Using 
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these CTL we showed that the loss of HIF function led to decreased transcript levels of 
the glucose transporters Glut1 and Glut3 and enzymes involved in glycolysis. Thus 
HIF1-α acts like a switch that is used by mTORC1 to convert its translational regulation 
of a single protein into the transcriptional regulation of many proteins. This study also 
showed a marked decrease in the expression of effector molecules like perforin, 
granzymes in the ARNT deficient CTL. However, it was evident that the change in 
perforin levels was not directly caused by the loss of HIF activity but rather indirectly 
by the decreased glycolytic activity, an effect that had been noticed in earlier studies318. 
HIF deletion furthermore led to altered trafficking behaviour of CTL increasing 
transcription levels of several chemokines, chemokine receptors and cell adhesion 
molecules like CD62L. Overall, the HIF transcription factor complex is a critical down-
stream target of mTORC1 signalling that controls aspects of CTL metabolism, effector 
function and trafficking. 
However, the transcription of the effector molecules IFN-γ, the IL-12 receptor and TNF 
family members was not affected by the loss of HIF activity and must thus be controlled 
by a different, HIF-independent, mechanism. We have no precise mechanism for this 
yet, but it is known that Interleukin-12 supports high expression of IFN-γ177 so the 
observed down regulation of IFN-γ expression due to rapamycin treatment might be at 
least partially due the observed reduction in IL-12 signalling caused by the down 
regulation of its receptor.  
Another transcription factor that has been shown to be controlled by mTORC1 
signalling in human transformed and fly cell lines is SREBP1/2241. In conditions with 
high mTORC1 activity, SREBP1/2 accumulates in the nucleus of a cell and drives the 
transcription of genes involved in lipid and cholesterol biogenesis241. Our rapamycin 
treated cell on the other hand showed a decrease in the transcript level of these genes, 
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indicating decreased SREBP transcriptional activity. However, SREBP transcript levels 
are not affected in experiments. How does mTORC1 signalling control SREBP1/2 
transcription? An explanation might be given by studies performed in other cell systems 
which show elevated SREBP1/2 levels in cells with a Tsc2-/- background341.  The 
authors demonstrate an involvement of S6K in the SREBP1/2 up regulation but the 
exact mechanism is still not known. However, a mechanism involving postranslational 
control of this transcription factor would explain why we are not able to change 
differences in the micro array experiment. A recent study by Kidani et al.342 further 
supports this idea. They showed that expression of SREBP proteins required intact 
mTORC1 signalling and that failure to up regulate SREBPs led to impaired T cell 
activation and reduced effector function of CTL. 
Other metabolic pathways, like the oxidative phosphorylation pathway as a whole was 
not affected by rapamycin, apart from one subunit of Complex IV, Cox7a2l, which 
showed a more than 50% increase in transcript levels. It has been reported that this 
subunit can be directly regulated by p53343. As presented before, CTL treated with 
rapamycin show a decreased proliferation rate which is accompanied by an up 
regulation of transcript involved in cell cycle control (Figure 5.2). The complex network 
of cell cycle regulators might lead to the stabilisation of p53 which in return would lead 
to an increase in Cox7a2l transcription. However, this increase in transcript levels does 
not translate into higher protein levels than the other OxPhos subunits (Figure 5.14, B) 
meaning that the expression of this subunit is mostly controlled on a posttranscriptional 
level. 
How do the changes in transcript and protein levels compare? In this and in the previous 
chapter we already established that mTORC1 inhibition lead to the  down regulation of 
the transcripts of several pathways (glycolysis, lipid biosynthesis) and effector 
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molecules (granzymes, perforin, Lymphotoxins) which ultimately leads to the down 
regulation of the corresponding proteins as well. However, most of the proteins changed 
in our SILAC approach were only changed on the protein but not on the transcript level. 
In addition to that, our pathway analysis of the proteome also revealed several pathways 
which do not seem to be transcriptionally regulated, but on solely on the protein level.  
Examples of rapamycin caused effects that were only detected in the MS based 
experiments are the changes in ribosome levels. All (cytoplasmic) ribosomal subunits 
show a coordinated down regulation solely due to non-transcriptional effects. This can 
be explained by a mechanism by which mTORC1 controls the translation efficiency of 
transcripts containing a 5’-TOP domain without affecting their abundance239, as it is the 
case for nearly all cytoplasmic ribosomal subunits. Several mitochondrial pathways 
(OxPhos, TCA cycle, glutaminolyis specific reactions) are also at least partially 
uncoupled from the transcriptional regulation and even override potential changes of 
transcript levels (cf. Cox7a2l in Figure 5.14, B). Even though most mitochondrial 
proteins are encoded by the nuclear genome and are subject to the regulation of the 
cytoplasmic translational machinery, once incorporated into the mitochondria their fate 
is controlled by the complex mechanism regulating mitochondrial protein homeostasis 
which is completely uncoupled from the corresponding transcript levels344,345,346. 
We also noticed differences between the gene expression control of up and down 
regulated proteins. Up regulated proteins and up regulated pathways showed a stronger 
disconnect between transcript and protein levels than the down regulated 
proteins/pathways. This indicates that the increase of proteins due to mTORC1 
inhibition is often likely due to posttranscriptional effects like increased translational 
efficiency or increased protein half-lives, whereas the down regulation of proteins is 
more likely to be caused by a down regulation of the corresponding transcripts. Our 
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results from the previous chapter indicated that proteasome levels in the cell are down 
regulated upon mTORC1 inhibition, which would lead to an increase of general protein 
half-live and might be an explanation for this observed effect. Another reason might be 
that many increases that we only see on the protein levels correspond to mitochondrial 
pathways (electron transport chain, TCA cycle, mitochondrial subunits of ribosomes) 
which are subject to the complex, transcriptionally independent regulation of 
mitochondrial homeostasis. 
 
What did we learn from the proteomics that we did not learn from the micro array 
experiments? 
We found more proteins to be regulated on the protein level than on the transcript level, 
many of which are most likely caused by non-transcriptional control of these proteins. 
This fact illustrates that using proteomic approaches is indispensable to fully understand 
the effects of rapamycin treatment on CTL. This is not surprising as transcriptional 
approaches are intrinsically limited to observe effects on the transcript levels, unless 
they are used in the context of ribosomal profiling which can also give insights into 
translational efficiency. But even these approaches will never be able to detect changes 
in protein levels caused by altered protein half-lives or changes in protein trafficking.  
Apart from this crucial intrinsic disadvantage of our micro array approach, it did show a 
more robust quantification which does not suffer from detection problems due to low 
protein abundances or problematic chemical properties of peptides. The micro array 
analysis was thus able to detect changes in the transcripts of proteins which were not 
robustly quantified in the proteomics approach like the adhesion molecules. The micro 
array also helped answering questions about the mechanism by which mTORC1 
controls certain pathways, e.g. the transcriptional control of glycolysis and several 
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effector molecules via the Hif1-α/ARNT complex. However, we showed in previous 
sections of this thesis that there is only a weak correlation between transcript and 
protein levels. Thus only quantitative proteomic approaches are suitable to answer 
questions involving protein abundances or stoichiometries. Furthermore, we already 
showed in earlier chapters that recent advances in chromatography and mass 
spectrometers  are helping to close the gap between transcriptomics and proteomics in 
regard to sensitivity and coverage and the first studies achieving near-complete 
coverage of proteomes have been published309,283. And already now we were able to 
highlight differences in protein levels that we would have not detected by just using the 
transcriptomics approach, examples for this are whole complexes like ribosomes but 
also specific regulatory proteins, which will be discussed in the following chapters of 
this thesis. 
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6. The role of mTORC2 signalling in CTL 
6.1. Introduction 
mTOR is the catalytic component of two protein kinase complexes, mTORC1 and 
mTORC2. The immunosuppressive drug rapamycin inhibits mTORC1 activity but does 
not directly affect activity of the mTORC2 complex. Genetic approaches using Raptor 
(to disturb mTORC1 signalling) and Rictor (to inhibit mTORC2 signalling) knockouts 
have been used to show the importance of mTORC2 signalling for CD4 T cell 
differentiation347,348. These studies showed that mTORC1 signalling was indispensable 
for the generation of TH1 and TH17 cells, while knocking out Rictor and thus inhibiting 
mTORC2 signalling lead to defects in the generation of TH2 cells. However, not much 
is known about the role of mTORC2 signalling for CD8 T cell biology. We will thus 
discuss the effects of a specific catalytic inhibitor of mTOR, KU-006374, which inhibits 
mTORC1 and mTORC2 on CTL. We will use the same approaches that were used in 
the previous two chapters, namely our transcriptomic analysis via Affymetrix micro 
array and SILAC based quantitative mass spectrometry. 
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6.2. Results 
We analysed our mass spectrometry data of the CTL proteome to see whether the 
canonical components of the mTORC2 pathway are expressed and thus potentially 
active in CTL. The data are presented in Figure 6.1. 
protein name complex detected 
Raptor 
mTORC1 
YES 
PRAS40 YES 
Rheb YES 
RagA YES 
RagC YES 
mTOR 
mTORC1/2 
YES 
mLST8 YES 
Deptor NO 
TTI1 YES 
Telo2 YES 
Rictor 
mTORC2 
YES 
mSIN1 YES 
Protor NO 
 
Figure 6.1: mTORC1/2 subunits detected by mass spectrometry 
Proteins involved in the formation of mTORC1 and mTORC2 are shown. YES/NO 
indicate whether the specific protein as found in the LFQ MS experiment.  
 
 
Apart from the inhibitory subunit Deptor, which is shared by both mTORC1 and 
mTORC2, and Protor, which is an mTORC2 specific subunit, all canonical mTORC1 
and mTORC2 subunit could be detected in our mass spectrometry data sets. 
As in the previous chapters we used the P14 TCR transgenic mouse model to generate 
CTL in vitro. Long term treatment with 20 nM rapamycin or 1 μM KU-0063796 led in 
both cases to the dephosphorylation of the mTORC1 substrate S6K Thr389 (Figure 6.2, 
A). Several phosphorylation sites on another mTORC1 substrate, 4EBP1, were also 
affected be either treatment, however, only KU-0063794 led to the complete 
dephosphorylation of the phoshophosites. KU-0063794 also affected the 
phosphorylation of the mTORC2 substrate PKB Ser473 and of NDRG1 Thr346. 
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NDRG1 is a direct substrate of serum and glucocorticoid kinase 1 (SGK1) which in turn 
is a substrate of mTORC2. We described the effect of rapamycin treatment on the 
proliferation rate of CTL in chapter 2. KU-0063794 treatment decreased, but not 
stopped, the proliferation rate of CTL to the same extent as rapamycin (Figure 6.2, B). 
The forward scatter profile of CTL treated with rapamycin or KU-0063794 also 
indicated that KU-0063794 and rapamycin had similar effects on CTL cell size and 
morphology (Figure 6.2, C). It has been proposed that mTORC1 controls protein 
synthesis rates by its effects on its down-stream effectors S6K and 4EBP1, an effect 
which we already illustrated in previous chapters. In order to see whether the complete 
loss of phosphorylation of 4EBP1 due to KU-0063794 treatment led to additional 
effects on the protein synthesis rate of CTL, we monitored the incorporation of a short 
pulse (15 minutes) of radiolabelled L-methionine into nascent proteins (Figure 6.2, D). 
Long term (> 24 h) treatment with either rapamycin or KU-0063794 led to similar 
decreases by 50% in the protein synthesis rate of CTL. However, the two compounds 
showed different kinetics regarding their inhibition of CTL protein synthesis rate. The 
rapamycin effect took approximately 24 hrs to reach its maximum inhibition, whereas 
the effect of KU-0063794 already plateaued after our first time point at 12 h of 
treatment.  
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Figure 6.2: Effects of rapamycin and KU-0063794 on mTORC1 and mTORC2 
kinase activity, cell proliferation, cell size and protein biosynthesis rate. 
(A) Immunoblot analysis of CTL treated with either rapamycin or KU-0063794. S6K 
and 4EBP1 were used as measure of mTORC1 activity. PKB Ser473 and NDRG1 T346 
as direct and indirect indicators for mTORC2 activity. SMCI was used as a loading 
control. * indicate overexposure of films to highlight differenecs between rapamycin 
and KU-0063794 treatment. (B) Growth curve of control cells and cells treated with 
either inhibitor. (C) Comparison of forward scatter or inhibitor treated CTL. (D) 
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Analysis of protein biosynthesis rate as determined by incorporation of L-methionine 
into nascent proteins. R: Rapamycin treated CTL, K: KU-0063794 treated cells.  
 
 
6.2.1. Comparison of rapamycin and KU-0063794 induced changes of the CTL 
transcriptome  
The transcriptional analysis of the previous chapter revealed that rapamycin treatment 
of CTL led to changes in the transcript levels of 618, with 327 transcripts being up and 
297 transcripts being down regulated. In order to see whether the inhibition of 
mTORC2 in addition to mTORC1 due to KU-0063794 treatment led to further effects 
on CTL transcript levels we repeated our transcriptomic analysis with the mTOR 
catalytic inhibitor. As previously described for the rapamycin treatment we used the 
Affymetrix 430.2 platform to detect changes in transcript levels. Both treatments caused 
very similar effects in CTL, as indicated by the general high correlation coefficients 
(Figure 6.3). Strikingly, all transcripts changed in the KU-0063794 treated CTL were 
also regulated in the rapamycin treated samples (Figure 6.3, B). Vice versa, all 
transcripts changed due to rapamycin treatment were also affected by the combined 
mTORC1/mTORC2 treatment to the same extent (Figure 6.3, C). The only exceptions 
are two micro array probes for nephroblastoma overexpressed gene (Nov), which were 
only up regulated in the rapamycin but not KU-0063794 treatment (highlighted in red). 
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Figure 6.3: Comparison of the effects of long term rapamycin and KU-0063794 on 
CTL transcript level. 
(A) Correlation all genes detected. (B) Like (A), but filtered for transcript due to KU-
0063794. (C) Like (A), but filtered for transcripts changed in rapamycin treated cells. 
Values in red indicate spearman coefficient of correlation. 
 
 
Due to the effects of KU-0063794 on the phosphorylation on PKB Ser473 we expected 
changes in the transcription of genes regulated by PKB. The PKB controlled 
transcriptional program in CTL has been described previously86. We were particularly 
interested in the effects of the mTOR inhibitor on expression of the gene targets of the 
transcription factor FoxO1, which regulates the expression of several genes including 
Klf2, IL7r, Ccr7 and S1pr186. FoxO1 is phosphorylated by protein kinase B on several 
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sites and these phosphorylations lead to the translocation of FoxO1 into the cytoplasm 
and sequestering by 14-3-3 proteins. High PKB activity thus switches off the expression 
of these FoxO1 controlled genes. KU-0063794 leads to the dephosphorylation of PKB 
Ser473 and we thus expect a re-expression of Foxo target genes. 
We thus compared the changes in transcript levels for these five genes in our rapamycin 
and KU-0063794 treated CTL and compared them to previously published data of CTL 
treated with AktI, an inhibitor specific for Akt/PKB349 (Figure 6.4). We furthermore 
investigated the effects of the inhibitor treatments on mRNA levels of the transcription 
factors T-bet and Eomesodermin, which have also been reported to be controlled by 
FoxO transcription factors350. 
 
Figure 6.4: Effects of rapamycin and KU-0063794 treatment on the transcription 
of FoxO targets and comparison to PKB inhibited cells. 
Heat map representation of transcript changed to due to mTORC1, mTORC1/2 or 
PKB/Akt inhibition. Red hues indicate up regulated, blue hues down regulated 
transcript. Fold changes are given as well. 
 
 
The transcription of the FoxO targets Klf2, Il7r, CCr7 and S1pr1 was not affected by 
any treatment other than the PKB inhibition, indicating that neither mTORC1 nor 
mTORC2 control the transcription of these genes. The two transcription factors T-bet 
and Eomesodermin were also not affected by any of the inhibitor treatments. The results 
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thus indicate that FoxO1 activity is still repressed despite the effects of mTORC2 
inhibition on the phosphorylation on PKB S473. 
 
 
6.2.2. Comparison of the mTORC1 and mTORC1/2 controlled proteomes 
As we demonstrated in the previous chapter that mTORC1 controls the expression of 
many proteins independent of their corresponding transcript levels, we wanted to know 
whether the same is also true for mTORC2. We thus decided to use the SILAC 
approach described in the previous chapter to investigate whether combined 
mTORC1/mTORC2 inhibition led to the regulation of any proteins that are not already 
regulated by mTORC1 inhibition alone. 
The experimental approach as the same as previously described. We used P14 LCMV 
TCR transgenic mouse model to generate CTL in vitro. In order to facilitate the 
metabolic labelling of the cells, CTL were cultured in SILAC T cell medium after 
activation and clonally expanded for 4 days. The cells were treated with rapamycin or 
KU-0063794 for 48 hrs before harvesting. Cells were then combined in a 1:1 ratio with 
controls cells and subjected to subcellular fraction before being separated by size 
exclusion chromatography into 33 fractions and analysed via LC-MC/MS and analysed 
by the MaxQuant software package. 
As with the transcriptomic analysis earlier, both treatments show a strong correlation 
(Figure 6.5, A), in particular when filtering only proteins that were robustly changed in 
any of the conditions (Figure 6.5, B).  Using the SILAC approach we could thus not 
detected any significant changes between the two conditions. 
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Figure 6.5: Comparison of rapamycin and KU-0063794 effects of the proteome of 
CTL. 
(A) Observed ratios for all proteins detected in at least replicates for each condition are 
shown. (B) Only protein that are robustly changed in at least one inhibitor treatment are 
shown. 
 
We know from previous studies that protein kinase B activity is important for the 
expression of Interferon-γ, as inhibition of PKB leads to the down regulation of IFN-γ 
transcript resulting in reduced protein levels86. However, it has been reported that 
SGK1, a down-stream kinase of mTORC2, represses the expression of Interferon-γ in 
CD4 cells351. We have also shown in earlier chapters of this thesis that mTORC1 
inhibition led to the decreased expression of Interferon-γ in CTL. Combined 
mTORC1/mTORC2 inhibition should affect all three aforementioned mechanisms of 
IFN-γ expression controls. We thus compared the effects of rapamycin and KU-
0063794 treatment on CTL to see whether the two treatments cause different effects on 
IFN-γ levels.  
We performed a flow cytometric analysis of intracellular levels of IFN-γ in CTL treated 
with rapamycin and KU-0063794 to compare the effects of both inhibitors (Figure 6.6, 
A). We could not detect any changes in either frequency of IFN+ cells or in the MFI of 
the intracellular IFN-γ stainings when comparing the two inhibitor treatments. We also 
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saw no differences between mTORC1 and combined mTORC1/2 inhibition, as both 
inhibitors reduce the secretion of IFN-γ by approximately 70% of the untreated cells. 
 
 
Figure 6.6: effects of Rapamycin and KU-0063794 inhibition on expression of IFN-
γ 
(A) Flow cytometry analysis of intracellular levels of IFN-γ in CTL. (B) ELISA 
analysis of IFN-γ secreted by CTL. 
Data are mean ±SD or representative of three experiments (**, p ≤ 0.01) 
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6.3. Discussion 
The aforementioned results describe the role of mTORC2 signalling in the context of a 
combined mTORC1 and mTORC2 inhibition using an mTOR catalytic inhibitor. 
Despite completely abrogating 4EBP1 phosphorylation and inhibiting mTORC2 
signalling we were not able to detect any differences on the transcriptome or proteome 
between long term rapamycin and KU-0063794 inhibited CTL. These data indicate that 
mTORC2 does not play a major role in CTL in the context of simultaneous mTORC1 
inhibition. This stands in stark contrast to CD4 T cells, for which it has been shown that 
mTORC2 signalling is indispensable for the generation of TH2 cells347. Other studies 
used genetic approaches to abrogate either just mTORC1 signalling (by knocking out 
the mTORC1 activator Rheb) or knocked out mTOR to prevent both mTORC1 and 
mTORC2 signalling352. This study proposed different phenotypes for the two different 
models: T cells generated from mTOR deficient mice did showed normal activation and 
initial IL-2 production. However, these cells failed to differentiate into TH1, TH2 or 
TH17 cells but differentiated to Tregs instead. On the other hand, T cells generated from 
the Rheb deficient mice are still able to generate TH2 T cells348. Thus mTORC2 seems 
to play a more important role in CD4+ T cells than it does in CD8+ T cells. 
However, we were particularly surprised that the inhibition of mTORC2 did not affect 
the expression of FoxO1 target genes. FoxO1 can be phosphorylated by PKB on several 
sites which leads to its translocation form the nucleus to the cytoplasm and binding to 
14-3-3 proteins and consequently to the inhibition of the transcription factor activity.  
As mTORC2 phosphorylates PKB on the hydrophobic motif site Ser473 we expected to 
see a change in the transcription in FoxO1 genes as KU-0063794 inhibition of mTOR 
led to decreased phosphorylation levels on that site. PKB Ser473 is required for the 
activation of PKB as it serves as a binding site for the phosphoinositide-dependent 
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kinase-1 (PDK1) which upon binding to that site phosphorylates PKB on the T-loop site 
Thr308 which leads to activation of PKB146. Thus Ser473 is important for the full kinase 
of activity of PKB. However, FoxO function as still repressed in the long term KU-
0063794 treatments indicating that PKB activity is not impaired under these conditions 
despite the loss of the phosphorylation at Ser473. 
Unfortunately, there are no inhibitors available that specifically inhibit mTORC2 
activity without affecting mTORC1 signalling. Therefore we are forced to use catalytic 
inhibitors which lead to the inhibition of both signalling complexes. It is thus possible 
that potential effects of mTORC2 are overridden and thus masked by the simultaneous 
inhibition of mTORC1. One potential example is the proposed role of SGK1 in 
suppressing IFN-γ transcription in CD4+ T cells351. These studies used mice deficient in 
SGK1 to describe its role in controlling TH1 and TH2 differentiation and suppressing 
IFN-γ production by controlling the expression of an isoform of the transcription factor 
TCF-1. It is possible that a similar mechanism by which SGK controls IFN-γ exists in 
CTL. However, we do not see a difference in the IFN-γ levels of CTL treated with 
rapamycin or KU-0063794, indicating that the mechanism by which the mTORC1 
inhibition down regulates IFN-γ levels overrides any potential SGK control of IFN-γ 
expression. Genetic approaches were also used in the past to selectively interrupt 
mTORC1 (by deleting Rheb) or mTORC2 (by deleting Rictor) signalling in CD4 T cells 
to describe their function348. However, it is not known whether Rheb or Rictor are 
involved in mTOR independent complexes and thus their deletion might not reflect 
impaired mTORC1 or mTORC2 function. 
Apart from the combined inhibition of mTORC1 and mTORC2, catalytic inhibitors of 
mTOR also show a more complete inhibition of mTORC1 than rapamycin as evident by 
the complete dephosphorylation of the partially rapamycin-resistant 4EBP1. As 4EBP1, 
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which is an inhibitor of the translation initiation factor eIF4e, is known a regulator of 
translation353, we expected a further reduction of protein synthesis of KU-0063794 
treated cells when compared to rapamycin treated cells. However, apart from the faster 
onset of the mTOR inhibition we were not able to see a difference in either protein 
biosynthesis rate or a general decrease of protein levels as evident by the SILAC 
approach. A recent study in a transformed cell line has shown that cells became resistant 
to a catalytic mTOR inhibitor by up regulating the expression of eIF4E upon chronic 
mTOR inhibition in order to maintain cell growth and protein translation354. CTL also 
up regulate eIF4e, type 3 upon long term rapamycin or KU-0063794 treatment as 
analysis of our SILAC data of both inhibitor treatments revealed. This up regulation 
might counter-act the 4EBP1 mediated inhibition in CTL with sustained mTORC1 
inhibition and furthermore level out the differences between the incomplete 
dephosphorylation of 4EBP1 due to rapamycin and the complete dephosphorylation by 
KU-0063794.   
 
Another mechanism by which CTL adapt to long term mTORC1 inhibition and which 
involves the S6K will be discussed in the next chapter. This mechanism will explain 
why rapamycin and KU-0063794 treatments showed such a similar phenotype despite 
the expected effects mediated by the mTORC2 substrate PKB.  
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7. Links between mTOR and PIP3 signalling in CTL 
7.1. Introduction 
In the previous chapter we demonstrated that combined long term inhibition of 
mTORC1 and mTORC2 with catalytic inhibitors of mTOR like KU-0063794 did not 
lead to major differences in the CTL transcriptome or proteome compared to just 
inhibiting mTORC1 signalling with rapamycin. We were particularly surprised that we 
did not see a difference between the two inhibitor treatments in the expression of genes 
controlled by the transcription factor FoxO1, whose transcriptional activity is regulated 
by protein kinase B (PKB) activity. PKB is activated by phosphorylation of Thr308 by 
PDK1 and on Ser473 by mTORC2 and both phosphorylations are required for full 
activity146. As mTORC2 inhibition leads to the loss of phosphorylation at Ser473 we 
expected that mTORC2 inhibition would thus cause loss of PKB activity, decreased 
phosphorylation of FoxO1 and therefore re-expression of its target genes. However, we 
did not see a re-expression of Foxo1 controlled genes in CTL treated with an mTOR 
catalytic inhibitor indicating that PKB activity was not affected by sustained 
mTORC1/2 inhibition. In this respect, Delgoffe and colleagues have examined this issue 
and shown that in T cells lacking mTORC2 complexes there is no TCR-induced 
phosphorylation of Akt-Ser473348. However, Akt-Thr308 phosphorylation is reduced 
but not ablated arguing that AktS473 phosphorylation may not be obligatory for Akt 
activation348. These experiments used genetic deletion of Rictor to study the role of the 
mTORC2 complex in T cells. In the following chapter we will investigate the effects of 
mTORC1 and combined mTORC1/2 catalytic inhibition on PKB activity in CTL in 
more detail. 
  
182 
 
7.2. Results 
7.2.1. Long term mTOR inhibition leads to dephosphorylation of PKB Ser473, but 
not PKB T308 and does not disrupt PKB activity 
We demonstrated in the previous chapter that inhibition of mTORC2 activity drastically 
reduces phosphorylation of the hydrophobic motif site Ser473 of PKB. However, we 
did not probe for the T-loop site Thr308 of PKB, which is phosphorylated by PDK1 and 
is required for PKB activity146. We thus performed immunoblot analyses of lysates of 
CTL generated from splenocytes derived from P14 TCR transgenic mice and probed for 
these two phosphorylation sites of PKB (Figure 7.1, A). CTL treated with KU-0063794 
for 48 hours showed no detectable PKB Ser473 phosphorylation. However, the 
phosphorylation of PKB Thr308 was not decreased by either rapamycin or KU-0063794 
treatment (Figure 7.1, A). In fact, Thr308 phosphorylation of PKB was increased when 
mTORC1 was inhibited for longer periods of time. 
We then performed a time course experiment using KU-0063794 (Figure 7.1, B). The 
data show that KU-0063794 led to the dephosphorylation of mTORC1 substrates like 
Thr389 on S6K and Ser65 on 4EBP1 as well as mTORC2 substrates like Ser473 on 
PKB within 10 minutes. This immediate de-phosphorylation of PKB Ser473 was 
accompanied by the de-phosphorylation of PKB Thr308. We also monitored the impact 
of KU-0063794 on PKB activity by measuring the phosphorylation of Thr24/32 on  
FoxO1/3a, a PKB substrate sequence86. These data showed that treatment of CTL with a 
catalytic mTOR inhibitor causes loss of PKB activity. However, the dephosphorylation 
of PKB Thr308 is only transient as normal phosphorylation levels are regained after 
approximately 6 hrs of KU-0063794 treatment. This re-phosphorylation of PKB is also 
mirrored by restoration of PKB activity as judged by corresponding FoxO1/3a 
phosphorylation at Thr24/32. 
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Figure 7.1: Time course of KU-0063794 treatment of CTL 
Immunoblotting of CTL generated from P14 LCM TCR transgenic mice. (A) 
Comparison of long term Rapamycin and KU-0063794 treatment on phosphorylation of 
Thr308 and Ser473 of PKB. SMCI was used as a loading control. (B) Time course of 
CTL treated with 1 μM KU-0063794 for 10 minutes to 18 hrs. Histone H3 was used as a 
loading control. Numbers on the right indicate molecular size (in kDa) 
 
 
7.2.2. The re-activation of PKB is dependent on the translocation of PDK1 to the 
plasma membrane via binding to phosphatidylinositol (3,4,5)-trisphosphate  
The interaction of PKB with the phospholipid phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) via its Pleckstrin homology (PH) domain is required for the activation of PKB. 
The interaction induces a conformational shift in PKB that enables 3-phosphoinosotide 
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dependent protein kinase-1 (PDK1) to phosphorylate Thr308 within the T-loop of 
PKB146. PDK1 itself is believed to be constitutionally active and the phosphorylation of 
its substrates like PKB is predominantly regulated by controlling the kinase-substrate 
interaction148. Two mechanisms that promote the interaction of PKD1 and PKB and the 
subsequent phosphorylation of Thr308 on PKB have been proposed355. The first is a 
phosphatidyl-(3,4,5)-trisphosphate (PIP3) dependent mechanism which relies on 
elevated levels of PIP3 in the cell membrane generated by high phosphatidyl-3,4-
bisphosphate 3-kinase (PI3K) activity. PDK1, like PKB, contains a PH domain which 
facilitates the recruitment of the kinase to the plasma membrane by high PIP3 levels. In 
contrast to PKB however, the association of PDK1 with the PIP3 is not required for 
PDK1 activity148. Recruitment of both PKB and PDK1 to the plasma membrane leads to 
the interaction of the two kinases and enables the efficient phosphorylation of PKB 
Thr308 by PDK1. The second mechanism by which PKB and PDK1 can interact with 
each other is the so-called PIF-pocket dependent mechanism. This mechanism depends 
on the phosphorylation of PKB Ser473 rather than high PIP3 levels. If PKB Ser473 is 
phosphorylated by mTORC2 it can recruit PDK1 by the PIF-pocket domain of PDK1 
and this interaction leads to the subsequent phosphorylation of PKB Thr308. However, 
even though high PIP3 levels are not required for the PIF-pocket mediated interaction of 
PKB and PDK1, binding of PKB to PIP3 via its PH domain is still essential for the 
induction of the conformational shift necessary for PKB Thr308 phosphorylation. Both 
mechanisms are illustrated in Figure 7.2. 
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Figure 7.2: Models of PKB activation by PDK1 
PIP3 and PIF-pocket dependent mechanism of PKB activation by PDK1 according to 
Najafov et al.355. PDK1 either associates with PKB via PH domains or via PIF-pocket 
dependent association via phosphorylation at Ser473 of PKB. 
  
 
 
At earlier time points of the KU-0063794 treatment we see a decrease in both Thr308 
and Ser473 of PKB (Figure 7.1, B). This indicates that at these time points the Ser473 
phosphorylation is required for Thr308 to be phosphorylated which can be explained 
with the aforementioned PIF-pocket dependent mechanism. Thr308 is then 
rephosphorylated whereas Ser473 levels remain low. The phosphorylation of PKB on 
Thr308 in the absence of phosphorylated Ser473 could happen if the cells switched 
from using the PIF-pocket dependent mechanism to co-localise PDK1 and PKB to using 
the PIP3-dependent mechanism.  
Why would cells switch to the PIP3 dependent mechanism for the co-localisation of 
PDK1 and PKB? One explanation could be that mTOR signalling restrains PIP3 levels 
and subsequently PIP3 signalling such that in the presence of mTOR inhibitors the 
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levels of PIP3 increase. This type of mTOR controlled negative feedback pathway has 
been described extensively before247,248,249. For example, the insulin receptor substrate 
(IRS) 1/2 has been shown to be involved in an mTORC1 negative feedback pathway 
controlling PIP3 levels in mouse embryonic fibroblasts247 and later in the context of 
multiple myeloma356. IRS1/2 are adaptor molecules that can be phosphorylated on 
tyrosine residues and thus serve as a docking site for the PI3K p85 SH2 domain, leading 
to the membrane recruitment of the p85/p110 PI3K complex. IRS1/2 can also be 
phosphorylated on serine/threonine residues by S6K which targets the protein for 
proteasomal degradation357. High mTORC1-S6K activity thus causes cells to down 
regulate IRS2 levels which restrains PI3K membrane recruitment and thus restricts the 
generation of PIP3. More recently, phospho-proteomic studies in mouse embryonic 
fibroblasts have revealed that the expression of another adaptor molecule, Grb10, a 
negative regulator of receptor tyrosine kinases (RTK), is also controlled by 
mTORC1248,249: Elevated mTORC1 activity leads to stabilisation of this protein which 
in turn down regulates RTK activity and consequently PI3K activity.  
However neither the Grb10 nor the IRS1/2 mediated mechanisms have been described 
in CTL before. We thus wanted to know whether pronged mTORC1 inhibition leads to 
increased level of PIP3 in CTL. Hence we treated CTL with rapamycin or KU-0063794 
for different periods of time and determined intracellular PIP3 levels. These 
measurements were performed by Dr. Karen Anderson at the Babraham Institute in 
Cambridge using a HPLC-MS-based approach358. CTL treated with rapamycin or KU-
0063794 for 24h or longer showed a strong increase in PIP3 levels, indicating that 
chronic mTORC1 inhibition leads to increased PIP3 generation in CTL (Figure 7.3, A). 
CTL treated with either inhibitor for only 1 hour did not show this increase in PIP3. 
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Figure 7.3: prolonged mTORC1 inhibition leads to increased PIP3 levels in CTL 
Measurements of PIP3 levels in CTL treated for 1h, 24h or 48 h with rapamycin or KU-
0063794. PI3K inhibitor IC87714 was used as negative control. PIP3 levels were 
measured by HPLC-MS. *: p<0.05, **: p<0.01. 
 
To further test whether the co-localisation of PKB and PDK1 via PIP3 was important for 
the increased PKB activity seen in mTORC1 inhibited CTL, we assessed whether the 
PKB activity in CTL treated with rapamycin or KU-0063794 was still sensitive to PI3K 
inhibition or compounds that inhibit the PH-domain mediated interaction of PKB with 
PIP3. 
PI3K can be inhibited using a specific inhibitor for the p110δ subunit of PI3K, IC87114. 
P110δ is the predominant p110 isoform in CTL and is important for the activation of 
PKB86. Inhibiting PI3K activity with IC87114 led to the complete loss of PKB 
phosphorylation on both Thr308 and Ser473 (Figure 7.4, A), indicating that PI3K 
activity and thus PIP3 is required for the hyperphosphorylation of PKB Thr308 due to 
prolonged mTORC1 inhibition. 
PKB inhibitors like Akt-1/2 (AktI) bind to and inhibit the function of the PH domain of 
PKB and thus effectively inhibit PKB activity359. Treatment with AktI in CTL with 
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intact or disturbed mTORC1 signalling completely inhibited phosphorylation on both 
PKB Thr308 and Ser473 (Figure 7.4, B). This shows that the mechanism by which 
mTORC1 inhibition elevates PKB activity still requires PKB to bind to PIP3 via its PH 
domain in order to be phosphorylated on the two sites. However, inhibiting PKB 
activity with either IC87114 or AktI did not lead to a significant inhibition of mTORC1 
activity as Thr389 on S6K is still phosphorylated in these conditions. 
 
 
Figure 7.4: PI3K activity is required for hyperphosphorylation of PKB following 
long term mTORC1 inhibition. 
(A) Immunoblot analysis showing the effects of PI3K inhibition on CTL treated with 
rapamycin. CTL were treated with rapamycin for 48 hrs and IC87114 was added to the 
culture for 1 h before lysis. (B) Immunoblot analysis showing the effects of disturbed 
PH domain function of PKB in CTL treated with rapamycin. CTL were treated with 
rapamycin for 48 hrs and AktI was added to the culture for 1 h before lysis.   
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We then examined the impact of mTORC1 inhibition on PKB activity in CTL 
expressing PDK1 with a point mutation in its PH domain. This PDK1-K464E mutant is 
not able to bind PIP3360 and are thus not able to phosphorylate PKB Thr308 via the 
PIP3-dependant mechanism. The mutant therefore relies solely on the PIF-pocket 
dependent mechanism of PKB activation. It is important to remember that the function 
of the PH domain of PKB is not affected in these CTL and thus PKB will bind normally 
to PIP3 and perform the conformational shift required for the PDK1 interaction.  
We treated CTL derived from WT and PDK1-K465E splenocytes with rapamycin or 
KU-0063794 for 1 h or 48 h and compared the effects of chronic mTORC1 and 
combined mTORC1/2 inhibition on the activity of PKB (Figure 7.5). 
 
Figure 7.5: hyper-phosphorylation of PKB T308 is dependent on binding of PDK1 
to PIP3  
Western blotting of CTL derived from OT-I TCR transgenic splenocytes activated with 
SIINFEKL peptide. CTL are expressing either wild type PDK1 or a K465E mutant 
which is unable to bind PIP3. 
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CTL carrying the PDK1-K465E mutant showed lower baseline levels of PKB Thr308 
which has been shown previously150. Phosphorylation of RSK2 Ser227, another 
substrate of PDK1, was not impaired, as the PH domain of PDK1 is not involved in the 
phosphorylation of this site146. CTL expressing wild type PDK1 alleles initially lost 
PKB Thr308 phosphorylation when treated with KU-0063794 but were able to 
rephosphorylate the site after long term treatment as mentioned before. PKB Ser473 
remained dephosphorylated even after long term mTOR inhibition. In contrast to that, 
CTL expressing PDK1-K465E failed to rephosphorylate Thr308 after chronic mTOR 
inhibition. This shows that association of PDK1 with PIP3 is required for the 
rephosphorylation of PKB Thr308 if PKB Ser473 is not phosphorylated and thus cannot 
aid in the association of PKB and PDK1 via the PIF-pocket dependent mechanism. 
Therefore PDK1-K465E can neither bind to Ser473 on PKB in KU-0063794 treated 
CTL nor can it be translocated to the plasma membrane via PIP3-PH domain interaction 
due to the mutation and despite elevated PIP3 levels. 
Long term rapamycin treatment led to hyperphosphorylation of PKB Thr308 in both 
PDK1-WT and the PDK1-K465E mutant. Increased PIP3 levels thus lead to increased 
phosphorylation of Thr308 even if PDK1 cannot be recruited to the membrane any 
longer. However, the increased PIP3 levels could cause more PKB to associate with the 
plasma membrane and perform the conformational shift and thus priming it for PDK1 to 
phosphorylate PKB Thr308. Thus as long as PKB is phosphorylated on Ser473 the 
PDK1-K465E is still able to phosphorylate more PKB molecules, despite being limited 
to the PIF-pocket dependent mechanism for its interaction with PKB. 
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7.2.3. PTEN expression is reduced by mTORC1 inhibition but is not required for 
PKB hyperactivation. 
We then investigated how CTL up regulate their PIP3 levels upon mTORC1 inhibition. 
We thus analysed our mass spectrometry data for potential candidates. We discovered 
that Phosphatase and Tensin homolog (PTEN) was down regulated in our long term 
rapamycin treated CTL on the protein, but not in the transcript level (Figure 7.6, top). 
We further validated this finding via immunoblotting (Figure 7.6, bottom). 
 
Protein name Gene name 
Label-free ratio 
(Rapamycin:Ctrl) 
Micro-array ratio 
(Rapamycin:Ctrl) 
Phosphatase and Tension 
homolog PTEN PTEN 0.47 1.09 
 
 
Figure 7.6: mTORC1 activity sustains PTEN expression. 
Top: PTEN down regulation due to mTORC1 inhibition as evident by mass 
spectrometry and micro array data.  Bottom: Immunblots of CTL derived from P14 
TCR transgenic mice activated with gp33 and treated with rapamycin for 48 hrs or 
control cells. SMC was used as a loading control. 
 
PTEN is a lipid phosphatase with specificity for the 3′ position of PI(3,4,5)P3. PTEN 
thus dephosphorylates PIP3, leading to the formation of phosphatidylinositol-4,5-
bisphosphate361,362 (PtdIns(4,5)P2). PTEN thus negatively regulates PI(3,4,5)P3 
signalling. By using CTL derived from splenocytes lacking either one or both alleles of 
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PTEN we wanted to investigate whether reduction of PTEN levels on its own is 
sufficient to increase PKB Thr308 levels (Figure 7.7). 
 
Figure 7.7: Expression of PTEN limits PKB activity. 
Immunoblotting of CTL derived from polyclonal splenocytes activated with CD3CD/28 
antibody. Comparison of CTL derived from PTEN-/- X CD4-Cre+/- (PTEN+/+), PTENfl/- 
X CD4-Cre+/- (PTEN+/-) and PTENfl/fl X CD4-Cre+/- (PTEN-/-). SMCI was used as a 
loading control. 
 
The data in Figure 7.7 show that reducing PTEN levels in CTL by 50% is sufficient to 
increase both PKB Thr308 as well as PKB Ser473 phosphorylation with the 
homozygous knockout showing even higher phosphorylation levels than the 
heterozygous knockout. 
We then examined whether PTEN null CTL could further hyperactivate PKB Thr308 
phosphorylation following long term mTORC1 inhibition. We thus treated CTL lacking 
PTEN with rapamycin and KU-0063794 and compared the effects of PKB 
phosphorylation to control CTL (Figure 7.8). 
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Figure 7.8: PTEN down regulation is not required for hyper activation of PKB due 
to long term mTORC1 inhibition. 
Immunoblotting of CTL derived from polyclonal splenocytes activated with CD3CD/28 
antibody. Comparison of CTL derived from PTEN-/- X CD4-Cre+/- (PTEN+/+) and 
PTENfl/fl X CD4-Cre+/- (PTEN-/-). CTL treated with either rapamycin or KU-0063794 
for the indicated duration. 
 
 
As shown previously in Figure 7.7, PTEN deletion leads to elevated baseline PKB 
Thr308 and Ser473 phosphorylation levels in CTL. However, upon chronic exposure to 
either rapamycin or KU-0063794, CTL lacking PTEN increased Thr308 
phosphorylation even further. This indicates that the down regulation of PTEN 
expression due to chronic mTORC1 inhibition is not the sole mechanism to 
hyperactivate PKB activity and that other mechanisms are involved as well. 
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7.2.4. mTORC1 inhibition leads to elevated levels of insulin receptor substrate 2 
As mentioned before, the mTORC1 mediated negative feedback pathway controlling 
PI3K signalling has been studied extensively. Two mechanisms have been proposed: 
The first mechanism is mediated by Grb10, a negative regulator of PI3K activity whose 
expression is controlled by mTORC1 activity248,249. Chronic inhibition of mTORC1 
leads to the degradation of Grb10 and thus activates PIP3 signalling. However, analysis 
of our micro array and proteomics data did not indicate expression of Grb10 in CTL. 
The other mechanism by which mTORC1 could control PI3K signalling is via the 
insulin receptor substrate 1/2247. As mentioned earlier, IRS1/2 is an adaptor molecule 
and positive regulator of PI3K as it is required for the targeting of the p85 subunit of 
PI3K to the plasma membrane. If mTORC1 activity is high, it leads to the 
phosphorylation of IRS1/2 via S6K which targets it for proteasomal degradation. 
Chronic mTORC1 inhibition on the other hand leads to the accumulation of IRS1/2 and 
thus elevates PI3K activity. We were thus wondering whether IRS1 or IRS2 is 
expressed and phosphorylated in CTL. 
Previous members of the lab have performed global phospho-proteomic studies on 
CTL, detecting several thousand phosphorylated peptides in these experiments46. 
Analysis of these data as well as our transcriptomic and proteomics data sets revealed 
that the IRS isoform 2 is expressed and phosphorylated on several residues in CTL, 
including sites corresponding to the S6K phosphorylation consensus site. According to 
our data sets, IRS1 is not expressed in CTL. 
Our mass spectrometry data further indicated that IRS2 levels are indeed increased upon 
long term rapamycin treatment while IRS2 transcript levels were not affected by the 
drug treatment (Figure 7.9, top). We validated these findings using immunoblotting for 
IRS2 in CTL treated with rapamycin for 48 h. (Figure 7.9, A). Monitoring the time-
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dependent effects of rapamycin inhibition on the expression of IRS2 and 
phosphorylation of PKB 308 furthermore showed a correlation between IRS2 levels and 
PKB Thr308 phosphorylation in CTL (Figure 7.9, B), as both levels increase with 
prolonged exposure of CTL to the drug.  
 
 
Protein name Gene name 
Label-free ratio 
(Rapamycin:Ctrl) 
Micro-array ratio 
(Rapamycin:Ctrl) 
Insulin receptor substrate 2 Irs2 2.1 1.2 
    
 
 
Figure 7.9: mTORC1 activity limits IRS2 expression in CTL. 
Top: PTEN down regulation due to mTORC1 inhibition as evident by mass 
spectrometry and micro array data.  Bottom: Immunoblotting of CTL derived from P14 
TCR transgenic splenoytes activated with gp33. (A) CTL treated with or without 
rapamycin for 48 hrs. (B) Time course of effects induced by rapamycin treatment of 
CTL. 
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7.2.5. Chronic mTORC1 inhibition leads to activation of ERK signalling 
PI3K signalling is not the only signalling pathway demonstrated to be negatively 
regulated by mTORC1. Recent studies indicate that mTORC1 signalling also negatively 
regulates MAPK signalling363,249 in mouse embryonic fibroblasts and transformed cell 
lines and that this mTORC1-MAPK negative feedback pathway also relies on the ability 
of mTORC1 to control IRS1/2 expression363. 
MAPK kinase signalling plays an important role in CD8 T cell activation, proliferation 
and survival364. We thus investigated whether chronic mTORC1 inhibition increased 
ERK phosphorylation levels in CTL. 
 
Figure 7.10: Chronic mTORC1 inhibition leads to increased ERK phosphorylation 
levels. 
Immuoblotting of CTL treated with AktI, rapamycin or KU-0063794 for the indicated 
durations. SMC1 was used as a loading control. 
 
 
Chronic treatment of CTL with rapamycin or KU-0063794 led to increased levels of 
phosphorylation of threonine and tyrosine residues within the activation loop of both 
ERK1 and ERK2. Interestingly, the increased phosphorylation of ERK did not induce 
increased expression of known ERK regulated genes like CD69, Egr1/3, Fos and Jun.  
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7.3. Discussion 
In this chapter we demonstrated a crosstalk between mTORC1 and PI3K signalling in 
CTL. We could show that chronic mTORC1 inhibition leads to an increase in 
intracellular PIP3 levels and consequently in a hyper-activation of PKB activity. This 
surge of PIP3 was also able to overcome the initial dephosphorylation of PKB Thr308 
and consequent inactivation of PKB activity induced by combined mTORC1/2 
inhibition. PKB Thr308 is re-phosphorylated by PDK1 via a mechanism that no longer 
relies on the mTORC2 facilitated phosphorylation of Ser473 on PKB, but solely on 
increased PIP3 levels. This mechanism explains why we did not observe a re-expression 
of FoxO target genes in our long-term KU-0063794 treated cells as one would expect if 
PKB activity was impaired. We do not know the exact mechanism for this up-regulation 
of PIP3 levels, but we know that it is sensitive to PI3K inhibition. Studies in other cell 
models as well as our experiments also indicate that the adaptor protein IRS2 might be 
involved in this negative feedback mechanism. On the other hand, the down regulation 
of the tumour suppressor PTEN upon mTORC1 inhibition also increased PKB activity 
but is ultimately not solely responsible for the described feedback mechanism. We also 
showed that chronic mTORC1 inhibition leads to increased MAPK signalling activity as 
indicated by increased ERK activity. 
The results shown in this chapter thus clearly illustrate that mTORC2 activity is not 
necessarily required for PKB function. This is particularly important as several studies 
examining the role of mTORC2 in T cell function consider PKB as the main down-
stream effector of mTORC2 signalling347,321,365. mTORC2 is thought to be an important 
regulator of PKB activity as Ser473 phosphorylation of PKB is considered to be 
indispensable for PKB activity. However, the results presented in this chapter clearly 
demonstrate that Ser473 phosphorylation is not required for PKB activity in the context 
of high PIP3 levels. These elevated PIP3 levels enable the cells to switch from a PIF-
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pocket dependent mechanism of PKB activation which depends on intact mTORC2 
signalling to a PIP3 dependent mechanism, which is uncoupled from mTORC2 
signalling. Thus monitoring Ser473 phosphorylation is not sufficient in order to assess 
PKB activity and that monitoring Thr308 or PKB substrate phosphorylation is a more 
reliable readout. 
Due to the ability of PKB to inhibit the activity of the TSC1/TSC2 complex, a negative 
regulator of mTORC1 signalling366, many signalling models consider PI3K-PKB 
signalling to be indispensable for mTORC1 activity. However, the results presented 
here together with data previously published by the lab85 show that mTORC1 signalling 
in CTL is in fact independent of PI3K and PKB activity, as inhibition of PKB does not 
abrogate mTORC1 signalling. Furthermore, the data presented in this chapter show that 
it is actually mTORC1 signalling that is able to control PI3K and PKB activity. 
This link between mTORC1 and PI3K signalling is particularly interesting as it might 
present yet another mechanism by which rapamycin exerts its immunosuppressive 
effects. It has been recently shown that human patients carrying activating mutations in 
the p110δ subunit of PI3K leading to increased PIP3 levels suffer from several 
immundefects367,368. This is surprising as increased PIP3 levels are usually considered a 
positive signal for cells, however the authors argue that the increased PIP3 levels caused 
the cells to be more prone to activation-induced cell death and thus caused lymphopenia 
in the patients. This phenotype could be reversed by the use of PI3K inhibitors and thus 
reducing PIP3 levels. The elevated levels of PIP3 due to chronic mTORC1 inhibition 
might thus be another mechanism explaining the immunosuppressive effects of 
rapamycin. Studies have shown that mTORC1 controls T cell trafficking via regulation 
of adhesion molecules like CD62L and chemokine receptors155. However, PIP3 is also 
known to be a modulator of chemotaxis as it regulates the activity of the family of Rac 
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proteins, members of the Rho family of small GTPases which control actin dynamics 
and thus cell motility369. Furthermore, the PI3K-PKB-FoxO axis also controls the 
expression of several chemokine receptors, ligands, adhesion molecules, integrins and 
other proteins involved in CTL trafficking86. Thus the altered trafficking behaviour of 
CTL treated with rapamycin may not only be caused by direct effects of mTORC1 
signalling but also due to the indirect effects of prolonged mTORC1 inhibition on PIP3 
levels. 
Due to the lack of genetic models or suitable inhibitors we were unfortunately not able 
to further dissect the mechanism by which mTORC1 controls PIP3 levels. The proposed 
mTORC1-S6K-IRS2 feedback mechanism has been well established in other cells, 
however, no evidence of the existence of this pathway in lymphocytes has been reported 
before. As mentioned earlier, we do not have access to T cells lacking IRS2 so we 
cannot fully confirm the role of this protein in the feedback mechanism. We also tried 
using S6K specific inhibitors to test the involvement of this down-stream effector of 
mTORC1 in the regulation of IRS2. However, the effects of these inhibitors on S6K 
activity were inconclusive. 
Interestingly, the studies examining the effects of mTOR deletion in CD4+ T cells352 
also observed increased Thr308 phosphorylation of PKB upon mTOR deletion 
indicating that the mTOR-PI3K feedback mechanism is also relevant for CD4 T cell 
biology. 
We also demonstrated that mTORC1 signalling is required to sustain PTEN expression 
in CTL. The regulation of PTEN by mTORC1 in mouse embryonic fibroblasts has been 
demonstrated before370, however, the authors of the study suggest a role of the 
transcription factor HIF1α in the transcriptional regulation of PTEN by mTORC1. We 
could not see a regulation of PTEN transcript level in our rapamycin treated CTL 
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(Figure 7.6) or CTL deficient in HIF1 transcriptional activity, indicating that mTORC1 
controls PTEN levels by non-transcriptional mechanisms. On the other hand, PTEN 
deficient CTL treated with either rapamycin or KU-0063794 were still able to 
hyperphosphorylate PKB Thr308 indicating that PTEN is not crucial for the mTORC1 
mediated control of PIP3 levels. 
The effects on ERK signalling caused by chronic mTORC1 inhibition are also 
noteworthy. As mentioned before, we have no exact mechanism for this regulation and 
studies in other systems were also not able to fully understand the connection between 
the two signalling pathways, even though the involvement of IRS1/2 has been 
suggested371,363. ERK plays an important role in the activation of T cells and is activated 
down-stream of the T cell receptor372 or by IL-2 signalling373. Despite its role as a 
positive regulator of T cell activation, elevated levels of ERK signalling represent an 
early event during activation-induced cell death374 and inhibition of this signalling 
pathway is observed in many malignant lymphocytes375. Thus the elevated ERK 
signalling upon chronic mTORC1 inhibition might be another facet of the 
immunosuppressive effects of rapamycin, similar to the elevated PIP3 levels mentioned 
earlier.   
Lastly, the effects of mTORC1 inhibition on the expression of both PTEN and IRS2 are 
examples of how just using our transcriptomic data would not have been sufficient to 
detect this regulation. Both proteins appear to be regulated by non-transcriptional 
mechanisms which could not be addressed by the micro array analysis but required 
methods which detect protein level directly like the quantitative mass spectrometry 
based approaches utilised in the previous chapters.  
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8. Concluding remarks and outlook 
The title of this thesis is “The Role of the Mammalian Target of Rapamycin (mTOR) in 
Cytotoxic T Lymphocytes”. What is its role? Using high resolution quantitative mass 
spectrometry and micro array analysis we have shown that mTOR is an important 
regulator of CTL transcription and translation controlling the expression of several 
hundred genes in CTL. Importantly, inhibition of mTORC1 does not just lead to a 
general down regulation of gene expression in CTL but it rather reprograms gene 
expression CTL and thus up- and down-regulates equal numbers of proteins in CTL. It 
particularly regulates the expression of metabolic regulators, effector molecules, 
adhesion molecules and adaptor molecules. 
CTL have been described as “The Foot Soldiers of the Immune System”372 so the role 
of mTOR is to supply the logistics (by regulating the metabolism), weaponry (control of 
effector molecules) and facilitate the mobilisation of the troops (control of CTL 
trafficking). We now know how mTOR facilitates some of these effects, e.g. the control 
of metabolic pathways and some effector molecules by controlling Hif1α expression85. 
However, we still do not know how mTOR signalling controls the expression of other 
important effector molecules like IFN-γ and preliminary experiments in the lab have 
shown a complex regulation of these molecules. 
We also showed that the traditional linear PI3K-PKB-mTOR pathway postulated for 
other cell models does not apply to CTL. On the contrary, the inhibition of mTORC1 
led to a dramatic increase in PIP3 levels and changed the way how CTL activate PKB. 
We have also mapped the abundance and isoform specificity for more than 6700 protein 
in CTL. These data constitute a valuable resource which will aid the future research in 
the lab. One such example might be the role of Glut1 and Glut3 in CTL. Whereas recent 
papers have emphasized the importance of Glut1 for T cell differentiation and 
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function376, not much research has been dedicated to explore the role of Glut3 which is 
expressed at equal levels in CTL and thus might play an equally important role in CTL. 
As it is becoming easier and cheaper to perform high resolution quantitative mass 
spectrometry on all kinds of tissue, hopes are high that the systematic mapping of tissue 
specific proteomes might change the research in a similar way as the wide-spread 
availability of the genomes of humans and other species did. The first studies drafting 
maps of the human proteome have been published recently266,267, collating the 
proteomic data for dozens of human tissue samples, including several haematopoietic 
cells. A comparable project mapping transcript levels for different kind of immune cells 
already exists in the form of the Immunological Genome Project. Expanding this 
initiative by mapping the specific proteomes of immune cells would be an equally 
invaluable resource and would help the immunological community tremendously. 
 
 
 
 
  
203 
 
References 
1.Schatz, D. G. & Ji, Y. Recombination centres and the orchestration of V(D)J 
recombination. Nature reviews. Immunology 11, 251-63 (2011). 
2.Palmer, E. & Naeher, D. Affinity threshold for thymic selection through a T-cell 
receptor-co-receptor zipper. Nature reviews. Immunology 9, 207-13 (2009). 
3.Wang, H. et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harbor 
perspectives in biology 2, a002279 (2010). 
4.Iwashima, M., Irving, B. A., van Oers, N. S., Chan, A. C. & Weiss, A. Sequential 
interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science (New 
York, N.Y.) 263, 1136-9 (1994). 
5.Samelson, L. E., Davidson, W. F., 3rd, H. C. M. & Klausner, R. D. Abnormal tyrosine 
phosphorylation on T-cell receptor in lymphoproliferative disorders. Nature 324, 674-6 
(1986). 
6.Straus, D. B. & Weiss, A. Genetic evidence for the involvement of the lck tyrosine 
kinase in signal transduction through the T cell antigen receptor. Cell 70, 585-93 
(1992). 
7.van Oers, N. S., Killeen, N. & Weiss, A. Lck regulates the tyrosine phosphorylation of 
the T cell receptor subunits and ZAP-70 in murine thymocytes. The Journal of 
experimental medicine 183, 1053-62 (1996). 
8.Xu, C. et al. Regulation of T cell receptor activation by dynamic membrane binding 
of the CD3epsilon cytoplasmic tyrosine-based motif. Cell 135, 702-13 (2008). 
9.Fernandes, R. A. et al. What controls T cell receptor phosphorylation? Cell 142, 668-9 
(2010). 
10.Chow, L. M., Fournel, M., Davidson, D. & Veillette, A. Negative regulation of T-
cell receptor signalling by tyrosine protein kinase p50csk. Nature 365, 156-60 (1993). 
11.McNeill, L. et al. The differential regulation of Lck kinase phosphorylation sites by 
CD45 is critical for T cell receptor signaling responses. Immunity 27, 425-37 (2007). 
12.Veillette, A., Rhee, I., Souza, C. M. & Davidson, D. PEST family phosphatases in 
immunity, autoimmunity, and autoinflammatory disorders. Immunological reviews 228, 
312-24 (2009). 
13.Chan, A. C., Irving, B. A., Fraser, J. D. & Weiss, A. The zeta chain is associated 
with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with 
ZAP-70, a 70-kDa tyrosine phosphoprotein. Proceedings of the National Academy of 
Sciences of the United States of America 88, 9166-70 (1991). 
14.Chan, A. C., Iwashima, M., Turck, C. W. & Weiss, A. ZAP-70: a 70 kd protein-
tyrosine kinase that associates with the TCR zeta chain. Cell 71, 649-62 (1992). 
15.Wange, R. L., Malek, S. N., Desiderio, S. & Samelson, L. E. Tandem SH2 domains 
of ZAP-70 bind to T cell antigen receptor zeta and CD3 epsilon from activated Jurkat T 
cells. The Journal of biological chemistry 268, 19797-801 (1993). 
16.Chan, A. C. et al. Activation of ZAP-70 kinase activity by phosphorylation of 
tyrosine 493 is required for lymphocyte antigen receptor function. The EMBO journal 
14, 2499-508 (1995). 
17.Paz, P. E. et al. Mapping the Zap-70 phosphorylation sites on LAT (linker for 
activation of T cells) required for recruitment and activation of signalling proteins in T 
cells. The Biochemical journal 356, 461-71 (2001). 
18.Zhang, W. et al. Association of Grb2, Gads, and phospholipase C-gamma 1 with 
phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell 
angigen receptor-mediated signaling. The Journal of biological chemistry 275, 23355-
61 (2000). 
204 
 
19.Liu, S. K., Fang, N., Koretzky, G. A. & McGlade, C. J. The hematopoietic-specific 
adaptor protein gads functions in T-cell signaling via interactions with the SLP-76 and 
LAT adaptors. Current biology : CB 9, 67-75 (1999). 
20.Gilliland, L. K. et al. Lymphocyte lineage-restricted tyrosine-phosphorylated 
proteins that bind PLC gamma 1 SH2 domains. The Journal of biological chemistry 
267, 13610-6 (1992). 
21.Joseph, R. E., Min, L., Xu, R., Musselman, E. D. & Andreotti, A. H. A remote 
substrate docking mechanism for the tec family tyrosine kinases. Biochemistry 46, 
5595-603 (2007). 
22.Bogin, Y., Ainey, C., Beach, D. & Yablonski, D. SLP-76 mediates and maintains 
activation of the Tec family kinase ITK via the T cell antigen receptor-induced 
association between SLP-76 and ITK. Proceedings of the National Academy of Sciences 
of the United States of America 104, 6638-43 (2007). 
23.Gonen, R., Beach, D., Ainey, C. & Yablonski, D. T cell receptor-induced activation 
of phospholipase C-gamma1 depends on a sequence-independent function of the P-I 
region of SLP-76. The Journal of biological chemistry 280, 8364-70 (2005). 
24.Carpenter, G. & Ji, Q. S. Phospholipase C-gamma as a signal-transducing element. 
Experimental cell research 253, 15-24 (1999). 
25.Streb, H., Irvine, R. F., Berridge, M. J. & Schulz, I. Release of Ca2+ from a 
nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-
trisphosphate. Nature 306, 67-9 (1983). 
26.Barr, V. A., Bernot, K. M., Shaffer, M. H., Burkhardt, J. K. & Samelson, L. E. 
Formation of STIM and Orai complexes: puncta and distal caps. Immunological reviews 
231, 148-59 (2009). 
27.Clapham, D. E. Calcium signaling. Cell 131, 1047-58 (2007). 
28.Hogan, P. G., Chen, L., Nardone, J. & Rao, A. Transcriptional regulation by 
calcium, calcineurin, and NFAT. Genes & development 17, 2205-32 (2003). 
29.Calne, R. Y. et al. Cyclosporin A in patients receiving renal allografts from cadaver 
donors. Lancet 2, 1323-7 (1978). 
30.Tamás, P. et al. Regulation of the energy sensor AMP-activated protein kinase by 
antigen receptor and Ca2+ in T lymphocytes. The Journal of experimental medicine 
203, 1665-70 (2006). 
31.Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that 
maintains energy homeostasis. Nature reviews. Molecular cell biology 13, 251-62 
(2012). 
32.Matthews, S. A. & Cantrell, D. A. New insights into the regulation and function of 
serine/threonine kinases in T lymphocytes. Immunological reviews 228, 241-52 (2009). 
33.Jun, J. E., Rubio, I. & Roose, J. P. Regulation of ras exchange factors and cellular 
localization of ras activation by lipid messengers in T cells. Frontiers in immunology 4, 
239 (2013). 
34.Monks, C. R., Kupfer, H., Tamir, I., Barlow, A. & Kupfer, A. Selective modulation 
of protein kinase C-theta during T-cell activation. Nature 385, 83-6 (1997). 
35.Dustin, M. L. & Depoil, D. New insights into the T cell synapse from single 
molecule techniques. Nature reviews. Immunology 11, 672-84 (2011). 
36.Quann, E. J., Merino, E., Furuta, T. & Huse, M. Localized diacylglycerol drives the 
polarization of the microtubule-organizing center in T cells. Nature Immunology 10, 
627-35 (2009). 
37.Rosse, C. et al. PKC and the control of localized signal dynamics. Nature reviews. 
Molecular cell biology 11, 103-12 (2010). 
38.Ma, J. S. Y., Haydar, T. F. & Radoja, S. Protein kinase C delta localizes to secretory 
lysosomes in CD8+ CTL and directly mediates TCR signals leading to granule 
205 
 
exocytosis-mediated cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 181, 
4716-22 (2008). 
39.Matsumoto, R. et al. Phosphorylation of CARMA1 plays a critical role in T Cell 
receptor-mediated NF-kappaB activation. Immunity 23, 575-85 (2005). 
40.Letschka, T. et al. PKC-theta selectively controls the adhesion-stimulating molecule 
Rap1. Blood 112, 4617-27 (2008). 
41.Fagerholm, S., Morrice, N., Gahmberg, C. G. & Cohen, P. Phosphorylation of the 
cytoplasmic domain of the integrin CD18 chain by protein kinase C isoforms in 
leukocytes. The Journal of biological chemistry 277, 1728-38 (2002). 
42.Matthews, S. A., Rozengurt, E. & Cantrell, D. Protein kinase D. A selective target 
for antigen receptors and a downstream target for protein kinase C in lymphocytes. The 
Journal of experimental medicine 191, 2075-82 (2000). 
43.Rozengurt, E. Protein kinase D signaling: multiple biological functions in health and 
disease. Physiology (Bethesda, Md.) 26, 23-33 (2011). 
44.Spitaler, M., Emslie, E., Wood, C. D. & Cantrell, D. Diacylglycerol and protein 
kinase D localization during T lymphocyte activation. Immunity 24, 535-46 (2006). 
45.Matthews, S. A. et al. Unique functions for protein kinase D1 and protein kinase D2 
in mammalian cells. The Biochemical journal 432, 153-63 (2010). 
46.Navarro, M., Goebel, J., Feijoo-Carnero, C., Morrice, N. & Cantrell, D. 
Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone 
deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nature 
Immunology 12, 352-61 (2011). 
47.Simon, M. A., Bowtell, D. D., Dodson, G. S., Laverty, T. R. & Rubin, G. M. Ras1 
and a putative guanine nucleotide exchange factor perform crucial steps in signaling by 
the sevenless protein tyrosine kinase. Cell 67, 701-16 (1991). 
48.Moodie, S. A., Willumsen, B. M., Weber, M. J. & Wolfman, A. Complexes of 
Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science (New York, 
N.Y.) 260, 1658-61 (1993). 
49.Genot, E. & Cantrell, D. A. Ras regulation and function in lymphocytes. Current 
opinion in immunology 12, 289-94 (2000). 
50.Harriague, J. & Bismuth, G. Imaging antigen-induced PI3K activation in T cells. 
Nature Immunology 3, 1090-6 (2002). 
51.Huppa, J. B., Gleimer, M., Sumen, C. & Davis, M. M. Continuous T cell receptor 
signaling required for synapse maintenance and full effector potential. Nature 
Immunology 4, 749-55 (2003). 
52.Garçon, F. et al. CD28 provides T-cell costimulation and enhances PI3K activity at 
the immune synapse independently of its capacity to interact with the p85/p110 
heterodimer. Blood 111, 1464-71 (2008). 
53.Costello, P. S., Gallagher, M. & Cantrell, D. A. Sustained and dynamic inositol lipid 
metabolism inside and outside the immunological synapse. Nature Immunology 3, 
1082-9 (2002). 
54.Vanhaesebroeck, B. et al. P110delta, a novel phosphoinositide 3-kinase in 
leukocytes. Proceedings of the National Academy of Sciences of the United States of 
America 94, 4330-5 (1997). 
55.Fukazawa, T. et al. T cell activation-dependent association between the p85 subunit 
of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding 
phosphotyrosyl protein pp36/38. The Journal of biological chemistry 270, 20177-82 
(1995). 
56.Shim, E. K. et al. Association of the Src homology 2 domain-containing leukocyte 
phosphoprotein of 76 kD (SLP-76) with the p85 subunit of phosphoinositide 3-kinase. 
FEBS letters 575, 35-40 (2004). 
206 
 
57.Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of 
Ras. Nature 370, 527-32 (1994). 
58.Wabnitz, G. H., Nebl, G., Klemke, M., Schröder, A. J. & Samstag, Y. 
Phosphatidylinositol 3-kinase functions as a Ras effector in the signaling cascade that 
regulates dephosphorylation of the actin-remodeling protein cofilin after costimulation 
of untransformed human T lymphocytes. Journal of immunology (Baltimore, Md. : 
1950) 176, 1668-74 (2006). 
59.Castellino, F. & Germain, R. N. Cooperation between CD4+ and CD8+ T cells: 
when, where, and how. Annual review of immunology 24, 519-40 (2006). 
60.Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. 
Two types of murine helper T cell clone. I. Definition according to profiles of 
lymphokine activities and secreted proteins. Journal of immunology (Baltimore, Md. : 
1950) 136, 2348-57 (1986). 
61.Wan, Y. Y. Multi-tasking of helper T cells. Immunology 130, 166-71 (2010). 
62.Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a 
lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 6, 1123-32 
(2005). 
63.Stockinger, B., Veldhoen, M. & Martin, B. Th17 T cells: linking innate and adaptive 
immunity. Seminars in immunology 19, 353-61 (2007). 
64.Hirota, K., Ahlfors, H., Duarte, J. H. & Stockinger, B. Regulation and function of 
innate and adaptive interleukin-17-producing cells. EMBO reports 13, 113-20 (2012). 
65.Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. 
Nature reviews. Immunology 10, 170-81 (2010). 
66.Hirota, K. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. 
Nature Immunology 12, 255-63 (2011). 
67.Vahedi, G. et al. Helper T-cell identity and evolution of differential transcriptomes 
and epigenomes. Immunological reviews 252, 24-40 (2013). 
68.Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and 
immune tolerance. Cell 133, 775-87 (2008). 
69.Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, 
results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature genetics 27, 
68-73 (2001). 
70.Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by 
the transcription factor Foxp3. Science (New York, N.Y.) 299, 1057-61 (2003). 
71.Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead 
transcription factor foxp3. Immunity 22, 329-41 (2005). 
72.Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature genetics 27, 20-1 
(2001). 
73.Pandiyan, P., Zheng, L., Ishihara, S., Reed, J. & Lenardo, M. J. CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T 
cells. Nature Immunology 8, 1353-62 (2007). 
74.Read, S., Malmström, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 
plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control 
intestinal inflammation. The Journal of experimental medicine 192, 295-302 (2000). 
75.Shevach, E. M., McHugh, R. S., Piccirillo, C. A. & Thornton, A. M. Control of T-
cell activation by CD4+ CD25+ suppressor T cells. Immunological reviews 182, 58-67 
(2001). 
76.Boehmer, von, H. Mechanisms of suppression by suppressor T cells. Nature 
Immunology 6, 338-44 (2005). 
77.Michalek, R. D. & Rathmell, J. C. The metabolic life and times of a T-cell. 
Immunological reviews 236, 190-202 (2010). 
207 
 
78.Badovinac, V. P., Haring, J. S. & Harty, J. T. Initial T cell receptor transgenic cell 
precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. 
Immunity 26, 827-41 (2007). 
79.van Stipdonk, M. J. B. et al. Dynamic programming of CD8+ T lymphocyte 
responses. Nature Immunology 4, 361-365 (2003). 
80.Yoon, H., Kim, T. S. & Braciale, T. J. The cell cycle time of CD8+ T cells 
responding in vivo is controlled by the type of antigenic stimulus. PloS one 5, e15423 
(2010). 
81.vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. Science (New York, 
N.Y.) 324, 1029-33 (2009). 
82.WARBURG, O. On the origin of cancer cells. Science (New York, N.Y.) 123, 309-14 
(1956). 
83.Wang, R. et al. The Transcription Factor Myc Controls Metabolic Reprogramming 
upon T Lymphocyte Activation. Immunity 35, 871-882 (2011). 
84.Marko, A. J., Miller, R. A., Kelman, A. & Frauwirth, K. A. Induction of glucose 
metabolism in stimulated T lymphocytes is regulated by mitogen-activated protein 
kinase signaling. PloS one 5, e15425 (2010). 
85.Finlay, D. K. et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 
integrate metabolism and migration of CD8+ T cells. The Journal of experimental 
medicine 209, 2441-53 (2012). 
86.Macintyre, A. N. et al. Protein kinase B controls transcriptional programs that direct 
cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34, 224-36 
(2011). 
87.McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. Cytotoxic T-cell 
immunity to influenza. The New England journal of medicine 309, 13-7 (1983). 
88.Harty, J. T., Tvinnereim, A. R. & White, D. W. CD8+ T cell effector mechanisms in 
resistance to infection. Annual review of immunology 18, 275-308 (2000). 
89.Lee, S., Dunmire, S. & McSorley, S. J. MHC class-I-restricted CD8 T cells play a 
protective role during primary Salmonella infection. Immunology letters 148, 138-43 
(2012). 
90.White, D. W., Wilson, R. L. & Harty, J. T. CD8+ T cells in intracellular bacterial 
infections of mice. Research in immunology 147, 519-24 (1996). 
91.Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-
dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 
82-6 (1998). 
92.Cemerski, S. et al. The balance between T cell receptor signaling and degradation at 
the center of the immunological synapse is determined by antigen quality. Immunity 29, 
414-22 (2008). 
93.Dustin, M. L., Chakraborty, A. K. & Shaw, A. S. Understanding the structure and 
function of the immunological synapse. Cold Spring Harbor perspectives in biology 2, 
a002311 (2010). 
94.Kuhné, M. R. et al. Linker for activation of T cells, zeta-associated protein-70, and 
Src homology 2 domain-containing leukocyte protein-76 are required for TCR-induced 
microtubule-organizing center polarization. Journal of immunology (Baltimore, Md. : 
1950) 171, 860-6 (2003). 
95.Tschopp, J., Masson, D. & Stanley, K. K. Structural/functional similarity between 
proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. 
Nature 322, 831-4 (1986). 
96.Thiery, J. et al. Perforin pores in the endosomal membrane trigger the release of 
endocytosed granzyme B into the cytosol of target cells. Nature Immunology 12, 770-7 
(2011). 
208 
 
97.Odake, S. et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite 
mapping with peptide thioester substrates and inhibition of enzyme activity and 
cytolysis by isocoumarins. Biochemistry 30, 2217-27 (1991). 
98.Atkinson, E. A. et al. Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation 
is primarily the result of the direct action of granzyme B. The Journal of biological 
chemistry 273, 21261-6 (1998). 
99.Heibein, J. A., Barry, M., Motyka, B. & Bleackley, R. C. Granzyme B-induced loss 
of mitochondrial inner membrane potential (Delta Psi m) and cytochrome c release are 
caspase independent. Journal of immunology (Baltimore, Md. : 1950) 163, 4683-93 
(1999). 
100.Balaji, K. N., Schaschke, N., Machleidt, W., Catalfamo, M. & Henkart, P. A. 
Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after 
degranulation. The Journal of experimental medicine 196, 493-503 (2002). 
101.Baran, K. et al. Cytotoxic T lymphocytes from cathepsin B-deficient mice survive 
normally in vitro and in vivo after encountering and killing target cells. The Journal of 
biological chemistry 281, 30485-91 (2006). 
102.Bossi, G. & Griffiths, G. M. Degranulation plays an essential part in regulating cell 
surface expression of Fas ligand in T cells and natural killer cells. Nature medicine 5, 
90-6 (1999). 
103.Algeciras-Schimnich, A. et al. Molecular ordering of the initial signaling events of 
CD95. Molecular and Cellular Biology 22, 207-20 (2002). 
104.Tanaka, M., Itai, T., Adachi, M. & Nagata, S. Downregulation of Fas ligand by 
shedding. Nature medicine 4, 31-6 (1998). 
105.Suda, T., Hashimoto, H., Tanaka, M., Ochi, T. & Nagata, S. Membrane Fas ligand 
kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. 
The Journal of experimental medicine 186, 2045-50 (1997). 
106.Kriegler, M., Perez, C., DeFay, K., Albert, I. & Lu, S. D. A novel form of 
TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the 
complex physiology of TNF. Cell 53, 45-53 (1988). 
107.Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis 
factor-alpha from cells. Nature 385, 729-33 (1997). 
108.Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-
alpha therapies: the next generation. Nature reviews. Drug discovery 2, 736-46 (2003). 
109.Kägi, D. et al. Fas and perforin pathways as major mechanisms of T cell-mediated 
cytotoxicity. Science (New York, N.Y.) 265, 528-30 (1994). 
110.Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T-cell cytotoxicity is 
mediated through perforin and Fas lytic pathways. Nature 370, 650-2 (1994). 
111.Ratner, A. & Clark, W. R. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-
mediated lysis. Journal of immunology (Baltimore, Md. : 1950) 150, 4303-14 (1993). 
112.Wohlleber, D. et al. TNF-induced target cell killing by CTL activated through 
cross-presentation. Cell reports 2, 478-87 (2012). 
113.Lukacs, N. W., Strieter, R. M., Chensue, S. W., Widmer, M. & Kunkel, S. L. TNF-
alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. 
Journal of immunology (Baltimore, Md. : 1950) 154, 5411-7 (1995). 
114.Osborn, L. et al. Direct expression cloning of vascular cell adhesion molecule 1, a 
cytokine-induced endothelial protein that binds to lymphocytes. Cell 59, 1203-11 
(1989). 
115.Cemerski, S. & Shaw, A. Immune synapses in T-cell activation. Current opinion in 
immunology 18, 298-304 (2006). 
116.Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an 
overview of signals, mechanisms and functions. Journal of leukocyte biology 75, 163-
89 (2004). 
209 
 
117.Müllbacher, A. et al. Antigen-dependent release of IFN-gamma by cytotoxic T cells 
up-regulates Fas on target cells and facilitates exocytosis-independent specific target 
cell lysis. Journal of immunology (Baltimore, Md. : 1950) 169, 145-50 (2002). 
118.Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T 
cell differentiation. Nature reviews. Immunology 12, 749-61 (2012). 
119.Ahmed, R. & Gray, D. Immunological memory and protective immunity: 
understanding their relation. Science (New York, N.Y.) 272, 54-60 (1996). 
120.Kaech, S. M. & Wherry, E. J. Heterogeneity and cell-fate decisions in effector and 
memory CD8+ T cell differentiation during viral infection. Immunity 27, 393-405 
(2007). 
121.Cui, W. & Kaech, S. M. Generation of effector CD8+ T cells and their conversion 
to memory T cells. Immunological reviews 236, 151-66 (2010). 
122.Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T 
lymphocytes from normal human bone marrows. Science (New York, N.Y.) 193, 1007-8 
(1976). 
123.Gillis, S. & Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. 
Nature 268, 154-6 (1977). 
124.Bazan, J. F. Structural design and molecular evolution of a cytokine receptor 
superfamily. Proceedings of the National Academy of Sciences of the United States of 
America 87, 6934-8 (1990). 
125.Taniguchi, T. et al. Structure and expression of a cloned cDNA for human 
interleukin-2. Nature 302, 305-10 (1983). 
126.Leonard, W. J. et al. Molecular cloning and expression of cDNAs for the human 
interleukin-2 receptor. Nature 311, 626-31 (1984). 
127.Nikaido, T. et al. Molecular cloning of cDNA encoding human interleukin-2 
receptor. Nature 311, 631-5 (1984). 
128.Wang, H. M. & Smith, K. A. The interleukin 2 receptor. Functional consequences 
of its bimolecular structure. The Journal of experimental medicine 166, 1055-69 (1987). 
129.Johnson, K. et al. Soluble IL-2 receptor beta and gamma subunits: ligand binding 
and cooperativity. European cytokine network 5, 23-34 (1994). 
130.Noguchi, M. et al. Interleukin-2 receptor gamma chain mutation results in X-linked 
severe combined immunodeficiency in humans. Cell 73, 147-57 (1993). 
131.Cornish, G., Sinclair, L. & Cantrell, D. Differential regulation of T-cell growth by 
IL-2 and IL-15. Blood 108, 600-8 (2006). 
132.Boussiotis, V. A. et al. Prevention of T cell anergy by signaling through the gamma 
c chain of the IL-2 receptor. Science (New York, N.Y.) 266, 1039-42 (1994). 
133.Miyazaki, T. et al. Functional activation of Jak1 and Jak3 by selective association 
with IL-2 receptor subunits. Science (New York, N.Y.) 266, 1045-7 (1994). 
134.Friedmann, M. C., Migone, T. S., Russell, S. M. & Leonard, W. J. Different 
interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and 
synergistically mediate interleukin 2-induced proliferation. Proceedings of the National 
Academy of Sciences of the United States of America 93, 2077-82 (1996). 
135.Liao, W. et al. Priming for T helper type 2 differentiation by interleukin 2-mediated 
induction of interleukin 4 receptor alpha-chain expression. Nature Immunology 9, 1288-
96 (2008). 
136.Liao, W., Lin, J., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine 
receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nature 
Immunology 12, 551-9 (2011). 
137.Lin, J. et al. Critical Role of STAT5 transcription factor tetramerization for 
cytokine responses and normal immune function. Immunity 36, 586-99 (2012). 
210 
 
138.Yao, Z. et al. Stat5a/b are essential for normal lymphoid development and 
differentiation. Proceedings of the National Academy of Sciences of the United States of 
America 103, 1000-5 (2006). 
139.Nakajima, H. et al. An indirect effect of Stat5a in IL-2-induced proliferation: a 
critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 
7, 691-701 (1997). 
140.Imada, K. et al. Stat5b is essential for natural killer cell-mediated proliferation and 
cytolytic activity. The Journal of experimental medicine 188, 2067-74 (1998). 
141.Remillard, B. et al. Interleukin-2 receptor regulates activation of 
phosphatidylinositol 3-kinase. The Journal of biological chemistry 266, 14167-70 
(1991). 
142.Okkenhaug, K. Signaling by the phosphoinositide 3-kinase family in immune cells. 
Annual review of immunology 31, 675-704 (2013). 
143.Ravichandran, K. S., Igras, V., Shoelson, S. E., Fesik, S. W. & Burakoff, S. J. 
Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 
signaling. Proceedings of the National Academy of Sciences of the United States of 
America 93, 5275-80 (1996). 
144.Gu, H. et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt 
pathway. Molecular and Cellular Biology 20, 7109-20 (2000). 
145.Ciprés, A., Gala, S., Martinez-A, C., Mérida, I. & Williamson, P. An IL-2 receptor 
beta subdomain that controls Bcl-X(L) expression and cell survival. European Journal 
of Immunology 29, 1158-67 (1999). 
146.Pearce, L., Komander, D. & Alessi, D. The nuts and bolts of AGC protein kinases. 
Nature reviews. Molecular cell biology 11, 9-22 (2010). 
147.Calleja, V. et al. Intramolecular and intermolecular interactions of protein kinase B 
define its activation in vivo. PLoS biology 5, e95 (2007). 
148.Mora, A., Komander, D., van Aalten, D. M. F. & Alessi, D. R. PDK1, the master 
regulator of AGC kinase signal transduction. Seminars in cell & developmental biology 
15, 161-70 (2004). 
149.Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, N.Y.) 307, 
1098-101 (2005). 
150.Waugh, C., Sinclair, L., Finlay, D., Bayascas, J. & Cantrell, D. Phosphoinositide 
(3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein 
kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. 
Molecular and Cellular Biology 29, 5952-62 (2009). 
151.3rd, W. H. B., Meisenhelder, J., Hunter, T., Cavenee, W. K. & Arden, K. C. Protein 
kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix 
transcription factor FKHR1. Proceedings of the National Academy of Sciences of the 
United States of America 96, 7421-6 (1999). 
152.Calnan, D. R. & Brunet, A. The FoxO code. Oncogene 27, 2276-88 (2008). 
153.Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by 
regulating L-selectin, CCR7 and interleukin 7 receptor. Nature Immunology 10, 176-84 
(2009). 
154.Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress 
from lymphoid organs. Annual review of immunology 30, 69-94 (2012). 
155.Sinclair, L. V. et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR 
pathways control T lymphocyte trafficking. Nature Immunology 9, 513-521 (2008). 
156.Hand, T. W. et al. Differential effects of STAT5 and PI3K/AKT signaling on 
effector and memory CD8 T-cell survival. Proceedings of the National Academy of 
Sciences of the United States of America 107, 16601-6 (2010). 
211 
 
157.Barata, J. T. et al. Activation of PI3K is indispensable for interleukin 7-mediated 
viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia 
cells. The Journal of experimental medicine 200, 659-69 (2004). 
158.Manjunath, N. et al. Effector differentiation is not prerequisite for generation of 
memory cytotoxic T lymphocytes. The Journal of clinical investigation 108, 871-8 
(2001). 
159.Weninger, W., Crowley, M. A., Manjunath, N. & Andrian, von, U. H. Migratory 
properties of naive, effector, and memory CD8(+) T cells. The Journal of experimental 
medicine 194, 953-66 (2001). 
160.Duke, R. C. & Cohen, J. J. IL-2 addiction: withdrawal of growth factor activates a 
suicide program in dependent T cells. Lymphokine research 5, 289-99 (1986). 
161.Collison, L. W. & Vignali, D. A. A. Interleukin-35: odd one out or part of the 
family? Immunological reviews 226, 248-62 (2008). 
162.Jones, L. L. & Vignali, D. A. A. Molecular interactions within the IL-6/IL-12 
cytokine/receptor superfamily. Immunologic research 51, 5-14 (2011). 
163.Presky, D. H. et al. A functional interleukin 12 receptor complex is composed of 
two beta-type cytokine receptor subunits. Proceedings of the National Academy of 
Sciences of the United States of America 93, 14002-7 (1996). 
164.Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, 
with biological activities similar as well as distinct from IL-12. Immunity 13, 715-25 
(2000). 
165.Pflanz, S. et al. WSX-1 and glycoprotein 130 constitute a signal-transducing 
receptor for IL-27. Journal of immunology (Baltimore, Md. : 1950) 172, 2225-31 
(2004). 
166.Collison, L. W. et al. The composition and signaling of the IL-35 receptor are 
unconventional. Nature Immunology 13, 290-9 (2012). 
167.Delgoffe, G. M., Murray, P. J. & Vignali, D. A. A. Interpreting mixed signals: the 
cell's cytokine conundrum. Current opinion in immunology 23, 632-8 (2011). 
168.Vignali, D. A. A. & Kuchroo, V. K. IL-12 family cytokines: immunological 
playmakers. Nature Immunology 13, 722-8 (2012). 
169.Ma, X. & Trinchieri, G. Regulation of interleukin-12 production in antigen-
presenting cells. Advances in immunology 79, 55-92 (2001). 
170.van de Vosse, E. et al. IL-12Rβ1 deficiency: mutation update and description of the 
IL12RB1 variation database. Human mutation 34, 1329-39 (2013). 
171.Airoldi, I. et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity 
and malignancy. Blood 106, 3846-53 (2005). 
172.Cooper, A. M. et al. Mice lacking bioactive IL-12 can generate protective, antigen-
specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is 
present. Journal of immunology (Baltimore, Md. : 1950) 168, 1322-7 (2002). 
173.Curtsinger, J. M. et al. Inflammatory cytokines provide a third signal for activation 
of naive CD4+ and CD8+ T cells. Journal of immunology (Baltimore, Md. : 1950) 162, 
3256-62 (1999). 
174.Keppler, S. J., Theil, K., Vucikuja, S. & Aichele, P. Effector T-cell differentiation 
during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of 
CD8(+) T cells. European Journal of Immunology 39, 1774-83 (2009). 
175.Starbeck-Miller, G. R., Xue, H. & Harty, J. T. IL-12 and type I interferon prolong 
the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in 
vivo. The Journal of experimental medicine 211, 105-20 (2014). 
176.Wilson, D. C., Matthews, S. & Yap, G. S. IL-12 signaling drives CD8+ T cell IFN-
gamma production and differentiation of KLRG1+ effector subpopulations during 
Toxoplasma gondii Infection. Journal of immunology (Baltimore, Md. : 1950) 180, 
5935-45 (2008). 
212 
 
177.Rao, R. R., Li, Q., Odunsi, K. & Shrikant, P. A. The mTOR Kinase Determines 
Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of 
Transcription Factors T-bet and Eomesodermin. Immunity 32, 67-78 (2010). 
178.Vézina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new 
antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the 
active principle. The Journal of antibiotics 28, 721-6 (1975). 
179.Martel, R. R., Klicius, J. & Galet, S. Inhibition of the immune response by 
rapamycin, a new antifungal antibiotic. Canadian journal of physiology and 
pharmacology 55, 48-51 (1977). 
180.Hori, T. et al. Establishment of an interleukin 2-dependent human T cell line from a 
patient with T cell chronic lymphocytic leukemia who is not infected with human T cell 
leukemia/lymphoma virus. Blood 70, 1069-72 (1987). 
181.Bierer, B. E. et al. Two distinct signal transmission pathways in T lymphocytes are 
inhibited by complexes formed between an immunophilin and either FK506 or 
rapamycin. Proceedings of the National Academy of Sciences of the United States of 
America 87, 9231-5 (1990). 
182.Kuo, C. J. et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 
kinase. Nature 358, 70-3 (1992). 
183.Terada, N., Franklin, R. A., Lucas, J. J., Blenis, J. & Gelfand, E. W. Failure of 
rapamycin to block proliferation once resting cells have entered the cell cycle despite 
inactivation of p70 S6 kinase. The Journal of biological chemistry 268, 12062-8 (1993). 
184.Brennan, P., Babbage, J. W., Thomas, G. & Cantrell, D. p70(s6k) integrates 
phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T 
lymphocytes. Molecular and Cellular Biology 19, 4729-38 (1999). 
185.Breslin, E. M., White, P. C., Shore, A. M., Clement, M. & Brennan, P. LY294002 
and rapamycin co-operate to inhibit T-cell proliferation. British journal of 
pharmacology 144, 791-800 (2005). 
186.Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the 
immunosuppressant rapamycin in yeast. Science (New York, N.Y.) 253, 905-9 (1991). 
187.Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-
receptor complex. Nature 369, 756-8 (1994). 
188.Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. 
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion 
and is homologous to yeast TORs. Cell 78, 35-43 (1994). 
189.Chiu, M. I., Katz, H. & Berlin, V. RAPT1, a mammalian homolog of yeast Tor, 
interacts with the FKBP12/rapamycin complex. Proceedings of the National Academy 
of Sciences of the United States of America 91, 12574-8 (1994). 
190.Sabers, C. J. et al. Isolation of a protein target of the FKBP12-rapamycin complex 
in mammalian cells. The Journal of biological chemistry 270, 815-22 (1995). 
191.Lempiäinen, H. & Halazonetis, T. D. Emerging common themes in regulation of 
PIKKs and PI3Ks. The EMBO journal 28, 3067-73 (2009). 
192.Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, 
have distinct roles in cell growth control. Molecular Cell 10, 457-68 (2002). 
193.Laplante, M. & Sabatini, D. M. Regulation of mTORC1 and its impact on gene 
expression at a glance. Journal of Cell Science 126, 1713-9 (2013). 
194.Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 497, 
217-23 (2013). 
195.Sarbassov, dos, D. D. et al. Prolonged Rapamycin Treatment Inhibits mTORC2 
Assembly and Akt/PKB. Molecular Cell 22, 159-168 (2006). 
196.García‑Martínez, J. et al. Ku-0063794 is a specific inhibitor of the mammalian 
target of rapamycin (mTOR). Biochemical Journal 421, 29-42 (2009). 
213 
 
197.Porta, C., Paglino, C. & Mosca, A. Targeting PI3K/Akt/mTOR Signaling in 
Cancer. Frontiers in oncology 4, 64 (2014). 
198.Campistol, J. M. et al. Practical recommendations for the early use of m-TOR 
inhibitors (sirolimus) in renal transplantation. Transplant international : official journal 
of the European Society for Organ Transplantation 22, 681-7 (2009). 
199.Garg, S., Bourantas, C. & Serruys, P. W. DES the year in review: controversies. 
Minerva cardioangiologica 61, 99-123 (2013). 
200.Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 
108-112 (2009). 
201.Li, Q. et al. A Central Role for mTOR Kinase in Homeostatic Proliferation Induced 
CD8+ T Cell Memory and Tumor Immunity. Immunity 34, 541-553 (2011). 
202.Battaglia, M., Stabilini, A. & Roncarolo, M. Rapamycin selectively expands 
CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743-8 (2005). 
203.Jones, R. G. & Thompson, C. B. Revving the engine: signal transduction fuels T 
cell activation. Immunity 27, 173-8 (2007). 
204.Pearce, E. L. Metabolism in T cell activation and differentiation. Current opinion in 
immunology 22, 314-20 (2010). 
205.Pearce, E. L., Poffenberger, M. C., Chang, C. & Jones, R. G. Fueling Immunity: 
Insights into Metabolism and Lymphocyte Function. Science (New York, N.Y.) 342, 
1242454 (2013). 
206.Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1. Science (New York, N.Y.) 320, 1496-501 (2008). 
207.Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. & Guan, K. Regulation of 
TORC1 by Rag GTPases in nutrient response. Nature cell biology 10, 935-45 (2008). 
208.Tee, A. R. et al. Tuberous sclerosis complex-1 and -2 gene products function 
together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream 
signaling. Proceedings of the National Academy of Sciences of the United States of 
America 99, 13571-6 (2002). 
209.Dibble, C. C. et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex 
upstream of mTORC1. Molecular Cell 47, 535-46 (2012). 
210.Manning, B. D. & Cantley, L. C. Rheb fills a GAP between TSC and TOR. Trends 
in biochemical sciences 28, 573-6 (2003). 
211.Yee, W. M. & Worley, P. F. Rheb interacts with Raf-1 kinase and may function to 
integrate growth factor- and protein kinase A-dependent signals. Molecular and 
Cellular Biology 17, 921-33 (1997). 
212.Saucedo, L. J. et al. Rheb promotes cell growth as a component of the insulin/TOR 
signalling network. Nature cell biology 5, 566-71 (2003). 
213.Betz, C. & Hall, M. N. Where is mTOR and what is it doing there? The Journal of 
Cell Biology 203, 563-74 (2013). 
214.Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. 
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product 
tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular Cell 10, 
151-62 (2002). 
215.Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. TSC2 is phosphorylated and inhibited 
by Akt and suppresses mTOR signalling. Nature cell biology 4, 648-57 (2002). 
216.Menon, S. et al. Spatial control of the TSC complex integrates insulin and nutrient 
regulation of mTORC1 at the lysosome. Cell 156, 771-85 (2014). 
217.Demetriades, C., Doumpas, N. & Teleman, A. A. Regulation of TORC1 in response 
to amino acid starvation via lysosomal recruitment of TSC2. Cell 156, 786-99 (2014). 
218.Cai, S. et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and 
membrane partitioning. The Journal of Cell Biology 173, 279-89 (2006). 
214 
 
219.Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. 
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous 
sclerosis and cancer pathogenesis. Cell 121, 179-93 (2005). 
220.Sancak, Y. et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein 
kinase. Molecular Cell 25, 903-15 (2007). 
221.Wang, L., Harris, T. E., Roth, R. A. & Lawrence, J. C., Jr. PRAS40 regulates 
mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. The 
Journal of biological chemistry 282, 20036-44 (2007). 
222.vander Haar, E., Lee, S., Bandhakavi, S., Griffin, T. J. & Kim, D. Insulin signalling 
to mTOR mediated by the Akt/PKB substrate PRAS40. Nature cell biology 9, 316-23 
(2007). 
223.Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J. & Proud, C. G. The tuberous 
sclerosis protein TSC2 is not required for the regulation of the mammalian target of 
rapamycin by amino acids and certain cellular stresses. The Journal of biological 
chemistry 280, 18717-27 (2005). 
224.Roccio, M., Bos, J. L. & Zwartkruis, F. J. T. Regulation of the small GTPase Rheb 
by amino acids. Oncogene 25, 657-64 (2006). 
225.Bar-Peled, L., Schweitzer, L. D., Zoncu, R. & Sabatini, D. M. Ragulator is a GEF 
for the rag GTPases that signal amino acid levels to mTORC1. Cell 150, 1196-208 
(2012). 
226.Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface 
and is necessary for its activation by amino acids. Cell 141, 290-303 (2010). 
227.Sinclair, L. et al. Control of amino-acid transport by antigen receptors coordinates 
the metabolic reprogramming essential for T cell differentiation. Nature Immunology 
14, 500-8 (2013). 
228.Cham, C. M. & Gajewski, T. F. Glucose availability regulates IFN-gamma 
production and p70S6 kinase activation in CD8+ effector T cells. Journal of 
immunology (Baltimore, Md. : 1950) 174, 4670-7 (2005). 
229.Nakaya, M. et al. Inflammatory T cell responses rely on amino acid transporter 
ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40, 
692-705 (2014). 
230.Waickman, A. T. & Powell, J. D. mTOR, metabolism, and the regulation of T-cell 
differentiation and function. Immunological reviews 249, 43-58 (2012). 
231.Carr, E. L. et al. Glutamine uptake and metabolism are coordinately regulated by 
ERK/MAPK during T lymphocyte activation. Journal of immunology (Baltimore, Md. : 
1950) 185, 1037-44 (2010). 
232.Bar-Peled, L. & Sabatini, D. M. Regulation of mTORC1 by amino acids. Trends in 
cell biology 24, 400-6 (2014). 
233.Rolf, J. et al. AMPKα1: A glucose sensor that controls CD8 T-cell memory. 
European Journal of Immunology 43, 889-896 (2013). 
234.Sengupta, S., Peterson, T. R. & Sabatini, D. M. Regulation of the mTOR complex 1 
pathway by nutrients, growth factors, and stress. Molecular Cell 40, 310-22 (2010). 
235.Dibble, C. C. & Manning, B. D. Signal integration by mTORC1 coordinates 
nutrient input with biosynthetic output. Nature cell biology 15, 555-64 (2013). 
236.Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. The 
Biochemical journal 408, 297-315 (2007). 
237.Yang, K., Neale, G., Green, D. R., He, W. & Chi, H. The tumor suppressor Tsc1 
enforces quiescence of naive T cells to promote immune homeostasis and function. 
Nature Immunology 12, 888-97 (2011). 
238.Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational 
control. Nature reviews. Molecular cell biology 10, 307-18 (2009). 
215 
 
239.Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA 
translation. Nature 485, 109-13 (2012). 
240.Zhang, Y. et al. Coordinated regulation of protein synthesis and degradation by 
mTORC1. Nature (2014). doi:10.1038/nature13492 
241.Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to 
Akt-dependent cell growth. Cell metabolism 8, 224-36 (2008). 
242.Boya, P., Reggiori, F. & Codogno, P. Emerging regulation and functions of 
autophagy. Nature cell biology 15, 713-20 (2013). 
243.Korolchuk, V. I. et al. Lysosomal positioning coordinates cellular nutrient 
responses. Nature cell biology 13, 453-60 (2011). 
244.Poüs, C. & Codogno, P. Lysosome positioning coordinates mTORC1 activity and 
autophagy. Nature cell biology 13, 342-4 (2011). 
245.Ganley, I. G. et al. ULK1.ATG13.FIP200 complex mediates mTOR signaling and 
is essential for autophagy. The Journal of biological chemistry 284, 12297-305 (2009). 
246.Weichhart, T. et al. The TSC-mTOR signaling pathway regulates the innate 
inflammatory response. Immunity 29, 565-77 (2008). 
247.Harrington, L. et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling 
via regulation of IRS proteins. The Journal of Cell Biology 166, 213-23 (2004). 
248.Hsu, P. P. et al. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of 
mTORC1-Mediated Inhibition of Growth Factor Signaling. Science 332, 1317-1322 
(2011). 
249.Yu, Y. et al. Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 
Substrate That Negatively Regulates Insulin Signaling. Science 332, 1322-1326 (2011). 
250.He, S. et al. Characterization of the metabolic phenotype of rapamycin-treated 
CD8+ T cells with augmented ability to generate long-lasting memory cells. PloS one 6, 
e20107 (2011). 
251.Arbonés, M. L. et al. Lymphocyte homing and leukocyte rolling and migration are 
impaired in L-selectin-deficient mice. Immunity 1, 247-60 (1994). 
252.Springer, T. A. Traffic signals on endothelium for lymphocyte recirculation and 
leukocyte emigration. Annual review of physiology 57, 827-72 (1995). 
253.Galkina, E. et al. T lymphocyte rolling and recruitment into peripheral lymph nodes 
is regulated by a saturable density of L-selectin (CD62L). European Journal of 
Immunology 37, 1243-53 (2007). 
254.Mora, J. R. & Andrian, von, U. H. T-cell homing specificity and plasticity: new 
concepts and future challenges. Trends in immunology 27, 235-43 (2006). 
255.Nier, A. Some reminiscences of mass spectrometry and the Manhattan Project. 
Journal of Chemical Education (1989). 
256.Karas, M. & Hillenkamp, F. Laser desorption ionization of proteins with molecular 
masses exceeding 10,000 daltons. Analytical chemistry 60, 2299-301 (1988). 
257.Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. & Whitehouse, C. M. 
Electrospray ionization for mass spectrometry of large biomolecules. Science (New 
York, N.Y.) 246, 64-71 (1989). 
258.Fenn, J. B. Electrospray wings for molecular elephants (Nobel lecture). 
Angewandte Chemie (International ed. in English) 42, 3871-94 (2003). 
259.Steen, H. & Mann, M. The ABC‘s (and XYZ’s) of peptide sequencing. Nature 
reviews. Molecular cell biology 5, 699-711 (2004). 
260.Olsen, J. V. et al. A dual pressure linear ion trap Orbitrap instrument with very high 
sequencing speed. Molecular & cellular proteomics : MCP 8, 2759-69 (2009). 
261.James, P. Protein identification in the post-genome era: the rapid rise of proteomics. 
Quarterly reviews of biophysics 30, 279-331 (1997). 
262.Anderson, N. L. & Anderson, N. G. Proteome and proteomics: new technologies, 
new concepts, and new words. Electrophoresis 19, 1853-61 (1998). 
216 
 
263.Lamond, A. I. et al. Advancing cell biology through proteomics in space and time 
(PROSPECTS). Molecular & cellular proteomics : MCP 11, O112.017731 (2012). 
264.Nagaraj, N. et al. System-wide perturbation analysis with nearly complete coverage 
of the yeast proteome by single-shot ultra HPLC runs on a bench top Orbitrap. 
Molecular & cellular proteomics : MCP 11, M111.013722 (2012). 
265.Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic 
analysis of eleven common cell lines reveals ubiquitous but varying expression of most 
proteins. Molecular & cellular proteomics : MCP 11, M111.014050 (2012). 
266.Kim, M. et al. A draft map of the human proteome. Nature 509, 575-81 (2014). 
267.Wilhelm, M. et al. Mass-spectrometry-based draft of the human proteome. Nature 
509, 582-7 (2014). 
268.Makarov, A. & Scigelova, M. Coupling liquid chromatography to Orbitrap mass 
spectrometry. Journal of chromatography. A 1217, 3938-45 (2010). 
269.Ong, S. & Mann, M. Mass spectrometry-based proteomics turns quantitative. 
Nature chemical biology 1, 252-62 (2005). 
270.Ong, S. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a 
simple and accurate approach to expression proteomics. Molecular & cellular 
proteomics : MCP 1, 376-86 (2002). 
271.Mann, M. Functional and quantitative proteomics using SILAC. Nature reviews. 
Molecular cell biology 7, 952-8 (2006). 
272.Trinkle-Mulcahy, L. et al. Identifying specific protein interaction partners using 
quantitative mass spectrometry and bead proteomes. The Journal of Cell Biology 183, 
223-39 (2008). 
273.Soufi, B. et al. Stable isotope labeling by amino acids in cell culture (SILAC) 
applied to quantitative proteomics of Bacillus subtilis. Journal of proteome research 9, 
3638-46 (2010). 
274.de Godoy, L. M. F. et al. Status of complete proteome analysis by mass 
spectrometry: SILAC labeled yeast as a model system. Genome biology 7, R50 (2006). 
275.Urbaniak, M. D., Guther, M. L. S. & Ferguson, M. A. J. Comparative SILAC 
proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages. 
PloS one 7, e36619 (2012). 
276.Everley, P. A., Krijgsveld, J., Zetter, B. R. & Gygi, S. P. Quantitative cancer 
proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool 
for prostate cancer research. Molecular & cellular proteomics : MCP 3, 729-35 (2004). 
277.Loyet, K. M., Ouyang, W., Eaton, D. L. & Stults, J. T. Proteomic profiling of 
surface proteins on Th1 and Th2 cells. Journal of proteome research 4, 400-9 (2005). 
278.Larance, M. et al. Stable-isotope labeling with amino acids in nematodes. Nature 
methods 8, 849-51 (2011). 
279.Sury, M. D., Chen, J. & Selbach, M. The SILAC fly allows for accurate protein 
quantification in vivo. Molecular & cellular proteomics : MCP 9, 2173-83 (2010). 
280.Zanivan, S., Krueger, M. & Mann, M. In vivo quantitative proteomics: the SILAC 
mouse. Methods in molecular biology (Clifton, N.J.) 757, 435-50 (2012). 
281.Luber, C. A. et al. Quantitative proteomics reveals subset-specific viral recognition 
in dendritic cells. Immunity 32, 279-89 (2010). 
282.Ritorto, M. S., Cook, K., Tyagi, K., Pedrioli, P. G. & Trost, M. Hydrophilic strong 
anion exchange (hSAX) chromatography for highly orthogonal peptide separation of 
complex proteomes. Journal of proteome research 12, 2449-57 (2013). 
283.Ly, T. et al. A proteomic chronology of gene expression through the cell cycle in 
human myeloid leukemia cells. eLife 3, e01630 (2014). 
284.Colinge, J. & Bennett, K. L. Introduction to computational proteomics. PLoS 
computational biology 3, e114 (2007). 
217 
 
285.Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. 
Nature Biotechnology 26, 1367-72 (2008). 
286.Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant 
environment. Journal of proteome research 10, 1794-805 (2011). 
287.Nesvizhskii, A. I., Vitek, O. & Aebersold, R. Analysis and validation of proteomic 
data generated by tandem mass spectrometry. Nature methods 4, 787-97 (2007). 
288.Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in 
large-scale protein identifications by mass spectrometry. Nature methods 4, 207-14 
(2007). 
289.Cox, J. et al. MaxLFQ allows accurate proteome-wide label-free quantification by 
delayed normalization and maximal peptide ratio extraction. Molecular & cellular 
proteomics : MCP (2014). doi:10.1074/mcp.M113.031591 
290.Schwanhäusser, B. et al. Global quantification of mammalian gene expression 
control. Nature 473, 337-42 (2011). 
291.Pircher, H., Bürki, K., Lang, R., Hengartner, H. & Zinkernagel, R. M. Tolerance 
induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 
342, 559-61 (1989). 
292.Hagenbeek, T. J. et al. Murine Pten(-/-) T-ALL requires non-redundant 
PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic 
exit. Cancer letters 1-12 (2013). doi:10.1016/j.canlet.2013.12.027 
293.Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell 
development, function, and survival. Immunity 15, 763-74 (2001). 
294.Larance, M. et al. Characterization of MRFAP1 turnover and interactions 
downstream of the NEDD8 pathway. Molecular & cellular proteomics : MCP 11, 
M111.014407 (2012). 
295.Da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4, 
44-57 (2009). 
296.Da Huang, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. Nucleic acids 
research 37, 1-13 (2009). 
297.Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene 
Ontology Consortium. Nature genetics 25, 25-9 (2000). 
298.Liu, G. et al. NetAffx: Affymetrix probesets and annotations. Nucleic acids 
research 31, 82-6 (2003). 
299.Tian, Q. et al. Integrated genomic and proteomic analyses of gene expression in 
Mammalian cells. Molecular & cellular proteomics : MCP 3, 960-9 (2004). 
300.Lord, S. J., Rajotte, R. V., Korbutt, G. S. & Bleackley, R. C. Granzyme B: a natural 
born killer. Immunological reviews 193, 31-8 (2003). 
301.Leader, M., Collins, M., Patel, J. & Henry, K. Vimentin: an evaluation of its role as 
a tumour marker. Histopathology 11, 63-72 (1987). 
302.Pearce, E. L. et al. Control of effector CD8+ T cell function by the transcription 
factor Eomesodermin. Science (New York, N.Y.) 302, 1041-3 (2003). 
303.Intlekofer, A. M. et al. Effector and memory CD8+ T cell fate coupled by T-bet and 
eomesodermin. Nature Immunology 6, 1236-44 (2005). 
304.Mazurek, S., Boschek, C. B., Hugo, F. & Eigenbrodt, E. Pyruvate kinase type M2 
and its role in tumor growth and spreading. Seminars in cancer biology 15, 300-8 
(2005). 
305.Dombrauckas, J. D., Santarsiero, B. D. & Mesecar, A. D. Structural basis for tumor 
pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-29 
(2005). 
218 
 
306.Beck, M. et al. The quantitative proteome of a human cell line. Molecular systems 
biology 7, 549 (2011). 
307.Maier, T., Güell, M. & Serrano, L. Correlation of mRNA and protein in complex 
biological samples. FEBS letters 583, 3966-73 (2009). 
308.Lundberg, E. et al. Defining the transcriptome and proteome in three functionally 
different human cell lines. Molecular systems biology 6, 450 (2010). 
309.Nagaraj, N. et al. Deep proteome and transcriptome mapping of a human cancer 
cell line. Molecular systems biology 7, 548 (2011). 
310.Schwanhäusser, B. et al. Global quantification of mammalian gene expression 
control. Nature 473, 337-342 (2011). 
311.Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from 
proteomic and transcriptomic analyses. Nature reviews. Genetics 13, 227-32 (2012). 
312.López, M. D. & Samuelsson, T. Early evolution of histone mRNA 3' end 
processing. RNA (New York, N.Y.) 14, 1-10 (2008). 
313.Fox, C. J., Hammerman, P. S. & Thompson, C. B. Fuel feeds function: energy 
metabolism and the T-cell response. Nature reviews. Immunology 5, 844-52 (2005). 
314.Maciver, N. J. et al. Glucose metabolism in lymphocytes is a regulated process with 
significant effects on immune cell function and survival. Journal of leukocyte biology 
84, 949-57 (2008). 
315.Brodsky, J. L. & McCracken, A. A. ER protein quality control and proteasome-
mediated protein degradation. Seminars in cell & developmental biology 10, 507-13 
(1999). 
316.Sontag, E. M., Vonk, W. I. M. & Frydman, J. Sorting out the trash: the spatial 
nature of eukaryotic protein quality control. Current Opinion in Cell Biology 26, 139-46 
(2014). 
317.Joshi, N. S. et al. Increased numbers of preexisting memory CD8 T cells and 
decreased T-bet expression can restrain terminal differentiation of secondary effector 
and memory CD8 T cells. Journal of immunology (Baltimore, Md. : 1950) 187, 4068-76 
(2011). 
318.Cham, C. M., Driessens, G., O'Keefe, J. P. & Gajewski, T. F. Glucose deprivation 
inhibits multiple key gene expression events and effector functions in CD8+ T cells. 
European Journal of Immunology 38, 2438-50 (2008). 
319.Simpson, I. A. et al. The facilitative glucose transporter GLUT3: 20 years of 
distinction. American journal of physiology. Endocrinology and metabolism 295, E242-
53 (2008). 
320.Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a 
novel B7 family member leads to negative regulation of lymphocyte activation. The 
Journal of experimental medicine 192, 1027-34 (2000). 
321.Powell, J. D. & Delgoffe, G. M. The Mammalian Target of Rapamycin: Linking T 
Cell Differentiation, Function, and Metabolism. Immunity 33, 301-311 (2010). 
322.Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid 
metabolism. Nature 460, 103-7 (2009). 
323.Kim, D. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that 
signals to the cell growth machinery. Cell 110, 163-75 (2002). 
324.Bandhakavi, S. et al. Quantitative nuclear proteomics identifies mTOR regulation 
of DNA damage response. Molecular & cellular proteomics : MCP 9, 403-14 (2010). 
325.Fingar, D. C., Salama, S., Tsou, C., Harlow, E. & Blenis, J. Mammalian cell size is 
controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes & 
development 16, 1472-87 (2002). 
326.Fingar, D. C. et al. mTOR controls cell cycle progression through its cell growth 
effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and 
Cellular Biology 24, 200-16 (2004). 
219 
 
327.Kay, J. E., Kromwel, L., Doe, S. E. & Denyer, M. Inhibition of T and B 
lymphocyte proliferation by rapamycin. Immunology 72, 544-9 (1991). 
328.SIRLIN, J. L. On the incorporation of methionine 35S into proteins detectable by 
autoradiography. The journal of histochemistry and cytochemistry : official journal of 
the Histochemistry Society 6, 185-90 (1958). 
329.Sinclair, L. et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR 
pathways control T lymphocyte trafficking. Nature Immunology 9, 513-21 (2008). 
330.Ewen, C. L., Kane, K. P. & Bleackley, R. C. A quarter century of granzymes. Cell 
death and differentiation 19, 28-35 (2012). 
331.Athié-M, V., Flotow, H., Hilyard, K. L. & Cantrell, D. A. IL-12 selectively 
regulates STAT4 via phosphatidylinositol 3-kinase and Ras-independent signal 
transduction pathways. European Journal of Immunology 30, 1425-34 (2000). 
332.Kirkwood, K. J., Ahmad, Y., Larance, M. & Lamond, A. I. Characterisation of 
Native Protein Complexes and Protein Isoform Variation using Size-Fractionation 
Based Quantitative Proteomics. Molecular & cellular proteomics : MCP 1-55 (2013). 
doi:10.1074/mcp.M113.032367 
333.Brosnan, J. T. Interorgan amino acid transport and its regulation. The Journal of 
nutrition 133, 2068S-2072S (2003). 
334.Mayer, C. & Grummt, I. Ribosome biogenesis and cell growth: mTOR coordinates 
transcription by all three classes of nuclear RNA polymerases. Oncogene 25, 6384-91 
(2006). 
335.Yamashita, R. et al. Comprehensive detection of human terminal oligo-pyrimidine 
(TOP) genes and analysis of their characteristics. Nucleic acids research 36, 3707-15 
(2008). 
336.Schrader, E. K., Harstad, K. G. & Matouschek, A. Targeting proteins for 
degradation. Nature chemical biology 5, 815-22 (2009). 
337.Boisvert, F. et al. A quantitative spatial proteomics analysis of proteome turnover 
in human cells. Molecular & cellular proteomics : MCP 11, M111.011429 (2012). 
338.Ley, K. & Kansas, G. S. Selectins in T-cell recruitment to non-lymphoid tissues and 
sites of inflammation. Nature reviews. Immunology 4, 325-35 (2004). 
339.Pause, A. et al. Insulin-dependent stimulation of protein synthesis by 
phosphorylation of a regulator of 5'-cap function. Nature 371, 762-7 (1994). 
340.Semenza, G. L. HIF-1: upstream and downstream of cancer metabolism. Current 
opinion in genetics & development 20, 51-6 (2010). 
341.Düvel, K. et al. Activation of a metabolic gene regulatory network downstream of 
mTOR complex 1. Molecular Cell 39, 171-83 (2010). 
342.Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the 
metabolic programming of effector T cells and adaptive immunity. Nature Immunology 
14, 489-99 (2013). 
343.Krieg, A. J., Hammond, E. M. & Giaccia, A. J. Functional analysis of p53 binding 
under differential stresses. Molecular and Cellular Biology 26, 7030-45 (2006). 
344.Hoppins, S. The regulation of mitochondrial dynamics. Current Opinion in Cell 
Biology 29C, 46-52 (2014). 
345.Jensen, M. B. & Jasper, H. Mitochondrial Proteostasis in the Control of Aging and 
Longevity. Cell metabolism 20, 214-225 (2014). 
346.Hällberg, B. M. & Larsson, N. Making Proteins in the Powerhouse. Cell 
metabolism 20, 226-240 (2014). 
347.Lee, K. et al. Mammalian target of rapamycin protein complex 2 regulates 
differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 
32, 743-53 (2010). 
220 
 
348.Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T 
cells through the selective activation of signaling by mTORC1 and mTORC2. Nature 
Immunology 12, 295-303 (2011). 
349.Lindsley, C. W. et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of 
isozyme selective inhibitors. Bioorganic & medicinal chemistry letters 15, 761-4 
(2005). 
350.Rao, R., Li, Q., Bupp, M.  . & Shrikant, P. Transcription Factor Foxo1 Represses T-
bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation. 
Immunity 36, 374-387 (2012). 
351.Heikamp, E. B. et al. The AGC kinase SGK1 regulates TH1 and TH2 
differentiation downstream of the mTORC2 complex. Nature Immunology 15, 457-64 
(2014). 
352.Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and 
regulatory T cell lineage commitment. Immunity 30, 832-44 (2009). 
353.Gingras, A. C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N. & Hay, N. 4E-BP1, 
a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) 
signaling pathway. Genes & development 12, 502-13 (1998). 
354.Cope, C. L. et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E 
to maintain cap-dependent translation. Journal of Cell Science 127, 788-800 (2014). 
355.Najafov, A., Shpiro, N. & Alessi, D. R. Akt is efficiently activated by PIF-pocket- 
and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. 
The Biochemical journal 448, 285-95 (2012). 
356.Shi, Y., Yan, H., Frost, P., Gera, J. & Lichtenstein, A. Mammalian target of 
rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-
regulating the insulin-like growth factor receptor/insulin receptor substrate-
1/phosphatidylinositol 3-kinase cascade. Molecular cancer therapeutics 4, 1533-40 
(2005). 
357.Briaud, I. et al. Insulin receptor substrate-2 proteasomal degradation mediated by a 
mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates 
protein kinase B-mediated signaling pathway in beta-cells. The Journal of biological 
chemistry 280, 2282-93 (2005). 
358.Clark, J. et al. Quantification of PtdInsP3 molecular species in cells and tissues by 
mass spectrometry. Nature methods 8, 267-72 (2011). 
359.Barnett, S. F. et al. Identification and characterization of pleckstrin-homology-
domain-dependent and isoenzyme-specific Akt inhibitors. The Biochemical journal 385, 
399-408 (2005). 
360.Bayascas, J. R. et al. Mutation of the PDK1 PH domain inhibits protein kinase 
B/Akt, leading to small size and insulin resistance. Molecular and Cellular Biology 28, 
3258-72 (2008). 
361.Myers, M. P. et al. The lipid phosphatase activity of PTEN is critical for its tumor 
supressor function. Proceedings of the National Academy of Sciences of the United 
States of America 95, 13513-8 (1998). 
362.Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The 
PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the 
phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of 
Sciences of the United States of America 95, 15587-91 (1998). 
363.Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation 
through a PI3K-dependent feedback loop in human cancer. The Journal of clinical 
investigation 118, 3065-74 (2008). 
364.D'Souza, W. N., Chang, C., Fischer, A. M., Li, M. & Hedrick, S. M. The Erk2 
MAPK regulates CD8 T cell proliferation and survival. Journal of immunology 
(Baltimore, Md. : 1950) 181, 7617-29 (2008). 
221 
 
365.Rao, R. R., Li, Q., Bupp, M. R. G. & Shrikant, P. A. Transcription factor Foxo1 
represses T-bet-mediated effector functions and promotes memory CD8(+) T cell 
differentiation. Immunity 36, 374-87 (2012). 
366.Huang, J. & Manning, B. D. A complex interplay between Akt, TSC2 and the two 
mTOR complexes. Biochemical Society transactions 37, 217-22 (2009). 
367.Angulo, I. et al. Phosphoinositide 3-kinase δ gene mutation predisposes to 
respiratory infection and airway damage. Science (New York, N.Y.) 342, 866-71 (2013). 
368.Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding 
the PI(3)K catalytic subunit p110δ result in T cell senescence and human 
immunodeficiency. Nature Immunology 15, 88-97 (2014). 
369.Ridley, A. J. Rho GTPases and actin dynamics in membrane protrusions and 
vesicle trafficking. Trends in cell biology 16, 522-9 (2006). 
370.Falguni, das et al. Unrestrained mammalian target of rapamycin complexes 1 and 2 
increase expression of phosphatase and tensin homolog deleted on chromosome 10 to 
regulate phosphorylation of Akt kinase. The Journal of biological chemistry 287, 3808-
22 (2012). 
371.Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate 
that negatively regulates insulin signaling. Science (New York, N.Y.) 332, 1322-6 
(2011). 
372.Zhang, N. & Bevan, M. CD8+ T Cells: Foot Soldiers of the Immune System. 
Immunity 35, 161-168 (2011). 
373.Karnitz, L. M., Burns, L. A., Sutor, S. L., Blenis, J. & Abraham, R. T. Interleukin-2 
triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. 
Molecular and Cellular Biology 15, 3049-57 (1995). 
374.Zhu, L., Yu, X., Akatsuka, Y., Cooper, J. A. & Anasetti, C. Role of mitogen-
activated protein kinases in activation-induced apoptosis of T cells. Immunology 97, 26-
35 (1999). 
375.Despouy, G., Joiner, M., Le Toriellec, E., Weil, R. & Stern, M. H. The TCL1 
oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK 
pathways. Blood 110, 4406-16 (2007). 
376.Macintyre, A. N. et al. The glucose transporter Glut1 is selectively essential for 
CD4 T cell activation and effector function. Cell metabolism 20, 61-72 (2014). 
 
  
222 
 
Supplementary tables 
  
223 
 
protein 
rank 
transcipt 
rank protein names 
fract. 
abund. 
cumul. 
abund. 
1 2778 Histone H4 3.1% 3.1% 
2 3 Isoform Short of Thymosin beta-4 2.2% 5.4% 
3 64 Vimentin 1.7% 7.0% 
4 47 Prothymosin alpha 1.6% 8.7% 
5 9 Peptidyl-prolyl cis-trans isomerase A 1.6% 10.3% 
6 4 60S acidic ribosomal protein P2 1.5% 11.8% 
7 348 Cofilin-1 1.4% 13.2% 
8 96 Alpha-enolase 1.2% 14.4% 
9 7 60S acidic ribosomal protein P1 1.2% 15.6% 
10 120 Eukaryotic translation initiation factor 5A-1 1.0% 16.7% 
11 1 Granzyme B(G,H) 1.0% 17.7% 
12 75 Glyceraldehyde-3-phosphate dehydrogenase 0.9% 18.6% 
13 56 L-lactate dehydrogenase A chain 0.7% 19.3% 
14 2642 Putative RNA-binding protein 3 0.7% 20.0% 
15 2 Elongation factor 1-alpha 1 0.7% 20.7% 
16 5301 Histone H3.2 0.7% 21.4% 
17 201 Protein S100-A4 0.6% 22.1% 
18 100 Heat shock protein HSP 90-beta 0.6% 22.7% 
19 173 Fructose-bisphosphate aldolase A 0.6% 23.4% 
20 76 Phosphoglycerate kinase 1 0.6% 24.0% 
21 116 Triosephosphate isomerase 0.6% 24.6% 
22 228 Transgelin-2 0.6% 25.2% 
23 34 40S ribosomal protein S8 0.5% 25.8% 
24 78 Heat shock cognate 71 kDa protein 0.5% 26.3% 
25   Histone H2A type 1-F 0.5% 26.8% 
26 2092 Vesicle-trafficking protein SEC22b 0.5% 27.3% 
27 4269 Actin, alpha skeletal muscle 0.5% 27.8% 
28 97 GTP-binding nuclear protein Ran 0.5% 28.3% 
29 834 14-3-3 protein zeta/delta 0.5% 28.8% 
30 37 Galectin-1 0.5% 29.2% 
31 808 40S ribosomal protein SA 0.5% 29.7% 
32 744 Translationally-controlled tumor protein 0.4% 30.1% 
33   Thioredoxin 0.4% 30.5% 
34 70 Elongation factor 2 0.4% 30.9% 
35 275 Phosphoglycerate mutase 1 0.4% 31.3% 
36 197 Profilin-1 0.4% 31.7% 
37 260 Plastin-2 0.4% 32.1% 
38 194 40S ribosomal protein S25 0.4% 32.5% 
39 203 SH3 domain-binding glutamic acid-rich-like protein 3 0.4% 32.9% 
40 22 40S ribosomal protein S14 0.4% 33.3% 
41 52 40S ribosomal protein S17 0.4% 33.6% 
42 787 40S ribosomal protein S20 0.4% 34.0% 
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43 20 60S ribosomal protein L23a 0.4% 34.4% 
44 84 60S ribosomal protein L27 0.4% 34.7% 
45 57 Nucleoside diphosphate kinase B 0.4% 35.1% 
46   Histone H1.5 0.4% 35.4% 
47 72 Nucleophosmin 0.4% 35.8% 
48 40 40S ribosomal protein S28 0.3% 36.1% 
49 219 Heat shock protein HSP 90-alpha 0.3% 36.5% 
50 105 Coronin-1A 0.3% 36.8% 
51 186 78 kDa glucose-regulated protein 0.3% 37.1% 
52 253 Rho GDP-dissociation inhibitor 2 0.3% 37.5% 
53 62 40S ribosomal protein S12 0.3% 37.8% 
54 5489 Histone H1.4 0.3% 38.1% 
55 63 60S ribosomal protein L18 0.3% 38.4% 
56 33 40S ribosomal protein S7 0.3% 38.7% 
57 1539 Protein disulfide-isomerase A3 0.3% 39.0% 
58 1021 Nucleolin 0.3% 39.3% 
59 259 10 kDa heat shock protein, mitochondrial 0.3% 39.7% 
60 35 Ubiquitin-40S ribosomal protein S27a 0.3% 40.0% 
61 575 Rho GDP-dissociation inhibitor 1 0.3% 40.3% 
62   Beta-actin-like protein 2 0.3% 40.5% 
63   Heterogeneous nuclear ribonucleoprotein A1 0.3% 40.8% 
64 1739 60S ribosomal protein L31 0.3% 41.1% 
65 153 Calmodulin 0.3% 41.4% 
66 375 Guanine nucleotide-binding protein subunit beta-2-like 1 0.3% 41.7% 
67 163 High mobility group protein B2 0.3% 41.9% 
68 4022 Annexin A2 0.3% 42.2% 
69 15 40S ribosomal protein S3a 0.3% 42.5% 
70 109 Isoform Smooth muscle of Myosin light polypeptide 6 0.3% 42.8% 
71 36 40S ribosomal protein S11 0.3% 43.0% 
72 44 60S ribosomal protein L17 0.3% 43.3% 
73 93 Peroxiredoxin-1 0.3% 43.6% 
74 43 Isoform HF2 of Granzyme A 0.3% 43.8% 
75 54 60S ribosomal protein L12 0.3% 44.1% 
76 79 Proliferating cell nuclear antigen 0.3% 44.3% 
77 732 Chromobox protein homolog 3 0.3% 44.6% 
78 919 14-3-3 protein epsilon 0.3% 44.9% 
79 123 Ran-specific GTPase-activating protein 0.3% 45.1% 
80   Heterogeneous nuclear ribonucleoprotein A/B 0.2% 45.4% 
81 12 40S ribosomal protein S4, X isoform 0.2% 45.6% 
82   60S acidic ribosomal protein P0 0.2% 45.8% 
83 174 Transketolase 0.2% 46.1% 
84 85 Thy-1 membrane glycoprotein 0.2% 46.3% 
85 17 60S ribosomal protein L38 0.2% 46.6% 
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86 266 Peptidyl-prolyl cis-trans isomerase FKBP1A 0.2% 46.8% 
87 748 60S ribosomal protein L11 0.2% 47.0% 
88 258 60S ribosomal protein L3 0.2% 47.3% 
89 220 Endoplasmin 0.2% 47.5% 
90   Histone H1.3 0.2% 47.7% 
91 108 ATP synthase subunit beta, mitochondrial 0.2% 47.9% 
92 73 60S ribosomal protein L22 0.2% 48.1% 
93 1978 40S ribosomal protein S3 0.2% 48.4% 
94 119 40S ribosomal protein S6 0.2% 48.6% 
95 1029 Chloride intracellular channel protein 1 0.2% 48.8% 
96 21 60S ribosomal protein L9 0.2% 49.0% 
97 5416 Macrophage migration inhibitory factor 0.2% 49.2% 
98 588 40S ribosomal protein S18 0.2% 49.4% 
99 87 Histidine triad nucleotide-binding protein 1 0.2% 49.7% 
100 694 40S ribosomal protein S19 0.2% 49.9% 
 
Figure S1: List of 100 most abundant proteins in CTL. 
100 most abundant in CTL are shown sorted by descending abundance. Corresponding 
ranking according to mRNA levels is also shown. 
fract. abund.: fractional abundance for specific protein; cum. abund.: cumulative 
abundance 
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protein name gene name protein fold change t-test 
ratio 
Exp1 
ratio 
Exp2 
ratio 
Exp3 
transcript 
fold change 
transcript 
significant 
Ubiquinone biosynthesis monooxygenase COQ6 Coq6 15.3 0.058 38.4 4.0 23.4 1.0 NO 
Sideroflexin-2 Sfxn2 14.9 1.000 14.9 
 
1/∞ 1.0 NO 
Limbin Evc2 10.9 0.533 ∞ 152.9 0.8 0.9 NO 
Tyrosine-protein kinase Fyn Fyn 10.0 1.000 
 
10.0 
 
1.0 NO 
L-selectin Sell 8.1 0.014 12.2 5.2 8.5 6.2 YES 
Tetratricopeptide repeat protein 5 Ttc5 6.4 0.141 1.4 15.7 12.7 0.9 NO 
Cellular retinoic acid-binding protein 2 Crabp2 5.7 1.000 
 
5.7 
 
1.2 NO 
Isoform ICAD-S of DNA fragmentation factor subunit alpha Dffa 5.6 0.465 1.2 1/∞ 25.8 0.8 NO 
Isoform 2 of Serine/threonine-protein kinase MRCK alpha Cdc42bpa 5.1 1.000 
  
5.1 1.0 NO 
Programmed cell death protein 4 Pdcd4 5.0 0.003 5.8 4.2 5.1 1.8 YES 
Probable palmitoyltransferase ZDHHC19 Zdhhc19 4.8 0.390 
 
14.2 1.6 1.0 NO 
Isoform 2 of Kinesin-like protein KIF20B Kif20b 4.6 0.448 
 
17.0 1.3 
  Isoform 3 of Interleukin enhancer-binding factor 3 Ilf3 4.3 1.000 
 
4.3 
 
1.0 NO 
Histone H2A.V H2afv 4.3 0.143 
 
3.1 6.0 1.9 YES 
Muscleblind-like protein 3 Mbnl3 4.3 0.153 12.9 4.2 1.4 1.3 NO 
Interferon-induced guanylate-binding protein 2 Gbp2 4.1 0.001 3.8 4.3 4.1 2.8 YES 
Lymphocyte antigen 6C2 Ly6c2 4.1 0.120 8.3 5.7 1.4 
  Transmembrane protein 14C Tmem14c 3.9 1.000 ∞ 3.9 
 
1.0 NO 
Numb-like protein Numbl 3.9 0.438 61.7 0.7 1.3 1.0 NO 
Cysteine and histidine-rich protein 1 Cyhr1 3.8 0.036 4.3 2.3 5.5 1.0 NO 
Isoform Short of H-2 class II histocompatibility antigen gamma chain Cd74 3.8 0.024 2.6 5.4 3.8 1.0 NO 
Transgelin-3 Tagln3 3.6 0.049 
 
4.0 3.3 0.9 NO 
Protein APCDD1 Apcdd1 3.6 1.000 
  
3.6 1.1 NO 
C-type lectin domain family 2 member D Clec2d 3.5 0.012 3.6 2.7 4.4 1.5 YES 
Aspartate--tRNA ligase, mitochondrial Dars2 3.3 0.034 4.3 2.1 4.0 1.4 YES 
Integrin alpha-E Itgae 3.3 1.000 3.3 
  
1.8 NO 
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Isoform 2 of Protein piccolo Pclo 3.3 0.044 2.8 5.3 2.3 1.1 NO 
G-protein coupled receptor 161 Gpr161 3.2 0.136 3.1 1.4 7.4 1.0 NO 
Keratin, type II cytoskeletal 2 oral Krt76 3.2 0.029 2.9 4.7 2.4 1.3 YES 
Isoform 2 of Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma Pip5k1c 3.1 1.000 3.1 
  
1.0 NO 
Isoform 2 of Epimerase family protein SDR39U1 Sdr39u1 3.0 0.015 3.0 3.9 2.4 
  Neurofilament medium polypeptide Nefm 3.0 0.023 2.8 4.2 2.4 1.0 NO 
Guanylate-binding protein 5 Gbp5 3.0 0.019 2.6 2.5 4.1 
  Methylated-DNA--protein-cysteine methyltransferase Mgmt 2.9 0.308 13.9 1.5 1.1 0.9 NO 
Keratin, type II cytoskeletal 1 Krt1 2.9 1.000 2.9 
  
1.0 NO 
Kallikrein-8 Klk8 2.8 0.408 6.2 1.3 
 
1.2 NO 
Protein FAM64A Fam64a 2.8 0.097 1.9 5.7 2.2 
  Intermediate conductance calcium-activated potassium channel protein 4 Kcnn4 2.8 1.000 
 
2.8 
 
1.2 NO 
Cystatin-C Cst3 2.8 0.006 2.7 3.3 2.5 1.2 NO 
Protein FAM65B Fam65b 2.8 0.033 1.9 3.5 3.2 
  Isoform 2 of NACHT, LRR and PYD domains-containing protein 6 Nlrp6 2.8 0.074 
 
3.1 2.5 1.3 NO 
NEDD4-like E3 ubiquitin-protein ligase WWP1 Wwp1 2.8 0.057 
 
2.5 3.0 0.9 NO 
H-2 class II histocompatibility antigen, A beta chain H2-Ab1 2.8 0.026 3.5 2.0 3.0 0.6 NO 
Isoform 2 of Box C/D snoRNA protein 1 Znhit6 2.8 0.380 
 
1.4 5.5 
  Isoform 1S of Ral GTPase-activating protein subunit alpha-1 Ralgapa1 2.8 0.037 2.0 2.6 4.0 
  Intercellular adhesion molecule 2 Icam2 2.7 0.000 2.6 2.8 2.8 2.2 YES 
Phosphoinositide 3-kinase regulatory subunit 5 Pik3r5 2.7 0.058 2.5 3.0 ∞ 1.1 NO 
Isoform 2 of DDB1- and CUL4-associated factor 10 Dcaf10 2.7 0.069 
 
2.4 3.0 
  Small integral membrane protein 4 Smim4 2.7 0.312 1.6 
 
4.6 
  Probable G-protein coupled receptor 132 Gpr132 2.7 0.180 2.0 
 
3.6 1.1 NO 
Neutrophil cytosol factor 1 Ncf1 2.7 0.001 2.5 2.8 2.6 1.1 NO 
Metalloendopeptidase OMA1, mitochondrial Oma1 2.6 1.000 
  
2.6 1.1 NO 
Coiled-coil domain-containing protein 96 Ccdc96 2.6 0.087 
 
2.3 3.0 1.0 NO 
Tubulin beta-3 chain Tubb3 2.6 0.462 2.9 0.4 15.9 0.9 NO 
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Isoform 3 of SH3 domain-containing kinase-binding protein 1 Sh3kbp1 2.6 0.333 
 
1.5 4.6 1.0 NO 
O-acetyl-ADP-ribose deacetylase MACROD1 Macrod1 2.6 0.099 3.3 4.0 1.4 1.3 NO 
HSPB1-associated protein 1 Hspbap1 2.6 0.032 2.7 3.4 1.9 1.2 NO 
Alpha-N-acetylgalactosaminidase Naga 2.6 0.230 5.4 3.7 0.9 0.7 YES 
Repressor of RNA polymerase III transcription MAF1 homolog Maf1 2.6 0.002 2.5 2.5 2.8 1.3 NO 
Eukaryotic translation initiation factor 2 subunit 3, Y-linked Eif2s3y 2.6 0.158 2.0 
 
3.3 1.1 NO 
Constitutive coactivator of PPAR-gamma-like protein 2 Fam120c 2.6 0.011 3.0 2.1 2.7 
  Alpha/beta hydrolase domain-containing protein 14B Abhd14b 2.5 0.287 1.1 9.0 1.6 1.1 NO 
Isoform 2 of Protein Wiz Wiz 2.5 0.474 
 
6.0 1.1 1.1 NO 
Caspase-2 Casp2 2.5 0.027 2.0 3.4 2.3 1.5 YES 
Hexaprenyldihydroxybenzoate methyltransferase, mitochondrial Coq3 2.5 0.006 2.2 2.5 2.8 0.9 NO 
Histone H2A type 2-B Hist2h2ab 2.5 0.115 2.4 1.4 4.6 
  Isoform 2 of Zinc finger protein 740 Znf740 2.5 0.062 
 
2.3 2.7 
  Sideroflexin-3 Sfxn3 2.5 0.036 3.0 2.9 1.7 1.0 NO 
Cytochrome c oxidase subunit 2 Mtco2 2.5 0.105 1.8 4.6 1.8 
  JmjC domain-containing protein 7 Jmjd7 2.5 0.005 2.8 2.4 2.2 
  NAD-dependent protein deacetylase sirtuin-3 Sirt3 2.5 0.065 2.0 4.0 1.9 1.3 YES 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 Ndufa13 2.4 0.229 6.9 1.3 1.7 0.9 NO 
Myosin-1 Myh1 2.4 0.233 3.4 
 
1.7 1.0 NO 
Tripartite motif-containing protein 35 Trim35 2.4 0.198 1.7 6.1 1.4 1.0 NO 
Myotubularin-related protein 14 Mtmr14 2.4 0.097 1.9 4.4 1.8 1.5 YES 
Pyrin and HIN domain-containing protein 1 Pyhin1 2.4 0.065 1.5 3.1 3.0 0.7 NO 
Isoform 2 of Lactadherin Mfge8 2.4 0.134 4.5 1.3 2.4 1.3 NO 
Isoform 2 of SUN domain-containing protein 2 Sun2 2.4 0.007 2.5 2.1 2.6 
  Guanine nucleotide-binding protein G(olf) subunit alpha Gnal 2.4 0.384 
 
4.4 1.3 1.0 NO 
Major facilitator superfamily domain-containing protein 8 Mfsd8 2.4 1.000 
  
2.4 0.9 NO 
Carbonic anhydrase 2 Ca2 2.4 0.017 3.0 2.1 2.1 
  tRNA methyltransferase 112 homolog Trmt112 2.4 0.047 3.0 1.6 2.8 
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Isoform 2 of Rho guanine nucleotide exchange factor 18 Arhgef18 2.4 0.016 1.9 2.5 2.8 1.0 NO 
Vacuolar protein sorting-associated protein 37B Vps37b 2.4 0.061 3.7 1.9 1.8 1.7 YES 
Actin-related protein 2/3 complex subunit 4 Arpc4 2.4 0.097 4.0 2.2 1.5 0.9 NO 
Spectrin beta chain, erythrocytic Sptb 2.3 1.000 
 
2.3 
   Neutrophil cytosol factor 2 Ncf2 2.3 0.509 1.0 5.6 
 
0.9 NO 
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Aga 2.3 1.000 2.3 
  
1.1 NO 
Natural killer cells antigen CD94 Klrd1 2.3 0.184 1.8 3.0 
 
1.3 NO 
Isoform 5 of Protein NLRC3 Nlrc3 2.3 1.000 
 
2.3 1/∞ 1.2 NO 
Sodium/hydrogen exchanger 9 Slc9a9 2.3 1.000 
 
2.3 
 
1.0 NO 
Granzyme C Gzmc 2.3 0.008 2.6 2.4 2.0 0.9 NO 
Ubiquitin-like domain-containing CTD phosphatase 1 Ublcp1 2.3 0.041 2.7 1.6 2.8 1.1 NO 
Kelch-like protein 11 Klhl11 2.3 0.237 1.7 6.2 1.2 1.0 NO 
Putative lipoyltransferase 2, mitochondrial Lipt2 2.3 1.000 2.3 
    Dipeptidyl peptidase 2 Dpp7 2.3 0.056 1.8 1.9 3.5 1.1 NO 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 Ndufb3 2.3 0.236 2.0 5.8 1.1 1.0 NO 
Protein S100-A1 S100a1 2.3 0.080 3.2 1.4 2.7 1.2 NO 
Protein S100-A13 S100a13 2.3 0.095 1.9 4.0 1.6 1.2 NO 
T-cell receptor alpha chain C region Tcra 2.3 0.264 0.9 5.5 2.6 1.2 NO 
Transmembrane protein 206 Tmem206 2.3 0.217 1.7 1.2 5.7 
  H-2 class II histocompatibility antigen, A-B alpha chain H2-Aa 2.3 0.148 1.1 3.6 3.0 1.1 NO 
GTP-binding protein GEM Gem 2.3 0.011 2.2 2.7 2.0 1.0 NO 
Cryptochrome-1 Cry1 2.3 1.000 2.3 
  
1.2 NO 
Nucleoside diphosphate-linked moiety X motif 8, mitochondrial Nudt8 2.3 0.031 3.1 2.0 2.0 0.9 NO 
Maternal embryonic leucine zipper kinase Melk 2.3 0.191 2.3 4.7 1.1 1.7 YES 
Isoform 2 of WD repeat domain phosphoinositide-interacting protein 4 Wdr45 2.3 0.263 3.3 1.6 ∞ 1.3 NO 
WD and tetratricopeptide repeats protein 1 Wdtc1 2.3 0.314 0.8 6.9 2.1 1.1 NO 
Protein Jade-2 Phf15 2.3 0.090 1.3 2.9 3.0 1.3 NO 
Isoform 2 of Dedicator of cytokinesis protein 1 Dock1 2.3 0.008 2.4 2.4 1.9 1.0 NO 
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G2/M phase-specific E3 ubiquitin-protein ligase G2e3 2.3 0.026 2.9 2.2 1.8 
  Isoform 2 of GPI ethanolamine phosphate transferase 1 Pign 2.2 0.217 
 
1.7 3.0 1.0 NO 
Cyclin-dependent kinases regulatory subunit 1 Cks1b 2.2 0.042 1.9 3.1 1.9 1.6 YES 
Intraflagellar transport protein 81 homolog Ift81 2.2 0.184 
 
2.8 1.8 1.0 NO 
T-cell immunoreceptor with Ig and ITIM domains Tigit 2.2 0.048 1.8 3.2 1.9 
  Probable peptide chain release factor C12orf65 homolog, mitochondrial 2.2 1.000 
  
2.2 
  tRNA pseudouridine synthase-like 1 Pusl1 2.2 0.003 2.1 2.4 2.2 
  DNA-directed DNA/RNA polymerase mu Polm 2.2 1.000 2.2 
  
1.1 NO 
Isoform 2 of Solute carrier family 12 member 6 Slc12a6 2.2 1.000 2.2 
  
1.0 NO 
Isoform 2 of Ubinuclein-1 Ubn1 2.2 0.387 
 
3.9 1.3 1.1 NO 
Coiled-coil domain-containing protein 82 Ccdc82 2.2 1.000 2.2 
  
1.1 NO 
Protein C-ets-1 Ets1 2.2 0.223 2.5 1.0 4.5 1.2 NO 
Steryl-sulfatase Sts 2.2 0.218 2.9 
 
1.7 1.0 NO 
Sorting nexin-25 Snx25 2.2 0.062 2.4 2.0 
 
1.0 NO 
rRNA methyltransferase 1, mitochondrial Mrm1 2.2 0.171 
 
2.7 1.8 1.2 NO 
Nuclear receptor subfamily 2 group C member 2 Nr2c2 2.2 0.054 1.7 2.0 3.2 1.0 NO 
Isoform 3 of LETM1 domain-containing protein 1 Letmd1 2.2 0.098 1.3 3.3 2.4 1.0 NO 
Methylglutaconyl-CoA hydratase, mitochondrial Auh 2.2 0.013 1.8 2.5 2.3 1.1 NO 
Heterogeneous nuclear ribonucleoproteins A2/B1 Hnrnpa2b1 2.2 0.120 2.3 3.5 1.3 
  Isoform 2 of Poly(U)-specific endoribonuclease Endou 2.2 0.276 3.1 
 
1.5 
  Sodium channel modifier 1 Scnm1 2.2 0.130 1.3 2.0 3.8 1.0 NO 
Isoform Cytoplasmic+peroxisomal of Malonyl-CoA decarboxylase, 
mitochondrial Mlycd 2.2 0.141 2.9 3.1 1.1 1.1 NO 
Isoform 3 of N-acetyltransferase ESCO1 Esco1 2.2 0.561 1.1 0.5 18.9 0.9 NO 
Dipeptidyl peptidase 4 Dpp4 2.2 0.352 4.0 4.2 0.6 1.2 NO 
Dihydropyrimidinase-related protein 1 Crmp1 2.1 0.002 2.3 2.1 2.1 1.2 NO 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 Ndufb4 2.1 0.250 4.4 2.5 0.9 0.9 NO 
Isoform Short of Transcription intermediary factor 1-alpha Trim24 2.1 0.008 2.3 2.3 1.9 1.0 NO 
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Protein Hikeshi L7rn6 2.1 0.015 2.6 1.9 2.1 
  Zinc finger protein 609 Znf609 2.1 0.140 3.2 2.7 1.1 
  NGFI-A-binding protein 1 Nab1 2.1 0.047 
 
2.3 2.0 1.1 NO 
Probable histidine--tRNA ligase, mitochondrial Hars2 2.1 0.270 5.0 2.2 0.9 1.0 NO 
Proline dehydrogenase 1, mitochondrial Prodh 2.1 0.206 
 
2.7 1.7 1.1 NO 
Hemogen Hemgn 2.1 0.054 1.6 2.1 3.0 1.8 YES 
DNA fragmentation factor subunit alpha Dffa 2.1 0.113 1.2 3.2 2.4 0.8 NO 
Tumor necrosis factor alpha-induced protein 8-like protein 2 Tnfaip8l2 2.1 0.146 1.4 1.7 4.0 1.0 NO 
Insulin receptor substrate 2 Irs2 2.1 1.000 ∞ 
 
2.1 1.2 NO 
Pancreatic progenitor cell differentiation and proliferation factor Ppdpf 2.1 1.000 2.1 
    Enkurin domain-containing protein 1 Enkd1 2.1 0.532 0.9 4.8 
   Protein SET Set 2.1 0.380 0.6 2.4 6.3 1.1 NO 
Palmitoyl-protein thioesterase 1 Ppt1 2.1 0.005 2.1 2.3 1.9 1.1 NO 
Probable methyltransferase-like protein 15 Mettl15 2.1 0.007 1.9 2.2 2.3 
  Cytochrome c oxidase subunit 7A2, mitochondrial Cox7a2 2.1 0.113 1.4 3.5 2.0 0.9 NO 
Isoform Gamma of Receptor-type tyrosine-protein phosphatase R Ptprr 2.1 1.000 2.1 
  
0.9 NO 
Proteolipid protein 2 Plp2 2.1 0.133 3.9 1.7 1.5 1.2 NO 
von Willebrand factor A domain-containing protein 5A Vwa5a 2.1 0.056 2.3 2.8 1.5 
  PIH1 domain-containing protein 1 Pih1d1 2.1 0.173 3.4 2.6 1.0 1.1 NO 
Voltage-dependent P/Q-type calcium channel subunit alpha-1A Cacna1a 2.1 0.520 11.0 0.4 2.0 1.0 NO 
Vitamin K epoxide reductase complex subunit 1 Vkorc1 2.1 1.000 2.1 
  
1.2 NO 
Protein SCO1 homolog, mitochondrial Sco1 2.1 0.094 2.6 2.7 1.3 1.2 NO 
Neudesin Nenf 2.1 0.141 3.7 1.9 1.3 1.6 YES 
Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Lpgat1 2.1 0.394 3.5 
 
1.2 0.9 NO 
Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform Ppp3cc 2.1 0.062 1.5 2.9 2.0 1.1 NO 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
STT3A Stt3a 2.1 0.413 2.5 6.3 0.6 1.0 NO 
Lymphocyte activation gene 3 protein Lag3 2.0 0.012 2.4 1.8 2.0 1.4 NO 
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Cytochrome c oxidase subunit 6C Cox6c 2.0 0.104 1.7 3.3 1.5 1.1 NO 
Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 37 Usp37 2.0 0.363 0.7 5.5 2.3 1.2 NO 
Stathmin Stmn1 2.0 0.001 2.1 2.0 2.0 2.3 YES 
28S ribosomal protein S12, mitochondrial Mrps12 2.0 0.301 1.1 5.6 1.4 0.8 NO 
Cytoplasmic FMR1-interacting protein 1 Cyfip1 2.0 0.251 1.4 4.9 1.2 1.0 NO 
 
Figure S2: Proteins more than 2-fold up-regulated upon mTORC1 inhibition. 
All proteins with an average up-regulation of more than 2-fold are shown. Ratios for the individual replicates are given. Proteins found in either Ctrl or 
rapamycin treated samples were assigned a ratio of ∞ (when found only in control) or 1/∞ (when only found in rapamycin treated cells). Ratios from 
micro array analysis are also given. 
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protein name gene name protein fold change t-test 
ratio 
Exp1 
ratio 
Exp2 
ratio 
Exp3 
transcript 
fold change 
transcript 
significant 
Homeobox protein Nkx-3.2 Nkx3-2 0.1 0.288 
 
0.0 0.2 1.0 NO 
Ornithine decarboxylase Odc1 0.2 0.002 0.2 0.1 0.2 1.0 NO 
Interferon gamma Ifng 0.2 0.003 0.2 0.2 0.2 0.2 YES 
Myosin-7B Myh7b 0.2 0.042 0.3 0.1 0.2 1.0 NO 
Metallothionein-1 Mt1 0.2 1.000 0.2 
  
0.9 NO 
Acyl-CoA-binding domain-containing protein 6 Acbd6 0.2 0.096 0.1 0.2 0.6 1.0 NO 
Rho-related GTP-binding protein Rho6 Rnd1 0.2 0.657 0.0 4.3 3.5 0.9 NO 
RING finger and CHY zinc finger domain-containing protein 1 Rchy1 0.2 0.086 0.5 0.1 0.2 0.9 NO 
Granzyme G Gzmg 0.2 1.000 
 
0.2 
 
0.0 YES 
Isoform 2 of Cellular nucleic acid-binding protein Cnbp 0.3 0.049 0.1 0.4 0.3 1.0 NO 
Isoform IIa of Prolyl 4-hydroxylase subunit alpha-2 P4ha2 0.3 0.028 0.2 0.3 0.4 0.4 YES 
Interferon-related developmental regulator 1 Ifrd1 0.3 0.077 
 
0.2 0.3 0.6 YES 
CDGSH iron-sulfur domain-containing protein 3, mitochondrial Cisd3 0.3 0.273 0.5 0.1 1/∞ 
  Disintegrin and metalloproteinase domain-containing protein 8 Adam8 0.3 0.005 0.2 0.3 0.2 0.4 YES 
Complement component C1q receptor Cd93 0.3 0.061 0.2 0.2 0.5 0.9 NO 
Atlastin-1 Atl1 0.3 0.583 0.0 
 
1.5 
  Mitochondrial import inner membrane translocase subunit Tim17-A Timm17a 0.3 0.043 0.4 0.3 0.2 0.9 NO 
Isoform 4 of Cytoplasmic polyadenylation element-binding protein 4 Cpeb4 0.3 0.006 0.3 0.4 0.3 0.6 NO 
Protein FAM171A2 Fam171a2 0.3 1.000 
 
0.3 
   Sulfatase-modifying factor 2 Sumf2 0.3 0.049 0.4 0.4 0.2 1.0 NO 
Cysteine and glycine-rich protein 2 Csrp2 0.3 0.101 0.3 0.4 
 
0.7 NO 
RING-box protein 2 Rnf7 0.3 0.280 0.5 0.2 1/∞ 1.0 NO 
Neuroserpin Serpini1 0.3 0.298 
 
0.2 0.6 1.1 NO 
Heme oxygenase 1 Hmox1 0.3 0.046 0.5 0.2 0.3 0.6 YES 
Tumor necrosis factor receptor superfamily member 9 Tnfrsf9 0.3 0.052 0.4 0.2 0.4 0.7 YES 
Exonuclease 1 Exo1 0.3 0.393 
 
0.7 0.1 1.1 NO 
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Lipoma HMGIC fusion partner-like 3 protein Lhfpl3 0.3 0.254 0.2 
 
0.5 1.0 NO 
Cellular nucleic acid-binding protein Cnbp 0.3 0.040 0.5 0.3 0.2 1.0 NO 
Fatty acid desaturase 2 Fads2 0.3 0.018 0.3 0.4 0.2 0.7 NO 
Enhancer of filamentation 1 Nedd9 0.3 0.032 0.2 0.3 0.5 0.7 NO 
Sorting nexin-32 Snx32 0.3 0.561 0.1 1.3 
   Isoform 1B of Cytoplasmic dynein 1 intermediate chain 1 Dync1i1 0.3 1.000 0.3 
  
1.0 NO 
Cytochrome b-c1 complex subunit 6, mitochondrial Uqcrh 0.3 0.141 0.7 0.4 0.1 1.1 NO 
Metallothionein-3 Mt3 0.4 0.145 0.6 0.1 0.5 0.9 NO 
Creatine kinase B-type Ckb 0.4 0.002 0.3 0.4 0.4 0.5 YES 
Leukocyte elastase inhibitor A Serpinb1a 0.4 0.003 0.3 0.4 0.3 0.6 NO 
FERM domain-containing protein 8 Frmd8 0.4 0.003 0.4 0.4 0.3 
  Serine/threonine-protein kinase Chk2 Chek2 0.4 1.000 
  
0.4 1.2 YES 
Phosphomevalonate kinase Pmvk 0.4 0.004 0.4 0.3 0.4 0.6 YES 
Asparagine synthetase [glutamine-hydrolyzing] Asns 0.4 0.035 0.5 0.3 0.4 0.4 YES 
Zinc finger protein-like 1 Zfpl1 0.4 0.356 0.6 0.1 1.1 1.0 NO 
NADP-dependent malic enzyme Me1 0.4 0.012 0.4 0.4 0.3 
  Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Pck2 0.4 0.000 0.4 0.4 0.4 0.6 YES 
Tubulin beta-6 chain Tubb6 0.4 0.016 0.4 0.5 0.3 0.7 NO 
Cleavage and polyadenylation specificity factor subunit 4 Cpsf4 0.4 0.063 0.4 0.2 0.6 1.1 NO 
Amyloid protein-binding protein 2 Appbp2 0.4 1.000 0.4 
  
1.0 NO 
Tetraspanin-31 Tspan31 0.4 0.222 0.5 
 
0.3 0.7 NO 
Isoform 3 of Tripartite motif-containing protein 16 Trim16 0.4 0.050 0.6 0.3 0.4 0.6 YES 
Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 C1galt1 0.4 0.230 0.1 0.6 0.7 1.0 NO 
GPI mannosyltransferase 3 Pigb 0.4 0.265 0.2 0.6 
 
1.0 NO 
Isoform 3 of Profilin-2 Pfn2 0.4 0.144 0.6 0.2 0.6 0.7 NO 
Long-chain-fatty-acid--CoA ligase 3 Acsl3 0.4 0.005 0.4 0.4 0.3 1.0 NO 
Lymphocyte antigen 6E Ly6e 0.4 0.388 2.2 0.2 0.2 1.4 NO 
Ras-related protein Rab-3D Rab3d 0.4 0.137 0.2 0.8 0.4 0.9 NO 
235 
 
Mediator of RNA polymerase II transcription subunit 28 Med28 0.4 0.205 1.1 0.2 0.3 1.0 NO 
Stomatin-like protein 1 Stoml1 0.4 1.000 0.4 
  
0.9 NO 
KAT8 regulatory NSL complex subunit 1 Kansl1 0.4 0.023 0.5 0.3 0.4 
  Isoform 2 of Zinc finger protein 367 Znf367 0.4 0.516 
 
0.2 1.0 
  Isoform 2 of Nuclear distribution protein nudE-like 1 Ndel1 0.4 1.000 
 
0.4 
 
0.8 NO 
Armadillo repeat-containing X-linked protein 2 Armcx2 0.4 0.236 0.6 
 
0.3 0.6 NO 
Ubiquitin-associated protein 1 Ubap1 0.4 0.180 1.0 0.3 0.3 0.9 NO 
Mediator of RNA polymerase II transcription subunit 11 Med11 0.4 0.092 0.4 0.2 0.7 1.0 NO 
Ras-related protein Rab-28 Rab28 0.4 0.697 2.3 0.1 
 
0.8 NO 
MAGUK p55 subfamily member 2 Mpp2 0.4 0.054 0.6 0.3 0.3 1.0 NO 
Four and a half LIM domains protein 2 Fhl2 0.4 0.240 0.9 0.1 0.6 0.8 NO 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic Hmgcs1 0.4 0.033 0.4 0.3 0.6 0.6 NO 
Dual specificity protein phosphatase 3 Dusp3 0.4 0.011 0.5 0.4 0.4 0.8 NO 
Liprin-alpha-2 Ppfia2 0.4 0.090 0.5 0.2 0.6 1.0 NO 
Ubiquitin-conjugating enzyme E2 A Ube2a 0.4 0.025 0.3 0.4 0.5 0.9 NO 
Zinc finger CCHC domain-containing protein 10 Zcchc10 0.4 0.167 0.5 1/∞ 0.3 0.9 NO 
ATP synthase subunit s-like protein Atp5sl 0.4 0.448 
 
0.2 0.9 
  Protein-lysine methyltransferase METTL21D Mettl21d 0.4 0.228 0.6 0.3 ∞ 
  SUZ domain-containing protein 1 Szrd1 0.4 0.106 0.2 0.5 0.6 
  Integrin alpha-V Itgav 0.4 0.055 0.6 0.4 0.3 1.0 NO 
Protein unc-119 homolog A Unc119 0.4 0.156 0.8 0.5 0.2 0.7 YES 
Zinc fingers and homeoboxes protein 2 Zhx2 0.4 0.417 0.1 1.1 0.9 0.9 NO 
Eukaryotic translation initiation factor 4H Eif4h 0.4 0.007 0.4 0.4 0.5 1.0 NO 
Mitochondrial uncoupling protein 2 Ucp2 0.4 1.000 0.4 
  
0.9 NO 
Isoform 1B of Beta-arrestin-1 Arrb1 0.4 0.110 0.4 0.7 0.2 0.6 NO 
Interleukin-10 Il10 0.4 0.304 0.1 0.4 1.3 0.7 NO 
Sphingolipid delta(4)-desaturase DES1 Degs1 0.4 0.203 0.3 1.1 0.3 1.0 NO 
Protein slowmo homolog 2 Slmo2 0.4 0.169 0.6 0.7 0.2 1.0 NO 
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E3 ubiquitin-protein ligase TRIM32 Trim32 0.4 0.122 0.2 0.7 0.5 0.9 NO 
Protein FAM101B Fam101b 0.4 1.000 0.4 
    BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 
1 Kctd13 0.4 1.000 0.4 
  
1.0 NO 
DCN1-like protein 5 Dcun1d5 0.4 0.029 0.4 0.6 0.4 1.0 NO 
Transmembrane protein 131 Tmem131 0.4 0.118 0.8 0.3 0.4 0.9 NO 
P2Y purinoceptor 14 P2ry14 0.4 0.016 0.5 0.4 0.5 0.8 NO 
Isoform 3 of Receptor-type tyrosine-protein phosphatase epsilon Ptpre 0.4 0.148 0.2 0.8 0.5 0.9 NO 
Flavin reductase (NADPH) Blvrb 0.4 0.113 0.6 0.2 0.6 0.7 YES 
Pyrin and HIN domain-containing protein 1-like 0.4 1.000 0.440 0.4 
   Isoform 2 of STE20-related kinase adapter protein alpha Strada 0.4 0.514 0.2 
 
1.0 
  PHD finger-like domain-containing protein 5A Phf5a 0.4 0.193 0.9 0.2 0.4 1.0 NO 
NADPH--cytochrome P450 reductase Por 0.4 0.083 0.4 0.7 0.3 0.9 NO 
Polypeptide N-acetylgalactosaminyltransferase 6 Galnt6 0.4 0.128 0.3 0.8 0.5 0.7 NO 
Voltage-gated hydrogen channel 1 Hvcn1 0.4 0.103 0.7 0.4 0.3 0.8 NO 
G1/S-specific cyclin-D3 Ccnd3 0.4 0.277 1.3 0.3 0.3 1.1 NO 
Origin recognition complex subunit 3 Orc3 0.4 1.000 0.4 
    Branched-chain-amino-acid aminotransferase, cytosolic Bcat1 0.4 0.072 0.5 0.6 0.3 0.7 NO 
Phosphopantothenate--cysteine ligase Ppcs 0.4 0.235 1.0 0.2 0.5 0.9 NO 
Isoform 2 of Tropomyosin alpha-1 chain Tpm1 0.4 0.311 0.2 0.5 1.2 1.0 NO 
Cytoskeleton-associated protein 4 Ckap4 0.5 0.075 0.7 0.4 0.3 1.0 NO 
N(6)-adenine-specific DNA methyltransferase 2 N6amt2 0.5 0.398 0.3 0.2 2.0 1.0 NO 
Perforin-1 Prf1 0.5 0.039 0.3 0.6 0.5 0.4 YES 
Isoform B of SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily B member 1 Smarcb1 0.5 0.166 0.6 0.2 0.8 1.1 NO 
Phosphoinositide 3-kinase adapter protein 1 Pik3ap1 0.5 0.160 0.6 0.2 0.7 0.8 NO 
Alpha-1,2-mannosyltransferase ALG9 Alg9 0.5 0.170 0.2 0.7 0.7 1.0 NO 
Serine/threonine-protein kinase N2 Pkn2 0.5 0.053 0.5 0.3 0.6 1.0 NO 
C-C chemokine receptor type 2 Ccr2 0.5 1.000 0.5 
  
0.9 NO 
237 
 
Epididymis-specific alpha-mannosidase Man2b2 0.5 0.035 0.4 0.4 0.6 0.9 NO 
Kinesin light chain 3 Klc3 0.5 0.161 0.3 0.4 0.9 0.8 NO 
Ankyrin repeat domain-containing protein 10 Ankrd10 0.5 0.165 0.3 0.3 1.0 1.1 NO 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Plod2 0.5 0.000 0.5 0.5 0.5 0.7 NO 
E3 ubiquitin-protein ligase HECTD1 Hectd1 0.5 0.045 0.7 0.4 0.4 0.8 NO 
Interferon-induced protein with tetratricopeptide repeats 1 Ifit1 0.5 1.000 0.5 
  
1.2 NO 
Dynactin subunit 6 Dctn6 0.5 0.161 0.2 0.6 0.7 0.9 NO 
Sterile alpha motif domain-containing protein 9-like Samd9l 0.5 0.346 0.3 1.6 0.2 0.7 YES 
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein 
phosphatase PTEN Pten 0.5 0.013 0.5 0.6 0.4 1.1 NO 
Adenylate kinase 4, mitochondrial Ak4 0.5 0.009 0.5 0.4 0.5 
  Isoform 2 of CKLF-like MARVEL transmembrane domain-containing protein 7 Cmtm7 0.5 0.202 0.2 1.0 0.4 1.2 NO 
Proteasome assembly chaperone 3 Psmg3 0.5 0.270 1.2 0.2 0.4 
  SLAM family member 7 Slamf7 0.5 0.054 0.6 0.3 0.5 0.8 YES 
CLK4-associating serine/arginine rich protein Clasrp 0.5 0.130 0.3 0.4 0.8 
  Isoform 6 of Runt-related transcription factor 2 Runx2 0.5 0.187 
 
0.4 0.6 0.9 NO 
Ceramide synthase 5 Cers5 0.5 0.217 0.3 0.4 1.1 
  Retinoblastoma-like protein 2 Rbl2 0.5 0.004 0.5 0.5 0.4 1.0 NO 
Cysteine--tRNA ligase, cytoplasmic Cars 0.5 0.006 0.4 0.4 0.5 0.8 NO 
Cathepsin B Ctsb 0.5 0.066 0.6 0.3 0.6 0.9 NO 
60S ribosomal protein L30 Rpl30 0.5 0.165 0.9 0.3 0.4 1.1 NO 
Asparagine--tRNA ligase, cytoplasmic Nars 0.5 0.010 0.5 0.4 0.5 0.6 YES 
WD repeat domain-containing protein 83 Wdr83 0.5 0.024 0.4 0.5 0.6 
  Nucleobindin-2 Nucb2 0.5 0.073 0.7 0.3 0.5 0.8 NO 
Protein phosphatase Slingshot homolog 2 Ssh2 0.5 0.056 0.7 0.4 0.4 1.4 YES 
ADP-ribosylation factor GTPase-activating protein 3 Arfgap3 0.5 0.034 0.6 0.5 0.4 0.8 NO 
Ubiquitin-conjugating enzyme E2 O Ube2o 0.5 0.043 0.4 0.6 0.5 1.2 NO 
CAS1 domain-containing protein 1 Casd1 0.5 0.347 1.4 0.2 0.4 1.1 NO 
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Activating signal cointegrator 1 complex subunit 2 Ascc2 0.5 0.259 0.7 0.2 0.8 1.2 NO 
Isoform Short of Eukaryotic translation initiation factor 4H Eif4h 0.5 1.000 0.5 
  
1.0 NO 
Actin, cytoplasmic 2 Actg1 0.5 0.164 0.6 0.8 0.3 0.7 YES 
Zinc transporter 7 Slc30a7 0.5 0.200 1.0 0.4 0.3 0.9 NO 
Glioma pathogenesis-related protein 1 Glipr1 0.5 0.316 0.7 0.3 
 
0.9 NO 
Apolipoprotein B receptor Apobr 0.5 0.019 0.6 0.4 0.5 
  Bifunctional 3-phosphoadenosine 5-phosphosulfate synthase 1 Papss1 0.5 0.023 0.5 0.4 0.6 0.7 YES 
H-2 class I histocompatibility antigen, Q10 alpha chain H2-Q10 0.5 1.000 
  
0.5 0.3 YES 
Glia-derived nexin Serpine2 0.5 0.046 0.7 0.5 0.4 0.5 YES 
Protein lin-7 homolog B Lin7b 0.5 1.000 0.5 
  
1.0 NO 
Isoform 2 of Poly [ADP-ribose] polymerase 9 Parp9 0.5 0.093 0.8 0.4 0.4 1.1 NO 
Solute carrier family 2, facilitated glucose transporter member 1 Slc2a1 0.5 0.191 0.3 0.4 1.0 0.6 YES 
Interleukin-12 receptor subunit beta-1 Il12rb1 0.5 0.009 0.5 0.4 0.6 0.7 YES 
Isoform 2 of Polypeptide N-acetylgalactosaminyltransferase 2 Galnt2 0.5 0.097 0.6 0.6 0.3 0.8 NO 
Succinate dehydrogenase assembly factor 2, mitochondrial Sdhaf2 0.5 0.086 0.7 0.3 0.5 
  Isoform 2 of Chitobiosyldiphosphodolichol beta-mannosyltransferase Alg1 0.5 0.113 0.4 1/∞ 0.6 0.9 NO 
Synaptosomal-associated protein 23 Snap23 0.5 0.078 0.5 0.7 0.3 0.8 NO 
ADP-ribosylation factor-like protein 6-interacting protein 1 Arl6ip1 0.5 0.047 0.7 0.5 0.4 1.3 NO 
Protein Wiz Wiz 0.5 1.000 0.5 
 
1/∞ 1.1 NO 
Isoform 2 of Zinc finger MIZ domain-containing protein 1 Zmiz1 0.5 0.111 0.3 0.6 0.7 1.1 NO 
Golgi reassembly-stacking protein 2 Gorasp2 0.5 0.006 0.5 0.5 0.5 0.8 NO 
Kinesin-like protein KIF13A Kif13a 0.5 0.189 
 
0.4 0.6 1.0 NO 
Isoform 2 of Sequestosome-1 Sqstm1 0.5 0.435 0.9 
 
0.3 0.9 NO 
Histone-lysine N-methyltransferase SETDB1 Setdb1 0.5 0.173 1.0 0.3 0.4 1.1 NO 
Figure S3: Proteins more than 2-fold down-regulated upon mTORC1 inhibition. 
All proteins with an average down-regulation of more than 2-fold are shown. Ratios for the individual replicates are given. Proteins found in either Ctrl 
or rapamycin treated samples were assigned a ratio of ∞ (when found only in control) or 1/∞ (when only found in rapamycin treated cells). Ratios from 
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micro array analysis are also given. 
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probe set ID gene title gene symbol fold change 
1419480_at selectin, lymphocyte Sell 6.5 
1419481_at selectin, lymphocyte Sell 5.9 
1423756_s_at insulin-like growth factor binding protein 4 Igfbp4 3.3 
1429351_at kelch-like 24 (Drosophila) Klhl24 3.1 
1437405_a_at insulin-like growth factor binding protein 4 Igfbp4 3.1 
1426852_x_at nephroblastoma overexpressed gene Nov 2.9 
1418240_at guanylate nucleotide binding protein 2 Gbp2 2.9 
1424923_at serine (or cysteine) peptidase inhibitor, clade A, member 3G Serpina3g 2.8 
1419042_at interferon inducible GTPase 1 Iigp1 2.8 
1435906_x_at guanylate nucleotide binding protein 2 Gbp2 2.7 
1426851_a_at nephroblastoma overexpressed gene Nov 2.5 
1448113_at similar to Pr22///similar to Stathmin 1/oncoprotein 18///stathmin 1 LOC100039888///LOC623112///Stmn1 2.5 
1419043_a_at interferon inducible GTPase 1 Iigp1 2.4 
1449925_at chemokine (C-X-C motif) receptor 3 Cxcr3 2.4 
1428559_at follicular lymphoma variant translocation 1 Fvt1 2.3 
1428029_a_at H2A histone family, member V H2afv 2.3 
1448364_at cyclin G2 Ccng2 2.3 
1428224_at heterogeneous nuclear ribonucleoprotein D-like Hnrpdl 2.2 
1437187_at E2F transcription factor 7///similar to E2F transcription factor 7 E2f7///LOC639365 2.1 
1417804_at RAS, guanyl releasing protein 2 Rasgrp2 2.1 
1422814_at asp (abnormal spindle)-like, microcephaly associated (Drosophila) Aspm 2.1 
1427161_at centromere protein F Cenpf 2.1 
1439068_at type 1 tumor necrosis factor receptor shedding aminopeptidase regulator Arts1 2.1 
1416488_at cyclin G2 Ccng2 2.1 
1420805_at myosin light chain 2, precursor lymphocyte-specific Mylc2pl 2.1 
1452426_x_at NA NA 2.1 
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1415849_s_at stathmin 1 Stmn1 2.1 
1452389_at CD antigen 27///similar to Tumor necrosis factor receptor superfamily member 7 precursor (CD27L receptor) (T-cell activation antigen CD27) Cd27///LOC100048672 2.0 
1452073_at RIKEN cDNA 6720460F02 gene 6720460F02Rik 2.0 
1451190_a_at SH3-binding kinase 1 Sbk1 2.0 
1416326_at cysteine-rich protein 1 (intestinal) Crip1 2.0 
1417971_at nurim (nuclear envelope membrane protein) Nrm 2.0 
1436515_at RIKEN cDNA E030004N02 gene E030004N02Rik 2.0 
1455031_at cell division cycle 2-like 6 (CDK8-like) Cdc2l6 2.0 
1433623_at zinc finger protein 367 Zfp367 1.9 
1449207_a_at kinesin family member 20A Kif20a 1.9 
1436460_at cDNA sequence BC030440 BC030440 1.9 
1434891_at prostaglandin F2 receptor negative regulator Ptgfrn 1.9 
1433892_at sperm associated antigen 5 Spag5 1.9 
1418553_at rho/rac guanine nucleotide exchange factor (GEF) 18 Arhgef18 1.9 
1423847_at non-SMC condensin I complex, subunit D2 Ncapd2 1.9 
1424033_at splicing factor, arginine/serine-rich 7 Sfrs7 1.9 
1423909_at transmembrane protein 176A Tmem176a 1.9 
1416757_at Zwilch, kinetochore associated, homolog (Drosophila) Zwilch 1.9 
1416746_at H2A histone family, member X H2afx 1.9 
1456393_at RIKEN cDNA 2310002J21 gene 2310002J21Rik 1.9 
1434997_at cell division cycle 2-like 6 (CDK8-like) Cdc2l6 1.9 
1423466_at chemokine (C-C motif) receptor 7 Ccr7 1.9 
1453107_s_at RIKEN cDNA 4933413G19 gene///forkhead box M1///phosphatidylethanolamine binding protein 1 4933413G19Rik///Foxm1///Pebp1 1.9 
1422513_at cyclin F Ccnf 1.9 
1435573_at OTU domain containing 5 Otud5 1.9 
1432478_a_at IBR domain containing 3 Ibrdc3 1.9 
1436036_at Wolf-Hirschhorn syndrome candidate 1 (human) Whsc1 1.9 
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1448466_at cell division cycle associated 5 Cdca5 1.9 
1418199_at hemogen Hemgn 1.8 
1452377_at myeloid/lymphoid or mixed-lineage leukemia 1 Mll1 1.8 
1430514_a_at CD99 antigen Cd99 1.8 
1419749_at tRNA aspartic acid methyltransferase 1 Trdmt1 1.8 
1447541_s_at integrin, alpha E, epithelial-associated Itgae 1.8 
1425436_x_at killer cell lectin-like receptor subfamily A, member 10///killer cell lectin-like receptor subfamily A, member 9///killer cell lectin-like receptor, subfamily A, member 3 Klra10///Klra3///Klra9 1.8 
1437370_at shugoshin-like 2 (S. pombe) Sgol2 1.8 
1429478_at RIKEN cDNA 6720463M24 gene 6720463M24Rik 1.8 
1421571_a_at lymphocyte antigen 6 complex, locus C1///lymphocyte antigen 6 complex, locus C2///similar to Lymphocyte antigen 6C precursor (Ly-6C) 
LOC100041546///LOC1000
45833///Ly6c1///Ly6c2 1.8 
1447818_x_at Ras homolog enriched in brain like 1 Rhebl1 1.8 
1452712_at heterogeneous nuclear ribonucleoprotein A3 Hnrpa3 1.8 
1455585_at ring fnger protein 168 Rnf168 1.8 
1429095_at centromere protein P Cenpp 1.8 
1422697_s_at jumonji, AT rich interactive domain 2 Jarid2 1.8 
1428976_at thymopoietin Tmpo 1.8 
1439695_a_at M-phase phosphoprotein 1 Mphosph1 1.8 
1448878_at Max dimerization protein 3 Mxd3 1.8 
1452209_at plakophilin 4 Pkp4 1.8 
1448591_at cathepsin S Ctss 1.8 
1455818_at RIKEN cDNA 4930427A07 gene 4930427A07Rik 1.8 
1434561_at additional sex combs like 1 (Drosophila) Asxl1 1.8 
1417292_at interferon gamma inducible protein 47 Ifi47 1.8 
1427162_a_at ELK4, member of ETS oncogene family Elk4 1.8 
1435306_a_at kinesin family member 11 Kif11 1.8 
1418264_at centromere protein K Cenpk 1.8 
1418840_at programmed cell death 4 Pdcd4 1.8 
243 
 
1460403_at PC4 and SFRS1 interacting protein 1 Psip1 1.8 
1443466_s_at polymerase (RNA) III (DNA directed) polypeptide B Polr3b 1.8 
1424629_at breast cancer 1 Brca1 1.8 
1416988_at mutS homolog 2 (E. coli) Msh2 1.8 
1456055_x_at polymerase (DNA directed), delta 1, catalytic subunit Pold1 1.8 
1451306_at cell division cycle associated 7 like Cdca7l 1.7 
1453556_x_at CD99 antigen Cd99 1.7 
1454952_s_at non-SMC condensin II complex, subunit D3 Ncapd3 1.7 
1420081_s_at DNA segment, Chr 2, ERATO Doi 750, expressed D2Ertd750e 1.7 
1450033_a_at signal transducer and activator of transcription 1 Stat1 1.7 
1419226_at CD96 antigen Cd96 1.7 
1417445_at NDC80 homolog, kinetochore complex component (S. cerevisiae) Ndc80 1.7 
1416558_at maternal embryonic leucine zipper kinase Melk 1.7 
1435000_at G1 to S phase transition 1 Gspt1 1.7 
1428304_at establishment of cohesion 1 homolog 2 (S. cerevisiae) Esco2 1.7 
1435938_at cytoskeleton associated protein 2-like Ckap2l 1.7 
1437900_at RIKEN cDNA 4930523C07 gene 4930523C07Rik 1.7 
1460555_at RIKEN cDNA 6330500D04 gene 6330500D04Rik 1.7 
1455990_at kinesin family member 23 Kif23 1.7 
1436199_at NA NA 1.7 
1451516_at Ras homolog enriched in brain like 1 Rhebl1 1.7 
1456080_a_at serine incorporator 3 Serinc3 1.7 
1420477_at nucleosome assembly protein 1-like 1 Nap1l1 1.7 
1450034_at signal transducer and activator of transcription 1 Stat1 1.7 
1435597_at ATPase family, AAA domain containing 5 Atad5 1.7 
1452912_at RIKEN cDNA 2600005O03 gene 2600005O03Rik 1.7 
1460314_s_at 
histone cluster 1, H3a///histone cluster 1, H3b///histone cluster 1, H3c///histone cluster 1, H3d///histone cluster 1, 
H3e///histone cluster 1, H3f///histone cluster 1, H3g///histone cluster 1, H3h///histone cluster 1, H3i///histone cluster 
2, H2aa1///histone cluster 2, H3b///histone cluster 2, H3c1///histone cluster 2, H3c2 
Hist1h3a///Hist1h3b///Hist1h
3c///Hist1h3d///Hist1h3e///H
ist1h3f///Hist1h3g///Hist1h3
1.7 
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h///Hist1h3i///Hist2h2aa1///
Hist2h3b///Hist2h3c1///Hist2
h3c2 
1455790_at E2F transcription factor 2 E2f2 1.7 
1455228_at Wolf-Hirschhorn syndrome candidate 1 (human) Whsc1 1.7 
1428105_at TPX2, microtubule-associated protein homolog (Xenopus laevis) Tpx2 1.7 
1416802_a_at cell division cycle associated 5 Cdca5 1.7 
1416155_at high mobility group box 3 Hmgb3 1.7 
1437580_s_at NIMA (never in mitosis gene a)-related expressed kinase 2 Nek2 1.7 
1427233_at teashirt zinc finger family member 1 Tshz1 1.7 
1424380_at vacuolar protein sorting 37B (yeast) Vps37b 1.7 
1424156_at retinoblastoma-like 1 (p107) Rbl1 1.7 
1418126_at chemokine (C-C motif) ligand 5 Ccl5 1.7 
1443837_x_at B-cell leukemia/lymphoma 2 Bcl2 1.7 
1433685_a_at RIKEN cDNA 6430706D22 gene 6430706D22Rik 1.7 
1437611_x_at kinesin family member 2C Kif2c 1.7 
1417299_at NIMA (never in mitosis gene a)-related expressed kinase 2 Nek2 1.7 
1416060_at TBC1 domain family, member 15 Tbc1d15 1.7 
1420915_at signal transducer and activator of transcription 1 Stat1 1.7 
1421963_a_at cell division cycle 25 homolog B (S. pombe) Cdc25b 1.7 
1453865_a_at OTU domain containing 5 Otud5 1.7 
1439736_at RIKEN cDNA 5830453J16 gene 5830453J16Rik 1.7 
1416958_at nuclear receptor subfamily 1, group D, member 2 Nr1d2 1.7 
1423577_at ankyrin repeat domain 32 Ankrd32 1.7 
1434699_at RIKEN cDNA 6030408C04 gene 6030408C04Rik 1.7 
1456485_at nuclear protein in the AT region Npat 1.7 
1435005_at centromere protein E Cenpe 1.7 
1438006_at RIKEN cDNA 4933439F18 gene 4933439F18Rik 1.7 
1451128_s_at kinesin family member 22 Kif22 1.7 
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1439269_x_at minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 1.7 
1424781_at receptor accessory protein 3 Reep3 1.7 
1448650_a_at polymerase (DNA directed), epsilon Pole 1.7 
1458589_at NA NA 1.7 
1427891_at GTPase, IMAP family member 6 Gimap6 1.7 
1415788_at ubiquitin-like domain containing CTD phosphatase 1 Ublcp1 1.7 
1434789_at DEP domain containing 1B Depdc1b 1.7 
1433862_at extra spindle poles-like 1 (S. cerevisiae) Espl1 1.7 
1449346_s_at RIO kinase 1 (yeast) Riok1 1.7 
1434767_at expressed sequence C79407 C79407 1.7 
1448398_s_at ribosomal protein L22 Rpl22 1.7 
1452314_at kinesin family member 11 Kif11 1.7 
1428522_at transcription termination factor, RNA polymerase II Ttf2 1.7 
1437868_at cDNA sequence BC023892 BC023892 1.7 
1416309_at nucleolar and spindle associated protein 1 Nusap1 1.7 
1440770_at B-cell leukemia/lymphoma 2 Bcl2 1.7 
1416722_at high mobility group 20A Hmg20a 1.7 
1440825_s_at coiled-coil domain containing 28A///similar to coiled-coil domain containing 28A Ccdc28a///LOC100045472 1.7 
1421546_a_at Rac GTPase-activating protein 1 Racgap1 1.7 
1428850_x_at CD99 antigen Cd99 1.7 
1429383_at casein kinase 1, gamma 3///similar to casein kinase 1, gamma 3 Csnk1g3///LOC100047516 1.7 
1424780_a_at receptor accessory protein 3 Reep3 1.7 
1437432_a_at tripartite motif protein 12 Trim12 1.7 
1438676_at macrophage activation 2 like Mpa2l 1.7 
1442454_at topoisomerase (DNA) II alpha Top2a 1.7 
1427202_at RIKEN cDNA 4833442J19 gene 4833442J19Rik 1.7 
1420093_s_at heterogeneous nuclear ribonucleoprotein D-like Hnrpdl 1.6 
1428830_at ataxia telangiectasia mutated homolog (human) Atm 1.6 
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1417166_at PC4 and SFRS1 interacting protein 1 Psip1 1.6 
1452268_at RIKEN cDNA 2810485I05 gene 2810485I05Rik 1.6 
1450710_at jumonji, AT rich interactive domain 2 Jarid2 1.6 
1448627_s_at PDZ binding kinase Pbk 1.6 
1429252_at RIKEN cDNA 0610010K14 gene 0610010K14Rik 1.6 
1452972_at tetratricopeptide repeat domain 32 Ttc32 1.6 
1450627_at progressive ankylosis Ank 1.6 
1448187_at polymerase (DNA directed), delta 1, catalytic subunit Pold1 1.6 
1452681_at deoxythymidylate kinase Dtymk 1.6 
1460678_at kelch domain containing 2 Klhdc2 1.6 
1423092_at inner centromere protein Incenp 1.6 
1433893_s_at sperm associated antigen 5 Spag5 1.6 
1434390_at Heterogeneous nuclear ribonucleoprotein U Hnrpu 1.6 
1434426_at non-SMC condensin II complex, subunit D3 Ncapd3 1.6 
1426810_at jumonji domain containing 1A Jmjd1a 1.6 
1433543_at anillin, actin binding protein (scraps homolog, Drosophila) Anln 1.6 
1422527_at histocompatibility 2, class II, locus DMa H2-DMa 1.6 
1418442_at exportin 1, CRM1 homolog (yeast) Xpo1 1.6 
1430811_a_at NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) Nuf2 1.6 
1435694_at Rho GTPase activating protein 26 Arhgap26 1.6 
1435753_a_at nuclear casein kinase and cyclin-dependent kinase substrate 1 Nucks1 1.6 
1449171_at Ttk protein kinase Ttk 1.6 
1434427_a_at ring finger protein 157 Rnf157 1.6 
1434630_at ankyrin repeat domain 28 Ankrd28 1.6 
1433832_at unc-84 homolog B (C. elegans) Unc84b 1.6 
1447483_s_at Small nucleolar RNA host gene (non-protein coding) 7 Snhg7 1.6 
1456698_s_at heterogeneous nuclear ribonucleoprotein D-like Hnrpdl 1.6 
1460564_at suppressor of hairy wing homolog 2 (Drosophila) Suhw2 1.6 
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1448441_at CDC28 protein kinase 1b Cks1b 1.6 
1426834_s_at RIKEN cDNA D930015E06 gene D930015E06Rik 1.6 
1436318_at TAR DNA binding protein Tardbp 1.6 
1424208_at prostaglandin E receptor 4 (subtype EP4) Ptger4 1.6 
1428467_at TAR DNA binding protein Tardbp 1.6 
1451246_s_at aurora kinase B Aurkb 1.6 
1416602_a_at RAD52 homolog (S. cerevisiae) Rad52 1.6 
1452313_at RIKEN cDNA 5930416I19 gene 5930416I19Rik 1.6 
1439040_at centromere protein E Cenpe 1.6 
1428694_at RIKEN cDNA 5033413D16 gene 5033413D16Rik 1.6 
1435474_at TAF5 RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf5 1.6 
1450920_at cyclin B2 Ccnb2 1.6 
1424128_x_at aurora kinase B Aurkb 1.6 
1434691_at splicing factor, arginine/serine-rich 2, interacting protein Sfrs2ip 1.6 
1419152_at RIKEN cDNA 2810417H13 gene 2810417H13Rik 1.6 
1453226_at RIKEN cDNA 3000004C01 gene 3000004C01Rik 1.6 
1424278_a_at baculoviral IAP repeat-containing 5 Birc5 1.6 
1421073_a_at prostaglandin E receptor 4 (subtype EP4) Ptger4 1.6 
1418640_at sirtuin 1 ((silent mating type information regulation 2, homolog) 1 (S. cerevisiae) Sirt1 1.6 
1452534_a_at high mobility group box 2 Hmgb2 1.6 
1451358_a_at Rac GTPase-activating protein 1 Racgap1 1.6 
1459869_x_at RIKEN cDNA 4930402E16 gene 4930402E16Rik 1.6 
1450644_at zinc finger protein 36, C3H type-like 1 Zfp36l1 1.6 
1446085_at NA NA 1.6 
1436747_at RIKEN cDNA 1110014K08 gene 1110014K08Rik 1.6 
1438096_a_at deoxythymidylate kinase Dtymk 1.6 
1433640_at far upstream element (FUSE) binding protein 1 Fubp1 1.6 
1433696_at hematological and neurological expressed 1-like Hn1l 1.6 
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1417910_at cyclin A2 Ccna2 1.6 
1449060_at kinesin family member 2C///similar to Kinesin-like protein KIF2C (Mitotic centromere-associated kinesin) (MCAK) Kif2c///LOC631653 1.6 
1459293_at NA NA 1.6 
1449699_s_at RIKEN cDNA C330027C09 gene C330027C09Rik 1.6 
1430574_at cyclin-dependent kinase inhibitor 3 Cdkn3 1.6 
1416901_at Niemann Pick type C2 Npc2 1.6 
1426221_at loss of heterozygosity, 11, chromosomal region 2, gene A homolog (human) Loh11cr2a 1.6 
1447363_s_at budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) Bub1b 1.6 
1416698_a_at CDC28 protein kinase 1b Cks1b 1.6 
1455345_at PHD finger protein 15 Phf15 1.6 
1452162_at WD repeat domain 48 Wdr48 1.6 
1452592_at microsomal glutathione S-transferase 2 Mgst2 1.6 
1434860_at NMDA receptor-regulated gene 3 Narg3 1.6 
1418004_a_at transmembrane protein 176B Tmem176b 1.6 
1455103_at similar to Probable ATP-dependent RNA helicase DDX46 (DEAD box protein 46) LOC100046698 1.6 
1417793_at interferon inducible GTPase 2 Iigp2 1.6 
1415810_at ubiquitin-like, containing PHD and RING finger domains, 1 Uhrf1 1.6 
1429900_at RIKEN cDNA 5330406M23 gene 5330406M23Rik 1.6 
1417586_at timeless homolog (Drosophila) Timeless 1.6 
1424571_at similar to Probable ATP-dependent RNA helicase DDX46 (DEAD box protein 46) LOC100046698 1.6 
1417167_at exosome component 5 Exosc5 1.6 
1450677_at checkpoint kinase 1 homolog (S. pombe) Chek1 1.6 
1422462_at ubiquitin-conjugating enzyme E2T (putative) Ube2t 1.6 
1443733_x_at polymerase (DNA-directed), delta 3, accessory subunit Pold3 1.6 
1452232_at UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 7 Galnt7 1.6 
1442083_at arginine/serine-rich coiled-coil 2 Rsrc2 1.6 
1426002_a_at cell division cycle 7 (S. cerevisiae) Cdc7 1.6 
1447275_at Bardet-Biedl syndrome 12 (human) Bbs12 1.6 
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1429499_at F-box protein 5 Fbxo5 1.6 
1416030_a_at minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 1.6 
1435226_at IBR domain containing 3 Ibrdc3 1.6 
1452969_at ATPase, Ca++ transporting, plasma membrane 1 Atp2b1 1.6 
1417926_at non-SMC condensin II complex, subunit G2 Ncapg2 1.6 
1435302_at TAF4B RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf4b 1.6 
1418851_at tripartite motif protein 39 Trim39 1.6 
1419838_s_at polo-like kinase 4 (Drosophila) Plk4 1.6 
1425811_a_at cysteine and glycine-rich protein 1 Csrp1 1.6 
1429588_at RIKEN cDNA 2810474O19 gene 2810474O19Rik 1.6 
1460573_at expressed sequence AI848100 AI848100 1.6 
1435397_at cDNA sequence BC038156 BC038156 1.5 
1416299_at Shc SH2-domain binding protein 1 Shcbp1 1.5 
1428280_at FIP1 like 1 (S. cerevisiae) Fip1l1 1.5 
1436738_at PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) Pif1 1.5 
1423440_at RIKEN cDNA 1110001A07 gene 1110001A07Rik 1.5 
1455311_at DiGeorge syndrome critical region gene 8 Dgcr8 1.5 
1437251_at cell division cycle associated 2 Cdca2 1.5 
1448493_at polyadenylate-binding protein-interacting protein 2 Paip2 1.5 
1436427_at PRP4 pre-mRNA processing factor 4 homolog B (yeast) Prpf4b 1.5 
1416664_at cell division cycle 20 homolog (S. cerevisiae) Cdc20 1.5 
1426846_at centromere protein T Cenpt 1.5 
1416031_s_at minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 1.5 
1456735_x_at acid phosphatase-like 2 Acpl2 1.5 
1437313_x_at high mobility group box 2 Hmgb2 1.5 
1455173_at G1 to S phase transition 1 Gspt1 1.5 
1432264_x_at cytochrome c oxidase subunit VIIa polypeptide 2-like Cox7a2l 1.5 
1422698_s_at jumonji, AT rich interactive domain 2 Jarid2 1.5 
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1428052_a_at zinc finger, MYM domain containing 1 Zmym1 1.5 
1425495_at zinc finger protein 62 Zfp62 1.5 
1448165_at caspase 2 Casp2 1.5 
1450886_at germ cell-specific gene 2 Gsg2 1.5 
1435952_at Transcribed locus NA 1.5 
1436161_at PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) Pds5b 1.5 
1428600_at ninein Nin 1.5 
1434695_at denticleless homolog (Drosophila) Dtl 1.5 
1424539_at ubiquitin-like 4 Ubl4 1.5 
1438320_s_at minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 1.5 
1438852_x_at minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae) Mcm6 1.5 
1436707_x_at non-SMC condensin I complex, subunit H Ncaph 1.5 
1419403_at cDNA sequence BC017612 BC017612 1.5 
1422460_at MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) Mad2l1 1.5 
1434911_s_at Rho GTPase activating protein 19 Arhgap19 1.5 
1449523_at B-cell CLL/lymphoma 7C Bcl7c 1.5 
1426838_at polymerase (DNA-directed), delta 3, accessory subunit Pold3 1.5 
1460713_at cDNA sequence BC048355 BC048355 1.5 
1452242_at centrosomal protein 55 Cep55 1.5 
1429477_at non-SMC condensin II complex, subunit H2 Ncaph2 1.5 
1448240_at membrane-bound transcription factor peptidase, site 1 Mbtps1 1.5 
1433957_at RIKEN cDNA C030048B08 gene C030048B08Rik 1.5 
1454967_at Transcribed locus NA 1.5 
1435773_at RIKEN cDNA 4930547N16 gene 4930547N16Rik 1.5 
1422418_s_at similar to suppressor of Ty 4 homolog 2///suppressor of Ty 4 homolog 1 (S. cerevisiae)///suppressor of Ty 4 homolog 2 (S. cerevisiae) 
LOC100041294///LOC1000
46679///Supt4h1///Supt4h2 1.5 
1454875_a_at retinoblastoma binding protein 4 Rbbp4 1.5 
1418040_at transmembrane protein 186 Tmem186 1.5 
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1437911_at RIKEN cDNA 6330416L07 gene 6330416L07Rik 1.5 
1435737_a_at nuclear distribution gene E homolog 1 (A nidulans) Nde1 1.5 
1418281_at RAD51 homolog (S. cerevisiae) Rad51 1.5 
1429387_at GRB2-related adaptor protein Grap 1.5 
1417821_at DNA segment, Chr 17, human D6S56E 5 D17H6S56E-5 1.5 
1455161_at expressed sequence AI504432 AI504432 1.5 
1453307_a_at anaphase-promoting complex subunit 5 Anapc5 1.5 
1452954_at ubiquitin-conjugating enzyme E2C Ube2c 1.5 
1452540_a_at 
H2b histone family, member A///histone cluster 1, H2bc///histone cluster 1, H2be///histone cluster 1, H2bl///histone 
cluster 1, H2bm///histone cluster 1, H2bp///histone cluster 2, H2bb///histone pseudogene///similar to Hist1h2bj 
protein 
Hist1h2bc///Hist1h2be///Hist
1h2bl///Hist1h2bm///Hist1h2
bp///Hist2h2bb///LOC10004
6213///LOC665622///RP23-
38E20.1 
1.5 
1433973_at selenophosphate synthetase 1 Sephs1 1.5 
1453018_at nuclear VCP-like Nvl 1.5 
1447877_x_at DNA methyltransferase (cytosine-5) 1 Dnmt1 1.5 
1429390_at acid phosphatase-like 2 Acpl2 1.5 
Figure S4: Transcripts up-regulated upon rapamycin treatment. 
All transcripts with a statistically significant up-regulation of more than 1.5 are shown. 
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probe set ID gene title gene symbol fold change 
1420344_x_at granzyme D Gzmd 0.1 
1420343_at granzyme D Gzmd 0.1 
1450171_x_at granzyme E Gzme 0.1 
1418679_at granzyme F Gzmf 0.1 
1425947_at interferon gamma Ifng 0.2 
1452794_x_at 
Speer1-like///predicted gene, EG545728///predicted gene, EG623898///predicted gene, EG667901///similar to 
EG545728 protein///spermatogenesis associated glutamate (E)-rich protein 1, pseudogene 1 
EG545728///EG623898///E
G667901///LOC545732///L
OC623998///LOC667974///
LOC668008///LOC668017//
/Speer1-ps1 0.2 
1437171_x_at gelsolin Gsn 0.3 
1427347_s_at tubulin, beta 2a Tubb2a 0.3 
1424268_at spermine oxidase Smox 0.3 
1415964_at stearoyl-Coenzyme A desaturase 1 Scd1 0.3 
1456312_x_at gelsolin Gsn 0.3 
1425145_at interleukin 1 receptor-like 1 Il1rl1 0.3 
1416645_a_at alpha fetoprotein Afp 0.3 
1448213_at annexin A1 Anxa1 0.3 
1451584_at hepatitis A virus cellular receptor 2 Havcr2 0.4 
1455898_x_at solute carrier family 2 (facilitated glucose transporter), member 3 Slc2a3 0.4 
1415965_at stearoyl-Coenzyme A desaturase 1 Scd1 0.4 
1451862_a_at perforin 1 (pore forming protein) Prf1 0.4 
1419030_at ERO1-like (S. cerevisiae) Ero1l 0.4 
1437052_s_at solute carrier family 2 (facilitated glucose transporter), member 3 Slc2a3 0.4 
1441917_s_at transmembrane protein 40 Tmem40 0.4 
1416871_at a disintegrin and metallopeptidase domain 8 Adam8 0.4 
1421578_at chemokine (C-C motif) ligand 4 Ccl4 0.4 
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1433988_s_at RIKEN cDNA C230098O21 gene C230098O21Rik 0.4 
1448318_at adipose differentiation related protein Adfp 0.4 
1419029_at ERO1-like (S. cerevisiae) Ero1l 0.4 
1449254_at secreted phosphoprotein 1 Spp1 0.4 
1421031_a_at RIKEN cDNA 2310016C08 gene 2310016C08Rik 0.4 
1438385_s_at glutamic pyruvate transaminase (alanine aminotransferase) 2 Gpt2 0.4 
1451828_a_at acyl-CoA synthetase long-chain family member 4 Acsl4 0.4 
1425615_a_at phosphoenolpyruvate carboxykinase 2 (mitochondrial) Pck2 0.4 
1415995_at caspase 6 Casp6 0.4 
1415673_at phosphoserine phosphatase Psph 0.4 
1423306_at RIKEN cDNA 2010002N04 gene 2010002N04Rik 0.4 
1451095_at asparagine synthetase Asns 0.4 
1456225_x_at tribbles homolog 3 (Drosophila) Trib3 0.4 
1422804_at serine (or cysteine) peptidase inhibitor, clade B, member 6b Serpinb6b 0.4 
1424140_at galactose-4-epimerase, UDP Gale 0.4 
1426065_a_at tribbles homolog 3 (Drosophila) Trib3 0.4 
1436212_at transmembrane protein 71 Tmem71 0.4 
1418649_at EGL nine homolog 3 (C. elegans) Egln3 0.4 
1421732_at glutamine repeat protein 1 Glrp1 0.4 
1416168_at serine (or cysteine) peptidase inhibitor, clade F, member 1 Serpinf1 0.4 
1424356_a_at meteorin, glial cell differentiation regulator-like Metrnl 0.4 
1437247_at fos-like antigen 2///similar to fos-like antigen 2 Fosl2///LOC634417 0.4 
1433966_x_at asparagine synthetase Asns 0.4 
1426808_at lectin, galactose binding, soluble 3 Lgals3 0.5 
1451461_a_at aldolase 3, C isoform Aldoc 0.5 
1454731_at myosin X Myo10 0.5 
1452714_at tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 Tanc1 0.5 
1455106_a_at creatine kinase, brain Ckb 0.5 
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1428444_at ankyrin repeat and SOCS box-containing protein 2 Asb2 0.5 
1416431_at tubulin, beta 6 Tubb6 0.5 
AFFX-
MURINE_b1_at NA NA 0.5 
1428306_at DNA-damage-inducible transcript 4 Ddit4 0.5 
1426471_at zinc finger protein 52 Zfp52 0.5 
1417335_at sulfotransferase family, cytosolic, 2B, member 1 Sult2b1 0.5 
1426972_at SEC24 related gene family, member D (S. cerevisiae) Sec24d 0.5 
1448175_at EH-domain containing 1 Ehd1 0.5 
1449324_at ERO1-like (S. cerevisiae) Ero1l 0.5 
1450650_at myosin X Myo10 0.5 
1434976_x_at eukaryotic translation initiation factor 4E binding protein 1 Eif4ebp1 0.5 
1416666_at serine (or cysteine) peptidase inhibitor, clade E, member 2 Serpine2 0.5 
1417562_at eukaryotic translation initiation factor 4E binding protein 1 Eif4ebp1 0.5 
1453313_at sestrin 3 Sesn3 0.5 
1429475_at RIKEN cDNA 2810457I06 gene///similar to RIKEN cDNA 2810457I06 
2810457I06Rik///LOC67722
4 0.5 
1422601_at serine (or cysteine) peptidase inhibitor, clade B, member 9 Serpinb9 0.5 
1435137_s_at 
RIKEN cDNA 1200015M12 gene///RIKEN cDNA 1200016E24 gene///RIKEN cDNA A130040M12 gene///RIKEN 
cDNA E430024C06 gene 
1200015M12Rik///1200016
E24Rik///A130040M12Rik//
/E430024C06Rik 0.5 
1423176_at transducer of ErbB-2.1 Tob1 0.5 
1416303_at LPS-induced TN factor Litaf 0.5 
1447800_x_at NA NA 0.5 
1455679_at oligonucleotide/oligosaccharide-binding fold containing 2A Obfc2a 0.5 
1417772_at glyoxylate reductase/hydroxypyruvate reductase Grhpr 0.5 
1459903_at sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A Sema7a 0.5 
1427932_s_at 
RIKEN cDNA 1200003I10 gene///RIKEN cDNA 1200015M12 gene///RIKEN cDNA 1200016E24 gene///RIKEN 
cDNA A130040M12 gene///RIKEN cDNA E430024C06 gene///similar to gag protein 
1200003I10Rik///1200015M
12Rik///1200016E24Rik///A
130040M12Rik///E430024C 0.5 
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06Rik///LOC100039464 
1453021_at syntaxin binding protein 5 (tomosyn) Stxbp5 0.5 
1434140_at mcf.2 transforming sequence-like Mcf2l 0.5 
1416503_at latexin Lxn 0.5 
1422537_a_at inhibitor of DNA binding 2 Id2 0.5 
1418350_at heparin-binding EGF-like growth factor Hbegf 0.5 
1440298_at similar to trem-like transcript 2///triggering receptor expressed on myeloid cells-like 2 LOC100047904///Treml2 0.5 
1422470_at BCL2/adenovirus E1B interacting protein 1, NIP3 Bnip3 0.5 
1450698_at dual specificity phosphatase 2 Dusp2 0.5 
1449085_at PHD finger protein 10 Phf10 0.5 
1434895_s_at protein phosphatase 1, regulatory (inhibitor) subunit 13B Ppp1r13b 0.5 
1423918_at rhomboid domain containing 1 Rhbdd1 0.5 
1453238_s_at 
RIKEN cDNA 3930401B19 gene///RIKEN cDNA A130040M12 gene///RIKEN cDNA E430024C06 gene///similar 
to gag protein 
3930401B19Rik///A130040
M12Rik///E430024C06Rik//
/LOC100039378///LOC1000
39583///LOC100041150///L
OC100041274///LOC10004
1962///LOC100043154///LO
C100043406///LOC1000482
90 0.5 
1449007_at B-cell translocation gene 3///predicted gene, EG654432///similar to BTG3 
Btg3///EG654432///LOC100
048453 0.5 
1449221_a_at ribosome binding protein 1 Rrbp1 0.5 
1421679_a_at cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 0.5 
1437356_at Epstein-Barr virus induced gene 2 Ebi2 0.5 
1450871_a_at branched chain aminotransferase 1, cytosolic Bcat1 0.6 
1423543_at SWA-70 protein Swap70 0.6 
1426724_at calponin 3, acidic///similar to calponin 3, acidic Cnn3///LOC100047856 0.6 
1433446_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1///similar to Hmgcs1 protein Hmgcs1///LOC100040592 0.6 
1422433_s_at isocitrate dehydrogenase 1 (NADP+), soluble Idh1 0.6 
256 
 
1436836_x_at calponin 3, acidic///similar to calponin 3, acidic Cnn3///LOC100047856 0.6 
1436590_at protein phosphatase 1, regulatory (inhibitor) subunit 3B Ppp1r3b 0.6 
1418295_s_at diacylglycerol O-acyltransferase 1 Dgat1 0.6 
1433443_a_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1///similar to Hmgcs1 protein Hmgcs1///LOC100040592 0.6 
1415780_a_at armadillo repeat containing, X-linked 2 Armcx2 0.6 
1419647_a_at immediate early response 3 Ier3 0.6 
1438439_at G protein-coupled receptor 171 Gpr171 0.6 
1434301_at RIKEN cDNA D330050I23 gene D330050I23Rik 0.6 
1428587_at transmembrane protein 41B Tmem41b 0.6 
1416687_at procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 Plod2 0.6 
1424704_at runt related transcription factor 2 Runx2 0.6 
1428909_at RIKEN cDNA A130040M12 gene A130040M12Rik 0.6 
1426721_s_at TCDD-inducible poly(ADP-ribose) polymerase Tiparp 0.6 
1452058_a_at ring finger protein 11 Rnf11 0.6 
1433445_x_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1///similar to Hmgcs1 protein Hmgcs1///LOC100040592 0.6 
1438391_x_at hydroxysteroid (17-beta) dehydrogenase 10 Hsd17b10 0.6 
1435176_a_at inhibitor of DNA binding 2 Id2 0.6 
1435264_at elastin microfibril interfacer 2 Emilin2 0.6 
1435630_s_at acetyl-Coenzyme A acetyltransferase 2 Acat2 0.6 
1426123_a_at ribosome binding protein 1 Rrbp1 0.6 
1435913_at beta-1,4-N-acetyl-galactosaminyl transferase 4 B4galnt4 0.6 
1417697_at sterol O-acyltransferase 1 Soat1 0.6 
1426600_at solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 0.6 
1422544_at myosin X Myo10 0.6 
1418737_at nudix (nucleoside diphosphate linked moiety X)-type motif 2 Nudt2 0.6 
1448118_a_at cathepsin D Ctsd 0.6 
1451020_at glycogen synthase kinase 3 beta Gsk3b 0.6 
1417303_at mevalonate (diphospho) decarboxylase Mvd 0.6 
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1424638_at cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 0.6 
1420353_at lymphotoxin A Lta 0.6 
1451776_s_at homeobox only domain Hod 0.6 
1433804_at Janus kinase 1 Jak1 0.6 
1416011_x_at EH-domain containing 1 Ehd1 0.6 
1438180_x_at HCLS1 associated X-1///silica-induced gene 111 Hax1///Silg111 0.6 
1418437_a_at MAX-like protein X Mlx 0.6 
1452394_at cysteinyl-tRNA synthetase Cars 0.6 
1449056_at RIKEN cDNA E330009J07 gene E330009J07Rik 0.6 
1449037_at cAMP responsive element modulator Crem 0.6 
1418436_at syntaxin 7 Stx7 0.6 
1448663_s_at mevalonate (diphospho) decarboxylase Mvd 0.6 
1416010_a_at EH-domain containing 1 Ehd1 0.6 
1456204_at small nucleolar RNA host gene (non-protein coding) 8 Snhg8 0.6 
1436842_at RIKEN cDNA B230380D07 gene B230380D07Rik 0.6 
1417696_at sterol O-acyltransferase 1 Soat1 0.6 
1449437_at DNA segment, Chr 6, Wayne State University 163, expressed D6Wsu163e 0.6 
1449170_at piwi-like homolog 2 (Drosophila) Piwil2 0.6 
1448286_at hydroxysteroid (17-beta) dehydrogenase 10 Hsd17b10 0.6 
1427893_a_at phosphomevalonate kinase Pmvk 0.6 
1428666_at asparaginyl-tRNA synthetase Nars 0.6 
1450241_a_at ecotropic viral integration site 2a Evi2a 0.6 
1444088_at NA NA 0.6 
1449303_at sestrin 3 Sesn3 0.6 
1428662_a_at homeobox only domain Hod 0.6 
1433444_at 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1///similar to Hmgcs1 protein Hmgcs1///LOC100040592 0.6 
1426187_a_at HCLS1 associated X-1 Hax1 0.6 
1419091_a_at annexin A2 Anxa2 0.6 
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1427918_a_at ras homolog gene family, member Q Rhoq 0.6 
1416067_at interferon-related developmental regulator 1 Ifrd1 0.6 
1449118_at dihydrolipoamide branched chain transacylase E2 Dbt 0.6 
1434773_a_at solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 0.6 
1434225_at SWA-70 protein Swap70 0.6 
1452717_at solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 24 Slc25a24 0.6 
1448135_at activating transcription factor 4 Atf4 0.6 
1423602_at Tnf receptor-associated factor 1 Traf1 0.6 
1428365_a_at lon peptidase 1, mitochondrial Lonp1 0.6 
1422612_at hexokinase 2///hypothetical protein LOC100043412///hypothetical protein LOC100047934 
Hk2///LOC100043412///LO
C100047934 0.6 
1434642_at hydroxysteroid (17-beta) dehydrogenase 11 Hsd17b11 0.6 
1426530_a_at kelch-like 5 (Drosophila) Klhl5 0.6 
1424981_at neurolysin (metallopeptidase M3 family) Nln 0.6 
1423947_at RIKEN cDNA 1110008P14 gene 1110008P14Rik 0.6 
1452784_at integrin alpha V Itgav 0.6 
1420618_at cytoplasmic polyadenylation element binding protein 4 Cpeb4 0.6 
1460362_at RIKEN cDNA 2410001C21 gene 2410001C21Rik 0.6 
1418319_at RIKEN cDNA 1810047C23 gene 1810047C23Rik 0.6 
1456739_x_at armadillo repeat containing, X-linked 2 Armcx2 0.6 
1426599_a_at solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 0.6 
1417406_at SERTA domain containing 1 Sertad1 0.6 
1420614_at dynein light chain Tctex-type 3 Dynlt3 0.6 
1423082_at Der1-like domain family, member 1 Derl1 0.6 
1438957_x_at CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 Cds2 0.6 
1450646_at cytochrome P450, family 51 Cyp51 0.6 
1419550_a_at serine/threonine kinase 39, STE20/SPS1 homolog (yeast) Stk39 0.6 
1420502_at spermidine/spermine N1-acetyl transferase 1 Sat1 0.6 
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1460469_at tumor necrosis factor receptor superfamily, member 9 Tnfrsf9 0.6 
1434399_at 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6///similar to UDP-N-acetyl-
alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 Galnt6///LOC100047499 0.6 
1453181_x_at phospholipid scramblase 1 Plscr1 0.6 
1453127_at protein phosphatase 1J Ppm1j 0.6 
1424465_at coiled-coil domain containing 58 Ccdc58 0.6 
1416041_at serum/glucocorticoid regulated kinase Sgk 0.6 
1426397_at transforming growth factor, beta receptor II Tgfbr2 0.6 
1428615_at purinergic receptor P2Y, G-protein coupled, 5 P2ry5 0.6 
1448704_s_at histocompatibility 47 H47 0.6 
1456046_at CD93 antigen Cd93 0.6 
1450634_at ATPase, H+ transporting, lysosomal V1 subunit A Atp6v1a 0.6 
1453851_a_at growth arrest and DNA-damage-inducible 45 gamma Gadd45g 0.6 
1418831_at plakophilin 3 Pkp3 0.6 
1420407_at leukotriene B4 receptor 1 Ltb4r1 0.6 
1435342_at potassium inwardly-rectifying channel, subfamily K, member 6 Kcnk6 0.6 
1452095_a_at histocompatibility 47 H47 0.6 
1437199_at dual specificity phosphatase 5 Dusp5 0.6 
1421457_a_at SAM domain, SH3 domain and nuclear localization signals, 1 Samsn1 0.6 
1417695_a_at sterol O-acyltransferase 1 Soat1 0.6 
1449078_at ST3 beta-galactoside alpha-2,3-sialyltransferase 6 St3gal6 0.6 
1434657_at Expressed sequence AI314027 AI314027 0.6 
1435735_x_at histocompatibility 47 H47 0.6 
1438992_x_at activating transcription factor 4 Atf4 0.6 
1418932_at nuclear factor, interleukin 3, regulated///similar to NFIL3/E4BP4 transcription factor LOC100046232///Nfil3 0.6 
1417481_at receptor (calcitonin) activity modifying protein 1 Ramp1 0.6 
1416381_a_at peroxiredoxin 5 Prdx5 0.6 
1452866_at asparaginyl-tRNA synthetase Nars 0.6 
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1430029_a_at tetraspanin 31 Tspan31 0.6 
1455105_at protein tyrosine phosphatase, non-receptor type 12 Ptpn12 0.6 
1428154_s_at phosphatidic acid phosphatase type 2 domain containing 1 Ppapdc1 0.6 
1420394_s_at glycoprotein 49 A///leukocyte immunoglobulin-like receptor, subfamily B, member 4 Gp49a///Lilrb4 0.6 
1438511_a_at RIKEN cDNA 1190002H23 gene 1190002H23Rik 0.6 
1429335_at small nuclear RNA activating complex, polypeptide 1 Snapc1 0.6 
1416367_at RIKEN cDNA 1110001J03 gene 1110001J03Rik 0.6 
1435017_at melanoma nuclear protein 13 Mel13 0.7 
1435031_at transmembrane protein 120A Tmem120a 0.7 
1451442_at coiled-coil domain containing 104 Ccdc104 0.7 
1435640_x_at RIKEN cDNA A130040M12 gene A130040M12Rik 0.7 
1421947_at guanine nucleotide binding protein (G protein), gamma 12 Gng12 0.7 
1455104_at MAX dimerization protein 1 Mxd1 0.7 
1421624_a_at enabled homolog (Drosophila) Enah 0.7 
1421302_a_at guanine nucleotide binding protein, alpha 15 Gna15 0.7 
1426257_a_at seryl-aminoacyl-tRNA synthetase Sars 0.7 
1415890_at 3'-phosphoadenosine 5'-phosphosulfate synthase 1 Papss1 0.7 
1460603_at sterile alpha motif domain containing 9-like Samd9l 0.7 
1420013_s_at lanosterol synthase Lss 0.7 
1416610_a_at chloride channel 3 Clcn3 0.7 
1416921_x_at aldolase 1, A isoform Aldoa 0.7 
1433531_at acyl-CoA synthetase long-chain family member 4 Acsl4 0.7 
1424342_at forty-two-three domain containing 1 Fyttd1 0.7 
1448304_a_at RAB6, member RAS oncogene family Rab6 0.7 
1426554_a_at phosphoglycerate mutase 1 Pgam1 0.7 
1433604_x_at aldolase 1, A isoform Aldoa 0.7 
1434799_x_at aldolase 1, A isoform Aldoa 0.7 
1460521_a_at oligonucleotide/oligosaccharide-binding fold containing 2A Obfc2a 0.7 
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1451074_at ring finger protein 13 Rnf13 0.7 
1418911_s_at acyl-CoA synthetase long-chain family member 4 Acsl4 0.7 
1418326_at 
similar to solute carrier family 7 (cationic amino acid transporter, y+ system), member 5///solute carrier family 7 
(cationic amino acid transporter, y+ system), member 5 LOC100047619///Slc7a5 0.7 
1416556_at tetraspanin 31 Tspan31 0.7 
1452000_s_at seryl-aminoacyl-tRNA synthetase Sars 0.7 
1425515_at phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) Pik3r1 0.7 
1438682_at phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) Pik3r1 0.7 
1416069_at phosphofructokinase, platelet Pfkp 0.7 
1424697_at DTW domain containing 1 Dtwd1 0.7 
1428975_at sushi domain containing 3 Susd3 0.7 
Figure S5: Transcripts down-regulated upon rapamycin treatment. 
All transcripts with a statistically significant down-regulation of more than 1.5 are shown. 
 
